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General introduction
10 Chapter 1
Multiple sclerosis 
General features 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system (CNS). The oligodendrocyte is the myelin-producing cell of the CNS and 
encircles its lipid bilayer membrane around multiple axons. Myelin serves as an 
isolation sheath for axons. This insulation is critical for protection against harmful 
components and establishes proper neuronal signaling and transmission. In MS, 
immune-mediated attacks against components of the myelin sheath and axons 
are thought to eventually lead to impaired nerve conduction and motor functions1-
3. Demyelinated, multifocal sharp-edged lesions (plaques) are the pathological 
hallmark of MS. Processes of astrocytes fill up demyelinated areas and form scars, 
a process referred to as astrogliosis. The presence of multiple scars in the CNS has 
led to the name multiple sclerosis. 
Clinical assessment of myelin and axonal damage 
A specific feature of MS is the appearance and sometimes disappearance 
of CNS lesions in time and space. The distribution of these lesions can be 
monitored by various magnetic resonance imaging (MRI) techniques4, which 
visualize the expanded extracellular space within the plaque. In the CNS of MS 
patients, so-called T1- or T2-weighted MR images show black holes or white 
spots, respectively. Furthermore, blood-brain barrier damage can be detected 
by gadolinium enhancement of T1-weighted lesions, with the use of the tracer 
gadolinium diethylene-triamine-pentaacetic acid (DTPA). This tracer can pass the 
compromised blood-brain barrier (BBB) in active MS lesions. T2-weighted lesions 
represent areas with demyelination and/or astrogliosis. MRI-detected lesions are 
not directly correlated with disease activity5. Especially cerebral lesions can be 
clinically silent, whereas cerebellar, brain stem and spinal cord lesions are in general 
accompanied by clinical signs of deficit. In the post-inflammatory phase, burnt-out 
lesions can be partially repaired. This repair process involves the regeneration of 
myelin around axons by oligodendrocytes, leading to shadow plaque formation. 
Permanent scars are formed when astrogliosis precedes remyelination. 
In contrast to the possible regeneration of myelin and immigration of precursor 
oligodendrocytes into demyelinated lesions, axonal and/or neuronal damage is an 
irreversible event. Axonal damage is present already in the early stages of MS6, but 
can be clinically silent, since the CNS is capable to fully compensate for a certain 
amount of functional loss7,8. In MS, it is known that axonal loss accumulates in 
time. After reaching a certain threshold of axonal/neuronal degeneration, functional 
damage becomes permanent. It is assumed that axonal/neuronal degeneration 
plays a central role in disease progression towards the irreversible secondary-
progressive phase9. The extent of neuronal and axonal damage can be reflected by 
magnetic resonance spectroscopy, using the decreased concentration of N-acetyl 
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aspartate as a measure for brain atrophy. In addition, T1-weighted black holes on 
MRI are also thought to represent areas with axonal damage. 
Disease course 
MS mostly affects young adults. The clinical disease course is highly heterogeneous. 
In general, the disease course can be categorized into four distinct forms; relapsing-
remitting, primary-progressive, secondary-progressive and progressive-relapsing 
MS (Figure 1)10.
In relapsing-remitting MS (85-90% of patients), periods of decline (relapses) are 
alternated by periods of complete or incomplete remission, with a stable course 
between attacks. Seventeen percent of relapsing-remitting MS patients have a 
benign form of MS. This form is defined by a fully functional neurological system, 
for at least fifteen years after disease onset. After a certain period of time, about 
40% of relapsing-remitting MS patients develop a progressive neurodegenerative 
secondary disorder, known as the progressive phase and categorized as secondary-
progressive MS. Primary-progressive MS patients (10-15%) develop a gradual 
and nearly continuous disease progression from onset, with minor fluctuations. 
Plateaus, remissions and acute relapses are all absent. In the course of time, 
primary-progressive MS can also convert into a secondary-progressive MS phase. 
It is not known what triggers the transition into a secondary-progressive phase. 
The transition might be explained by the fact that irreversible axonal and neuronal 
damage accumulate over time, into the extent of permanent disability and extensive 
brain atrophy. In this phase, MS patients do not respond to immunotherapy. A small 
group of MS patients (<5%) develop a progressive-relapsing disease course. This 
form is defined by a progressive course from onset, with acute relapses. Between 
relapses, patients show a continuous progression of disability. 
Besides the four major forms of MS (Figure 1), also other sub forms of MS 
exist. In a small proportion of MS patients, an acute, malignant disease course is 
manifested, characterized by a severe disability or even death within months after 
disease onset. Acute disseminated encephalomyelitis (ADEM) can be erroneously 
diagnosed as MS, because ADEM patients also develop acute disability in a short 
time period11,12. However, the CNS pathology of ADEM patients does not show 
the typical sharp-edged plaques as seen in MS patients. The classification of 
variants of MS, including the sub forms Marburg’s type of acute MS, Devic’s type of 
neuromyelitis optica, Baló’s concentric sclerosis, Schilder’s myelinoclastic diffuse 
sclerosis and disseminated encephalomyelitis patients has recently been reviewed 
and revised by Poser and Brinar13. 
Etiology 
As described above, the disease course of individual MS patients is highly variable, 
and is possibly caused by different immunopathological mechanisms. MS is a 
disease with unknown etiology and affects about 1 in 1.000 individuals. Prevalence 
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and incidence studies have shown that the individual susceptibility risk for MS 
development is variable14 and is dependent on a combination of host factors (e.g. 
genes and hormones) and exogenous factors (e.g. infections)15-18. A genetic basis 
clinical
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Figure 1. Classification of clinical MS courses. 
The disease course in MS patients is heterogeneous and can be subdivided into four main categories. 
Relapsing-remitting (RR) MS is characterized by acute attacks, followed by full or partial recovery, with 
periods of clinical silence of the disease between the relapses. RR MS can progress into a secondary-
progressive (SP) disease course, which is defined by disease progression with possible relapses and 
minor remissions. Primary-progressive (PP) and progressive-relapsing (PR) MS both show progression 
from onset and includes acute relapses in the latter form. Irreversible axonal damage is already present 
early after MS onset and accumulates over time. Progressive clinical deficit may develop after reaching 
a certain treshold of axonal loss and brain atrophy. Based on Lublin et al., 199610, Compston and Coles, 
2002337. 
General introduction 13
is underscored by a concordance rate of approximately 31% among monozygotic 
twins and 5% among dizygotic twins19. Furthermore, although low (± 2%), the 
recurrence risk factor in first-degree relatives is increased 20- to 40-fold compared 
with the risk factor in the general population20. In children from conjugal MS pairs, 
the risk factor is increased by 10-fold, compared to children with one affected MS 
parent. Many genetic association or linkage studies have consistently shown that 
in Caucasian Europeans and North Americans the HLA class II alleles DR15/DQ6 
(namely DRB1*1501, DQB1*0601) on chromosome 6p21 are associated with 
an 3.6-fold elevated risk for MS development21,22. Likewise, genetic variants for 
the TNF-α gene, located in the same linkage group, have been identified as a 
susceptibility factor for MS development. In addition, a considerable number of low-
risk, non-HLA genes are also thought to contribute to MS susceptibility. Hormonal 
factors can influence MS incidence and disease course as well. MS is more 
common in females than in males, with an approximate ratio of 2:1. Especially 
during and after pregnancy a reduced number of relapses are observed, which 
may partially be related to hormonal changes. In sharp contrast, a deterioration of 
disease symptoms is observed post-partum. 
The fact that about 60% of monozygotic twins are not concordant for MS, strongly 
argues in favour of an additional role of exogenous factors in MS susceptibility23. 
From migration studies, it became apparent that besides genetic predisposition, 
exogenous factors contribute as well to the risk of MS development14. Loss of 
genetic isolation in Sardinia, by the immigration of soldiers during World War II, 
may have increased MS incidence by transmittable agents. People, who migrate 
before the age of 15 years, acquire the relative risk factor of the new location. 
Emigrants who move later in life maintain the susceptibility risk of their original 
location24,25. Moreover, the prevalence of MS can vary within homogeneous genetic 
populations and is higher in areas with a moderate climate26. In summary, there is 
substantial evidence that genetic predisposition and environmental factors both 
contribute to MS susceptibility.  
Microbial factors
The immune system plays a considerable role in the destruction of myelin and 
axonal components in the CNS of MS patients. It is not known where and how 
these inflammatory attacks are initiated. The initial event may take place within the 
CNS, i.e. by tissue damage initiated by trauma or microbial infection. Alternatively, 
the initial trigger might take place in peripheral lymphoid organs, i.e. by activation 
of a CNS-specific immune response. In general, there are two points of view on 
the formation of MS lesions. The outside-in model suggests that inflammation 
is followed by demyelination and subsequent axonal damage. The inside-out 
model, on the other hand implies that axonal injury triggers inflammation and 
demyelination. Hence, the immune response in MS could be a secondary event 
in which lesions develop from the axons to the myelin. Several studies imply that 
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axonal damage may actually occur first, as reviewed recently27,28. In both models, 
loss of CNS tissue integrity, in genetically susceptible hosts, can induce release of 
CNS antigens to the periphery, where priming or reactivation of autoreactive T and 
B cells can take place in secondary lymphoid organs29-32. 
Other CNS inflammatory demyelinating diseases are clearly associated 
with infections, such as ADEM (associated with a post-viral or post-vaccination 
inflammation), human T-lymphotropic virus type 1 (HLTV-1)-associated myelopathy/
tropical spastic paraparesis and subacute sclerosing panencephalitis, caused 
by the reactivation of latent measles virus. Theiler’s murine encephalomyelitis 
virus and mouse hepatitis virus both induce an immune-based demyelinating 
encephalomyelitis in mice with clinical and pathological features of human MS33. 
However, so far no specific pathogen has been identified as relevant in the 
development of MS. This does not exclude a microbial involvement in the etiology 
of MS, since it is known that diverse antecedent viral and bacterial infections are 
frequently associated with MS relapses34-36. 
An encounter with microbes may activate autoreactive T and B cells and 
subsequently initiate chronic CNS inflammation. Both in healthy individuals 
and MS patients, myelin-specific T and B cells are present in the periphery31,37. 
This suggests that suppressive mechanisms are operational which maintain the 
immune system in a state of tolerance to self-antigens of the CNS. CD4+ and CD8+ 
regulatory T cells play an important role in the down regulation of inflammation in 
experimental autoimmune encephalomyelitis (EAE), an animal model for MS38,39. 
Interestingly, it was recently demonstrated that the functional CNS-specific CD4+ 
and CD8+ T cell responses were distinct in MS patients and healthy individuals40. 
Compared to healthy subjects, CNS-specific CD4+ T cell responses of MS patients 
were associated with elevated expression levels of IFN-γ, whereas IL-4 and IL-5 
levels were decreased. These data suggest that in MS patients CD4+ CNS-specific 
T cell responses are polarized towards the T helper (Th) 1 phenotype. In MS 
patients, CD8+ CNS-specific T cells expressed elevated levels of both IFN-γ and IL-
10. It is unclear at present whether this cytokine-profile represents pathogenic and/
or regulatory CD8+ T cells. Myelin-specific CD4+ and CD8+ T cells can potentially be 
activated or reactivated by infectious agents through diverse mechanisms41: 
a. molecular mimicry
b. bacterial and viral superantigens 
c. modulation of antigen presenting cell (APC) function
Molecular mimicry and superantigens 
Autoantigen-specific T cells and B cells can cross-react with foreign antigens, a 
concept known as molecular mimicry42-44. Some examples of viruses that share 
conserved sequences with myelin proteins in humans are Epstein-Barr virus, human 
herpes virus type 6, measles and papilloma virus. By using autoantigen-specific T 
cell clones from MS patients, it was functionally demonstrated that cross-reactivity 
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is possible with peptides from several viral and bacterial strains45. Activation 
of autoreactive T cells by bacterial superantigens has also been functionally 
demonstrated in EAE. EAE can be induced in susceptible animals upon active 
immunization with myelin components in adjuvant. Additional administration of the 
superantigen staphylococcal enterotoxin B induced relapses and exacerbations of 
mouse EAE by stimulation of Vβ8 receptors on autoantigen-specific T cells46.
Modulation of APC function 
EAE animal models have furthermore shown that interplay between the innate 
and adaptive immune system is a prerequisite for development of autoimmunity. 
A strong adjuvant containing heat-killed M. tuberculosis (complete Freund’s 
adjuvant, CFA) is required for the induction of EAE by active immunization with 
autoantigens. In EAE, a proinflammatory immune response is raised against 
microbial products present in the adjuvant mix. This immune response can also 
activate neighbouring T and B cells with other antigen-specific receptors, e.g. for 
an autoantigen in adjuvant. Bacterial compounds, such as lipopolysaccharides 
(LPS) can engage innate receptors, such as Toll-like receptors (TLR), expressed 
on and within APC. Receptor triggering provides a proinflammatory signal and 
furthermore facilitates (auto)antigen uptake and presentation by MHC-II molecules. 
In addition to bacterial components, viral components, such as cytosin-guanosin 
dinucleotides (CpG) oligodinucleotides, can also induce TLR9 activation and exert 
similar proinflammatory effects on APC. Interestingly, both LPS and CpG have 
been implicated as proinflammatory modulators in EAE development47-50. 
In the initial inflammatory attack, T and B cells are reactive against the myelin 
antigen used for immunization. However, at later stages in the disease T and B 
cell responses are also raised against other myelin peptides, a process referred 
to as epitope spreading. In EAE and MS, initiation and progression of disease are 
associated with T and B cell reactivity against new myelin epitopes51-54. Epitope 
spreading is first observed within the same protein (intermolecular spreading) and 
can proceed to different proteins (intramolecular spreading). Microbial products 
through bystander activation can influence epitope spreading. Taken together, in 
initial and in subsequent inflammatory attacks, both bacterial and viral components 
can modulate APC function and induce bystander activation by inducing 
proinflammatory cytokines, and by relieving T regulatory immunosupression.    
Model of cellular events in the pathogenesis of MS and EAE
Autoantigen-specific T cells are present in the periphery, but are nonpathogenic 
under normal circumstances. In Figure 2, a hypothetical model is shown in which 
the sequence of events is schematically represented. In susceptible hosts, insults 
with microbes or microbial particles (as M. tuberculosis in CFA) can create a 
proinflammatory environment by stimulating innate receptors of APC. APC may 
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present microbial antigens that are cross-reactive with myelin antigen(s), which 
can be present in peripheral lymph nodes55, in the context of MHC-I or MHC-II. 
Autoantigens are presented in a proinflammatory setting (IL-1, IL-6, IL-12) to naïve 
Th cells. IL-12 and the more recently discovered IL-23 and IL-27 are structurally 
related, heterodimeric cytokines that regulate cell-mediated immune responses 
and Th1 inflammatory reactions in EAE56,57. In this proinflammatory setting, CD4+ 
Th1 and CD8+ T cytotoxic cells develop. Ligation of costimulatory molecules on 
APC and T cells, such as CD40-CD154 and CD80-CD28, results in T cell activation 
and expansion. Autoantigen-specific CD4+ Th1 cells produce proinflammatory 
mediators such as IFN-γ, TNF-α, osteopontin (OPN) and matrix metalloproteinases 
(e.g. MMP-2 and MMP-9). CD4+ Th1 cells promote APC activation, provide help 
for the activation and expansion of autoreactive B cells and CD8+ T cells, and 
cause delayed-type hypersensitivity (DTH)58,59. At this stage of immune activation, 
immunosuppression by regulatory T cells is blocked via TLR engagement by 
inflammatory mediators, such as IL-660. 
Upon activation, antigen-specific T cells can enter the circulation and adhere 
to the endothelium of the BBB (Figure 2). T cell derived cytokines (e.g. IFN-γ 
and TNF-α) induce activation of endothelial cells. Activated T cells can normally 
enter into the perivascular space, but exit when they fail to encounter their 
respective antigens. T cell migration into the CNS is mediated by adhesion 
molecule interactions on activated T cells and endothelial cells (tethering: E- and 
P-selectins, α4 integrin/VLA-1 and transmigration: α4 integrin/VLA-1 and LFA-
1/ICAM-1). Subsequent transmigration requires the passage through several 
barriers, including an endothelial cell layer, endothelial basement membrane, 
epithelial leptomeningeal cell layer (not depicted in Figure 2), parenchymal 
basement membrane and astrocyte endfeet61. Thus, the first step of transmigration 
Figure 2. Model of cellular events in the pathogenesis of MS and EAE.
The sequence of events in the pathogenesis of MS remains largely unknown and current concepts rely 
predominantly on EAE studies. The initial event may occur in the CNS (i.e. damage mediated by trauma 
or infection) or in the periphery (i.e. activation of autoreactive lymphocytes). It is generally believed that 
after an unknown insult naïve autoreactive T cells (CD4+ and CD8+) and B cells are primed by APC in a 
proinflammatory environment in secondary lymphoid organs (e.g. lymph node). Activated autoreactive 
T cells express chemokine receptors, which enable the cells to recognize the site of inflammation, where 
chemokines are secreted. T cells adhere to the endothelial cells of the CNS, by contacting adhesion 
molecules. T cells can transmigrate through the endothelial cells into the perivascular space, and 
subsequently form perivascular cuffs. At the basal side of the endothelial cell, the basement membrane 
is reformed around the T cell. T cell migration through the extracellular matrix (ECM) is facilitated 
by the production of gelatinases (MMP-2/9). Proinflammatory cytokines (e.g. TNF-α) likely mediate 
transmigration across the parenchymal transmembrane and astrocyte endfeet. In the CNS parenchyma, 
T cells recognize their specific peptide targets, presented by MHC molecules on microglia, the APC of 
the CNS. This interaction initiates a cascade of events, including the attraction of other cell types and 
initiation of diverse effector functions (antibody-, cytokine-, complement- and cell-mediated damage). 
This inflammatory cascade leads to the degeneration of myelin and axonal loss. APC represents 
macrophages or dendritic cells. TCR represents T cell receptor. PRR represents pattern-recognition 
reception. Modified from Waubant et al., 1997338.
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requires crossing of the endothelial cell layer and endothelial basement membrane. 
Interestingly, recent studies have demonstrated that T cells migrate through CNS 
endothelial cells by a transcellular pathway62. After endothelial transmigration, the 
endothelial basement membrane is reformed. Other cell types, such as neutrophils, 
transmigrate between tight junctions of CNS endothelial cells. Cells have to migrate 
through the extracellular matrix (ECM) of the perivascular space to reach the CNS 
parenchyma. This process is facilitated by the gelatinases MMP-2 and MMP-9, 
which can degrade type IV collagen of the ECM. In order to infiltrate the CNS 
parenchyma, additional proinflammatory mediators are likely required to pass the 
parenchymal basement membrane and astrocyte endfeet. 
Autoantigen-specific T cells do not recognize intact myelin proteins. In the 
CNS parenchyma, autoantigen-specific T cells activate resident microglial cells, 
the APC of the CNS. After phagocytosis and proteolytic processing of myelin by 
microglia, CD4+ T cells can encounter their respective antigens in the context of 
MHC-II. This initiates an inflammatory cascade with edema, cytokines (e.g. TNF-α, 
IL-12 and OPN), chemokines (e.g. CCL-19 and CCL-21), MMP and complement- 
mediated reactions (e.g. deposition of the membrane attack complex). Antibodies 
against myelin antigens can cause direct demyelination, possibly in combined 
action with complement components. In the context of autoantigen presented by 
MHC-I molecules, CD8+ T cells can directly attack neurons and all glial cell types, 
including astrocytes, microglia and oligodendrocytes. CD8+ T cells can directly 
induce target cell death, by the release of cytotoxic granules containing perforines 
and granzymes. 
Counter mechanisms may dampen the inflammatory immune responses in 
the CNS or the periphery, including induction of apoptosis of inflammatory cells 
or induction of Th2 cells (IL-4, IL-5, IL-13), Th3 cells (TGF-β) or Tr1 cells (IL-10)63. 
Also resident microglia and astrocytes may restore homeostasis by producing anti-
inflammatory cytokines, such as IL-10. 
Experimental autoimmune encephalomyelitis
There is an urgent need to further elucidate the mechanisms involved in the 
immunopathogenesis of MS, since so far no long-lasting beneficial therapy has 
been developed. Therefore it is important to develop new therapeutic strategies 
and diagnostic tools to monitor treatment efficacy. In this thesis we describe the 
contribution of bacterial stimulation by peptidoglycan (PG) and immune modulation 
of CD97 and CD44variant isoforms in MS and in different animal models for MS. 
To determine whether these factors play a role in MS, we first assessed whether 
these bacterial components and molecules are present or expressed in post-
mortem MS brain tissue, respectively. For obvious ethical and practical reasons, it 
is not possible to determine the functional aspects of PG, CD97 and CD44 in MS 
patients. As an alternative, EAE animal models are highly useful to investigate the 
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molecular events involved in the immunopathogenesis of CNS autoimmunity. 
By using EAE models, several aspects of the clinical and pathological features 
of MS patients can be validated. The disease course in EAE is dependent on the 
encephalitogen, the protocol of immunization, and the species or strains used. We 
have analyzed EAE in two different monkey species and two different mouse strains. 
Thus far, spontaneous EAE development in mice is only observed in proteolipid 
protein (PLP)139-151-specific T cell receptor transgenic mice
64 or myelin basic protein 
(MBP)-specific T cell receptor transgenic mice with a deficiency for RAG165. In 
other mice, EAE needs to be induced by immunization or adoptive transfer. Well-
known autoantigens used for immunization are total protein or peptides of myelin; 
MBP, myelin oligodendrocyte glycoprotein (MOG) and PLP. In the non-human 
primate species used in this thesis, EAE was induced by active immunization with 
human myelin or recombinant human MOG peptides. EAE in mice was induced 
by active immunization with MOG or PLP peptides or by the adoptive transfer 
of autoantigen-specific effector T cells, as described below. By using active (by 
immunization) versus passive (by adoptive transfer) EAE induction, a distinction 
can be made between the priming and effector phase of the immune response, 
and adjuvant effects can be excluded. The fundamentally distinct disease course 
and pathological presentation of the different EAE models might be representative 
for different forms and aspects of human encephalomyelitis. As an example, 
ADEM and acute MS forms may be modelled by acute EAE in rhesus monkeys, 
immunized with recombinant human MOG1-125 in CFA. Characteristics of the EAE 
models that were used in this thesis are summarized in Table 1. 
Mouse EAE models
There are many advantages in using mouse EAE models. Mice are small, easily 
bred, relatively low in costs and moreover, many mouse-specific reagents are 
available. Mouse EAE models are well documented and over the years, much 
knowledge about immunopathogenic mechanisms and immunomodulating 
therapies in MS has been extrapolated from EAE mouse models. A major advantage 
of using mouse models is the possibility to genetically modulate genes of interest 
in EAE susceptible mouse strains. EAE in mice is characterized by mononuclear 
cell infiltrates in the CNS accompanied by clinical signs of paralysis. The disease 
can be induced in different susceptible mouse strains by immunization with myelin 
autoantigen in CFA. 
In this thesis we used C57BL/6 and SJL/J mice and induced EAE by active 
immunization or adoptive transfer (Table 1). To induce EAE in C57BL/6 mice, animals 
were immunized with MOG35-55 in CFA. In this mouse strain, additional injections 
with Bordetella pertussis toxin (PTX) are required for disease development. PTX 
has been shown to stimulate the innate and adaptive immune response in the 
development and expansion of autoantigen-specific Th cells66,67. Furthermore, 
via stimulating TLR4, PTX can mediate leukocyte recruitment and adhesion to 
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the BBB68. For EAE induction in SJL/J mice three different active immunization 
protocols were used. Mice were immunized with PLP139-151 in CFA. Subsequently 
they were injected with either PTX, heat inactivated B. pertussis bacteria or did 
not receive additional injections. These groups develop a monophasic, chronic, or 
relapsing-remitting disease course respectively, and mimic different pathological 
aspects of MS, such as inflammation, demyelination and axonal suffering (Table 1). 
Upon active immunization, autoantigen-specific naïve CD4+ T cells are activated 
and polarized into CD4+ Th1 cells in secondary lymphoid organs draining the 
injection sites. Already after several days, autoantigen-specific CD4+ Th1 cells can 
be isolated. Upon in vitro re-stimulation with the antigen, highly encephalitogenic 
effector T cells are re-activated, which expand clonally. In the last decades of MS 
and EAE research the focus has been on the role of encephalitogenic CD4+ Th1 
cells69,70. However, it was shown that CD8+ T cells outnumber the CD4+ T cells71,72 
and are clonally expanded in MS brain lesions73. Here, CD8+ T cells are in close 
contact with MHC-I-expressing oligodendrocytes and axons, with their cytotoxic 
granules in the direction of the contact zone between the T cell and the target 
cell74. Additionally, microglia, astrocytes and neurons can serve as targets for CD8+ 
cytotoxic T cells. Furthermore, EAE studies have shown that like CD4+ Th1 cells, 
encephalitogenic CD8+ cells can also transfer disease into naïve recipients75-77. 
In EAE models, immunomodulating treatments can be assessed in different 
stages of the disease course, e.g. before disease onset, at the peak of the 
disease burden and during remissions. In our studies, for instance, we assessed 
the functional contributions of PG, CD97 and CD44variant isoforms 7 and 10 in 
the development of mouse EAE. In the different phases of the disease course, 
CNS tissues were isolated for immunopathological or flow cytometric analysis, 
and secondary lymphoid organs were isolated to determine antigen-specific T cell 
proliferation and cytokine production (Table 2).
Non-human primate EAE models 
EAE susceptible mouse strains are of inbred nature and therefore restricted in 
immune response variability. This can be seen as an advantage, because isolated 
effects in cellular responses can be determined. But restriction in variability is a 
disadvantage with respect to the validation of such effects in comparison to MS 
patients. In essence, in genetic terms a homogeneous mouse strain represents 
only one individual. Non-human primates are of outbred nature and genetically and 
immunologically closely related to humans78. In non-human primate EAE models, 
the efficacy of new treatments for MS can be assessed pre-clinically by using 
human-specific reagents.
Two frequently used non-human primate EAE models are the rhesus macaque 
(Macaca mulatta) and the common marmoset (Callithrix jacchus)(Table 1)79,80. 
Rhesus monkeys are old-world monkeys and have an evolutionary distance 
to humans of 35 million years. Rhesus monkeys are infected by largely similar 
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pathogens and follow a similar disease course compared with humans. Both humans 
and rhesus monkeys share MHC-II DP, DR and DQ loci and moreover, antigens can 
be presented and recognized across the species barrier. In MOG- and MBP-specific 
responses, epitope specificity is comparable with humans. In rhesus monkeys, 
EAE susceptibility is associated with the Mamu-DP locus. Upon immunization 
with recombinant human MOG1–125, representing the complete extracellular N-
terminal domain, rhesus EAE monkeys develop a hyperacute disease course, 
similar to acute forms of MS and ADEM81. A variable disease course was observed 
after immunization of rhesus monkeys with a synthetic peptide  (phMOG34-56), 
ranging from mild clinical signs to a hyperacute disease79(B.A. ‘t Hart, in prep). 
Marmoset monkeys are new world-monkeys and have an evolutionary distance 
to humans of 55 million years. Humans and marmoset monkeys share many 
general and disease-related features, e.g. neuroanatomy, T and B cell receptors, 
CNS immunopathology and MRI characteristics of lesions, as recently reviewed by 
‘t Hart et al.82. Disease susceptibility is highly associated with Caja-DRB*W1201-
restricted activation of pMOG14-36 autoantigen-specific CD4
+ T cells. The disease 
course in marmoset monkeys closely resembles chronic MS. Marmoset monkeys 
immunized with MS-derived human myelin develop a relapsing-remitting or 
secondary-progressive disease course83. Immunization of marmoset monkeys 
with recombinant human MOG results in the development of a primary progressive 
disease course, with a broad variation in the onset of clinical signs, ranging between 
2 and 16 weeks79,84. This variation in length of the asymptomatic period appears to 
be associated with the extent of MOG-specific epitope spreading85, a phenomenon 
also known to be involved in relapse development in mouse EAE53. 
Pathological features of MS and non-human primate EAE brain 
lesions
Neuropathology of MS brain lesions
The most important pathological hallmark of MS is the presence of demyelinated 
lesions in the CNS. These lesions are mainly localized in white matter tracts of 
periventricular regions, cerebellum, brain stem, spinal cord and optic nerves. 
However, lesions can also be present in the gray matter of the cortex. In inflammatory 
lesions different infiltrated leukocyte subsets can be found i.e. macrophages (MΦ), 
dendritic cells (DC), T cells, B cells and granulocytes, which are mostly located in 
the perivascular space, but these cells can also infiltrate into the brain parenchyma. 
Furthermore, also resident microglia and astrocytes can be activated (i.e. express 
HLA-II molecules). Subsequently, these cells are able to produce inflammatory 
mediators, such as IL-12, IL-23 and nitric oxide (NO). In addition, deposits of 
antibodies (e.g. anti-MOG)86 and complement components (e.g. C9neo antigen)87 
provide evidence for humoral autoimmune-mediated reactions in MS brain tissue30. 
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Both cellular and humoral autoimmune reactions result in demyelinated areas, with 
denuded or damaged axons and oligodendrocytes. 
Lesion staging systems in MS pathology
In all lesion staging systems, the term ‘active’ defines the process of active myelin 
breakdown, as can be demonstrated by myelin products in phagocytosing cells. 
There are three well documented and frequently used lesion staging systems 
which were compared by van der Valk and de Groot88. These include the staging 
systems of Lassmann and Brück89,90, Bö and Trapp91,92 and the Vienna consensus 
system93.  
Lassmann and Brück staging system 
The Lassmann and Brück staging system is based on the timing of demyelination. 
Myelin is composed of 20-25% proteins and 75-80% lipids. Myelin proteins are 
differentially distributed within the myelin sheath. Myelin associated glycoprotein 
(MAG, 3% w/w of whole myelin) is located in the periaxonal space. MBP (30%) is 
a cytosolic protein, and PLP (50%) is integrated in the myelin membrane. MOG 
(0.05%) is located at the outer membrane and can therefore easily be accessed 
by the immune system. Demyelination of axons appears to be an ordered event, in 
which MOG and MAG are the first proteins found within MΦ. Luxol fast blue (LFB) 
staining can be used as a marker for early demyelination. Later on, PLP, MBP and 
periodic acid-Schiff (PAS; glycolipid staining)-containing MΦ are present within the 
lesions. According to the sequential myelin degradation, the system of Lassmann 
and Brück consists of the following stages:
1. early active, associated with MRP-14-expressing MΦ containing myelin (by 
 LFB staining) and/or MOG/MAG-positive products
2. late active, associated with lysozyme-expressing MΦ (27E10+MRP14-) with 
 PAS-positive products and a small amount of LFB-positive products
3. inactive, presence of PAS, but not LFB-positive material in MΦ and a limited 
 degree of inflammation
4. early remyelinating, defined by the presence of many lymphocytes, MΦ and 
 clusters of thinly myelinated axons
5. late remyelinating (shadow plaques), with few MΦ, astrogliosis and thinly 
 myelinated axons 
Bö and Trapp staging system 
The system of Bö and Trapp is mainly based on cellular criteria and recognizes 
three different lesion stages: 
1. active (demyelinating), hypercellular lesions 
2. chronic active, lesions with a hypocellular center and a hypercellular rim
3. chronic inactive, hypocellular lesions
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Vienna consensus 
In the Vienna consensus inflammatory criteria (Bö and Trapp) and demyelinating 
criteria (Lassmann and Brück) have been combined into a basic four-points staging 
system93. A more detailed characterization was recently put forward by Lucchinetti 
et al., who defined four different active demyelinating lesion patterns, based on 
myelin protein loss, geography and extension of plaques, pattern of oligodendrocyte 
destruction and immunological evidence of immunoglobulin and complement 
deposits94. The most frequently observed type I and II lesions are localized around 
small veins and venules and are defined as T cell-mediated or T cell plus antibody-
mediated lesions, respectively. In contrast, type III and IV lesions are characterized 
by ill-defined borders, diffuse spread into the white matter, oligodendrocyte 
dystrophy and are supposed to be related to virus- or toxin-induced demyelination 
and not of autoimmune origin. Type III lesions appear predominantly in MS patients 
with an acute disease course. Type IV lesions are rarely found.         
Adapted lesion staging system from Bö/Trapp by van der Valk/de Groot
We have used a staging system described by van der Valk and de Groot, which is a 
modified version of the system used by Bö and Trapp. This system is also based on 
both inflammation and demyelination criteria88,95. All stages, except the pre-active 
lesions, have been described in detail by Bö et al.91 and Trapp et al.92. Van der 
Valk and de Groot introduced a lesion stage that supposedly precedes the active 
lesion stages, the pre-active lesion. These pre-active lesions are more extensively 
described in relation to MRI measurements96. It was found that the majority of 
macroscopically invisible lesions detected by MRI were of the pre-active stage. It is, 
however, not proven that these lesions are the first stage in MS brain pathology and 
that all these pre-active lesions will progress into active lesions. Van der Valk and 
de Groot included this stage since it represents abnormalities in the white matter, 
which may give insight into the development of active lesions. 
Four different lesion stages are recognized:
1.  pre-active, defined as abnormalities of the white matter with clusters of 
 activated HLA-II-expressing microglial cells and/or perivascular inflammatory 
 cells, but no demyelinated areas, or  myelin-breakdown  products within MΦ
2.  active demyelinating, defined by the presence of myelin breakdown products 
 in MΦ, which can be visualized by oil red O, a histochemical staining for 
 neutral lipids
3. chronic active,  characterized by  an  active  hypercellular  rim  and  an inactive 
 hypocellular center
4.  chronic inactive, characterized by a hypocellular area with few or no myelin-
 containing MΦ
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Neuropathology of rhesus and marmoset EAE monkeys 
Rhesus monkeys immunized with MOG1–125 develop an acute EAE. In the brain, 
large demyelinated hemorrhagic/necrotic lesions are present which contain 
abundant numbers of neutrophils and extensive axonal damage79. In phMOG34-56-
immunized rhesus monkeys, brain pathology is characterized by a variable degree of 
demyelination and axonal pathology (B.A. t’ Hart, in prep.). Lesions contain abundant 
numbers of T cells, MΦ and few neutrophils. In some animals acute lesions occur, 
similar to CNS lesions in ADEM patients.
The neuropathological features of myelin-induced EAE in marmosets are highly 
comparable to MS lesion pathology83. In the CNS white matter of marmoset monkeys 
with EAE, lesions are characterized by focal demyelinated areas, containing cellular 
infiltrates with activated HLA-II+ CD40+ MΦ, CD154+ T cells, B cells, Th1 and Th2 
cytokines, MMP and anti-MOG antibodies86,97. The lesions can be classified as type 
II lesions, described by Lucchinetti et al.94, based on the presence of T cell-mediated 
inflammation and antibody-mediated primary demyelination. Axonal pathology can 
vary in EAE lesions of marmoset monkeys, since axonal pathology was not observed 
in inflammatory inactive lesions, while in inflammatory active lesions damaged axons 
were present, as demonstrated by the accumulation of β-amyloid precursor protein 
and reduced phosphorylation of neurofilaments98. Moreover, in chronic inactive 
lesions, severe axonal destruction was observed, accompanied by astrogliosis and 
remyelination83,86. 
MOG-induced EAE lesions in marmoset monkeys are characterized by 
predominantly sharply defined demyelinated areas with inflammatory cells. These 
lesions are categorized as early active lesions based on the Lassmann and Brück 
staging system89. Axonal structures are relatively well conserved in these lesions. 
In marmoset monkeys, a small number of lesions are chronic inactive and contain 
substantially damaged axons. The number of these chronic inactive lesions 
seems to increase with the progression of disease, as determined by serial MRI 
measurements84. 
Bacterial peptidoglycan, a cofactor in the pathogenesis of 
autoimmune diseases
Intestinal flora and chronic inflammation
Microbial components may stimulate harmful immune responses against natural 
antigens (e.g. commensal bacteria and food antigens) in patients with inflammatory 
bowel disease (IBD) or self antigens in patients with rheumatoid arthritis (RA) and 
MS. Such components may be derived from infections by bacterial or viral pathogens. 
In addition, all mucosal, and particularly the mucosal surface of the gastrointestinal 
tract, serve as a constant major microbial source. From birth onwards the intestinal 
tract is colonized by maternal-derived and environmental-derived microbes. At least 
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500 different bacterial species are present within the intestinal tract. One gram of 
stool contains 1x106 – 1x108 aerobic bacteria and 1x109 - 1x1010 obligate anaerobic 
organisms, of which 50% are Gram-positive. Under normal circumstances a symbiosis 
is present between enteric bacteria and the digestive system. Both the epithelial cell 
lining and the enteric bacterial cell layer function as an anatomical barrier against 
harmful agents. Colonization of the gut is not only important as a physical barrier, 
but also for digestive functions, development of the gut associated lymphoid tissue, 
limiting intestinal inflammation and minimizing the invasion of pathogens across the 
single-cell layered epithelial barier. 
External changes, such as diet and stress may change the normally stable 
intestinal bacterial composition. Several studies provide evidence that the composition 
of the intestinal flora plays a role in the development of the systemic autoimmune 
diseases IBD and RA99-101. Patients with IBD suffer from a chronic inflammation of the 
gastrointestinal tract and this inflammation appears to result from an inappropriate 
immune response to the normal intestinal flora. Interestingly, 5-23% of IBD patients 
additionally suffer from RA101, with a common direct positive relationship between the 
activity of both diseases. The intestinal Gram-positive anaerobic bacteria in early RA 
patients differ significantly from healthy controls102,103. Experimental animal models 
have demonstrated that arthritis can be induced in susceptible animals upon injection 
of cell wall components of a selected group of commensal Gram-positive strains101. 
Other Gram-positive strains were shown to be nonarthritogenic. One of the major 
components of Gram-positive bacteria is PG. PG is able to induce inflammatory 
responses, similar to Gram-negative LPS. It has been proposed previously that PG 
stimulates chronic inflammation in RA and MS104,105. In this thesis we investigated 
whether bacterial PG may functionally contribute to the disease course in MS, by 
using animal models.
The bridge between innate and adaptive immunity
The dependency of the adaptive immune response on components of the innate 
immune system is a well established concept. The innate immune system utilizes 
serum and cell surface regulatory proteins to efficiently trigger adaptive immune 
responses. The bridge between innate and adaptive immunity is regulated by cell 
associated and soluble pattern-recognition receptors (PRR) as well as components 
of the complement system, as has been thoroughly reviewed recently106-108. Upon 
activation, cells express a distinct repertoire of surface molecules which are involved 
in the orchestration of subsequent effector functions. CD97 and CD44 are cell surface 
molecules which cover a wide variety of biological responses e.g. cell activation, 
migration, adhesion and extravasation into inflammatory sites, and apoptosis. 
Additionally, these molecules have been indicated to play a substantial role in chronic 
inflammation, i.e in RA and IBD. In this thesis we assessed whether CD97 and 
CD44variant isoforms are involved in the immunopathogenesis of MS and mouse EAE. 
In the following paragraphs an introduction will be given about PG, CD97 and CD44.
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Peptidoglycan
PG is a strong, rigid structure formed by three-dimensional cross-linked layers of 
glycan backbones with peptide bridges. In Gram-positive bacteria, PG contains 10 
to 70 layers and accounts for approximately 40-70% of the cell wall mass (Figure 
3a). In contrast, PG in Gram-negative bacteria contains 1 or 2 layers and constitutes 
only 10% of the cell wall mass109. PG surrounds the cytoplasmic membrane and 
functions to withstand osmotic pressures exerted from the cytoplasm110. PG is 
essential for the structure, replication and survival of bacteria. PG is composed 
of two repeating alternating amino sugars, N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc), attached to each other by β-1,4-glycosidic bonds. 
This glycan chain is conserved in all bacteria and is usually N-acetylated and 
sometimes O-acetylated. Muramic acid is a unique structural component of PG 
and can therefore be used as a marker for PG detection by mass spectrometry 
or high performance liquid chromatography. The glycan chains are cross-linked 
via attachment of tetra or pentapeptides, the stem peptides of PG. Stem peptides 
can be attached directly to each other or indirectly via interpeptide bridges. 
Between different bacteria, interpeptide bridges can vary in length and amino acid 
composition111,112. Some stem peptides are connected with only one glycan chain, 
and are not cross-linked to other stem peptides. 
Teichoic acids (TA) and lipoteichoic acids (LTA) are dispersed through the PG 
network and may stay in the PG layer after partial digestion. These unique structures 
for Gram-positive bacteria are water-soluble polymers, which contain chemically 
modified ribose or glycerol connected by phosphates. Antigenic determinants, 
such as sugars or D-alanine may be attached to the hydroxyl sites of ribose and 
glycerol. LTA contains an acyl group and is anchored to the cytoplasmic membrane. 
In contrast, TA is non-acetylated and is covalently attached to PG strands.
Variation of PG stem peptides 
PG can be divided into group A, and the less common group B PG, depending 
on the position of stem peptide cross-linkage111. The connection of group A PG is 
formed between position 3 of one stem peptide chain and position 4 of another stem 
peptide chain (Figure 3b). Stem peptides of group B PG are connected at position 
2 and 4. The first two amino acids attached to MurNAc of the glycan backbone vary 
between different bacterial strains. In group A, L-alanine is always the first amino 
acid attached to MurNAc of the glycan backbone, followed by a D-glutamine in the 
second stem peptide position. The MurNac-L-ala-D-Glu, called muramyl dipeptide 
(MDP), is the smallest conserved motif of PG. In PG of group B, the first amino acid 
attached to MurNAc is a glycine or L-serine, followed by D-glutamine. 
PG is further subdivided according to the diamino amino acid of position 3 in 
the stem peptide. These specific diamino amino acids also vary between different 
strains113 and have been show to play an essential role in the recognition of PG by 
receptors of the innate immune system. Gram-negative bacteria and occasional 
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Figure 3. Structural composition of PG in Gram-positive and Gram-negative bacteria.
The architecture of PG differs in Gram-positive and Gram-negative bacteria. (a) PG is a major cell wall 
component of Gram-positive, but a minor component of the cell wall of Gram-negative bacteria. (b) PG is 
composed of two alternating sugar residues (G and M), which are connected via stem peptides (circles). 
Most Gram-positive bacteria contain an L-lysine at position three of the stem peptide (), whereas 
mDAP is present at this position in Gram-negative bacteria (). Cleavage by specific enzymes (arrows) 
results in the release of PG fragments with different sizes and biological activities. Enzyme cleavage 
sites have been indicated for the first G-M residue and are identical for the following G-M residues. 
(c) The recognition of PG by the innate immune receptors Nod1 (Card4) and Nod2 (Card15) depends 
on the structural motifs of the stem peptides. Nod1 recognizes GM-TriDAP structures of Gram-negative 
bacteria. Nod2 specifically detects GM-DP structures, present in both Gram-negative and Gram-positive 
bacteria. OM: outer membrane; CM: cytoplasmic membrane. Modified from Kaisho and Akira, 2001339 
and Girardin et al., 2003340.
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Gram-positive bacteria (genera Bacillus and Clostridium) contain m-diaminopimelic 
acid (mDAP) at position 3 (Figure 3b). mDAP is a precursor of L-lysine. mDAP-
containing stem peptides are usually directly cross-linked to other stem peptides. 
Most other Gram-positive bacteria have an L-lysine at position 3 and these stem 
peptides are mostly cross-linked via interpeptide bridges. Some Gram-positive 
bacteria contain L-ornithine at this position. Interestingly, 70% of pathogenic 
bacterial classes contain L-lysine at position 3, while 75% of non-pathogenic 
bacteria contain mDAP/L-ornithine114. These findings correlate well with the natural 
habitat of bacteria; 86% of L-lysine type bacteria colonize animals, while 75% of 
mDAP/L-ornithine-containing bacteria live outside living hosts (e.g. in soil). 
For our functional studies, we have used purified PG derived from the 
pathogenic Gram-positive bacterium Staphylococcus aureus (Figure 3)(chapter 2 
and 3). Together with more than ten other bacterial species, S. aureus contains an 
O-acetylation site at the C-6 hydroxyl group of MurNAc. S. aureus also contains an 
L-lysine at position 3 of the stem peptide, which can be connected to other stem 
peptides through a pentaglycine bridge. Within the structure of S. aureus115, and 
other bacteria as well, a great variety of stem peptide compositions can be found. 
PG is insoluble in its native form116, but can be enzymatically cleaved into smaller 
soluble portions by specific PG-degrading enzymes or antibiotics. We have used 
both insoluble and soluble PG (chapter 3).
Peptidoglycan degradation
Bacterial cell wall PG is constantly being synthesized and degraded. During 
these processes PG components can be released. By preventing the activity of 
bacterial transglycosidases and transpeptidases, penicillin and other clinically 
useful antibiotics can inhibit bacterial PG synthesis112. This results in the release 
of large uncrosslinked glycan chains. Three different PG-degrading enzymes, 
which act as natural antibiotics, are known in humans. The cleavage sites of these 
specific enzymes are depicted in Figure 3b. Lysozyme (N-acetylmuramidase) and 
N-acetylglucosaminidase cleave the β-1-4 glycosidic bond between GlucNAc and 
MurNAc or MurNAc and GlucNAc, respectively117,118. Cleavage by these specific 
enzymes results in the release of monomeric muropeptides. The third muralytic 
enzyme is N-acetylmuramyl-L-alanine amidase (NAMLAA), which was recently 
shown to be identical to peptidoglycan recognition protein long form (PGRP-L)119,120. 
NAMLAA breaks the bond between MurNAc and the L-alanine at position 1 of the 
stem peptide121. It is likely that many other as yet unidentified muralytic enzymes 
exist in humans. In addition, bacteriolytic enzymes can also degrade PG, such as 
endopeptidases, which cleave PG at the interpeptide bridges.  
The sensitivity of PG for degradation by enzymatic activity is dependent on 
the composition of the cell wall. O-acetylated PG is more resistant to degradation 
than non-O-acetylated PG122,123. In addition, PG is more resistant to degradation 
when there is a high degree of cross-linkage between the stem peptides124. Also, 
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polysaccharides, TA and LTA can inhibit muralytic degradation of PG to some 
extent. Differential persistence of PG within a cell type is thus determined by the 
structure of PG structure and the spectrum of relevant enzymes and receptors (see 
below). 
Bacterial pattern recognition receptors
The innate immune system can recognize certain viral and bacterial motifs, 
the so-called pathogen associated molecular patterns (PAMP). PAMP are 
specifically recognized by a diverse repertoire of PRR, expressed by particular 
hematopoietic cells (e.g. APC) and non-hematopoietic cells (e.g. epithelial cells). 
PRR which recognize bacterial PAMP include CD14, members of the TLR family 
and nucleotide-binding oligomerization domain (Nod) receptors. Such molecules 
relevant in the studies in this thesis are briefly introduced below. 
CD14
CD14 is present as a cell surface receptor expressed by myelomonocytic cells 
and as a soluble molecule found in serum125,126. Cell surface and soluble CD14 
are identical in amino acid composition and only differ by the presence of the 
glycoylphosphatidylinositol (GPI) structure in membrane bound CD14. CD14 
functions as a co-receptor for LPS recognition of Gram-negative bacteria127. CD14 
can also serve as a co-receptor for the detection of Gram-positive cell wall structures, 
including PG128,129. But, LPS and PG differ in CD14 ligation and subsequent induced 
responses upon CD14 receptor triggering, as described below. 
Unlike PG, LPS is bound in serum by LPS-binding protein, which modifies 
LPS aggregates into single LPS molecules and delivers LPS to membrane bound 
CD14130. In this way, LPS-binding proteins greatly enhance CD14-mediated 
responses. Also soluble CD14 can transport LPS molecules to cell membranes. 
These complexes can either induce activation of cells which normally do not 
express membrane bound CD14 or can enhance responses of membrane CD14-
expressing cells131,132. By binding of soluble CD14, PG can also enhance responses 
of CD14-expressing cells132, but cannot induce activation of CD14-negative cells133. 
Furthermore, CD14 contains discrete binding sites that are partially similar and 
partially different for LPS and PG134. Binding of PG to CD14 is likely dependent 
on the glycan backbone of PG. Low-molecular weight fragments of PG, such 
as MDP, disaccharide dipeptides or pentapeptides do not bind CD14, whereas 
high molecular weight polymeric PG does bind CD14129,134. Since CD14 does not 
contain a transmembrane domain it is unlikely that CD14 by itself can mediate 
cell activation. Therefore it is generally assumed that CD14 functions as a ligand-
binding co-receptor, which delivers and enhances cell activation mediated by other 
membrane expressed PRR, such as TLR. 
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Toll-like receptors
TLR are type-I transmembrane molecules that contain extracellular leucine-rich 
repeats and cytoplasmic TIR domains (Toll/IL-1 receptor). So far 13 mammalian 
TLR have been identified. TLR play a critical role in the induction of innate immune 
responses. Bacteria can be recognized and discriminated by TLR2 (+ TLR1 or 
TLR6), TLR4, TLR5 and TLR9, discussed briefly below.
TLR2 recognizes many different bacterial components, including PG, 
LTA, lipoproteins, MALP-2, the synthetic PAM3CysK4, lipopeptides and 
lipoarabinomannan from M. tuberculosis. For its functional activation, TLR2 needs 
to form heterodimers with either TLR1 or TLR6. For example, TLR2 cooperates 
with TLR6 for the recognition of MALP-2 as was demonstrated by the analyses of 
knock-out mice. 
PG is recognized by TLR2/6 heterodimers135. TLR2/6 molecules are recruited 
into MΦ phagosomes where they recognize intracellular PG136. It has been 
suggested previously that TLR2 directly binds to PG by a sequence of 25 amino 
acids in the extracellular domain of TLR2137. However, the concept that PG 
stimulates cells via TLR2 has become controversial. Recently, it was demonstrated 
that PG-induced effects were related to the presence of LTA and TA contaminations 
in PG preparations138. During PG preparation, LTA and TA components are difficult 
to remove completely. In concordance, LTA signals via TLR2139,140 and is a potent 
inducer of proinflammatory cytokines by APC141,142.     
Interestingly, TLR2-induced responses can be enhanced or inhibited by 
interacting with TLR6 and TLR1, respectively143. Furthermore, it was demonstrated 
that TLR2 might distinguish between different Gram-positive bacteria, since TLR2 
transfected CHO cells respond to heat-killed Listeria monocytogenes, but not to 
group B Streptococci144. TLR2 expression is restricted to phagocytic cells and 
epithelial cells. In humans, TLR2 is predominantly expressed by monocytes, MΦ, 
DC and to a lesser extent by neutrophils and a few other cells145,146. In contrast, 
TLR1 and TLR6 are constitutively expressed by many cell types145. Taken together, 
TLR2 plays an essential role in recognition of a variety of bacterial antigens, and 
may regulate innate responses by cooperating for PAMP binding with different TLR 
and CD14.   
TLR4 functions as the cell signaling receptor for Gram-negative bacterial LPS. LPS 
is embedded in the outer membrane via its lipid portion (lipid A) and exposes its 
O-polysaccharides (O-antigen) outside the bacterial surface. LPS recognition by 
TLR4 is complex and requires several accessory molecules, such as LPS-binding 
protein, CD14 and MD2. MD2 is a small protein that lacks a transmembrane region. 
For the recognition of LPS, TLR4 requires association with MD2147. In addition to 
LPS, TLR4 also appears to mediate inflammatory responses to many different self-
ligands (e.g. heat shock proteins) and non-self ligands (e.g. LTA), summarized by 
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Johnson et al.148. TLR4 is expressed by a variety of cell types, especially by cells of 
the immune system, including MΦ and DC149. 
TLR5 is involved in the recognition of flagellin, a highly conserved 55 kDa monomer 
obtained from bacterial flagella. Flagella are polymeric rope-like subunits, which 
extend from the outer membrane of bacteria and provide motility. Interestingly, 
TLR5 is expressed on the basolateral, but not apical surface of intestinal epithelial 
cells150. In this way, the innate immune system can recognize flagellin from 
pathogenic bacteria that have crossed the epithelial barrier, but ignore flagellin from 
commensal bacteria, which do not have the capacity to cross epithelial barriers 
under normal circumstances.  
  
TLR9 mediates inflammatory responses against unmethylated CpG, present 
in bacterial DNA, viral DNA and synthetic oligodeoxynucleotides151. The 
immunostimulatory capacities of bacterial DNA can be completely abrogated 
by a single nucleotide substitution or methylation of a cytosine residue152. In the 
mammalian genome, most DNA is methylated and is therefore not recognized by 
TLR9. Motifs of CpG that optimally stimulate TLR9 differ between mouse and man, 
due to differences in the extracellular regions of TLR9153. This suggests that TLR9 
directly recognizes CpG ligands. Interestingly, TLR9 is expressed intracellularly, but 
not on the cell surface. Therefore, signaling by unmethylated CpG DNA requires 
internalisation into late endosomal or lysosomal compartments154.   
 
Nod1 and Nod2 receptors
Nod proteins belong to the nucleotide-binding site leucine-rich repeat (NBS-LRR) 
family. Nod proteins are intracellular PRR and have been shown to regulate NF-κB 
activation and apoptosis induction155. Two Nod proteins, namely Nod1 (also known 
as Card4) and Nod2 (Card15) are specifically involved in the recognition of bacterial 
PG. The functional components of Nod1 are composed of an N-terminal caspase 
recruitment domain (CARD), an NBS domain and a C-terminal LRR domain156. 
Nod2 contains an additional CARD domain. CARD and NBS domains are crucial 
for the activation of NF-κB, whereas the LRR might play a negative regulatory role 
in the activation of NF-κB157. Furthermore, the C-terminal LRR domain is involved 
in the recognition of PG158,159. Nod1 is expressed in epithelial cells, whereas 
Nod2 is expressed in different myeloid cell types, including monocytes, DC and 
granulocytes160,161.
It appears that specific parts of the PG structure are responsible for its 
proinflammatory properties. Interestingly, Nod1 and Nod2 are distinct and non-
overlapping in their sensing specificity for PG fragments (Figure 3c). Nod1 
specifically detects Gram-negative (mDAP type) PG, composed of the following 
muropeptide: GlcNAc-MurNAc-L-ala-D-Glu-mDAP (GM-TriDAP)
162,163. The glycan 
backbone is dispensable herein, since γ-D-Glu-mDAP is the minimal motif required 
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for Nod1 recognition162,164. This structure has not been identified as naturally 
occurring bacterial product, in contrast to GM-TriDAP. The GM-TriDAP can be seen as 
a unique bacterial fingerprint, since both D-Glu and mDAP are absent in eukaryotic 
cells. For Nod1 recognition it is pivotal that mDAP is presented as the terminal 
amino acid, because cross-linked stem peptides and peptides containing four 
amino acids are not recognized by Nod1. 
In contrast to Nod1, Nod2 recognizes PG from both Gram-positive and Gram-
negative bacteria. Of note, Nod2-mediated recognition of PG is dependent on 
the presence of MurNAc. The minimally required structure for Nod2 recognition 
is MDP159,165. However, MDP is not naturally formed and is inactive in most 
experimental systems, except for experimental meningitis166. GlucNAc-MurNAc-L-
ala-D-Glu (GM-DP) is a naturally occurring bacterial product present in all bacteria, 
which is recognized by Nod2. In this manner, Nod2 can detect PG fragments from 
both Gram-positive and Gram-negative bacteria. More specific analysis revealed 
that longer stem peptides need to contain an L-lysine or L-ornithine at position 3 
(in Gram-positive bacteria) for recognition by Nod2164. In contrast, Nod2 does not 
recognize MurNAc-TriDAP. In addition to different recognition specificities for PG, 
Nod1 and Nod2 also differ in expression. We have used PG derived from S. aureus, 
which does not contain the motif required for Nod1 ligation (GM-TriDAP)
163,167, but 
contains the motif necessary for Nod2 ligation (Figure 3c)159,165.
Signaling via TLR and Nod receptors
Activation of intracellular signaling pathways by TLR leads to the transcription of 
several genes including inflammatory cytokines, chemokines, MHC-II molecules 
and costimulatory molecules168,169. Both TLR and IL-1R depend on signaling via 
conserved TIR (Toll/IL1R homology) domains. Interestingly, upon specific TLR 
ligation distinct signaling pathways are initiated, mediated by the use of distinct 
adapter proteins. So far, four different adaptor proteins have been identified, i.e. 
MyD88, Mal, Trif and Tram170. TLR activation results in the recruitment of the 
cytoplasmic adapter protein MyD88. MyD88 recruits and autophosphorylates 
serine/threonine kinases of the IRAK family. IRAK then associates with TRAF-6, 
which induces activation of TAK1 and MKK6. These kinases induce the degradation 
of Iκ-B and translocation of NF-κB to the nucleus, and activate MAP (mitogen-
activated protein) kinases, such as p38 and c-Jun N-terminal kinases. IRAK-M 
has been shown to be a negative regulator of TLR signaling171,172. TLR-mediated 
responses can also be mediated by an MyD88-independent pathway and lead to 
the activation of IRF-3 (interferon regulatory factor 3)173. Taken together, a growing 
body of evidence now indicates that there are different and multiple signaling 
pathways used by individual TLR.
Nod1 and Nod2 signaling is currently being characterized and these two 
molecules appear to use similar transduction pathways as TLR. The first step of 
Nod1/2 signaling involves the oligomerization of Nod174, followed by recruitment of 
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the CARD-containing adapter protein Rip2 (also known as RICK)175. Subsequently, 
Rip2 interacts with the regulatory subunit IKKγ (also known as NEMO) of the IKK 
complex, inducing NF-κB translocation to the nucleus. Nod1/Nod2 signaling is not 
dependent on the adapter molecule MyD88. In addition to the activation of NF-
κB, Nod1/Nod2 oligomerization induces caspase activation. In example, caspase 
1 and 9 both contain CARD domains, which can associate through homophilic 
interactions with the CARD domains of Nod1157,176. In addition, activation of Nod1 
results in the caspase-1 dependent release of active proinflammatory IL-1β177. 
Taken together, Nod-mediated signaling pathways involve both the activation 
of proinflammatory gene transcription and activation of pro-apoptotic caspases. 
These different pathways may interact to form a balance between the activation 
(i.e. by inducing proinflammatory cytokines, chemokines and costimulatory 
molecules) and the suppression (i.e. by inducing apoptosis and IL-10 production) 
of the host defence.
PG distribution and association with chronic inflammation
Immunohistochemical and mass spectrometric analysis revealed that PG is 
present within peripheral blood leukocytes178, and within MΦ and DC in spleen179 
from healthy donors. Most bacterial PG in tissues probably originates from 
absorption of commensal bacteria and bacterial products in the gut. This idea 
arose by the observation that PG is absent in umbilical vein blood of new-borns178, 
which lack gut flora. In accordance, PG is absent in spleen tissue from germ-
free and neonatal rats. Upon injection of PG in germ-free rats, or after the age 
of 10 weeks in conventional rats, PG can be detected in rat spleen sections, by 
immunohistochemistry180. 
Bacterial products are sampled from the intestine through specialized epithelial 
M cells or by DC. To this end, DC can penetrate the epithelial barrier with their 
dendrites and thereby sample the intestinal flora181-183. Both M cells and DC can 
deliver bacterial antigens into the Peyer’s patches, as part of the gut associated 
lymphoid tissue. M cells deliver the antigens to professional APC. The presence 
of PG is not restricted to lymphoid tissues, since in conventional rats also brain, 
liver and kidney contain PG184. It is assumed that the kidney clears PG from 
the circulation. This assumption emanated from the observation that small PG 
fragments are detected in urine after penicillin treatment185,186. 
Intraperitoneal injection of bacterial cell wall components or PG from specific 
bacterial strains is a widely used model for the induction of experimental 
arthritis187,188. By i.p. injection of PG in rats, it was demonstrated that the spleen 
and liver serve as natural reservoirs of specific PG subtypes. It was suggested that 
from these tissues PG is distributed, via the circulation, into the synovium and peri-
articular tissues189,190 and thereby can contribute to the exacerbations of arthritis. 
Furthermore, mouse studies demonstrated that i.v. injected radiolabeled PG is 
additionally distributed into the lung, intestine and brain191. Recent findings indicate 
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that the retention and arthritogenic capacity of PG is dependent on its chemical 
composition. Persistence and arthritogenicity of PG is specifically attributed to the 
L-lysine at the third position of the stem peptide192,193. 
Taken together, PG may act as a stimulating cofactor for the development and 
perpetuation of chronic inflammation, even in the absence of infection or bacterial 
replication. One of the driving ideas of our research is that APC can redistribute 
biologically active PG from the mucosa to secondary lymphoid organs as well as to 
sites of chronic inflammation and stimulate autoimmunity at both locations. Indeed, 
it was shown previously that PG isolated from sterile human spleen was biologically 
active. Human blood cells produced IL-1, IL-6 and TNF-α upon stimulation with 
spleen-derived PG179. In addition, spleen-derived PG induced CD4+ and CD8+ T 
cell proliferation, which depended on CD14 binding, proteolytic processing and 
MHC-I/II presentation of PG by APC194. Interestingly, elevated numbers of PG-
containing APC are present at sites of chronic inflammation in MS brain tissue105, 
RA synovial tissue104,195, bowel wall tissue of patients with Crohn’s disease (CD)196 
and in atherosclerotic plaques197. These cells expressed costimulatory molecules, 
MHC-II and cytokines104,105.   
Cellular events in inflammation; a role for CD97 and CD44variant 
isoforms
 
CD97
Class B EGF-TM7 receptors
CD97 molecules are composed of a seven-span transmembrane domain (TM7) 
and variable numbers of N-terminal epidermal growth factor (EGF) domains (Figure 
4). These structural characteristics are specific for members of the long N-terminal 
class B-TM7 receptor family (LNB-TM7). Family members that exclusively contain 
EGF domains in the extracellular region are referred to as EGF-TM7 receptors. 
Six EGF-TM7 receptors have been identified in man: CD97, EGF-like module 
containing mucin-like receptor protein 1 (EMR1)198, EMR2199, EMR3200, EMR4201 
and EGF-TM7-latrophilin-related protein (ETL)202. The mouse genome includes 
CD97203,204, EMR1205,206, EMR4207,208 and ETL209, but not EMR2 and EMR3. Mouse 
EMR1 and EMR4 are also known as the mouse MΦ marker F4/80 and the F4/80-
like-receptor (FIRE), respectively. 
Expression
CD97 expression is rapidly induced on activated T cells, B cells, monocytes, 
MΦ, DC and granulocytes, while the molecule is constitutively expressed at low 
levels by granulocytes, monocytes and resting T and B cells, but not by microglial 
cells210-212. Interestingly, soluble CD97α-subunits (sCD97) can be secreted under 
inflammatory conditions213. sCD97 is not found in normal human serum or plasma, 
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nor in supernatant of activated T cells214. The functional implications of sCD97 are 
unknown at the moment. Human CD97-EGF4 is expressed by monocytes, DC, 
MΦ and granulocytes215. Lymphocytes express CD97-EGF4 after stimulation with 
PMA, PHA or anti-CD3 Mab215. EMR2-EGF4 expression is restricted to cells of the 
myeloid lineage, such as monocytes and granulocytes215. It was suggested that MΦ 
and DC express higher levels of EMR2-EGF4 compared to monocytes.
Figure 4. Schematic structure of human and mouse CD97 isoforms.
The CD97 gene is transcribed into one polypeptide, which is proteolitically cleaved at the G-protein-
coupled receptor-proteolytic site () in the edoplasmatic reticulum. CD97 molecules are expressed as 
heterodimers at the cell surface, containing an extracellular α-subunit, which is non-covalently linked to 
an 7-TM β-subunit. Additionally, soluble CD97α isoforms can be secreted under inflammatory conditions. 
Due to alternative RNA splicing, the α-subunit can be extended by the addition of different numbers of 
EGF domains (). Human EGF4 and mouse EGF3 contain a binding site for chondroitin sulfate (CS). 
CM: cell membrane, hCD97: human CD97, mCD97: mouse CD97. From Leemans et al., 2004233.
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Structural characteristics 
Membrane bound CD97 molecules are expressed as heterodimers, consisting 
of an extracellular α-subunit non-covalently linked with a TM7 β-subunit (Figure 
4). The α-subunit is composed of a long stalk region and a variable number of 
EGF domains, which are formed by alternative RNA splicing. Three different 
CD97 isoforms can be distinguished, containing three, four or five EGF domains 
in humans. In mouse CD97, the longest isoform contains four EGF domains with 
an unidentified additional sequence of 45 amino acids between the second and 
third EGF domain. Mouse EGF domains 3 and 4 are homologues of human EGF 
domains 4 and 5, respectively. Human CD97 and EMR2 α-subunits are highly 
homologous, especially within the EGF domains, which differ by only six amino 
acids. Figure 4 represents the different isoforms of human (hCD97) and mouse 
CD97 (mCD97).
CD97 was originally described as a marker for immune activation. It has been 
postulated that CD97 is involved in signal transduction via the activation of G-
proteins. G-protein-coupled receptors activate a sequence of events that results 
in the influx of intracellular cyclic AMP and Ca2+. Accordingly, EGF-TM7 receptors 
may induce signal transduction via G-protein independent pathways, as has been 
reported for other TM7 receptors. By activation of G-proteins, other members of 
the TM7 family mediate cellular responses via an enormous diversity of signaling 
molecules with different chemical and functional properties. But, so far, several 
approaches have failed to support the concept that EGF-TM7 family members 
induce signaling via G-proteins. 
CD97 functions and ligands
EGF domains within CD97 contain Ca2+-binding sites and an RGD (Arg-Gly-Asp) 
sequences suggest functions associated with cell adhesion and migration. The 
RDG sequence is located at the COOH-terminal side of EGF5216. RGD sequences 
are attachment sites for a large number of adhesive ECM components and cell 
surface molecules, such as integrins217. In vitro assays have indeed shown that 
CD97 can function as an adhesion molecule, by binding its cellular ligand, CD55218, 
or by binding the ECM component chondroitin sulfate B (CS-B), also known as 
dermatan sulfate219. 
CD55 is also known as decay accelerating factor (DAF) and protects cells from 
complement-mediated damage by accelerating the decay of complement C3/C5 
convertases220. Furthermore, CD55 can function as an entry molecule for certain 
viruses221,222 and can interact with LPS/sCD14 complexes223. CD55 is expressed on 
a wide variety of cells which are in contact with complement, such as lymphocytes, 
erythrocytes, epithelial cells and endothelial cells220. Lymphocytes and erythrocytes 
are able to adhere to CD97-transfected COS cells, and this adherence is blocked 
specifically by Mab CLB-CD97L/1 directed against CD55, and by Mab CLB-
CD97/1 directed against the EGF domain 1 of CD97218. Binding of CD97 to CD55 
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is restricted to the interaction between EGF domains 1 and 2 of CD97 and short 
consensus repeat domains 1, 2 and 3 of CD55203,224-226. Accordingly, all CD97 
isoforms can bind to CD55, but larger CD97 isoforms (e.g. EGF1-5) have a 
significant lower affinity for CD55 than smaller isoforms225. Although the affinity of 
CD97-CD55 interactions is low, high avidity cellular interactions might be caused 
by multiple low affinity interactions, as has also been described for members of the 
immunoglobulin superfamily226,227. Despite the fact that the EGF domains 1, 2 and 5 
of EMR2 and CD97 differ only by three amino acids, EMR2 binds to CD55 with an 
affinity of at least one order of magnitude weaker compared to CD97199,226.
Recently, CS was identified as the second ligand for CD97, binding to human 
EGF domain 4 (or mouse EFG domain 3)219. CS binding is therefore restricted to 
the larger CD97 isoforms (EFG1-5 in human and EGF1-4 in mice). Furthermore, 
CS-B can also bind to EGF domain 4 of human EMR2. CS is a glycosaminoglycan 
(GAG) abundantly expressed in the ECM and on cell membranes and implicated 
in many biological processes, such as cell adhesion, proliferation and tissue 
repair228,229. Indeed, it was demonstrated that like CD97EGF1, also CD97EGF4 
is involved in cell adhesion. In vitro Mab blocking studies against CD97EGF1 
and CD97EGF4 revealed that cell binding was reduced to 37% by interference 
with CD55/CD97 interactions and to 16% by interference with CD97/CS-B 
interactions215. A synergistic effect was demonstrated when both receptor-ligand 
interactions were prevented, resulting in a complete abolishment of cell binding. 
GAG, like CS and heparan sulfate (HS), can also function as a collector of growth 
factors, cytokines, chemokines and protease inhibitors229. Thereby, these proteins 
are locally increased in concentration and can attract and activate other cells230,231. 
Additionally, cellular GAG can function as attachment sites for viruses and bacteria, 
facilitating entry into host cells. Taken together, alternative splicing regulates the 
binding of CD97 to its two defined ligands, CD55 and CS-B.
CD97 in inflammation
CD97 is expressed under different inflammatory conditions, e.g. in chronic 
eczematous dermatitis skin infiltrating T cells expressed high levels of CD97214. 
Previously, an in vivo role for CD97 in adhesion/migration was suggested by the co-
localization of CD97 and CD55-expressing cells in joints of RA patients. Intimal MΦ 
expressed CD97 while fibroblast-like synoviocytes in the intimal lining expressed 
CD55213. In addition, sCD97 was present in synovial fluid from RA patients and 
in pleural fluid containing inflammatory cells or malignant lymphoma cells213,214. 
Furthermore, within the same tumor, scattered tumor cells at the invasion front 
expressed higher levels of CD97 compared to tumor cells in the solid formation of 
colorectal and gastric carcinomas232. In vitro studies indicated that the migration 
and invasion capacity of colorectal tumor cells correlated with the expression level 
of CD97232. Interestingly, inducing CD97 levels, in a tetracycline-dependent system, 
could increase migration and invasiveness of fibrosarcoma cells.
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Recently, the first evidence for a functional role of CD97 was demonstrated 
in neutrophil migration/adhesion in two different in vivo model systems233. First, 
experimental colitis was induced in mice by administration of dextran sodium 
sulfate. Mice were subsequently injected with radioactively labeled neutrophils, 
which were pre-treated with Mab 1B2 anti-mouse CD97(EGF1) or control antibody. 
Homing of adoptively transferred neutrophils was significantly reduced upon 
blocking CD97EGF1. In a mouse model for pneumonia, blocking of CD97EGF1 
or CD97EGF3 reduced neutrophil infiltration. Furthermore, in a murine infectious 
model with Streptococcus pneumoniae, similar Mab treatment caused impaired 
neutrophil recruitment to infectious sites and subsequently reduced survival of 
mice. Collectively, these data led us to the hypothesis that CD97 is involved in the 
immunopathogenesis of MS and EAE.
CD44
Structural characteristics
CD44 is a type I transmembrane glycoprotein which exists in many different 
isoforms and ranges in molecular mass from approximately 85 to 250 kDa. The 
gene is encoded by 20 exons in humans and 21 exons in mice234-236. Unlike in mice, 
exon v1 in humans contains a stop codon and therefore is not expressed. Figure 5 
illustrates which exons encode the extracellular, transmembrane and intracellular 
domains of CD44. The backbone of CD44, present in all CD44 isoforms, is known 
as CD44 standard (CD44s) or hematopoietic CD44 (CD44H). CD44s consists of 
268 amino acids, 248 in the extracellular domain, 23 in the transmembrane domain 
and 3 or 70 in the cytoplasmic tail. Alternative RNA splicing of ten variant exons 
(exons v1-v10) generates a diversity of CD44variant (CD44v) isoform molecules. 
A combination of different variant protein domains, which are present in the 
extracellular domain, can elongate the CD44s backbone by a total of 381 amino 
acids. Further diversification is generated by post-translational modifications, such 
as O- and N-glycosylation, sulfation and attachment of GAG side chains like CS-A, 
CS-B, HS and keratan sulfate. The extracellular domain of CD44 can be subdivided 
into three parts, with different interspecies sequence homology: the amino-terminal 
domain (80-90% homology), the variable domain (64%), and the membrane-
proximal domain (34-45%)236,237. The transmembrane and cytoplasmic domains are 
well conserved, with a sequence homology of 80-90% between different species.
Expression 
Recently Cichy and Puré suggested that CD44 proteins may exist in three phases; 
as a cell surface transmembrane receptor, and as an extracellular molecule in 
body fluids (soluble CD44) and ECM238. CD44s is widely expressed by all mature 
leukocytes and by many non-hematopoietic cells, e.g. keratinocytes, epithelial 
cells, endothelial cells and fibroblasts. Resting cells express CD44s at low levels; 
this expression can be increased by cell activation induced with e.g. T cell receptor- 
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Figure 5. Schematic genetic and molecular structure of CD44.  
The extracellular domain of the CD44 backbone (or CD44 standard) is encoded by exons 1-5 and 
15-16 (). A large number of different CD44variant isoforms can be generated by alternative splicing 
of ten CD44variant exons (v1-v10). CD44v proteins are located in the extracellular domain of the 
CD44 standard molecule (v2-v10). CD44v1 is not transcribed in humans, because it contains a stop 
codon. Posttranslational modifications, by N-glycosylation (), O-glycosylation () and addition of 
glycosaminoglycan side chains (CS: chondroitin sulfate; HS: heparin sulfate) enlarges variation in 
CD44 molecules. CD44v3 contains HS side chains, which are docking sites for fibroblast growth factors 
(FGF) and chemokines (MIP-1β). CD44v6 and CD44v7 contain a binding site for osteopontin (OPN). 
Like v1-v10, exons 19 or 20 exons are alternatively spliced. Usually exon 20 is expressed, coding for 
a 70 amino acid cytoplasmic domain. When exon 19 is expressed, the cytoplasmic domain contains 
3 amino acids. CM: cell membrane. Modified from T.E.I.Taher, PhD thesis: CD44 & Met: the signaling 
perspective, 2002.
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or cytokine stimulation. In contrast to CD44s, resting leukocytes do not express 
CD44v isoforms. CD44v isoform expression is mainly restricted to epithelial cells, 
endothelial cells, activated leukocytes, memory cells and malignant cells239. The 
variation in CD44v isoform composition is likely limited to a hundred different 
isoforms. The expression levels of these isoforms depends on the cell type and its 
activation stage. Previously identified isoforms include CD44v4-7 (also known as 
CD44M or p-Meta1)240,241, CD44v6-7 (p-Meta2), CD44v8-10 (CD44R1 or CD44E on 
epithelial cells)241-243, CD44v10 (CD44R2)242, CD44v3-10, CD44v3,8-10, CD44v6-
10 and CD44v7-10244,245. 
Soluble CD44 molecules, including soluble CD44v isoforms, are likely 
predominantly generated by proteolytic cleavage of the extracellular domain 
of surface-bound CD44246. Membrane-type 1 and 3 metalloproteinases (MT1-
MMP or MMP-14 and MT3-MMP or MMP-16, respectively) are able to cleave or 
shed CD44247. In addition to cleavage, alternative RNA splicing can account for 
direct synthesis of soluble CD44 molecules235. Body fluid levels of soluble CD44 
are elevated during immune activation, inflammation, and tumor growth and 
metastasis248. Under physiological conditions, human and mouse serum contains 
low levels of soluble CD44 (5 and 2 µg/ml, respectively). Levels are increased (3-
10 µg/ml) in tumor bearing mice and in autoimmune prone mice, but decreased in 
immunodeficient mice (0.5 µg/ml). In addition to serum, also lymph fluid, arthritic 
synovial fluid and bronchoalveolar lavage fluid can contain soluble CD44248-250. 
Cleavage of CD44 has been shown to induce cell migration through hyaluronic acid 
(HA) in vitro, after detachment of the extracellular CD44 domain by MT1-MMP247. 
Interestingly, both CD44 and MT1-MMP were expressed at the leading edge of 
cells. Thus, CD44 cleavage may allow cells to detach from the ECM and to move 
to other locations. 
CD44 functions and ligands
CD44 has been shown to play a role in a wide diversity of biologicalprocesses, 
including phagocytosis251,252, signal transduction253, cell activation254, 
costimulation255, adhesion and extravasation256,257, apoptosis258-261, 
embryogenesis262, haematopoiesis263,264, tissue remodelling265 and tumor 
development266. The existence of many different isoforms may explain this wide 
functional variety. The transmembrane domain of CD44 has been suggested to 
mediate costimulatory responses255. CD40 ligation rapidly induces CD44s and 
CD44v7 expression255,259. CD44 can bind diverse ECM components, such as HA267, 
laminin268, collagen I, IV and fibronectin269,270, which is important for adhesion and 
transmigration of cells through the ECM271,272. Furthermore, GAG (heparan sulphate 
and CS), gelatinases273,274 and cytokines (e.g. OPN)275,276 attach to specific CD44 
molecules. In this way, CD44 serves as a docking site, which locally increases the 
concentration of these factors. CD44 can also function as a co-receptor for several 
molecules, such as VLA-4257 and tyrosine kinase receptors (ErbB4 and c-Met)272,277. 
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CD44 molecules are associated in lipid rafts and can induce signal transduction 
and cytoskeletal reorganization253,278,279. The role for CD44 as a co-receptor and 
its function in signal transduction and cytoskeletal reorganization is not described 
in this introduction, but has recently been reviewed by Ponta, Sherman and 
Herrlich272.
 
(Hyaluronic acid). HA is the most extensively studied ligand for CD44. Hyaluronate 
is an essential component of the ECM in all tissues, synthesized by fibroblasts, 
chondrocytes and mesothelial cells. It is composed of disaccharides of glycuronic 
acid and N-acetyl-D-glycosamine and regulates hydration and organization of 
the ECM. Normal ECM contains HA in a high molecular weight form. In contrast, 
at sites of inflammation and tissue injury, HA accumulates and is degraded 
by hyaluronidase, receptor-mediated endocytosis or peroxynitrate, into low 
molecular weight products with diverse inflammatory capacities280,281. Furthermore, 
HA expression is induced on microvascular endothelial cells after stimulation 
with proinflammatory cytokines (TNF-α, IL-1) or LPS281. HA-CD44 ligation can 
upregulate endothelial expression of VCAM-1 and ICAM-1237, molecules which are 
crucially involved in firm adhesion and transmigration. VLA-4, the functional ligand 
for VCAM-1, associates with CD44 and mediates extravasation of T cells into 
inflammatory sites257. The specific binding motif of CD44 for HA is confined to the 
distal N-terminal extracellular region of the CD44s backbone, the Bx7B motif (Figure 
5), suggesting that all CD44 molecules can bind HA282-284. However, in order to bind 
HA, CD44 molecules need to be activated, e.g. by T cell receptor stimulation, LPS, 
cytokines (IL-2, TNF-α) or chemokines (MIP-1β, IL-8)285-287. Interestingly, soluble 
CD44, anti-inflammatory cytokines (IL-14 and IL-10) and hyaluronidase all inhibit 
CD44-mediated HA binding288-291. This binding is dependent on phosphorylation 
of the cytoplasmic domain. Deletion of this domain abrogates HA binding292. The 
complexity of the CD44-HA interaction is further underscored by the fact that 
variations in cell type, CD44v isoform numbers, glycosylation, sulfation and GAG 
attachment also influence the binding affinity for HA285,293-296.
(Chondroitin- and heparin sulfate). Like CD97, also CD44 molecules can bind the 
GAG CS, with similar functional implications as described above (CD97 ligands). 
CS-decorated CD44 molecules can also bind other ECM components, such as 
collagen and fibronectin. In vitro studies have implicated that CS-CD44 interactions 
are involved in leukocyte rolling under physiological flow conditions297. CS is 
expressed by endothelial cells and may serve as an attachment site for circulating 
CD44-expressing cells. CD44 can contain HS chains. Modification of CD44 by CS 
or HS attachment provides additional binding sites for chemokines (e.g. MIP-1β)298, 
MMP-9273 and growth factors (e.g. heparin binding growth factor, basic fibroblast 
growth factor)299. HS GAG attachment is restricted to the variant 3 isoforms of 
CD44 298,299.  
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(Gelatinases). All isoforms of CD44 are associated with MMP-2 (gelatinase A) 
and MMP-9 (gelatinase B). Upon CD44 activation, pro-MMP-2 is secreted and 
converted into the proteolytically active form, through cleavage by MT1-MMP247. It 
was recently suggested that MMP-2 plays a role in downmodulating inflammation, 
by inactivating inflammatory mediators, such as IL-1β300, MCP-3301 and fibroblast 
growth factor receptors302. Moreover, genetic deletion of MMP-2 exacerbated 
antibody-induced arthritis in mice303. In contrast, MMP-9-deficiency reduced 
inflammation and arthritis severity. CD44 contains a docking site for proteolytically 
active MMP-9, which can degrade collagen type IV. MMP-9 and CD44 are 
concentrated at the leading edge of migrating cells, the invadopodia273,304. Thus, 
MMP-9 degradation of collagen IV can facilitate cell movement through the ECM. 
Furthermore, MMP-9 can cleave and activate latent TGF-β, which promotes tumor 
invasion and angiogenesis274.
(Osteopontin). By using distinct domains, OPN can bind αvβ1 integrins and CD44v6 
and CD44v7 containing isoforms276. Binding to CD44v isoforms is likely dependent 
on cooperative binding to β1-integrins276. OPN occurs as an immobilized molecule 
in mineralized ECM compartments and as a soluble molecule in body fluids. Several 
cell types can produce OPN, e.g. activated T cells, MΦ and NK cells. OPN exhibits 
both proinflammatory and anti-inflammatory effects, as reviewed by Denhardt 
et al.265. As a proinflammatory mediator OPN induces chemotaxis of T cells and 
MΦ, induces Th1 polarization, but inhibits Th2 cytokine production. Mice deficient 
for OPN exhibit impaired Th1 responses upon infection with Herpes simplex and 
Listeria monocytogenes305. As an anti-inflammatory mediator, OPN inhibits the 
production of NO. OPN is also involved in bone remodelling and myelin generation 
and degeneration265,306. Furthermore, it has been demonstrated that OPN-CD44 
interactions promote cell survival of mouse bone marrow cells307.    
CD44 in inflammation 
CD44 and its variant isoforms have been implicated to play a crucial role in the 
immunopathogenesis of different inflammatory and autoimmune diseases258,281,308. 
An elevated number of peripheral blood leukocytes expressed CD44v3, v6 and v7 
in patients with chronic IBD, RA and systemic lupus erythematosus compared to 
healthy donors309-311. Also at the site of chronic inflammation, CD44v isoforms are 
expressed by synovial fibroblasts (CD44v3, v6-v10) from arthritis patients and by 
skin-infiltrating leukocytes (CD44v3 and v10) from patients with the skin-associated 
autoimmune diseases vasculitis and bullous pemphigoid312-314.
The functional role of CD44 in chronic inflammatory disease models has been 
demonstrated by administration of anti-panCD44 Mab. Antagonistic anti-panCD44 
Mab binds all CD44 isoforms and can block CD44-HA interactions. Anti-panCD44 
treatment reduced disease severity in experimental models for arthritis315-317, 
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diabetes318, cutaneous disease319 and IL-2 induced vascular leakage syndrome320. 
However, treatment with the same antibody did not affect the development of 
experimental thyroiditis and Th1-mediated colitis321,322. Several studies have 
indicated that CD44v isoforms exert distinct functional activities. Mab anti-CD44v7 
treatment significantly reduced development of TNBS-induced experimental colitis, 
while Mab anti-CD44v6 did not influence the disease burden322. Furthermore, single 
administration of Mab anti-CD44v3, anti-CD44v6, anti-CD44v7 or anti-CD44v10 
reduced Th1-mediated DTH reactions, whereas Mab anti-CD44v6, but not anti-
CD44v7 diminished Th2-mediated allergic contact dermatitis323-325. Mab blocking 
of CD44v10 expression in mouse DTH and alopecia areata reduced the cellular 
infiltration at the site of inflammation325,326.
Although Mab studies have provided much knowledge about the function of 
CD44 molecules, results from these studies should be interpreted with some 
caution. First, it should be noted that Mab treatment efficacy is dependent on the 
quantity of antibody and time point(s) of administration. Second, upon binding to 
CD44, Mab anti-CD44 might also induce effects distinct from blocking CD44-HA 
interactions. Mice deficient for the whole CD44 gene, or specific CD44v exons 
provide an excellent model to study the role of CD44 in inflammation. For example, 
CD44-expressing or deficient hematopoietic cells can be separated from non-
hematopoietic cells, by generating bone marrow chimeras. In addition, adoptive 
transfer systems can be used to determine the effect of genetic deletion of CD44 
on the effector lymphocyte function, e.g. in EAE development. Despite the fact that 
CD44 is widely expressed and is involved in many biological functions, genetic 
deletion of CD44 in mice did not result in major developmental defects327,328. This 
may be due to the fact that other molecules may compensate for the functional 
loss of CD44. These molecules may include other HA-binding receptors, such as 
RHAMN, LYVE or TSG-6281.
Under inflammatory conditions, clear alterations in immune responses were 
observed in CD44 knock-out (CD44-/-) mice compared to wild type mice. Infection of 
CD44-/- mice with Cryptosporidium parvum caused exaggerated granuloma formation 
compared to wild type controls328. In a model for lung injury and inflammation, 
intratracheal injection of bleomycin caused accumulation of low molecular weight 
HA fragments and excess numbers of apoptotic neutrophils, resulting in persistent 
inflammation and even death329. These results were in contrast to those found in 
autoimmune disease models for RA. CD44-/- mice showed a strong reduction in 
infiltration and disease severity with regard to experimental arthritis272. Also in a 
chronic enterocolitis model (in IL-10-/- mice), combined deletion of the CD44v6+v7 
exons abrogated disease development259. Moreover, the single deletion of exon v7 
also substantially reduced TNBS-induced colitis. Reduced disease development 
was associated with decreased levels of IL-12 and increased numbers of apoptotic 
cells at the inflammatory site in the gut.
Previous studies indicate that CD44s is involved in the immunopathogenesis 
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of MS and EAE. CD44s was significantly higher expressed by peripheral blood 
lymphocytes from MS patients compared to control subjects330. Additionally, CD44s 
was abundantly expressed in inflammatory brain lesions of MS patients331 and 
EAE-affected mice332,333. In vivo administration of Mab anti-panCD44 resulted in 
a reduced EAE development by impairing the recruitment of autoantigen-specific 
T cells into the CNS334,335. Not much is known about the role of CD44v isoforms in 
MS and EAE development. Previously, we have shown that inflammatory cells in 
CNS lesions of EAE mice expressed the CD44v10 isoform, but not CD44v6. EAE, 
induced by PLP139-151, could be reduced by early treatment of SJL/J mice with a 
mixture of antibodies against CD44v6, v7 and v10 isoforms336. The mechanism 
underlying this blockade is unknown. We aimed to dissect the role of CD44v 
isoforms in order to improve our understanding of the pathogenesis of MS and to 
open new possibilities for immunotherapy. In line with the hypothesis that specific 
CD44v are involved in the pathogenesis of MS and EAE, we here determined 
whether CD44v isoforms are expressed in post-mortem MS brain lesions (chapter 
5). Furthermore, we specifically assessed the functional role of CD44v7 and 
CD44v10 in EAE development, by using mice with single deletions for these 
specific CD44v isoforms. 
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Aims of the thesis
The general aim of this thesis is to determine whether PG, CD97 and selected 
CD44v isoforms are functionally involved in MS and EAE development, and to 
elucidate the underlying cellular mechanisms. In the studies described in this 
thesis, we have used a combined approach of patient material and animal models, 
i.e. we analyzed post-mortem MS and/or non-human primate EAE brain tissue in 
order to determine PG presence and expression of CD97/CD44variant isoforms. 
Futhermore, we have assessed the functional contribution of PG, CD97 and 
CD44v7/v10 by using different mouse EAE models, including genetic knock-outs. 
Several studies have previously provided evidence that bacterial PG contributes 
to the immunopathogenesis of chronic inflammatory diseases. This concept was 
underscored by high numbers of immunocompetent PG-containing APC, present at 
sites of chronic inflammation in patients with MS105, RA104,195, atherosclerosis197 and 
CD196. PG might stimulate processes that contribute to inflammation in autoimmune 
diseases, in the periphery and/or at inflammatory sites, enhance APC function by 
inducing expression of MHC-II and costimulatory molecules, and by production 
of proinflammatory cytokines. The most important PG-degrading enzymes in 
mammals are lysozyme and the amidase NAMLAA. In joint action, lysozyme and 
NAMLAA clear PG intracellularly and abrogate its proinflammatory effects. 
Although PG is present in MS post-mortem brain, little is known about 
the potential functional role of PG, NAMLAA and lysozyme in MS and EAE 
development. Therefore, we first assessed whether elevated numbers of PG-
containing cells are also present in EAE-affected brain tissue compared to control 
brain tissue in two different non-human primate species. If so, this would provide 
new animal models to address PG functionality (chapter 2). Next, we investigated 
whether the number, location and cellular subtype of PG, NAMLAA, and lysozyme-
containing cells in EAE-affected brain and spleen tissue differ between monkeys 
with an acute disease course (rhesus monkey) and monkeys with a chronic disease 
course (marmoset). Additionally, we examined whether NAMLAA and lysozyme are 
expressed in MS and control brain tissue to address whether persistence of PG 
in tissue is related to the differential expression of the major degrading enzymes. 
To obtain functional insight into the role of PG in marmoset and rhesus monkey 
EAE, we assessed whether leukocytes from marmoset and rhesus monkeys 
are responsive to PG stimulation in vitro. In chapter 3, we investigated the 
hypothesis that PG stimulates autoimmune inflammatory responses in MS using 
EAE. In C57BL/6 mice, we have substituted M. tuberculosis by S. aureus PG as 
a single immunostimulatory component in adjuvant. In order to determine whether 
the structure of PG is important for its proinflammatory function, we have used 
both soluble and insoluble PG. We examined which cell type(s) may transport 
PG into secondary lymphoid organs during EAE development. To determine by 
which mechanisms PG may exert its effect in the development of EAE, we have 
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explored whether PG contributes to antigen uptake, expression of cytokines and 
costimulatory molecules and CD4+ T cell polarization in vitro.   
Upon activation of leukocytes in secondary lymphoid organs as well as 
inflammatory sites, subsequent events depend on the expression of cell surface 
molecules for e.g. costimulation, migration, adhesion/transmigration and apoptosis. 
Both cell-cell and cell-matrix interactions are crucial in the development of local 
inflammation, as occurring in the CNS of MS patients. CD97 and CD44v isoforms 
are involved in cell-cell and cell-matrix interactions, and contribute to inflammatory 
processes. Little is known about CD97 and CD44v isoforms in relation to MS 
and EAE development, despite abundant in vitro and in vivo evidence that these 
molecules codetermine the development of experimental arthritis and colitis. 
Therefore, we assessed whether CD97 and selected CD44v isoforms are involved 
in the immunopathogenesis of MS and EAE. 
In chapter 4 we determined whether CD97 and its cellular ligand, CD55, are 
expressed in MS brain lesions and whether this expression is related to the lesion 
stage. As sCD97 is secreted under inflammatory conditions, we assessed whether 
sCD97 is present in serum and cerebrospinal fluid of MS patients. We compared 
sCD97 serum levels in MS with other inflammatory and non-inflammatory 
neurological diseases and healthy controls. To further test the hypothesis that 
CD97-CD55 interactions contribute to the immunopathogenesis of MS, we also 
studied whether early treatment with CD97 Mab against EGF domain 1 affects EAE 
in SJL/J mice.
Whether CD44v isoforms are involved in the immunopathogenesis of MS and 
mouse EAE is studied in chapter 5. Since CD44v isoforms are upregulated under 
chronic inflammatory conditions, we explored which of the CD44v isoforms v3 to 
v10 are expressed in MS brain lesions, and whether this expression is related to 
the lesion stage. Moreover, we determined the kinetics of CD44v10 expression 
on different cell subsets in murine CNS tissue during EAE development. Previous 
mouse studies have indicated that CD44v7 and CD44v10 contribute to the 
development of Th1-mediated colitis and DTH responses. By using mice with 
a single genetic deletion for CD44v7 or CD44v10, we analyzed whether these 
isoforms contribute to the development of EAE, induced by active immunization 
or adoptive transfer. The EAE course of CD44v7- or CD44v10-deleted mice was 
reduced compared to wild type mice. To explore which mechanisms account for the 
reduced EAE development in CD44v7- and CD44v10-deleted mice, we analyzed 
the CNS tissue of these mice for infiltrates, and assessed the autoantigen-specific 
T cell proliferation and cytokine production.    
In chapter 6 we integrate the data obtained in the previous chapters and 
discuss them in the context of our hypothesis that PG, CD97 and CD44v isovorms 
contribute to the immunopathogenesis of MS. Furthermore, based upon the data 
presented, some lines of research to futher delineate the role of PG, CD97 and 
CD44v isoforms in MS are suggested.
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Abstract 
The clinical expression of an autoimmune disease depends on the activation of 
resident antigen presenting cells (APC) in the target organ(s), being in this study 
brain and spinal cord. Most evidence comes from rodent models, and it is unclear 
whether this principle holds in primates (including humans) and which potential 
APC stimuli reach the brain. We previously demonstrated that APC containing 
peptidoglycan (PG) are present in post-mortem multiple sclerosis (MS) brain. PG 
is a major cell wall component of Gram-positive bacteria exerting proinflammatory 
signals via TLR2 and Nod1/2 ligation. In the brain, PG may thus activate both 
infiltrating and resident APC. 
To assess how PG is brought into the brain and to investigate its functional 
relevance in demyelination, we systematically compared MS to non-human 
primates, which are genetically and immunologically closely related to humans and 
are therefore valuable models to analyze the regulation of chronic inflammation 
in MS. Localization of APC subsets containing PG, as well as their expression of 
enzymes degrading PG (lysozyme and NAMLAA) were determined in the two main 
primate EAE models for MS, with acute (rhesus monkey) versus chronic disease 
(marmoset). 
Distinct phagocytic subsets in MS and EAE brain carried PG, including 
granulocytes, macrophages and dendritic cells. The number of PG-containing 
cells in brain tissue during both acute and chronic disease was significantly higher 
compared to control animals, and acute EAE was accompanied by higher numbers 
of PG-containing cells in brain compared with chronic EAE. PG-degrading enzymes 
were scarcely expressed in monkey brain, spleen and in MS brain, favouring 
persistence of intracellular PG in the periphery as well as the CNS. Peripheral blood 
leukocytes from all three primate species produced IL-12p70 upon stimulation with 
PG purified from Staphylococcus aureus. 
The presence of a TLR/Nod ligand in the inflamed brain has major implications, 
since TLR are widely expressed in the CNS and their ligation potentially promotes 
inflammation and progression of demyelinating disease.
Introduction
The normal repertoire of humans and non-human primates contains significant 
numbers of potentially encephalitogenic T cells1-3. Under homeostatic conditions 
these cells are kept dormant by control mechanisms, involving regulatory Tr1 
cells. Whether autoreactive Th1 cells or regulatory Tr1 cells are induced critically 
depends on the maturation state of the antigen presenting dendritic cells (DC) in 
peripheral lymphoid organs4-6. The development of autoimmune encephalomyelitis 
critically depends on additional activation signals to CNS infiltrating autoreactive 
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T cells from resident antigen presenting cells (APC). Such additional signals are 
provided by CpG-TLR9 interaction10. Different from mice, neither the myeloid DC in 
the peripheral compartment nor the resident APC (microglia) of humans7 or rhesus 
monkeys (Bajramovic, unpublished) express TLR9. Hence, data obtained in mice 
on the disruption of tolerance by stimulation with CpG oligonucleotides8-10 cannot 
be easily extrapolated to primates (including humans). Hence we have investigated 
alternative TLR ligands in the primate CNS.
Bacterial peptidoglycan (PG) is a major cell wall component of Gram-positive 
bacteria and we have shown that PG has strong proinflammatory capacities in 
animal models of multiple sclerosis (MS)11. PG stimulates the innate immune 
system by binding to the Toll-like receptor (TLR)2/6, although this concept has 
recently been challenged12. Recently identified intracellular PG receptors are 
the Nod1 (Card4) and Nod2 (Card15) signaling receptors13-15. PG can induce 
signal transduction via TLR2 and Nod1/2 receptors within cells and via TLR2/6 
in association with CD14 on the cell surface. Activation of these receptors results 
in the induction of cell maturation and the production of several chemokines and 
proinflammatory cytokines such as TNF-α, IL-1 and IL-616-18. 
PG is a complex structure formed by three-dimensional cross-linked layers of 
glycan backbones with peptide bridges19. The glycan strands of PG in all bacterial 
species are composed of two alternating sugar residues, N-acetyl glucosamine 
(GlcNAc) and N-acetyl muramic acid (MurNAc)(Figure 1). Stem peptides cross-
link these glycan chains and differ in composition between bacteria strains. Stem 
peptides can be attached directly to each other or indirectly via interpeptide bridges 
(Figure 1). Between different bacteria, interpeptide bridges can vary in length and 
amino acid composition20,21. PG is digested by enzymes with different substrate 
specificities of which lysozyme and N-acetylmuramyl L-alanine amidase (NAMLAA) 
are the best characterized. Lysozyme is present in granules of phagocytes22-24 and 
partially degrades PG by hydrolyzing the bond between GlcNAc and MurNAc 
resulting in solubilized PG (Figure 1). We have previously identified and functionally 
characterized NAMLAA25-28, which was recently shown to be identical to the PG 
recognition protein long form (PGRP-L)29,30(Zhang et al., submitted). NAMLAA 
is expressed by neutrophilic granulocytes, but not by monocytes and resting 
macrophages (MΦ) under normal conditions. PG is cleaved by NAMLAA/PGRP-L 
between the MurNAc residue and the first L-alanine of the stem peptide (Figure 1). 
Due to its complex structure, PG is highly resistant to degradation under 
physiological conditions. Recently, it was shown that PG-induced responses were 
comparable in MΦ from NAMLAA/PGRP-L-deficient and wild type mice31. Most 
likely, several PG-degrading enzymes are necessary for complete PG-degradation. 
In vitro studies clearly show that the combined degradation of PG by lysozyme 
and NAMLAA reduces the proinflammatory potential of PG27. Because MΦ and DC 
contain lysozyme but lack NAMLAA, incomplete PG degradation may result in the 
persistence of intracellular bio-active PG. We have previously demonstrated that 
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PG is indeed present in MΦ and DC by immunohistochemical staining of human 
spleen sections with a monoclonal antibody (Mab) raised against PG isolated from 
the human faecal flora32. PG can also be detected in peripheral blood leukocytes, 
urine, liver and lymph nodes under normal conditions32-39. Furthermore, we have 
shown that PG derived from sterile human spleen is biologically active, since 
spleen-derived PG induced proinflammatory cytokine production by peripheral 
blood leukocytes39.
We have proposed that PG may act as a costimulating factor for the development 
of autoimmune disease in the absence of infection or bacterial replication. APC 
redistribute PG from the mucosa40-42 to secondary lymphoid organs and to sites of 
chronic inflammation and may stimulate autoimmune processes locally. We have 
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Figure 1. Representative structure of bacterial PG and location of NAMLAA/PGRP-L and 
lysozyme cleavage sites.
PG is composed of a long glycan backbone which contains two alternating sugar residues, N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc). Cross-linkage of the glycan 
backbones is achieved via stem peptide- and interpeptide-bridges, which differ in composition between 
bacteria strains. The stem peptides in S. aureus are composed of L-alanine-D-isoglutamine-L-lysine-D-
alanine-D-alanine87. The interpeptide bridges in S. aureus PG are formed by pentaglycines. NAMLAA 
hydrolyzes PG by cleaving the bond between the lactic acid group of MurNAc and the first amino acid of 
the peptide bridge (always L-alanine). In contrast, lysozyme hydrolyzes the bond between MurNAc and 
GlcNAc, the alternating residues forming the glycan backbone of all PG types. [I] interpeptide bridge.
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previously described PG-containing APC in sites of chronic inflammation in MS brain 
tissue43, rheumatoid arthritis synovial tissue32,44 and bowel wall tissue of patients with 
Crohn’s disease45. These cells were fully immunocompetent as determined by the 
expression of costimulatory molecules, HLA-II and proinflammatory cytokines43,44. In 
rodent animal models, PG has been shown to facilitate development of autoimmune 
disease. Injection of PG derived from different bacterial strains can induce chronic 
arthritis and colitis in susceptible rodents46,47. Moreover, we have demonstrated that 
PG induces DC maturation and contributes to the development of mouse experimental 
autoimmune encephalomyelitis (EAE), an animal model for MS11.
Mouse EAE models serve as useful tools to assess the functional relevance for 
PG in MS development. However, non-human primates may better represent the 
human situation, since differences in TLR2 gene expression and regulation occur 
between mice and humans48. It is likely that this species variation will affect the 
functional outcome of TLR2-induced responses. In this study, we used EAE in rhesus 
and marmoset monkeys to further investigate the relevance of PG in autoimmune 
encephalomyelitis. These non-human primates are outbred and are genetically 
and immunologically closely related to humans49. Upon immunization with myelin 
components non-human primates develop EAE with a similar pathology and disease 
course as MS patients. Two well described monkey EAE models are the rhesus 
monkey (Macaca mulatta) and the common marmoset (Callithrix jacchus) monkey50,51. 
EAE-affected rhesus monkeys develop large lesions in the brain, which contain 
abundant numbers of neutrophils52. This severe inflammatory necrosis is associated 
with an acute disease course. In contrast, marmosets develop a relapsing-remitting 
or primary-progressive disease course with perivascular lesions and demyelinated 
areas containing mainly MΦ, T and B cells in the central nervous system (CNS). The 
fundamentally distinct clinical and pathological presentation of EAE might represent 
different forms of human encephalomyelitis. Rhesus monkey EAE more closely 
resembles acute disseminated encephalomyelitis (ADEM), while marmoset EAE 
resembles chronic MS (‘t Hart et al., 2005, submitted). 
To address whether the TLR/Nod ligand PG is carried into primate brain, in this 
study we assessed whether the presence, location and numbers of PG-containing 
cells in brain and spleen tissue from rhesus monkeys with acute EAE differs from 
marmoset monkeys with a chronic disease course. In both models, we determined 
whether the number of PG-containing cells in the brain was related to the development 
of EAE. Additionally, we identified the cell types containing PG in both human (primate) 
and non-human primate brain. Since NAMLAA and lysozyme are enzymes involved in 
PG-clearance, we assessed whether these PG-degrading enzymes were differentially 
expressed in MS and non-demented control brain tissues and in EAE-affected versus 
non-EAE-affected monkey brain and spleen tissue. To obtain functional insight into 
the role of PG in rhesus monkey and marmoset EAE, we assessed in vitro whether 
leukocytes from rhesus monkey and marmoset monkeys are responsive to stimulation 
with PG from S. aureus, known to precipitate EAE in mice.
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Material and Methods
Non-human primate tissues
Spleen and brain tissue were obtained from marmosets and rhesus monkeys 
raised at the Biomedical Primate Research Centre (Rijswijk, The Netherlands), 
as described previously52,54. Brain tissues used for this study had been 
neuropathologically well characterized. All brain and spleen tissues were obtained 
from previous studies, hence no animals were sacrificed solely for the purpose of 
the current study. All experimental procedures with live animals had been approved 
by the Institutional Animal Care and Use Comittee. EAE was induced in marmoset 
monkeys by immunization with 20 mg whole human myelin or 0.1 mg recombinant 
human MOG emulsified in complete Freund’s adjuvant (CFA). As adjuvant controls, 
two randomly selected monkeys were immunized with 1 mg ovalbumine (Sigma 
Chemical Co, St. Louis, MO) in CFA, a protocol used for induction of arthritis. EAE 
was induced in rhesus monkeys by immunization with 0.32 mg recombinant human 
myelin oligodendrocyte glycoprotein (rhMOG1-125), or 0.1 mg MOG34-56 in CFA
52. As 
adjuvant controls, rhesus monkeys (n=2 monkeys) were immunized with 3 to 5 
mg bovine type II collagen in CFA55. Animals immunized with myelin antigen were 
examined daily for clinical symptoms of EAE. According to these examinations, all 
rhesus monkeys immunized with rhMOG1-125 (n=7) developed a hyperacute disease 
course, with a 24-48 h time period from the onset to full-blown disease52. Rhesus 
monkeys which were immunized with MOG34-56 in CFA developed a heterogeneous 
disease course50. The four monkeys which were included in this study were 
asymptomatic at day 28 after immunization. These monkeys were challenged with 
MOG34-56 in incomplete Freund’s adjuvant (IFA)(Table 1, animal 8 and 9) or with 
an irrelevant peptide MOG4-26 in IFA (Table 1, animal 6 and 7). After one or two 
homologous challenges both monkeys developed acute clinical signs of EAE within 
7 days after challenge and were sacrificed. The two rhesus monkeys which were 
challenged with irrelevant peptide remained asymptomatic.
From the thirty-seven marmoset monkeys which were immunized with myelin 
antigens twenty-eight developed EAE. In the other nine marmoset monkeys EAE 
development had been successfully blocked by experimental treatment with new 
immunotherapeutic reagents. Details regarding immunogens, day of sacrifice and 
development of EAE for both marmoset and rhesus monkeys are shown in Table 1 
and 2, respectively.
Brain tissue samples of MS patients and non-demented control subjects
Human autopsy brain tissue was provided by the Netherlands Brain Bank 
(Coordinator Dr. R. Ravid, Amsterdam). Information regarding MS patients and 
non-demented control subjects is shown in Table 3.
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Staging of MS brain lesions
As described previously56, brain lesions were characterized according to an 
internationally accepted staging system based on inflammation and demyelination 
criteria57,58, using three different markers, acid phosphatase (for MΦ, mircroglia), 
HLA-DR/DQ/DP (for APC) and neutral lipids (for ingested myelin). Pre-active lesions 
are caracterized by HLA-II-expressing clusters of activated microglia cells and few 
perivascular inflammatory cells. Pre-active lesion do not contain phagocytic cells 
containing myelin breakdown products or areas of demyelination. Active lesions 
are characterized by demyelinated areas. Phagocytic cells in these areas contain 
myelin breakdown products, which can be visualized by oil red O, a histochemical 
staining for neutral lipids. In these lesions strong expression of HLA-II is present on 
perivascular and parenchymal MΦ.
Immunohistochemistry
The immunohistochemical techniques used in this study have previously been 
described in detail59,60 with slight modifications. Sections from marmoset and rhesus 
monkey tissues were fixed for 10 min at room temperature in 4% paraformaldehyde 
in PBS with 0.02% (v/v) H2O2 in PBS to eliminate endogenous peroxidase activity. 
Human brain tissue sections were fixed at room temperature in fresh acetone 
containing 0.02% (v/v) H2O2. Remaining endogenous peroxidase activity was 
Table 1. Rhesus monkey-derived brain and spleen tissues.
animal immunogen clinical EAE day of sacrifice EAE score
1 collagen II - 100 0
2 collagen II - 100 0
3* collagen II - 71 0
4*# collagen II - 41 0
5*# collagen II - 31 0
6 phMOG4-26,1x boost phMOG34-56 - 138 0
7 phMOG4-26,1x boost phMOG34-56 - 138 0
8 phMOG34-56, 2x boost phMOG34-56 + 112 5
9§ phMOG34-56, 1x boost phMOG34-56 + 35 5
10*# rhMOG1–125 + 24 4
11* rhMOG1–125 + 17 4
12§ rhMOG1–125 + 18 4
13 rhMOG1–125 + 39 3
14 rhMOG1–125 + 32 4
15 rhMOG1–125 + 35 2.5
16*# rhMOG1–125 + 20 4
(rhMOG1–125 ) recombinant peptide, representing the complete extracellular N-terminal domain of human 
MOG, (phMOG34-56) synthetic peptide, representing an extracellular N-terminal domain of human MOG. 
(*) spleen tissues which were used for staining for PG and NAMLAA, (#) spleen tissues which were used 
for double staining, (§) brain tissues which were used for double staining.
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revealed by staining with 4-chloro-1-naphtol-phosphate, which results in a dark blue 
precipitate (Sigma). Slides were incubated with predetermined optimal dilutions of 
primary antibodies, overnight at 4°C in humidified atmosphere. 
PG-containing cells were demonstrated by staining with Mab 2E9-biotin. The 
specificity of the murine Mab 2E9, raised against normal human faeces PG-
polysaccharides, has been well documented previously43,61. Mab 2E9 recognizes 
PG-containing cell wall fragments, such as lysozyme-solubilized cell walls of 
different Gram-positive bacteria43,61. NAMLAA-containing cells were detected by 
staining with biotinylated Mab mouse anti-human NAMLAA-biotin IgG1 (AAA4) as 
described above28. Mab AAA4, raised against human serum amidase, specifically 
recognizes NAMLAA28(Zhang et al., 2005, submitted). Lysozyme-containing cells 
were detected by staining with polyclonal antibody rabbit anti-human lysozyme 
(Ab-1, Neomarkers, Fremont, CA), followed by biotinylated donkey anti-rabbit 
(Amersham Biosciences, Buckinghamshire, England). Incubations with secondary 
and tertiary reagents were done for 1 h at room temperature. Specific staining for 
PG, NAMLAA and lysozyme was revealed by peroxidase linked avidin (DAKO, 
Glostrup, Denmark) and 3-amino-9-ethylcarbazole (Sigma) as chromogen, 
resulting in a bright red staining.
Nuclei were counter-stained by hematoxylin. As negative controls the primary 
antibody was omitted and isotype matched control antibodies of irrelevant specificity 
were used. The controls did not display binding activity in tissue of monkeys and MS 
patients. Reactive human tonsil sections were included in each staining procedure 
as positive control tissue. Sections were evaluated by two independent observers.
Table 2. Marmoset-derived brain and spleen tissues.
animal immunogen clinical EAE day of sacrifice mean EAE score (range)
1 OVA - 49 0
2*# OVA - 49 0
3* none - n.a. 0
4*# none - n.a. 0
5-8 MOG - 53-155 0
9-20 MOG + 44-112 2.3 ± 1 (0-3)
9#§ MOG + 49 1.8
10#§ MOG + 49 1.9
12* MOG + 67 2.5
19* MOG + 67 2.5
20* MOG + 44 0
21-25 myelin - 86 0
26-41 myelin + 41-93 2.4 ± 1.2 (0-3.5)
36#§ myelin + 77 0
(*) spleen tissues which were used for staining for PG and NAMLAA, (#) spleen tissues which were used 
for double staining, (§) brain tissues which were used for double staining, (n.a.) not applicable.
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Immunofluorescent double labeling 
A double-staining procedure was used to determine which cell types contain PG and 
NAMLAA. In brief, marmoset spleen tissues were fixed with 4% paraformaldehyde 
and all other tissues were fixed with acetone, as described above. To reduce 
autofluorescence, slides were incubated with 0.1% sodium borohydride (Sigma) 
in MQ and 0.3M glycine (Sigma) in PBS. PG-containing cells were detected 
with Mab 2E9-FITC and NAMLAA-containing cells with Mab AAA4-FITC. Mabs 
CD11b (MΦ, microglia, DC, granulocytes)(Leu-15, BD Biosciences, San Jose, 
CA) and CD83 (DC)(HB15a, Immunotech, Marseille, France) were conjugated 
to AF594 (Molecular Probes Europe, Leiden, The Netherlands) according to the 
manufacturer’s instructions. Neutrophils were detected by staining with Mab mouse 
anti-neutrophil elastase (NP57, DAKO) followed by anti-mouse Ig-TRITC (DAKO). 
Since the available antibodies against human MΦ did not cross-react with rhesus 
monkey and marmoset MΦ, we were unable to determine the percentage of MΦ 
within the population of PG-containing cells. A histochemical staining for lipids was 
performed with 0.3% Sudan black B (BDH Laboratory Supplies, Poole, England) in 
70% ethanol, thereby reducing autofluoresence.
Table 3. Clinical and neuropathological data of MS patients and controls. 
Case Sex Age
(yrs)
pm time
(h: min)
Disease 
duration (yrs)
Progressive 
MS
Number of lesions (n)
Lesion stage
00/024 F 52 8:25 12 yes (1) pre-active 
(1) active demyelinating
00/82 M 34 <42:00 unknown unknown (4) pre-active
00/120 F 69 13:20 23 yes (1) pre-active
01/018 F 48 08:10 9 yes (2) pre-active
(1) active demyelinating
(1) chronic inactive
97/123 M 46 03:45 23 yes (1) pre-active
(3) active demyelinating
97/160* F 40 07:00 11 yes (2) pre-active
(2) active demyelinating
98/176 M 83 07:05 52 yes (1) pre-active
99/051 F 45 10:55 14 yes (1) pre-active
(1) active demyelinating
(1) chronic active 
99/066 M 69 16:45 43 yes (3) pre-active
96/013 F 68 10:30 n.a. n.a. non-demented control
no lesions
96/078 F 87 08:00 n.a. n.a. non-demented control
no lesions
From this patient two different tissue samples were stained, (M) male, (F) female, (pm) post-mortem, 
(n.a.) not applicable.
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Quantitation of PG-containing cells in brain 
The number of PG-containing cells in the parenchyma and infiltrates of brain tissue 
derived from marmoset and rhesus monkeys were quantitated by two independent 
observers. The surface area of the section was determined using a VIDAS-
RT image analysis system (Kontron Elektronik GmbH/Carl Zeiss, Weesp, The 
Netherlands). Area measurements were performed using a 1.6-fold magnification 
objective. The frequency of PG-containing cells in the brain parenchyma was 
calculated by dividing the number of PG-containing cells in the tissue section by 
the surface area of the section.
Peptidoglycan
Soluble PG (sPG) from S. aureus was prepared by gel-permeation chromatography62. 
The content of LPS in sPG was assessed to be < 15 pg/mg (acceptable background 
values), using a TLR4/MD2 transfected HEK293 cell line, with IL-8 production as a 
read-out. sPG induced a dose-dependent production of IL-8 by TLR2 transfected 
HEK293 cells (data not shown). There was no LTA contamination as revealed 
by HPLC analysis (data not shown). At present, purification and identification of 
biologically active components in sPG are being performed and may reveal other 
TLR2 agonists, as described by Travassos et al.12.
Stimulation of peripheral blood mononuclear cells (PBMC) and IL-12p70 
ELISA
Blood samples from rhesus monkeys and marmoset monkeys were collected as 
described previously, using lithium-heparin pre-coated tubes63. PBMC were isolated 
by Ficoll (LSM Lymphocyte Separation Medium, ICN Biomedicals, Aurora, OH) 
and cells were cultured in 25mM HEPES-buffered RPMI 1640 (Life Technologies, 
Glasgow, UK) supplemented with 10% FCS (ICN Biomedicals), penicillin and 
streptomycin (Invitrogen, Paisley, UK), Glutamax (Invitrogen), β-mercaptoethanol 
(Invitrogen). sPG was sonicated for 20 min and immediately added into the culture. 
Cells were seeded (4x105/well in 0.5 ml) with or without sPG (range 1 – 5 - 10 µg/ml) 
in 48-well plates (BD-Falcon) for 21 h. Supernatants were harvested and diluted 1:
1 in PBS/1%BSA (Sigma) and stored at –20°C for further analysis. According to the 
manufacturer’s instructions, concentration of IL-12p70 was determined by using 
monkey-specific IL-12 ELISA kits (U-Cytech, Utrecht, The Netherlands).
Statistical evaluation
Statistical evaluation was performed using SPSS 11 software. The Mann-Whitney U 
test was used to analyze differences. A value of p <0.05 was considered statistically 
significant.
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Results
Presence of TLR/Nod ligand in CNS correlates with infiltration
Brain and spleen tissues of rhesus monkeys and marmoset monkeys were stained 
for PG, NAMLAA- and lysozyme-containing cells. Animals were divided into 
different groups, based on immunization procedure and development of clinical 
EAE (Table 1 and 2). In agreement with previous findings50,52, large infiltrates 
were found in rhesus monkey EAE brain tissue compared to smaller infiltrates in 
marmoset EAE brain tissue (Figure 2A-C). As expected, a positive correlation was 
found (r=0.67 rhesus monkey and r=0.43 marmoset) between the size of infiltrates 
and the maximum number of PG-containing cells in infiltrates. The following two 
sections describe the assessment of PG, NAMLAA and lysozyme in 1) rhesus 
monkey and 2) marmoset brain tissue.
1) Elevated numbers of cells containing PG and NAMLAA in the CNS of rhesus 
 monkeys with EAE 
Infiltrates were absent in brain tissue of rhesus monkeys (n=2) immunized with 
collagen in CFA, whereas in one of two rhesus monkeys immunized with myelin 
antigens, but without EAE, one infiltrate (medium/large size) was present in the 
brain with only a few PG-containing cells (Table 4). In contrast, animals with 
clinical EAE had many PG- and NAMLAA-containing infiltrates, with high numbers 
of positive cells in the infiltrates (Figure 2C, 3A, 3B and Table 4). The maximum 
number of PG-containing cells in these rhesus monkey brain infiltrates was much 
higher compared to the maximum number found in infiltrates of marmoset EAE 
brain tissue, which can be explained by the differences in size of the infiltrates 
(Figure 2D, Table 4). A significantly higher number (p<0.05) of PG-containing cells 
was found in the parenchyma of EAE brain tissue compared to non-EAE brain 
tissue (Figure 2E). In contrast to NAMLAA-expression in the infiltrates, only few 
NAMLAA-containing cells were present in the parenchyma of rhesus monkey brain 
tissues (data not shown). 
Taken together, brain tissue of rhesus monkeys with EAE contains large 
infiltrates with abundant numbers of PG-containing cells and high numbers of 
NAMLAA-expressing cells. The number of NAMLAA-expressing cells is consistent 
with the abundant number of neutrophils present in these lesions. In contrast, only 
occasionally lysozyme-expressing cells were present near blood vessels (data not 
shown).
2) Elevated numbers of cells containing PG in the CNS of marmoset monkeys 
with EAE
One of two marmosets immunized with ovalbumin in CFA had two small infiltrates 
in the brain, which did not contain PG. In seven of nine marmosets immunized with 
myelin antigens but without EAE, brain infiltrates (of medium size, number 2.9 ± 2 
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Figure 2. PG-containing cells are present in rhesus and marmoset brain. 
Left column: rhesus brain tissue and right column marmoset brain tissue. Many cells in infiltrates of (A) 
rhesus EAE brain tissue (animal 9) and a modest cell number in infiltrates of marmoset EAE brain tissue 
(animal 10) contain PG (B, D). Significant higher numbers of cells in infiltrates of marmoset EAE brain 
tissue (D) contain PG when compared to control brain tissue. Many PG-containing infiltrates are present 
in rhesus EAE brain tissue (C). Significantly elevated numbers of PG-containing cells are present in the 
parenchyma of rhesus (E), but not in marmoset EAE brain tissue (F), compared to control brain tissue. 
Bar = 100 µm. (See Appendix page 221 for a full-color representation of this figure.)
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per section) were present with a few PG-containing cells (1 ± 0.8 per infiltrate). In 
twenty-five out of twenty-seven marmosets with EAE, brain infiltrates (3.3 ± 2.6 per 
section) were present with a modest number of PG-containing cells (10.5 ± 12.5 per 
infiltrate). The number of PG-containing cells in infiltrates of marmoset monkeys with 
EAE was significantly higher (p<0.05) than in animals without EAE (Figure 2B, D). In 
all marmoset groups a similar frequency of PG-containing cells (13.7 ± 17.5 per 100 
mm2) was present in the brain parenchyma (Figure 2F). Few cells within perivascular 
infiltrates expressed NAMLAA in EAE and non-EAE marmoset tissues (Figure 3F). 
No NAMLAA-containing cells were detected in the parenchyma of the brain. In brain 
and spleen tissue of marmoset monkeys we could not detect lysozyme-containing 
cells, while positive cells were found in human tonsil tissue. These data indicate 
that the antibody we used against human lysozyme is most likely not cross-reactive 
with marmoset lysozyme. In summary, these data show that PG-containing cells are 
present in a significantly higher number in marmoset brain infiltrates of EAE monkeys 
compared to non-EAE monkeys, whereas NAMLAA is only scarcely expressed.
Various phagocytic subsets contain PG and NAMLAA in monkey brain 
tissue
PG is present within MΦ/microglia, DC43 and granulocytes in MS brain tissue. The 
cell types containing PG- and NAMLAA in marmoset and rhesus monkey EAE brain 
tissue were identified by double staining for CD11b (MΦ, microglia, DC, granulocytes), 
Table 4. High numbers of PG-containing cells in rhesus EAE brain tissue.
PG-infiltrates NAMLAA-infiltrates
animal immunogen EAE infiltrate size /total infiltrates PG-cells /total infiltrates NAMLAA-cells
1 collagen II - - 0/0 0 0/0 0
2 collagen II - - 0/0 0 0/0 0
6 *phMOG34-56 - - 0/0 0 0/0 0
7 *phMOG34-56 - ++/+++ 1/1 2 0/0 0
10 rhMOG1–125 + + 1/1 1 0/0 0
8 #phMOG34-56 + ++ 6/13 27 1/13 5
11 rhMOG1–125 + ++/+++ 2/3 50 0/3 0
12 rhMOG1–125 + ++ 15/22 54 12/22 13
13 rhMOG1–125 + +++ 9/9 151 9/9 25
14 rhMOG1–125 + +++ 11/11 264 5/11 50
9 #phMOG34-56 + ++ 32/32 173 25/32 50
15 rhMOG1–125 + +++ 10/10 >300 10/10 100
(rhMOG1–125) recombinant peptide, representing the complete extracellular N-terminal domain of human 
MOG, (phMOG34-56) synthetic peptide, representing an extracellular N-terminal domain of human MOG, 
(*) booster with phMOG4-26, (#) booster with phMOG34-56.
infiltrate size
+ small
++ medium (>30 cells)
+++ large (hundred of cells)
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CD83 (DC) and neutrophil elastase (neutrophils). EAE-affected brain tissues from 
marmoset (n=3) and rhesus monkeys (n=2) were selected based on representative 
numbers of PG- and NAMLAA-containing cells. PG was mostly present in CD11b+ 
cells (87-100% of PG-containing cells) in both marmoset and rhesus monkey EAE 
brain tissue. Many neutrophils (62-65%) and also DC (16%) in rhesus monkey brain 
contained PG. PG was not detected within DC in marmoset brain tissue. The number 
of PG-and NAMLAA-containing granulocytes in marmoset tissues could not be 
determined since the available antibodies against human granulocytes did not cross-
react with marmoset granulocytes. 
In rhesus monkey EAE brain tissue, NAMLAA was mostly expressed by 
neutrophils (43-80% of NAMLAA-containing cells), CD11b+ cells (25-48%) and 
by some DC (7-8%). NAMLAA in marmoset EAE brain tissue was occasionally 
expressed by CD11b+ cells (0.5-1%), but not by DC. Comparing the number of 
CD11b+ PG-containing cells with CD11b+ NAMLAA-containing cells it can be 
speculated that PG and NAMLAA are generally present in different cells, i.e. PG is 
mostly present in cells that express CD11b, whereas NAMLAA is mostly expressed 
in CD11b- cells.
Figure 3. Restricted NAMLAA expression in MS and monkey EAE brain.
In rhesus EAE brain tissue (animal 9) many perivascular infiltrates are present with a moderate to high 
number of NAMLAA-containing cells (A, B). In marmoset EAE brain tissue (animal 10) some NAMLAA-
containing cells are localized near blood vessels (C). Foamy MΦ in active MS brain lesions (sample 
97-160) express NAMLAA (D). Expression of NAMLAA is restricted to a certain subpopulation of foamy 
MΦ (E). Occasionally also perivascular cells express NAMLAA in MS brain tissue (sample 00-082) (F). 
Bar = 100 µm. (See Appendix page 222 for a full-color representation of this figure.)
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Restricted expression of NAMLAA and lysozyme in MS brain
Previously, the number of PG-containing cells was determined in MS and non-
MS control brain tissue43. To determine whether PG-persistence in MS brain is 
associated with the expression of PG-degrading enzymes, we assessed whether 
NAMLAA- and lysozyme-containing cells are also localized at sites of inflammation 
in MS brain and in control brain tissue. Subsequently, we determined whether 
expression of NAMLAA and lysozyme in MS brain parallels the expression in 
marmoset and rhesus brain tissue. In MS brain (n=30 lesions from n=9 patients) 
with different lesion stages (Table 3), a few to a moderate number of NAMLAA-
containing cells were found. These cells had a foamy MΦ appearance, likely due to 
phagocytosed myelin, and were localized within active lesions (Figure 3D). Within 
the same active lesions also many NAMLAA-negative foamy cells were present, 
indicating that myelin-phagocytosing cells do not all or continuously produce 
NAMLAA (Figure 3E). Occasionally some NAMLAA-containing cells were present 
near blood vessels (Figure 3F). Pre-active perivascular infiltrates and parenchymal 
areas of the brain did not contain NAMLAA. NAMLAA-containing cells were absent 
in non-demented control brain tissues (n=2 patients). Lysozyme-containing cells 
were absent in all human brain tissues with the exception of occasional intravascular 
cells. In the positive control tissue, human tonsil, lysozyme-containing cells were 
present, confirming that the absence of lysozyme in human brain tissue cannot be 
explained by the failure of the staining. In summary, NAMLAA was expressed by 
a subpopulation of cells with a foamy MΦ appearance in active MS lesions and 
lysozyme was not expressed in MS and control brain.
Peripheral PG: Higher numbers of PG-containing cells in EAE-affected 
rhesus spleen
The priming and perpetuation of autoimmune-mediated reactions take place in 
secondary lymphoid organs. Activation signals to APC via TLR/Nod-stimulation 
can potentially influence these priming and effector responses and promote Th1 
cell development64-66. We have assessed whether EAE development in non-human 
primates is associated with a different number or localization of the putative TLR2/
Nod ligand PG, as well as NAMLAA and lysozyme in spleen. Therefore, we stained 
spleen tissues from EAE (n=3) and non-EAE (n=3) marmoset and rhesus monkeys 
(Table 1 and 2).
Table 5 shows the number of PG- and NAMLAA positive cell numbers in rhesus 
monkey spleen tissue. In all rhesus monkeys, a moderate number of PG-containing 
cells was present in the red pulp. However, in two EAE monkeys that developed 
EAE, PG-containing cells were also present in moderate numbers in the marginal 
zone (Figure 4A, B). No lysozyme-containing cells were found in these spleen 
sections. A moderate number of NAMLAA-containing cell clusters was present in 
the red pulp (data not shown) of non-EAE rhesus monkey spleen tissue, whereas 
individual NAMLAA-containing cells, were occasionally present in spleens of 
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EAE-affected rhesus monkeys. No clear differences in number or localization 
of PG- or NAMLAA-containing cells were found in EAE-affected and non EAE-
affected marmoset spleen (data not shown). In summary, these data suggest that 
higher numbers of PG-containing cells are present in rhesus monkey EAE spleen 
compared to non-EAE spleen. These differences were not seen in marmoset 
EAE spleen. No overt differences were observed in the expression of NAMLAA in 
marmoset and rhesus monkey spleen tissue.
Various phagocytic subsets contain PG and NAMLAA in monkey spleen 
tissue 
As in brain tissue, we identified the PG- and NAMLAA-containing cells in spleen 
tissues from rhesus monkey non-EAE (n=2) and EAE (n=2) and marmoset non-
EAE (n=2) and EAE (n=3) monkeys. We did not identify PG-containing cells in 
marmoset spleen, since only few cells contained PG and no differences were found 
between animals with or without EAE. PG in spleen tissue from both non-EAE and 
EAE rhesus monkeys was present in comparable numbers of CD11b+ cells (42-
Figure 4. High numbers of PG-containing cells in rhesus EAE spleen.
High numbers of PG-containing cells are present in the marginal zone of rhesus monkeys that developed 
EAE (animal 10)(A, B). In control immunized rhesus monkeys (animal 5) NAMLAA-expressing cells 
are present in clusters within the red pulp (C). Bar = 100 µm. (See Appendix page 222 for a full-color 
representation of this figure.)
Table 5. PG- and NAMLAA-containing cells in rhesus spleen.
animal immunogen EAE PG* NAMLAA cell clusters
4 collagen II - + +
5 collagen II - + +
3 collagen II - + +/-
10 rhMOG1-125 + ++ -
16 rhMOG1-125 + ++ -
11 rhMOG1-125 + + -
(-) no positive cells, (+/-) occasional cells, (+) few cells, (++) moderate cell number, (*) marginal zone, 
(rhMOG1–125) recombinant peptide, representing the complete extracellular N-terminal domain of human 
MOG. 
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50% of PG-containing cells) and neutrophils (40-68%). PG was only occasionally 
present within DC (~1%) in animals without EAE, whereas in animals with EAE 
more DC (5-14% of PG-containing cells) contained PG. About half (42-54%) of PG-
containing cells in rhesus monkey spleen expressed CD11b, irrespective of disease 
development. In rhesus monkey spleen, NAMLAA was predominantly expressed 
by neutrophils (75-91%) and by some DC (2-3%). Also in marmoset spleen tissue 
NAMLAA-containing cells are most likely granulocytes, whereas NAMLAA was not 
present within DC. Most NAMLAA-containing cells did not express CD11b (86-
99%). Thus, as in brain, splenic PG and NAMLAA are most likely present within 
different cell types, based on the expression pattern of CD11b.
Proinflammatory S. aureus derived sPG stimulates IL-12p70 production by 
monkey PBMC
Previously we have demonstrated that sPG, purified from the pathogenic bacterium 
S. aureus, exerts proinflammatory effects on mouse bone marrow-derived DC11. 
Moreover, sPG efficiently induced EAE in mice, when admixed with MOG35-55 
encephalitogenic peptide in IFA11. To further substantiate the pathogenic relevance 
of PG we determined whether S. aureus PG is capable to induce the prototypical 
Th1 promoting cytokine IL-12 by non-human primate PBMC. IL-12 is an important 
proinflammatory cytokine in the development of murine and non-human primate 
EAE59,67,68. PBMC from (n=2) marmoset monkeys, (n=2) rhesus monkeys and one 
human donor, as an intrinsic control, were stimulated with different concentrations 
of S. aureus sPG. As expected, S. aureus sPG induced a dose-dependent increase 
of IL-12p70 upon stimulation of human PBMC (Figure 5). Both rhesus monkeys 
(n=2) and marmoset (n=1) PBMC also produced elevated levels of IL-12p70 upon 
sPG stimulation, in a dose-dependent fashion (Figure 5). In conclusion, sPG from 
S. aureus induces a prototypical proinflammatory cytokine thought to be crucially 
involved in demyelinating disease.  
Discussion
Recent studies in EAE models have shown that innate immune responses within 
the CNS, usually induced by interaction of CpG oligonucleotides with TLR9, are of 
significant importance in the expression of autoimmunity. The absence of TLR9 on 
CNS APC in primates hampers direct translation of this principle to MS. We use 
non-human primate EAE models to bridge the immunological gap between the EAE 
mouse and the MS patient. Bacterial components can stimulate APC to produce a 
score of proinflammatory cytokines and chemokines and stimulate the development 
of antigen-specific Th1 cells. Bacterial PG is a candidate agonist of CNS APC, 
which stimulates cells via extracellular and intracellular receptors (TLR and Nod). 
Proinflammatory PG can be redistributed from the periphery into sites of chronic 
inflammation, such as rheumatoid joints44 and MS brain43. In relation to MS, we 
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compared EAE-affected rhesus monkeys, which develop an acute disease course 
with marmoset EAE monkeys, which develop chronic EAE50. We show here that in 
both monkey models for MS, EAE development is associated with a significantly 
elevated number of PG-containing cells in the brain. EAE-affected rhesus monkeys 
develop large brain lesions with many PG-containing cells, whereas EAE-affected 
marmoset monkeys develop infiltrates of medium size with a modest number of 
PG-containing cells. We hypothesize a causal relation between both features. Both 
in the CNS and in peripheral lymphoid organs, PG-containing cells may contribute 
to autoimmunity by producing proinflammatory mediators, induced by TLR/Nod 
ligation. The persistence of PG in MS and monkey EAE brain tissue might be due 
to the restricted expression of both NAMLAA and lysozyme. The fact that a TLR/
Nod ligand is transported into the brain during autoimmune encephalomyelitis and 
MS may have major consequences for disease development and perpetuation, as 
discussed below.
Activation of resident and infiltrated APC by TLR/Nod ligation in the CNS
In MS43 and rhesus monkey EAE brain tissue, PG is present within MΦ, DC and 
neutrophils suggesting that CNS infiltrating phagocytes are responsible for the 
transport of PG into the CNS. In the chronic marmoset EAE model, neutrophils are 
rarely found within the CNS and PG is detected mostly within MΦ. PG can induce 
proinflammatory signals through ligation of TLR213,14,69 and/or Nod receptors15,70. It 
has been described that different TLR are expressed on resident APC in the MS 
brain7. PG-induced responses in murine astrocytes are TLR2 dependent71 and 
Figure 5. S. aureus derived sPG induces IL-12p70 production by rhesus and marmoset APC.
PBMC from human (n=1), rhesus (n=2) or marmoset monkeys (n=2) were stimulated with different 
concentrations of sPG for 21 h. Supernatants were harvested and IL-12p70 was determined by ELISA.
0
500
1000
1500
2000
2500
human rhesus rhesus marmoset marmoset
IL
-1
2p
70
 (
pg
/m
l)
-
  1 µg/ml
 5 µg/ml
10 µg/ml
sPG
Bacterial peptidoglycan in primates with demyelinating disease 85
murine microglia produce numerous proinflammatory cytokines and chemokines 
after PG stimulation72,73. These data demonstrate that different resident cell 
types in the brain produce proinflammatory mediators upon stimulation with PG. 
Additionally, also blood-derived PG-containing brain infiltrating cells may locally 
produce proinflammatory mediators via TLR/Nod signaling pathways. Triggering of 
C-type lectin receptors may abrogate the proinflammatory effects of TLR-induced 
responses. Hence, it has been proposed that balancing of C-type lectin receptor 
and TLR-mediated signals to APC might be of importance in maintaining self-
tolerance in EAE and MS74.
Implications of TLR stimulation in tolerance regulation by APC 
Under normal conditions autoreactive T cells are controlled to prevent the 
development of autoimmune disease. Even high numbers of activated autoreactive 
T cells inside the target organ are not sufficient to induce autoimmune disease75. 
However, autoimmune disease can develop once the autoantigen is presented by 
resident APC of the CNS to autoreactive T cells in the presence of costimulation 
by TLR or CD40 ligands8,75-77. Both in the periphery and at the inflammatory site, 
immature APC have a major role in the maintenance of T cell tolerance to self-
antigens. For example, introduction of the PLP139-151 T cell receptor transgene 
into B10.S mice did not result in spontaneous EAE development. But when APC 
from B10.S PLP139-151 T cell receptor transgenic mice were activated by systemic 
TLR ligand administration, 33% of these mice developed EAE78. Moreover, TLR-
induced activation of CNS APC promoted EAE development in C57BL/6 mice10. 
It has recently been demonstrated that naïve myelin-specific T cells become 
activated in inflamed CNS by local APC79 and can cause disease progression by 
epitope spreading80,81. PG can activate local APC and form a possible trigger for the 
activation of T cells directed against endogenous myelin epitopes, participating in 
the perpetuation of demyelinating disease. 
With respect to the non-human primate EAE models, we here show a dose-
dependent induction of IL-12p70 upon sPG stimulation of peripheral blood 
leukocytes from both marmoset and rhesus monkeys (Figure 5). The p40 moiety 
of IL-12 is shared by the related family member IL-23, and plays an important role 
in the development of EAE82. It was very recently demonstrated that treatment 
with Mab anti-IL-12p40 of marmoset monkeys, initiated when MRI detectable 
lesions first appeared, limited lesion development (‘t Hart et al., 2005, submitted). 
Its importance is furthermore underscored by the fact that mice with an astrocyte-
targeted expression of IL-12p70 developed EAE after immunization with CFA and 
toxin, without specific autoantigen in the emulsion67. Thus, PG may contribute 
to inflammation and disease progression by promoting the production of Th1 
stimulating proinflammatory cytokines in the CNS and in secondary lymphoid 
organs. Interestingly, in EAE susceptible mouse strains, APC have a higher 
activation state compared with APC from EAE-resistant stains78. In accordance, we 
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are currently testing the hypothesis that the more acute EAE in rhesus monkeys is 
due to a higher sensitivity of rhesus monkey APC to TLR/Nod-induced activation 
than marmoset APC. This suggests that TLR/Nod genes may form a genetic 
susceptibility traint for acute demyelinating disease.
Persistence of PG in the CNS is related to restricted expression of degrading 
enzymes 
Previously, it was shown that radio-actively labeled PG-monomers accumulated 
over time in brain and intestine of mice83. More recently Zhang et al., demonstrated 
that injected arthritogenic PG was retained for several weeks in spleen, liver and 
synovial tissue of rats84. These data demonstrate that PG can be transferred into 
and retained at inflammatory sites. In order to understand the persistence of PG 
in MS and monkey EAE brain tissue we determined the expression of NAMLAA 
and lysozyme. These enzymes together are capable to abolish the proinflammatory 
capacity of PG27. 
 In the CNS of MS patients and EAE-affected monkeys one might expect many 
lysozyme-expressing cells, since infiltrates contain many phagocytosing cells and 
lysozyme is known to be present within granules of phagocytes22-24. However, in 
this study, we could not detect lysozyme-containing cells in infiltrates and in the 
parenchyma of MS brain tissue. Occasional intravascular cells containing lysozyme 
were found in non-demented controls, in MS and in rhesus monkey EAE brain tissue, 
which is in agreement with previous findings in MS brain tissue85,86. Also NAMLAA 
is expressed in a restricted manner in MS and EAE-affected marmoset brain, while 
in EAE-affected rhesus monkeys many NAMLAA-containing cells are present in 
the brain. Disease development in marmoset monkeys and MS patients is more 
chronic compared to rhesus monkeys, which develop an acute encephalomyelitis 
accompanied by large necrotic brain lesions with many neutrophils and MΦ50. This 
difference in pathology between MS / marmoset EAE and rhesus monkey EAE most 
likely accounts for the different numbers of NAMLAA- and PG-containing cells. In 
conclusion, these findings show that intracellular PG persists in MS and monkey 
brain tissue. Persistence of PG correlates with the absence or low numbers of 
NAMLAA- and lysozyme-expressing cells. Local conditions in the CNS may restrict 
expression of these enzymes.
PG can stimulate EAE in secondary lymphoid organs
PG-containing cells may stimulate autoimmune-mediated processes either in the 
CNS or in peripheral lymphoid organs. We here show that EAE development in 
rhesus monkeys is associated with a higher number of PG-containing APC in the 
marginal zone of the spleen. It was shown previously that PG derived from sterile 
human spleen induced T cell proliferation and proinflammatory cytokine production 
by peripheral blood leukocytes39. Splenic PG may thus be involved in monkey EAE 
development, possibly by stimulation of peripheral autoimmune-mediated processes. 
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We recently demonstrated that PG stimulates autoimmune-mediated processes in 
mouse EAE development11. Purified PG from S. aureus was added to an emulsion 
of IFA and MOG35-55. Already at four hours after immunization with this emulsion, PG-
containing cells were detected in the draining lymph nodes. At this site, PG stimulated 
autoantigen-specific T cell expansion and Th1 cell polarization. Subsequently, these 
mice developed EAE, whereas animals did not develop EAE upon injection with 
MOG35-55 in IFA without PG. Taken together these data show that a single bacterial 
component, PG, can create an inflammatory environment sufficient to break T cell 
tolerance. Moreover, in combination with autoantigen presentation, PG is sufficient 
to induce autoantigen-specific Th1 cell generation and EAE development. Given the 
costimulatory capacity of PG in EAE development, prevention of PG-trafficking and 
action may contribute to treat the activity of autoimmune disease in humans.
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Abstract
Upon stimulation by microbial products through Toll-like receptors (TLR), dendritic 
cells (DC) acquire the capacity to prime naïve T cells and to initiate a proinflammatory 
immune response. Recently, we have shown that antigen presenting cells (APC) 
within the CNS of multiple sclerosis (MS) patients contain peptidoglycan (PG), a 
major cell wall component of Gram-positive bacteria, which signals through TLR 
and NOD. 
In this study, we report that Staphylococcus aureus PG as a single component 
can support the induction of experimental autoimmune encephalomyelitis (EAE) in 
mice, an animal model for MS. Mice immunized with an encephalitogenic myelin 
oligodendrocyte glycoprotein peptide (MOG)-peptide in incomplete Freund’s 
adjuvant (IFA) did not develop EAE. In contrast, addition of PG to the emulsion 
was sufficient for priming of autoreactive Th1 cells and development of EAE. In 
vitro studies demonstrate that PG stimulates DC-mediated processes, reflected 
by increased antigen uptake, DC maturation, Th1 cell expansion, activation, and 
proinflammatory cytokine production.
These data indicate that PG-mediated interactions result in proinflammatory 
stimulation of antigen-specific effector functions, which are important in the 
development of EAE. These PG-mediated processes may occur both within the 
peripheral lymph nodes as well as in the CNS and likely involve recognition by TLR 
on DC. Thus, PG may provide a physiological trigger of DC maturation, and in this 
way disrupt the normal tolerance to self antigen. As such, PG signaling pathways 
may serve as novel targets for the treatment of MS.
Introduction
Multiple sclerosis (MS) is considered to be a chronic autoimmune disease of 
the CNS of unknown etiology critically driven by CD4+ Th1 cells. However, the 
presence of autoreactive T cells is clearly not the single determining factor for the 
development of MS, because myelin-reactive T cells are also found in healthy 
individuals1,2. This implies that other factors play an important role in the initiation 
and perpetuation of pathological autoantigen-specific immune processes.
Bacteria and viruses are prominent cofactors that have been implicated in 
autoimmune disease initiation and persistence3. As such, it has been shown 
that MS relapses are frequently associated with antecedent infections4,5, which 
in some cases are bacterial6. In experimental autoimmune encephalomyelitis 
(EAE), an animal model for MS, a strong adjuvant containing killed whole 
Mycobacterium tuberculosis (complete Freund’s adjuvant: CFA) is required for 
disease induction. When incomplete Freund’s adjuvant (IFA) emulsion is being 
used, animals will not develop EAE7,8. Microbial components, such as CpG-DNA 
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and LPS, are physiological stimuli of EAE development via innate receptors on 
antigen presenting cells (APC)9-11. These data indicate that non-infectious microbial 
components contribute to disease development in EAE and likely in MS. 
Peptidoglycan (PG) is an important bacterial cell wall component implicated in 
chronic inflammation12. We have previously demonstrated that PG isolated from 
sterile human spleen stimulates T cell proliferation and cytokine production13. 
Furthermore, we have shown that phagocytic cells may distribute PG to sites 
of chronic inflammation. At these sites, PG-containing dendritic cells (DC) and 
macrophages (MΦ) are present in high numbers and express costimulatory 
molecules and cytokines, as revealed by extensive in situ analysis of MS brain 
tissue14 and rheumatoid arthritis synovial tissue15,16. In conclusion, these data 
support the concept that biologically active PG can be transported by APC to 
lymphoid tissues and sites of chronic inflammation. Therefore, we hypothesized 
that PG acts as a supporting factor of autoimmune processes in MS.
As a mechanism of action, PG can activate the innate immune system through 
binding of extracellular and intracellular receptors17-19. Extracellular PG has been 
claimed to bind Toll-like receptor (TLR)2 in association with CD14, expressed 
on the cell surface of APC. Some internalized TLR ligands can also engage TLR 
in phagosomes20. In addition, two new intracellular receptors for PG fragments, 
Nod1/2 (Card4/15) have been described recently21,22. Although high numbers 
of immunocompetent PG-containing APC were found in MS brain tissue by in 
situ analysis, a functional role for PG in the pathogenesis of MS remains to be 
elucidated. We therefore assessed the role of PG in the development of mouse 
EAE. In order to achieve this, mice were immunized with autoantigen emulsified 
in IFA supplemented with PG. We used PG derived from Staphylococcus aureus, 
which does not contain the motif required for Nod1 ligation22, but contains the 
motif necessary for Nod2 ligation23,24. Mice were assessed for EAE development 
and draining lymph nodes were analyzed for the presence of PG-containing cells. 
Because DC play a prominent role in linking the innate and adaptive immune 
response, we assessed the functional role of PG in antigen uptake, DC maturation, 
and T cell polarization. Taken together, our data show that proinflammatory PG 
stimulates the development of autoimmune-mediated processes in EAE.  
Materials and Methods
Mice
Female C57BL/6 mice (8- to 12-wk-old) and BALB/c mice (6- to 10-wk-old) 
were purchased from Harlan (Horst, The Netherlands). OVA323-339-specific, MHC 
class II-restricted, T cell receptor transgenic (OT-II) mice, backcrossed on the 
C57BL/6 background, were bred within the facility. All animal experiments were 
performed with approval of the Erasmus University MC committee (Rotterdam, The 
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Netherlands) for animal ethics. Mice were housed under specified pathogen free 
conditions and received water and food ad libitum. Paralyzed mice with EAE scores 
over 2.5 were afforded easier access to food and water. 
Peptides, antibodies and PG 
Myelin oligodendrocyte glycoprotein (MOG)35-55 (MEVGWYRSPFSRVVHLYRNGK) 
was a kind gift from Dr. U. Günthert (Basel University, Basel, Zwitserland). Soluble 
PG (sPG) was prepared from S. aureus by gel-permeation chromatography25, and 
insoluble PG (iPG) was prepared with standard methods. The LPS content of both 
PG fractions was rigorously checked and was < 13 pg LPS/mg PG as measured 
by Limulus-amebocyte lysate assay, which are background values. Absence of 
LPS was further confirmed by in vitro culture with mouse bone marrow-derived 
DC. Purification and identification of the biologically active components in the sPG 
fractions are currently being performed, and might reveal other TLR2 agonists as 
recently described by Travassos et al.26.
PG of all bacterial species is composed of two alternating sugar residues, 
N-acetyl glucosamine (GlcNAc) and N-acetyl muramic acid (MurNAc) forming 
glycan strands. These strands are connected via stem peptides that differ from 
one bacterial species to another, and that have the sequence L-alanine-D-
isoglutamine-L-lysine-D-alanine-D-alanine in S. aureus. In addition, PG from S. 
aureus contains pentaglycine bridges. The complete peptidoglycan network is a 
highly complex ordered network, the detailed structure of which is subject of debate 
to this day27. The two main hydrolyzing enzymes capable of PG degradation are 
lysozyme and N-acetylmuramyl-L-alanine amidase (NAMLAA), which is identical 
to PG recognition protein long form (PGRP-L)28,29. Lysozyme hydrolyzes the bond 
between the two sugar moieties, whereas NAMLAA/PGRP-L hydrolyzes the lactate 
bond between N-acetyl muramic acid and the amino group of the first L-alanine. 
Induction and clinical evaluation of EAE 
C57BL/6 mice were immunized s.c., at four sites (axillar and inguinal), with 200 μg 
MOG35-55 in 0.1 ml PBS emulsified in an equal volume of CFA containing 200 μg 
M. tuberculosis (H37/Ra; Difco Laboratories, Detroit, Michigan, USA). Additionally 
mice were injected i.p. with 200 ng Bordetella pertussis toxin in 0.2 ml PBS on day 
0 and 2 after immunization (Sigma-Aldrich, St. Louis, Missouri, USA). Mice were 
weighed and scored for clinical signs of EAE daily according to the following scoring 
system: 0, no disease; 0.5, partial tail paralysis; 1, complete tail paralysis; 1.5, limb 
weakness without tail paralysis; 2, limb weakness and tail paralysis; 2.5, partial 
limb and tail paralysis; 3, complete hind or front limb paralysis; 3.5, paraplegia; 4, 
quadriplegia; 5, death due to EAE.
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Histology
The immunohistochemical techniques used in this study have previously been 
described in detail30,31. In brief, frozen sections of 6 µm were thaw-mounted 
on gelatin-coated glass slides and stored overnight in humidified atmosphere. 
Sections were air-dried for 1 h and fixed at room temperature in fresh acetone 
containing 0.02% (v/v) H2O2. Then the slides were air-dried for 10 min, washed 
with PBS and incubated with predetermined optimal dilutions of reagents overnight 
at 4°C in humidified atmosphere. Secondary and tertiary reagents were applied 
and incubated for 1 h at room temperature. Between each incubation, slides were 
washed twice with PBS/0.05%Tween20. Horseradish peroxidase (HRP) conversed 
3-amino-9-ethyl-carbazole into a bright red precipitate upon incubation for 10 min. 
Incubation of slides with naphthol-AS-MX phosphate (Sigma-Aldrich) and fast blue 
BB base (Sigma-Aldrich) for 30 min at 37°C resulted in a in a blue precipitate 
indicating alkaline phosphatase activity. As a negative control, the primary antibody 
was omitted. Nuclei were counterstained by hematoxylin.
Four to 7 weeks after immunization, mice were euthanized using CO2 and brain 
tissues were snap frozen in liquid nitrogen and stored at -80°C. To determine the 
cellular infiltration in the CNS, immunohistochemical stainings were performed 
on frozen sections with anti-mouse B220 (RA-3-6B2, BD Pharmingen, Alphen 
aan den Rijn, The Netherlands), anti-human cross-reactive to mouse CD3 
(DAKOCytomation, Glostrup, Denmark) and anti-mouse MHC-II (M5/114). For 
CD3, donkey anti-rabbit Ig-biotin (Amersham Biosciences, Buckinghamshire, 
England) was used as a conjugate. For B220 and MHC-II, rabbit anti-rat IgG-
biotin (DAKOCytomation) was used as a conjugate. As a tertiary step, slides were 
incubated with ABComplex-HRP (DAKOCytomation). 
To assess the presence of PG within the draining lymph nodes, we isolated 
axillary and inguinal lymph nodes at 4 and 96 h after immunization. Lymph nodes 
were snap frozen in liquid nitrogen and stored at -80°C. A double-staining procedure 
was used to determine which cell types contain PG. PG-containing cells were 
detected with Mab 15704-biotin (Gentaur Molecular Products, Brussels, Belgium) 
raised against S. aureus PG, followed by streptavidin-FITC (BD Biosciences, San 
Diego, California, USA). DC were detected by incubation with anti-mouse CD11c-
PE (HL3, BD Biosciences).  
Uptake of OVA by DC
DC were prepared as previously described32. Briefly, bone marrow was flushed 
with RPMI 1640 (Invitrogen Life Tachnologies, Paisley, UK) from femurs and tibiae 
of C57BL/6 mice. Cells were washed, enumerated, and plated in bacteriological 
100-mm-diameter petri-dishes. Cell-culture medium (TCM) was RPMI 1640 
supplemented with gentamicin (60 µg/ml) (Invitrogen Life Technologies), 2-
mercaptoethanol (5 x10-5 mol/L) (Sigma-Aldrich) and 5% (v/v) fetal calf serum 
(Biocell Laboratories, Rancho Dominguez, California, USA). At day 0 of the culture, 
98 Chapter 3
the cells were seeded at a concentration of 2x106/dish in medium containing 
recombinant mouse GM-CSF (200 IU/ml) (kindly provided by K. Thielemans, 
University of Brussels, Belgium). At day 3, TCM containing 200 IU/ml recombinant 
mouse GM-CSF was added. At days 6 and 8, half of the medium was collected, 
centrifuged, and the pellet was resuspended in TCM containing 200 IU/ml of 
recombinant mouse GM-CSF. At day 9 100 µl TCM containing 1x105 DC were 
plated in round bottom 96-well plates for 30 min at 4 or 37 °C. DC were pulsed 
with different concentrations (0, 0.01, 0.1, 1 mg/ml) of OVA-FITC (Molecular 
Probes, Eugene, Oregon, USA). The endotoxin level of FITC-OVA determined by a 
Limulus-amebocyte lysate assay (Bio Whittaker, Verviers, Belgium) was <0.001 µg, 
which was previously reported not to affect DCs33. DC were stimulated with 10 µg/
ml sPG or iPG. Cells were stained for 30 min at 4°C with anti-CD11c-APC (HL3, BD 
Biosciences) dissolved in PBS containing 0.5% bovine serum albumin and 0.01% 
sodium azide. Uptake of OVA-FITC was determined on CD11c-allophycocyanin-
gated cells by flow cytometry. Dead cells and debris were excluded using propidium 
iodide.
DC maturation assay
At day 9 of the culture, DC were pulsed overnight with either 100 ng/ml LPS, or 10 
µg/ml sPG or iPG. To exclude LPS contamination of the PG preparation, polymyxin 
B was added to the culture. Cells were centrifuged and supernatant were collected 
for cytokine analysis (IL-6, IL-10, IL-12p70, TNF-α). The maturation state of DC 
was determined by staining for 30 min with Mabs anti-CD11c-allophycocyanin, anti-
MHC class II-FITC (M5/114.5.2), in combination with anti-CD40-PE (3/23), anti-
CD80-PE (16-10A1), and anti-CD86-PE (GL-1) (all obtained from BD Biosciences) 
diluted in PBS containing 0.5% bovine serum albumin and 0.01% sodium azide. 
Maturation of DC was determined on CD11c-allophycocyanin-gated cells by flow 
cytometry. Dead cells and debris were excluded using propidium iodide.
OVA-specific T cell proliferation assay
DC were obtained from bone marrow culture as described above. At day 9 of culture, 
DC were plated in 24 well plates containing 2 ml of TCM, and pulsed with 10 mg/ml 
OVA-Worthington (Biochemical Corp, Lakewood, New Jersey, USA) for 24 h. At the 
dose we used in our experiments, the endotoxin level of OVA measured by a limulus-
amebocyte lysate assay (Bio Whittaker) was <0.001 µg. Simultaneously DC were 
stimulated with 100 ng/ml LPS (Escherichia coli, strain O26:B6, Sigma-Aldrich), 
10 µg/ml sPG, or iPG. OT-II cells were purified as described previously32. Briefly, 
lymph nodes and spleens were collected from OT-II mice. After red blood cell lysis, 
cells were labeled with CFSE. Cells were enumerated, and dead cells, stained for 
trypan blue, were excluded. After 24 h DC were washed and 1x104 DC were co-
cultured with 1x105 CFSE-labeled OVA T cell receptor transgenic CD4+ OT-II T cells 
in round bottom 96-well plates containing 200 µl TCM. Cells were centrifuged, and 
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supernatants were harvested and stored at -20 °C for cytokine analysis. Cells were 
resuspended and incubated with anti-Vα2-biotin and Vβ5.1/5.2-PE TCR Mabs 
(eBioscience, San Diego, California, USA) for 30 min at 4 °C. Biotinylated anti-Vα2 
was detected using streptavidin-allophycocyanin (BD Biosciences). Percentages 
of proliferating OVA-specific CD4+ T cells were determined by gating on cells that 
were double positive for Vα2 and Vβ5.1/5.2. Dead cells and debris were excluded 
using propidium iodide.
MOG35-55-specific T cell proliferation assay
For evaluation of MOG35-55-specific lymph node cell proliferation, mice were 
immunized with MOG35-55 in adjuvant. Mice were sacrificed and draining inguinal, 
brachial and axillar lymph nodes were isolated at 33 days after immunization. 
Lymph node cells were cultured for 4 days in 96-well plates in 200 µl of RPMI 
1640 supplemented with 10% heat-inactivated FCS (Sigma-Aldrich), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Bio Whittaker). Cells (4x105/well) were 
cultured at 37°C and 5% CO2 in the presence or absence of 10 µg/ml MOG35-55. 
After 72 h of culture, 1 µCi of [3H]thymidine (Amersham Biosciences) was added 
for 16 h. Incorporation of [3H]thymidine was measured in triplicate using a filtermat 
harvester and a beta-plate counter (Perkin Elmer, Wellesley, Massachusetts, USA). 
Supernatants from MOG35-55 proliferation assays were harvested 96 h after culture, 
centrifuged and stored for further cytokine analysis at -20°C.
Cytokine measurement by ELISA
According to the manufacturer’s instructions, concentrations of IL-4, IL-10, 
IL12-p70, IFN-γ and TNF-α were determined by using OptEIA ELISA kits (BD 
Biosciences).   
Statistical evaluations
Statistical evaluation was performed using SPSS 11 software. The Mann-Whitney U 
test was used to analyze differences in cytokine production and T cell proliferation. 
A value of p <0.05 was considered statistically significant.
Results
Both sPG and iPG are potent adjuvants for the induction of EAE 
PG is a known proinflammatory stimulator of the innate immune response, but 
very little is known about the possible role of PG in the development of MS and 
EAE. To determine whether PG by itself is a sufficient proinflammatory stimulus 
for the development of EAE, we added highly purified sPG or iPG from S. aureus 
to an emulsion of IFA and MOG35-55. In three independent experiments, standard 
induction of EAE by immunization of mice with MOG35-55 in CFA resulted in an EAE 
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incidence of 60 to 100%, with a normal EAE course (Figure 1 and Table 1). Mice 
immunized with MOG35-55 in IFA, as a negative control, did not develop EAE, as 
expected. In contrast, addition of sPG or iPG to IFA/MOG35-55 induced EAE with a 
disease incidence from 40 to 60%. Different dosages of sPG and iPG were used for 
EAE induction. High dosages of 250 μg sPG and 600 μg iPG did not induce EAE 
(Table 1). Importantly, however, lower PG dosages induced EAE with an incidence 
of 40 to 60%. The lowest effective dose for EAE induction with sPG (25 μg/ animal) 
Figure 1. Both sPG and iPG are potent adjuvants for the induction of EAE.
A and B, In two separate experiments C57BL/6 mice were immunized with MOG35-55 emulsified in CFA 
(). In (A) mice were immunized with MOG35-55 in IFA (), or IFA-25µg sPG (). In (B) mice were 
immunized with IFA-400µg iPG (). Mice were weighed and scored for clinical signs of EAE daily. Five 
animals were used for each group. Graphs show mean clinical scores of animals that developed EAE. 
(d.i.) disease incidence.
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was ten times lower than with iPG, in keeping with the higher biological activity 
described for sPG previously. These data demonstrate that PG is a potent adjuvant 
and can substitute whole M. tuberculosis in the induction for EAE.   
PG-adjuvant induces classical EAE histopathology
Brain tissue was examined by histology to assess whether the signs of paralysis of 
mice immunized with PG-containing adjuvant are associated with a characteristic 
EAE histopathology. In brain tissue of animals that developed EAE, infiltrates 
were found containing CD3+ T cells, B220+ B cells and MHC-II+ APC (Figure 2). 
A comparable number of infiltrates and infiltrating cells were detected in EAE mice 
injected with CFA and IFA-sPG, while the infiltrate size and number of infiltrating 
cells in IFA-iPG injected EAE mice was slightly lower (Table 2). These data 
confirm that paralysis induced with PG-containing adjuvant is associated with a 
characteristic EAE histopathology.   
PG-containing adjuvant promotes MOG35-55-specific Th1 cell polarization
It has been well established that EAE induction by immunization with an 
encephalitogenic antigen in CFA results in the generation of autoantigen-specific 
CD4+ IFN-γ producing T cells34. To address whether the PG component of bacteria 
is able to generate MOG35-55-specific Th1 cells, we determined MOG35-55-specific T 
cell proliferation and IFN-γ, IL-4 and IL-10 production at day 33 after immunization. 
Lymph node cells from mice immunized with MOG35-55 in CFA proliferated dose 
dependently and produced IFN-γ upon in vitro re-stimulation with MOG35-55 (Figure 
3). Mice immunized with MOG35-55 in IFA also showed antigen-specific proliferation, 
but only low amounts of IFN-γ were produced. Addition of sPG to the immunization 
mixture resulted in increased antigen-specific proliferation and IFN-γ production 
compared with immunization with IFA/MOG35-55. IL-4 and IL-10 were undetectable 
Table 1. Clinical parameters of EAE induced by sPG or iPG.
Adjuvant PG (µg/animal) Disease 
incidence (%) n=5
Onset
dayA
Maximum
scoreA
Cumulative
scoreA  (day 20)
CFA n.a. 60 8.7 ± 2.9 2.0 20.2 ± 8.8
IFA 0 0 0 0 0
IFA-sPG 25 60 7.0 2.0 15.8 ± 8.8
250 0 0 0 0
CFAB nd 100 9.5 ± 1.6 2.7 ± 0.5 24.0 ± 4.6
IFA-iPG 25 0 0 0 0
200 0 0 0 0
250 40 12.0 2.0 11.0 ± 4.2
400 60 13.7 ± 1.5 1.7 ± 0.6 9.8 ± 6.7
600 0 0 0 0
(A) Represented values are from animals that developed EAE, (B) mean values of two separate 
experiments, (n.a.) not applicable
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in any of the groups. These data show that PG creates an inflammatory 
environment. In combination with autoantigen presentation, PG can effectively 
induce autoantigen-specific Th1 cells.  
Table 2. Histological analysis of infiltrates in EAE brain tissue.
Adjuvant PG (µg/animal) Number Size
CFA n.a. >10 +
n.a. >10 +
n.a. 4-10 +
n.a. 4-10 +
n.a. >10 +
IFA-sPG 25 >10 +
25 4-10 +
25 >10 +
IFA-iPG 250 4-10 -/+
250 4-10 +
400 1-3 -/+
400 1-3 -/+
400 4-10 -/+
(n.a.) not applicable, (Number) number of inflammatory foci, Size; (-) no infiltrating cells, (-/+) 1-5 cells, 
(+) 6-20 cells
Figure 2. Immunization with PG-containing adjuvant induces classical EAE histopathology.
Brain tissues were isolated between 4 to 7 weeks after immunization. Frozen brain sections were 
stained with hematoxylin in combination with MHC-II (A, B), CD3 (C, D) and B220 (E, F). (See Appendix 
page 223 for a full-color representation of this figure.)
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PG is redistributed from the site of immunization to the draining lymph 
nodes
To determine whether PG is transported from the site of immunization to secondary 
lymphoid organs during EAE development, we injected PG in combination with 
IFA and MOG35-55 and isolated draining lymph nodes at different time points after 
immunization. Two mice per group were injected with either 25 μg sPG or 400 μg 
iPG in IFA/MOG35-55 emulsions, dosages of PG optimal for EAE induction. Two 
Figure 3. Immunization with PG-containing adjuvant stimulates the development of MOG35-55-
specific Th1 cells.
Draining lymph nodes from five individual mice per group were harvested at day 33 after immunization. 
(A), Cells were stimulated in vitro with 10 µg/ml MOG35-55, and proliferation was measured after 96 h 
of culture by [3H]thymidine incorporation. (B), Supernatants were harvested after 96 h of culture and 
measured by ELISA for IFN-γcontent. Mean values per group ± SD are shown.
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naïve mice were used as negative controls. Axillary, brachial, and inguinal lymph 
nodes were isolated and frozen at 4 and 96 h after immunization. Per mouse, four 
lymph nodes were analyzed for the presence of PG-containing cells. In naïve mice 
individual PG-containing cells were occasionally found in three out of eight lymph 
nodes (38%), in agreement with previous observations35,36. In contrast, we detected 
several clusters of PG-containing cells in > 90% of the draining lymph nodes from 
mice immunized with sPG and iPG. The number of PG-containing clusters did not 
vary between the time points (data not shown). These data indicate that APC can 
take up and transport PG from the site of immunization to the draining lymph nodes 
within hours. Double-labeling experiments identified cells in the PG-containing 
clusters as DC expressing CD11c (Figure 4). PG-containing clusters may thus 
contribute to the development of a proinflammatory environment to help generate 
MOG35-55-specific Th1 cells.   
Stimulation of DC by PG increases protein uptake and induces DC 
maturation
At the site of immunization, PG can be recognized by different cell types i.e. DC, 
MΦ, and granulocytes. Because PG was mainly observed in DC in the lymph 
Figure 4. PG is redistributed from the site of immunization to DC in draining lymph nodes.
Draining lymph nodes were isolated at 4 h after s.c. immunization with MOG35-55 in IFA-sPG. Frozen 
sections were stained by immunofluorescence for DC (CD11c in red, A) and for PG (green, B). Overlay 
in C demonstrates clusters of DC containing PG. D is a lightmicroscopic image of the same area. 
(See Appendix page 224 for a full-color representation of this figure.)
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nodes, we assessed whether PG stimulates protein uptake, cell maturation, T 
cell stimulation and polarization by this APC subset crucial for priming of T cells. 
For these experiments, immature mouse bone marrow-derived DC were used. 
To examine the effects of PG on protein uptake, DC were incubated with OVA 
conjugated to FITC in the presence or absence of 10 μg/ml PG at 4˚ or 37˚C. Different 
concentrations of OVA-FITC (0, 0.01, 0.1 and 1 mg/ml) were applied, and uptake was 
determined by flow cytometry. Incubation at 4˚C showed a dose-dependent passive 
uptake of OVA-FITC (data not shown). Addition of PG did not alter the uptake of 
OVA-FITC at 4˚C (Figure 5A). When cells were cultured at physiological temperature 
(37˚C), both sPG and iPG stimulated the uptake of OVA-FITC (Figure 5B). 
To assess the effects of PG on DC maturation, we stimulated DC with sPG or iPG. 
As a positive control, DC were stimulated with LPS. Maturation of DC was determined 
by the expression of MHC-II, CD40, CD80, and CD86 and by the induction of several 
cytokines. Both sPG and iPG stimulated expression of MHC-II, CD40, CD80 and 
CD86. Stimulation of DC with sPG efficiently induced expression of MHC-II, CD40, 
CD80 and CD86 to a similar or higher level as compared to LPS stimulation. These 
molecules were also induced by iPG, to a similar or lower level as compared with LPS 
(Figure 6A). Both sPG and iPG induced production of several cytokines, but with a 
different pattern of production. Whereas sPG induced production of all proinflammatory 
cytokines measured, iPG induced TNF-α, but not IL-6 and IL-12 (Figure 6B). IL-10 
was not produced under these conditions (data not shown). As predicted, addition of 
the LPS antagonist polymyxin B effectively inhibited LPS-induced maturation marker 
Figure 5. Stimulation of DC by PG increases protein uptake.
Immature DC were cultured in the absence or presence of OVA-FITC. DC were either not stimulated (thin 
lines) or stimulated with sPG (thick lines) or iPG (dotted lines). Uptake of OVA-FITC was determined at 
(A) 4°C or (B) 37°C after 30 min of incubation. Histograms represent the number of CD11c-gated cells. 
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Figure 6. PG induces maturation of bone marrow derived DC.
Immature DC were either not stimulated (white histogram, closed line) or stimulated with LPS (white 
histograms, dotted line), sPG or iPG (light-gray and dark-gray histograms respectively). A, Maturation 
of DC was determined by measuring expression of MHC-II, CD40, CD80 and CD86 by flow cytometry. 
Histograms represent the number of CD11c-gated cells. B, Supernatants were harvested, and 
production of IL-6, IL-12p70 and TNF-α was determined by ELISA. Dark-gray bars represent cells that 
were incubated with polymyxin B to exclude LPS contamination.  
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expression and cytokine production (Figure 6B), whereas no inhibition was seen when 
cells were stimulated with PG, demonstrating that the effects of PG were not the result 
of LPS contamination. Taken together, these data demonstrate that both forms of PG 
can stimulate protein uptake and induce DC maturation in vitro. 
PG-OVA pulsed DC stimulate T cell proliferation and Th1 cells polarization
After antigen uptake and migration of DC to the draining lymph nodes, mature 
DC will prime naïve T cells to proliferate and differentiate along a certain pathway, 
depending on the nature of the stimulus. To address whether sPG and iPG are 
able to stimulate antigen-specific T cell proliferation and Th1 cell polarization, we 
used an in vitro model system. Bone marrow-derived DC were cultured with OVA in 
combination with LPS, sPG, or iPG. After 24 h, the DC were incubated with CFSE-
labeled naïve OVA323-339 T cell receptor transgenic CD4
+ T cells. OVA-pulsed DC 
that were stimulated by LPS, sPG, or iPG, induced an increase in the OVA-specific 
T cell proliferation as compared to unstimulated cells (Figure 7B-E). Furthermore, 
both forms of PG induced significantly increased levels of IFN-γ compared with 
both non stimulated and LPS-stimulated DC (Figure 7F). Only low levels of IL-4 
and IL-10 were detected in all OVA-pulsed DC-T cell cultures (data not shown). In 
summary, these data show that PG stimulates antigen-specific T cell proliferation 
and Th1 cell development.
Discussion
Bacterial and viral components stimulate innate immune responses which potentially 
contribute to the development and persistence of autoimmune disease 3,5. Although 
it is very difficult to demonstrate mechanistic links between microbial agents and 
MS, it has been shown epidemiologically that antecedent infections are associated 
with an increased risk of relapse development4,5. Components of bacterial agents 
may function as physiological adjuvants and stimulate autoantigen-specific 
adaptive immune responses. In this study, we show that PG, a large bacterial cell 
wall component, can act as an environmental factor promoting CNS autoimmune 
disease development via innate immunity. 
PG from a vast array of different bacterial species can be derived from different 
anatomical sites, including all mucosa permanently exposed to the outside world. 
During bacterial infection, PG can be released, either from bacterial cells upon 
replication or upon uptake and processing by APC. In the absence of infections, 
the major bacterial load is located at mucosal sites. At these sites, i.e. the gut, DC 
may sample bacteria through the intestinal epithelium and subsequently migrate to 
secondary lymphoid organs37,38. Even under normal circumstances, some PG can 
be detected in the blood circulation, within the liver and within lymphoid tissues, 
reflecting physiologic processes dealing with exposure to bacterial components13,39-45. 
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We therefore hypothesized that bacterial PG can contribute to disease 
development and progression in MS and EAE in the absence of infection or 
bacterial replication. To functionally test this hypothesis we determined whether 
EAE could be induced by immunization of mice with an encephalitogenic peptide 
(MOG35-55) emulsified in IFA supplemented with S. aureus PG, asking whether PG 
by itself is a sufficient proinflammatory cofactor for induction of EAE. 
For our studies, we used two different types of S. aureus PG. We observed 
functional differences between sPG and iPG in vivo as well as in vitro. Although 
EAE could be induced with both types of PG, the effective dose for EAE induction 
was 10-fold lower for sPG compared with iPG. In vitro stimulation of DC with 
iPG only induced TNF-α production, whereas sPG could induce IL-6 and IL-12 
in addition to TNF-α. These data implicate that partially degraded PG is more 
effective in exerting proinflammatory effects than iPG. 
Figure 7. PG stimulates antigen-specific T cell proliferation and Th1 cell polarization. 
Immature DC were not stimulated (A) or stimulated with OVA (B) combined with LPS (C), sPG (D) or iPG 
(E) for 24 h. OVA323-339 T cell receptor transgenic CD4
+ T cells were incubated with all DC populations. 
A-E, After 6 days of culture, OVA323-339-specific T cell proliferation was assessed by flow cytometry 
using CFSE. F, Supernatants were harvested, and production of IFN-γ was determined by ELISA. 
Percentages indicate the number of divided OVA323-339-CD4
+ T cells. Histograms represent the number 
of cell divisions.
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High dosages of both sPG and iPG were not able to induce EAE. The reasons 
for this are not clear but may be related to dose-dependent induction of Th1 versus 
Th2 responses by administration of TLR ligands in vivo33. Furthermore, it has been 
shown that apoptosis of MΦ is induced by PG, as described by Fukui et al.46. As 
recently shown, TLR engagement triggers DC apoptosis through up-regulation of 
the proapoptotic Bcl-2 family member Bim. In this way, both innate and acquired 
immune system signals cooperate to determine DC lifespan, and hence also the 
longevity of T-DC interaction47,48.
L-lysine or diaminopimelic acid (DAP) at position three of the stem peptide 
are important structural components of PG. DAP-type PG is present in all Gram-
negative bacteria, whereas most Gram-positive bacteria contain lysine-type PG49. 
The intracellular PG-sensing molecules Nod1/2 discriminate between lysine-type 
and DAP-type PG50. Nod2 is a general sensor for both Gram-positive and Gram-
negative bacteria, through the recognition of muramyl dipeptide, the minimal motif 
found in all PG23,24. In contrast to Nod2, Nod1 specifically recognizes DAP-type 
PG21,22. Bacteria containing L-lysine can induce chronic arthritis, while bacteria 
with other peptides at this position are nonarthritogenic51. Several other studies 
have also identified the presence of L-lysine as typical for proinflammatory PG52-
54. Considering the arthritogenic effects of L-lysine at position three of the stem 
peptide, one might expect similar findings in EAE development. Indeed, we have 
now shown that EAE can be induced with lysine-type S. aureus-derived PG as 
adjuvant.
 Already at 4 hours after immunization, PG-containing clusters could be 
detected in the draining lymph nodes. These clusters persisted at least for 7 days 
after immunization. Others have also shown the persistence of PG-containing 
components until at least 63 days after injection of PG-polysaccharides by muramic 
acid detection, a specific component of PG, through gas chromatography and mass 
spectrometry40. PG degradation is mainly dependent on the enzymes lysozyme 
and NAMLAA/PGRP-L55. Recently, it was found that the PGRP-L is an amidase28,29 
and is identical to NAMLAA, which we have characterized in detail previously55,56. 
In contrast to granulocytes, MΦ and DC lack NAMLAA/PGRP-L, which may result 
in incomplete or delayed PG degradation and persistence of intracellular PG. This 
may explain why DC in MS brain tissue and in EAE lymph node tissues contain 
PG. The fact that PG is observed both in lymph nodes and in the CNS is important, 
because PG may act as a physiological proinflammatory adjuvant by stimulating 
autoantigen-specific immune responses. Indeed, in the current study, we could 
demonstrate that PG-containing adjuvant enhanced MOG35-55-specific lymph node 
cell proliferation and IFN-γ production at 4 weeks after immunization. 
DC recognize specific motifs on pathogens by expressing a diverse repertoire 
of pathogen-associated recognition receptors. Upon bacteria-induced stimulation, 
DC mature, migrate to the circulation, and prime the adaptive arm of the immune 
response by initiating the development of effector T cells in secondary lymphoid 
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organs57. Because we detected PG within DC in MS brain, rheumatoid arthritis 
synovium, and EAE lymphoid tissue, we addressed the functional role for PG in 
EAE development by in vitro simulation of the different processes involving DC that 
occur during immunization for EAE development. 
Early events after immunization include uptake of adjuvant and antigen by 
DC inducing their maturation. These processes can be accelerated by whole M. 
tuberculosis-containing adjuvant as has been demonstrated in vivo7. Also bacterial 
components like CpG-DNA are able to increase antigen uptake provided that the 
antigen is covalently linked to CpG-DNA58-60. In concordance with these studies, we 
now demonstrate that PG increases antigen uptake by DC. 
Upon stimulation with TLR ligands or cytokines, DC will mature and migrate to 
secondary lymphoid tissues to initiate T cell activation. It has been demonstrated 
that S. aureus PG may serve as a maturation signal for murine DC, by inducing 
the expression of CD86, MHC-II and the production of MIP-2 and proinflammatory 
cytokines61,62. Also, human monocytes secrete several chemokines (IL-8, MIP-1α) 
and proinflammatory cytokines (TNF-α, IL-1, IL-6 and IL-12) after PG stimulation, 
as shown by cDNA array analysis63. In agreement with these studies, we now show 
that both forms of S. aureus-derived PG induce DC maturation, as demonstrated 
by enhanced expression of MHC-II, costimulatory molecules, and production of 
proinflammatory cytokines. These proinflammatory cytokines, induced upon TLR 
stimulation, can exert direct effects on T cell polarization (i.e. IL-12)64,65 and T cell 
regulation (i.e. IL-6)66 and have been implicated in the pathogenesis of MS as well 
as EAE67-69.
Classical EAE induction is dependent on the presence of autoantigen and 
proinflammatory stimuli from adjuvant components (whole M. tuberculosis). A 
combination of both factors will result in the development of autoantigen-specific 
CD4+ Th1 cells within the secondary lymphoid organs. Not much is known about the 
effect of PG on T cell proliferation and differentiation. A recent report proposed that 
Th cell polarization is dependent on differential TLR ligation70. Our in vitro studies 
demonstrate that OVA-pulsed DC did induce T cell proliferation but did not induce 
Th1 cell development. However, when OVA-pulsed DC were co-incubated with 
PG, DC were able to induce OVA-specific Th1 cell development, which confirms 
previous reports71. In addition, PG stimulated OVA-DC increased the expansion of 
OVA-specific T cells, compared with OVA-pulsed DC alone. These data provide 
evidence that PG stimulates DC-mediated processes and serves as a potent 
proinflammatory trigger for the development of autoantigen-specific Th1 cells.
In this study, we show that the TLR-Nod2 ligand S. aureus PG acts as a 
proinflammatory factor that is involved in the development of autoimmune disease 
of the CNS. The contribution of PG on disease development is likely dependent on 
DC-mediated processes, because PG is located within DC in MS brain tissue and 
mouse EAE lymph node tissue. We have demonstrated that PG is able to potentiate 
different DC-mediated processes such as antigen uptake, DC maturation, and 
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subsequent induction and stimulation of autoantigen-specific Th1 cell development. 
Targeting PG receptors or their respective signaling pathways may well become a 
novel therapeutic strategy for the treatment of autoimmune disease in humans. 
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Abstract
CD97 is a recently identified seven-span transmembrane (7-TM) protein that 
is expressed by leukocytes early after activation. CD97 binds to its cellular 
ligand CD55 (decay accelerating factor), which protects several cell types from 
complement-mediated damage. The functional consequences of CD97-CD55 
binding are largely unknown, but previous data imply that CD97-CD55 interactions 
play a role in cellular activation, migration and adhesion under inflammatory 
conditions. 
 Here we examined the expression of CD97 and CD55 by immunohistochemistry 
in multiple sclerosis (MS). On the basis of established criteria for inflammation and 
demyelination, different lesion stages were distinguished in MS post-mortem brain 
tissue. In normal white matter, CD97 expression was not found, but CD55 was 
expressed with weak staining intensity on endothelial cells. In pre-active lesions, 
defined by abnormalities of the white matter, many infiltrating T cells, macrophages 
(MΦ) and microglia expressed CD97. CD55 was highly expressed by endothelial 
cells. In active lesions with myelin degradation, MΦ and microglia expressed both 
CD55 and CD97. Furthermore, a sandwich ELISA showed significantly (p<0.05) 
elevated levels of sCD97 in serum but not in cerebrospinal fluid of MS patients 
(37%) compared to healthy controls (8%). 
Collectively these data suggest that CD97-CD55 interactions are involved in the 
inflammatory processes in MS. CD55, which is expressed in lesions by vessels to 
protect against complement-mediated damage, might bind to CD97 on infiltrating 
leukocytes. This interaction may facilitate cell activation and migration through the 
blood-brain barrier. In addition CD97-CD55 interactions in the parenchyma of the 
brain may contribute to the inflammation. 
Introduction
One of the hallmarks of MS is the presence of inflammatory demyelinating lesions 
and axonal loss in the central nervous system (CNS). Lesions contain several blood-
derived mononuclear cell types, i.e. infiltrating monocytes, T cells and B cells, and 
resident microglial cells. The infiltrating cells have passed the blood-brain barrier 
via mechanisms that are still poorly understood. The cellular infiltration of the CNS 
is dependent on a complex interaction between adhesion molecules, chemokines, 
cytokines and proteases. Different effector functions of the inflammatory cells will 
finally result in impaired nerve conduction1. 
A molecule that may be involved in the inflammatory processes is CD97, a 
member of the EGF-TM7 family of class B seven-span transmembrane (7-TM) 
receptors2-4. Members of this family, including EMR1, EMR2, EMR3, ETL, and also 
the mouse microglia marker F4/80, are characterized by an extended extracellular 
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region with a variable number of epidermal growth factor-like (EGF) domains5-10. So 
far, CD97 is the only EGF-TM7 family member of which a ligand has been identified. 
Via its EGF domain region, CD97 binds CD55/decay accelerating factor (DAF), a 
molecule that protects cells from complement-mediated damage by accelerating 
the decay of C3/C5 convertases11,12. Affinity for CD55 differs from CD97 isoforms 
and, with 86 μM, is highest for the smallest isoform with three EGF domains13,14. 
The consequences of the CD97-CD55 interaction as well as the physiological 
function of CD97 are still poorly understood. 
Receptors of the EGF-TM7 family are expressed by cells of the immune system 
and by smooth muscle cells. Whereas expression of EMR1, EMR2, EMR3 and 
F4/80 is largely restricted to myeloid cells5-7,9,15 and of ETL to smooth muscle cells8, 
CD97 is found on a broad array of hematopoietic cells, smooth muscle cells and 
epithelial tumor cells2,16,17. With regard to hematopoetic cells, CD97 is expressed on 
activated lymphocytes, granulocytes, monocytes and all types of dendritic cells and 
macrophages (MΦ), except for microglia. Under inflammatory conditions, soluble 
CD97 (sCD97) is released, whereas sCD97 can be detected neither in normal 
human serum or plasma, nor in supernatant of activated T cells4. The cellular ligand 
of CD97, CD55, is expressed by several cell types in contact with complement, e.g. 
leukocytes, erythrocytes, epithelial cells and endothelial cells12.
Studies on rheumatoid arthritis (RA) suggest a role for the CD97-CD55 
interaction in the pathogenesis of autoimmune diseases4,18. In the intimal lining of 
rheumatoid synovial tissue, MΦ express high levels of CD97, while fibroblast-like 
synoviocytes are strongly CD55-positive. In addition, increased levels of soluble 
sCD97 were found in synovial fluid of RA patients compared to patients with 
osteoarthritis or reactive arthritis. 
In this study we examined the involvement of CD97 and its ligand in the cellular 
interactions of MS. To assess whether CD97 and CD55 are involved in MS, 
expression of CD97 and CD55 was determined by in situ analysis in relation to 
different brain lesion stages, which were distinguished on the basis of established 
inflammation and demyelination criteria19,20. Cell types in MS brain expressing 
CD97 and CD55 were characterized. In addition, the presence of sCD97 in CSF 
and in serum of MS patients was determined by ELISA.
Material and methods
Patient samples
Human autopsy brain tissue from MS patients and patients with non-neurological 
disorders was provided by the Netherlands Brain Bank in Amsterdam (Coordinator 
Dr. R. Ravid). Cerebrospinal fluid (CSF) samples (n=37), provided by the 
Department of Neurology, Erasmus MC in Rotterdam, were obtained from MS 
patients only. Serum samples were obtained from untreated MS patients (n=54; 
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including the patients from whom CSF was taken), from patients with other 
inflammatory neurological diseases (OIND), consisting of Guillain Barré syndrome, 
meningitis, myasthenia gravis and sarcoidosis (n=28), and from patients with 
other neurological diseases (OND), consisting of stroke, Parkinson disease and 
epilepsy (n=24). Serum samples (n=38) were also obtained from healthy blood 
bank donors.  
Immunohistochemistry
The immunohistochemical techniques used in this study have previously been 
described in detail21-23. In brief, frozen sections of 6 µm were thaw-mounted on 
gelatin-coated glass slides and stored overnight in humidified atmosphere. Sections 
were air-dried for 1 h and fixed at room temperature in fresh acetone containing 
0.02% (v/v) H2O2. Then the slides were air-dried for 10 min, washed with PBS and 
incubated with predetermined optimal dilutions of reagents (Table 1) overnight at 
4°C in humidified atmosphere. 
Incubations with secondary and tertiary reagents were done for 1 h at room 
temperature. Between each incubation, slides were washed twice with PBS/
0.05%Tween20. Horseradish peroxidase (HRP) activity was revealed by incubation 
for 10 min at room temperature with 3-amino-9-ethyl-carbazole, which resulted in 
a bright red precipitate. Incubation with naphthol-AS-MX phosphate (Sigma, Saint 
Louis, MO) and fast blue BB base (Sigma) for 30 min at 37°C was used to reveal 
alkaline phosphatase (AP) activity, resulting in a blue precipitate. For double staining, 
different combinations of antibodies were used. For CD3 and laminin detection in 
blue, goat anti-rabbit Ig-AP (DAKO, Glostrup, Denmark) in combination with rabbit 
anti-goat IgG-AP (Southern Biotechnology Associates Inc., Birmingham, AL) were 
used as conjugates. For CD55 and CD97 detection in blue, goat anti-mouse Ig-AP 
(DAKO) in combination with rabbit anti-goat IgG-AP were used. In addition, for 
CD55 in blue, horse anti-mouse IgG-biotin (Vector Laboratories, Burlingame, CA) 
in combination with avidin-AP (Sigma) were used. For CD55 and CD97 detection 
Table 1. Antibodies and reagents used for immunohistochemistry.
Marker Cellular specificity Clone designation
CD3 all T cells n.a.
CD55 lymphocytes/
activated endothelial cells
CLB-CD97L/1
CD97 activated lymphocytes/
granulocytes/monocytes/ MΦ/dendritic cells
CLB-CD97/1
HLA-DR MHC class II: 
MΦ/dendritic cells/ microglia
L-243-biotin
Laminin basement membrane of blood vessels n.a.
Acid phosphatase MΦ/microglia n.a.
oil red O myelin neutral lipids in phagocytic cells n.a.
Abbreviations: (n.a.) not applicable. Suppliers: CLB-CD97/1, CLB-CD97L/1 (CLB, Amsterdam, The 
Netherlands); CD3 antiserum, L-243-biotin, laminin antiserum (ICN Pharmaceuticals, Aurora, OH).
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in red, horse anti-mouse IgG-biotin in combination with ABComplex-HRP (DAKO) 
were used. HLA-DR-biotin was combined with ABComplex-HRP. Staining for AP 
activity was performed prior to staining for peroxidase activity. As a control, single 
stainings were performed in parallel with all the incubation steps of the double 
staining procedure, but omitting the first antibody incubation. Cells expressing one 
marker were stained red or blue, and cells expressing both markers were stained 
violet. All cell-specific reagents used are shown in Table 1. Human reactive tonsil 
was used as positive internal control tissue. As negative controls, sections were 
incubated with isotype-matched primary antibodies of irrelevant specificity, or the 
primary antibody was omitted. 
Staging of MS lesions
MS brain lesions were staged on the basis of internationally accepted inflammation 
and demyelination criteria, described earlier19,20, using three different markers, 
i.e. acid phosphatase, HLA-DR and neutral lipids. Acid phosphatase, an enzyme, 
which is present in lysosomes of cells of the monocytic lineage, is a useful marker 
to detect infiltrating monocytes, MΦ and microglial cells. Breakdown of myelin, 
i.e. active demyelination, was demonstrated by the detection of neutral lipids in 
antigen presenting cells by staining with oil red O. It should be noted that in a single 
brain section normal white matter and different lesion stages could all be present. 
Immunoreactivity of CD97 and CD55 was scored on a five-point scale based on 
positive cell numbers24.
ELISA for sCD97
A capture ELISA was used, essentially as described previously, to determine sCD97 
levels in CSF and serum, by using two monoclonal antibodies (Mabs) recognizing 
distinct epitopes on CD97. Mab CLB-CD97/1 is directed against the first EGF 
domain of the molecule, while Mab CLB-CD97/3 is directed against the stalk region 
of CD9718. Briefly, flatbottom microtiter plates (Nunc Maxisorb, Roskilde, Denmark) 
were coated with Mab CLB-CD97/3 (5 µg/ml in carbonate buffer, pH 9.5) overnight 
at 4oC. Plates were then blocked for 2 h with PBS, 2% full-fat milk and incubated 
overnight at 4oC with one in two dilutions of CSF or serum in high performance 
ELISA buffer (CLB). Subsequently, plates were incubated with biotin-conjugated 
Mab CLB-CD97/1 in high performance ELISA buffer for 1 h, and with poly-HRP 
(CLB) in high performance ELISA buffer for 1 h. Plates were washed with PBS, 
0.05% Tween-20 between all incubations. The color reaction was measured at 
OD450, using 3,3’,5,5’-tetramethylbenzidine and 0.02% H2O2 as the substrate 
(KPL, Guildford, UK). To calculate sCD97 levels, each ELISA included a serial 
dilution of a positive control, a fusion protein that has been generated by ligation of 
the total extracellular part of CD97 immediately upstream to the CH3-CH2-hinge 
region of human IgG1 (CD97-Fc3). Undiluted, the positive control contained 100 U/
ml by definition and a 1:100 dilution gave a half maximal OD450 value. Each ELISA 
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also included a negative control, a fusion protein containing the EGF domain region 
of CD97 without the stalk region (CD97-Fc1). The detection limit of the ELISA was 
0.01 U/ml. All samples containing more than 0.01 U/ml sCD97 were considered 
positive. The OD450 readings of the negative control were always smaller than, or 
equal to, the buffer control. 
Statistical analysis
Serum sCD97 levels in the MS, OIND, OND, and healthy control groups were 
compared with the Kruskal-Wallis and Mann-Whitney test, using Stata 6 software. A 
p value of < 0.05 was considered statistically significant.
Results
Expression of CD97 and CD55 in human MS brain
To investigate whether CD97 and CD55 are expressed in different lesion stages of 
MS brain tissue, immunohistochemistry was performed. Fifteen staged brain tissue 
samples from eight MS patients were tested for expression of CD97, and eight 
staged brain tissue samples from six MS patients for expression of CD55. In addition, 
expression of CD97 and CD55 was assessed in normal white matter from two 
patients with non-neurological diseases and in normal white matter from three MS 
patients. In normal white matter, no CD97 expression was found. The ligand CD55 
was occasionally expressed, with low staining intensity, on endothelial cells, but not 
on other cell types (Figure 1B). Pre-active lesions are characterized by clusters of 
activated microglial cells (HLA-DR positive), few perivascular inflammatory cells and 
no demyelination. In these lesions, few to moderate numbers of CD97-expressing 
cells were found, depending on the size of the infiltrate (Figure 1C). It was also found 
that parenchymal cells in pre-active lesions expressed CD97 (Figure 1A). Unlike 
CD97, CD55 was highly expressed by endothelial cells in pre-active lesions and in 
all other lesion stages (Figure 1D and Figure 1F; arrows). Occasionally, CD55 was 
expressed by infiltrating cells and parenchymal cells in pre-active lesions (Figure 
1D). Active lesions are characterized by the presence of phagocytic cells, which 
contain myelin degradation products like neutral lipids and myelin proteins. Many of 
these phagocytosing CD97-expressing cells were found in active lesions (Figure 1E; 
red). In these lesions, a moderate number of cells also expressed CD55 (Figure 1F; 
red). Most of the cells in chronic inactive lesions, which are defined as hypocellular, 
expressed CD97. In all lesion stages, the number of CD97-positive cells exceeded 
the number of CD55-positive cells. Table 2 provides an overview of the expression 
of CD97 and CD55 in all the four distinct lesion stages. These findings indicate that 
in all lesion stages CD97 and its ligand CD55 are expressed under inflammatory 
conditions in the CNS of MS patients. 
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Identification of cellular subsets which express CD97 and CD55
Double-labeling was applied to identify cell types which express CD97 and CD55. In 
pre-active lesions, vessels are surrounded by clusters of infiltrating cells. Laminin, a 
Figure 1. Expression of CD97 and CD55 in human MS brain.
Left column, CD97 expression; and right column, CD55 expression. In pre-active lesions, parenchymal 
cells as well as infiltrating cells expressed CD97 (A and C, respectively). In normal white matter, CD55 
was expressed at low levels by endothelial cells (B), while in pre-active lesions, CD55 was expressed at 
high levels by endothelial cells and by some infiltrating cells (D). In active lesions, in which phagocytic 
cells contain myelin debris, numerous cells expressed CD97 (E) and also a moderate number of 
cells expressed CD55 (F). Bar = 45µm. (See Appendix page 225 for a full-color representation of this 
figure.)
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component of the vessel basement membrane, was used as a marker for endothelial 
cells. In Figure 2A, double-labeling of a pre-active lesion is shown for CD97 in red and 
laminin in blue. No expression of CD97 by endothelium was found, while perivascular 
leukocytes did express CD97. 
Via double labeling of CD97 and CD3, we identified many infiltrating T cells 
expressing CD97 (Figure 2C). Furthermore, a moderate number of CD97-expressing 
infiltrating cells expressed HLA-DR and acid phosphatase, indicating activated 
MΦ/microglia (Figure 2E). In addition, in close vicinity to these perivascular 
cells, parenchymal cells expressed CD97 and co-expressed HLA-DR and acid 
phosphatase, implying that they are activated MΦ/microglia. In contrast to CD97, 
CD55 was co-expressed with laminin (Figure 2B). Only a few infiltrating T cells and 
MΦ or microglial cells expressed CD55 in pre-active lesions (Figure 2 D and F). In 
active lesions, CD97 and CD55 were both expressed by numerous activated MΦ or 
microglial cells (data not shown).  
In summary, these data show that both CD97 and CD55 are expressed in MS 
lesions by infiltrating T cells, MΦ and resident microglial cells. In addition, CD55 is 
also expressed by endothelial cells in MS lesions. 
sCD97 detection in CSF and serum 
To assess whether sCD97 can be used as an activation marker for disease in MS 
patients, we tested serum and CSF of MS patients for the presence of sCD97. Despite 
the abundant expression of CD97 in brain lesions of MS patients, sCD97 was not 
detected in any of the CSF samples (n=37) from MS patients. The possibility that CSF 
contained a factor that disturbed the ELISA was excluded by testing CSF samples to 
which recombinant CD97-Fc1 or natural sCD97 from synovial fluid had been added 
(data not shown). Significantly elevated sCD97 levels (p<0.05) were however found 
in more serum samples of MS patients (37%) than healthy controls (8%) (Figure 3). 
However, these elevated levels were not MS specific because serum of a number of 
patients with OIND (25%) or OND (25%) also contained elevated sCD97 levels. Within 
the MS patients, no specific correlation was found between serum levels of sCD97 
and clinical parameters, such as disease course, duration, onset, sex, or age.
Table 2. CD97 and CD55 expression in MS brain tissue.
Lesion stage CD97 (mean score) CD55 (mean score)
Normal white matter - -
pre-active +/++ ±
Active demyelinating ++/+++ +/++
Chronic active
    Hypercellular border
    Hypocellular centre
+++
±/+
++
-/±
Chronic inactive + -/±
Positive cell number: (-) no positive cells, (+/-) occasional cells, (+) few, (++) moderate number, compare 
to Figure 1C , (+++) abundant, compare to Figure 1E.
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Figure 2. Identification of CD97- and CD55-expressing cell types in pre-active MS brain lesions.
Left column, CD97 expression; and right column, CD55 expression. CD97 (red) is not expressed by 
endothelial cells (laminin in blue)(A). In contrast, double labeling showed co-expression (arrow) for CD55 
(red) and laminin (blue; asterisk)(B). Many infiltrating CD3+ T cells (blue) expressed CD97 (arrow)(C), 
and some expressed CD55 (arrow)(D). A moderate number of HLA-DR positive (red; asterisk) infiltrating 
MΦ and resident microglial cells co-expressed CD97 (arrow)(E), while only a few co-expressed CD55 
(arrow)(F). Bar = 45µm. Asterisks indicate single expression (red or blue). Arrows indicate double 
expression (purple). (See Appendix page 226 for a full-color representation of this figure.)
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Discussion
In this study, we analyzed expression of the EGF-TM7 receptor CD97 and its 
cellular ligand CD55/DAF in MS brain lesions. In agreement with previous findings 
we found that CD97 is not expressed by microglia under normal conditions16. 
However, microglial cells in MS in all lesional stages strongly express CD97. In 
addition, CD97 expression was found on infiltrating MΦ and T cells. In pre-active 
lesions, CD55 was only occasionally expressed by T cells and MΦ or microglial 
cells, while in active lesions, many MΦ/microglial cells co-expressed CD55 and 
CD97. Strikingly, high expression of CD55 was found on endothelial cells in 
both pre-active and active lesions, whereas in normal white matter only modest 
expression by endothelial cells was found.
These findings are reminiscent on the situation related to vessels in human 
tissue outside the brain, where CD55 is expressed on perivascular reticular cells, 
and CD97 on lymphoid cells and monocytes/MΦ within the vascular lumina and 
the surrounding tissue16. In inflamed RA joints, CD55 is found on fibroblast-like 
synoviocytes of the intimal lining and on endothelial cells, while CD97 is expressed 
by MΦ of the intimal lining and sublining18.
The perivascular location of CD97-expressing T cells and MΦ suggest that 
these cells recently entered the CNS from the peripheral blood. In parallel, CD55 
p < 0.05
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Figure 3. Levels of sCD97 in human serum.
MS: multiple sclerosis; OIND: other inflammatory neurological diseases; OND: other neurological 
diseases; HC: healthy controls.
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expression on the vessel walls was increased in all lesion stages. Given the binding 
properties of the CD97-CD55 complex, this expression pattern may suggest that 
leukocyte CD97 binding to endothelial CD55 contributes to adhesive and/or 
migratory events at the blood-brain barrier. The recent data of Boulday et al. argue 
against a role for CD55-CD97 interaction in static adherence of CD97-expressing 
leukocytes to CD55 transgenic porcine endothelial cells, but in this study, functional 
assays for migratory events were not performed25. It is possible, but yet unproven, 
that next to classical adhesion pathways via lymphocyte function-associated 
antigen-1 /intracellular adhesion molecule-1 and very late activation antigen-4 
/vascular cell adhesion molecule-126, additional pathways such as via CD97-CD55 
interaction contribute to activation and migration of the invading cells. 
An increase in endothelial CD55 expression probably functions primarily 
to reduce complement deposition. CD55 expression can be increased by the 
proinflammatory cytokines TNF-α and IFN-γ, and also by the membrane attack 
complex27. It is tempting to assume that circulating Th helper cells and activated 
monocytes secreting these cytokines contribute to the enhanced CD55 expression 
on the brain endothelium. In such a scenario, basically beneficial CD55 expression 
may also have deleterious side effects because of the capability to facilitate the 
entry of activated CD97-expressing leukocytes into the CNS. Next to its major 
role in protecting hematopoietic and endothelial cells from complement-mediated 
damage27, CD55 itself is also involved in cellular activation and signal transduction 
of different cell types28-32. Therefore, it is possible that binding of CD97 to CD55 leads 
to reverse signaling of the CD55-expressing cell. The physiological consequences 
of this reverse signaling are poorly understood. 
sCD97 levels were found by ELISA in serum, but not in CSF of a number of 
MS patients. It is currently unknown by what mechanism(s) sCD97 is generated. 
We presume this is a result of proteolytic cleavage of the extracellular part of 
the membrane-expressed receptor, because we have found no evidence for 
alternatively spliced mRNA that could generate a soluble variant (unpublished 
observations). The interaction of CD97 with CD55 may be the triggering event for 
release of sCD97, in analogy with other molecules33. sCD97 has been found in 
vivo at inflammatory sites and in B cell lymphoma, but is absent in normal serum or 
plasma4,18. In this study, we were not able to detect sCD97 in CSF of MS patients. 
In contrast, we detected significantly elevated sCD97 levels in serum of a number 
of MS patients compared to healthy controls. Levels of sCD97 were also elevated 
in serum of a number of patients with OIND and OND, indicating that sCD97 is not 
a useful marker for MS. Within the MS patients, no specific correlation was found 
between serum levels of sCD97 and clinical parameters, such as disease course, 
duration, onset, sex or age.
The discrepancy between high levels of sCD97 at the site of inflammation in RA 
(synovial fluid) and the absence in the CSF of MS patients is not without precedent. 
In general, ratios of activation markers in synovial fluid versus blood are above 1.0 
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under inflammatory circumstances34. In contrast, CSF concentrations of activation 
markers in MS patients most often are lower than in the blood, with CSF-blood 
ratios ranging from 0.1 to 0.01, sCD2735, sCD3036, sCD62L37, sCR-138, sFas39, sIL-
6R and sgp13040. Still, levels of such activation molecules are often elevated when 
compared with CSF concentrations of control groups. It is possible that in MS, CSF 
sCD97 concentrations are relatively elevated, but we failed to demonstrate this 
because the concentrations were below the threshold of our ELISA. 
In addition to sCD97, soluble CD2535 and soluble MHC class II41 are also only 
found in the serum, but not in the CSF of MS patients. MHC class II is abundantly 
expressed by MΦ/microglia in MS brain tissue. This indicates that membrane 
expression and soluble presence of certain molecules, like MHC class II and 
CD97, are not necessarily correlated. The mechanism(s), sites of release, and 
redistribution of sCD97 need to be further investigated.
In conclusion, this study introduces CD97-CD55 as a candidate receptor-
ligand pair that plays a role in cell migration and costimulation during MS. CD55 
expressed on brain endothelial cells may serve a dual role, i.e. protection of vessels 
from complement-mediated damage and functional ligation of CD97 on leukocytes. 
Furthermore CD97-CD55 interactions in the brain parenchyma might contribute to 
the chronic inflammation. The functional role of CD97 will be further elucidated in 
mouse EAE by treatment with blocking Mab or genetic deletion of CD97.
References 
1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med 
2000, 343:938-952.
2. Eichler W, Aust G, Hamann D: Characterization of an early activation-dependent antigen on 
lymphocytes defined by the monoclonal antibody BL-Ac(F2). Scand J Immunol 1994, 39:111-115.
3. Hamann J, Eichler W, Hamann D, Kerstens HM, Poddighe PJ, Hoovers JM, Hartmann E, Strauss 
M, van Lier RA: Expression cloning and chromosomal mapping of the leukocyte activation antigen 
CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an 
unusual extracellular domain. J Immunol 1995, 155:1942-1950.
4. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, Stetler-Stevenson MA, Siebenlist 
U, Kelly K: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with 
inflammation. J Immunol 1996, 157:5438-5447.
5. Baud V, Chissoe SL, Viegas-Pequignot E, Diriong S, N’Guyen VC, Roe BA, Lipinski M: EMR1, 
an unusual member in the family of hormone receptors with seven transmembrane segments. 
Genomics 1995, 26:334-344.
6. Lin HH, Stacey M, Hamann J, Gordon S, McKnight AJ: Human EMR2, a novel EGF-TM7 molecule 
on chromosome 19p13.1, is closely related to CD97. Genomics 2000, 67:188-200.
7. Stacey M, Lin HH, Hilyard KL, Gordon S, McKnight AJ: Human epidermal growth factor (EGF) 
module-containing mucin-like hormone receptor 3 is a new member of the EGF-TM7 family that 
recognizes a ligand on human macrophages and activated neutrophils. J Biol Chem 2001, 276:
18863-18870.
Expression of CD97 and its ligand CD55 in MS 127
8. Nechiporuk T, Urness LD, Keating MT: ETL, a novel seven-transmembrane receptor that is 
developmentally regulated in the heart. ETL is a member of the secretin family and belongs to the 
epidermal growth factor-seven-transmembrane subfamily. J Biol Chem 2001, 276:4150-4157.
9. McKnight AJ, Gordon S: The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc 
Biol 1998, 63:271-280.
10. Stacey M, Lin HH, Gordon S, McKnight AJ: LNB-TM7, a group of seven-transmembrane proteins 
related to family-B G-protein-coupled receptors. Trends Biochem Sci 2000, 25:284-289.
11. Hamann J, Vogel B, van Schijndel GM, van Lier RA: The seven-span transmembrane receptor 
CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996, 184:1185-1189.
12. Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and function. 
Annu Rev Immunol 1989, 7:35-58.
13. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, van Lier RA: Characterization of the CD55 
(DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 1998, 28:
1701-1707.
14. Lin HH, Stacey M, Saxby C, Knott V, Chaudhry Y, Evans D, Gordon S, McKnight AJ, Handford P, Lea 
S: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated 
protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 2001, 276:24160-
24169.
15. Kwakkenbos MJ, Chang GW, Lin HH, Pouwels W, De Jong EC, Van Lier RAW, Gordon S, Hamann 
J: The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed on myeloid 
cells. J Leukoc Biol 2002, 71:854-862.
16. Jaspars LH, Vos W, Aust G, Van Lier RA, Hamann J: Tissue distribution of the human CD97 EGF-
TM7 receptor. Tissue Antigens 2001, 57:325-331.
17. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, Scherbaum WA, Dralle H, Hoang-Vu C: 
CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 1997, 57:1798-1806.
18. Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP: Expression of the 
activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 1999, 
42:650-658.
19. van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, 
Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F: Axonal loss in 
multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann 
Neurol 1999, 46:747-754.
20. van der Valk P, De Groot CJ: Staging of multiple sclerosis (MS) lesions: pathology of the time frame 
of MS. Neuropathol Appl Neurobiol 2000, 26:2-10.
21. Schrijver IA, Melief MJ, Eulderink F, Hazenberg MP, Laman JD: Bacterial peptidoglycan 
polysaccharides in sterile human spleen induce proinflammatory cytokine production by human 
blood cells. J Infect Dis 1999, 179:1459-1468.
22. Laman JD, van Meurs M, Schellekens MM, de Boer M, Melchers B, Massacesi L, Lassmann H, 
Claassen E, ‘t Hart BA: Expression of accessory molecules and cytokines in acute EAE in marmoset 
monkeys (Callithrix jacchus). J Neuroimmunol 1998, 86:30-45.
23. Claassen E, Gerritse K, Laman JD, Boersma WJ: New immunoenzyme-cytochemical stainings for 
the in situ detection of epitope specificity and isotype of antibody forming B cells in experimental and 
natural (auto) immune responses in animals and man. J Immunol Methods 1992, 150:207-216
24. Cannella B, Raine CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann 
Neurol 1995, 37:424-435.
25. Boulday G, Hamann J, Soulillou JP, Charreau B: CD97-decay-accelerating factor interaction is not 
involved in leukocyte adhesion to endothelial cells. Transplantation 2002, 73:429-436.
26. Lee SJ, Benveniste EN: Adhesion molecule expression and regulation on cells of the central 
nervous system. J Neuroimmunol 1999, 98:77-88.
27. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO: Induction of decay-
accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial 
128 Chapter 4
cells against complement deposition. Blood 1999, 94:1673-1682.
28. Shibuya K, Abe T, Fujita T: Decay-accelerating factor functions as a signal transducing molecule for 
human monocytes. J Immunol 1992, 149:1758-1762.
29. Lund-Johansen F, Olweus J, Symington FW, Arli A, Thompson JS, Vilella R, Skubitz K, Horejsi V: 
Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidy
linositol-anchored antigens. Eur J Immunol 1993, 23:2782-2791.
30. Davis LS, Patel SS, Atkinson JP, Lipsky PE: Decay-accelerating factor functions as a signal 
transducing molecule for human T cells. J Immunol 1988, 141:2246-2252.
31. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM: Signal transduction 
through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein 
tyrosine kinases p56lck and p59fyn 1. J Immunol 1992, 149:3535-3541.
32. Tosello AC, Mary F, Amiot M, Bernard A, Mary D: Activation of T cells via CD55: recruitment of early 
components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998, 48:13-27.
33. Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, van Lier RA: Characterization of the 
human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994, 152:1762-1773.
34. Tak PP, Hintzen RQ, Teunissen JJ, Smeets TJ, Daha MR, van Lier RA, Kluin PM, Meinders AE, 
Swaak AJ, Breedveld FC: Expression of the activation antigen CD27 in rheumatoid arthritis. Clin 
Immunol Immunopathol 1996, 80:129-138.
35. Hintzen RQ, van Lier RA, Kuijpers KC, Baars PA, Schaasberg W, Lucas CJ, Polman CH: Elevated 
levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple 
sclerosis patients. J Neuroimmunol 1991, 35:211-217.
36. McMillan SA, McDonnell GV, Douglas JP, Droogan AG, Hawkins SA: Elevated serum and CSF 
levels of soluble CD30 during clinical remission in multiple sclerosis. Neurology 1998, 51:1156-
1160.
37. Baraczka K, Nekam K, Pozsonyi T, Jakab L, Szongoth M, Sesztak M: Concentration of soluble 
adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of 
patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. 
Neuroimmunomodulation 2001, 9:49-54.
38. Vedeler CA, Matre R, Sadallah S, Schifferli J: Soluble complement receptor type 1 in serum and 
cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. J Neuroimmunol 
1996, 67:17-20.
39. Boylan MT, Crockard AD, McDonnell GV, McMillan SA, Hawkins SA: Serum and cerebrospinal fluid 
soluble Fas levels in clinical subgroups of multiple sclerosis. Immunol Lett 2001, 78:183-187.
40. Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Korschenhausen D, Greenberg BD, Nolde T, 
Muller N, Trapmann H, König N, Moller HJ, Hampel H: CSF and serum levels of soluble interleukin-
6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J 
Neuroimmunol 1999, 99:218-223.
41. Ott M, Seidl C, Westhoff U, Stecker K, Seifried E, Fischer PA, Grosse-Wilde H: Soluble HLA class I 
and class II antigens in patients with multiple sclerosis. Tissue Antigens 1998, 51:301-304.
CHAPTER
5
Genetic deletion of CD44v7 and CD44v10 reduces 
the severity of mouse experimental autoimmune 
encephalomyelitis
Lizette Visser1, Britt Johansson2, Ainhoa Mielgo2, Debby van Riel1, 
Marie-José Melief1, Marjan van Meurs1, 
Jon D. Laman1 and Ursula Günthert2
shared last authorship
1Department of Immunology and MS Center ErasMS, Erasmus MC- 
University Medical Center Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands. 2Department of Clinical & Biological Sciences, Institute for 
Medical Microbiology, University of Basel, CH-4003 Basel, Switzerland
Manuscript in preparation
130 Chapter 5
Abstract
CD44variant isoforms (CD44v) are transmembrane molecules that have been 
suggested to play an important role in the development of various autoimmune 
disorders. Ten CD44variant exons (v1-v10) can be alternatively spliced and 
inserted into the CD44 standard (CD44s) backbone. 
Here we determined the functional role of CD44v isoforms in multiple sclerosis 
(MS) and experimental autoimmune encephalomyelitis (EAE), a mouse model of 
MS. Both CD44v3 and CD44v10 were expressed on glial cells and on perivascular 
infiltrating cells in post-mortem analyzed brain lesions of MS patients. In the EAE 
model, brain infiltrating CD44v10+ leukocytes preceded the onset a of EAE and 
paralleled EAE disease scores. Genetic deletion of CD44v7 or CD44v10 isoforms 
reduced clinical EAE burden, and the number of inflammatory infiltrates in the 
spinal cord. Furthermore, adoptive transfer experiments showed that CD44v7 
expression on effector T cells and antigen presenting cells both participate in the 
development of EAE. CD44v7/v10 expression may contribute to the development 
of MS and EAE by increasing the longevity of auotantigen-specific CD4+ T cells. 
In conclusion, we here show that the specific CD44v isoforms CD44v7 and 
CD44v10 are critically involved in the pathogenesis of EAE and MS. Targeting 
these CD44v isoforms might therefore reduce inflammatory processes and clinical 
symptoms in MS. 
Introduction
Multiple sclerosis (MS) is a common chronic and disabling autoimmune disease 
of the CNS and often affects young adults. No efficient and long lasting therapies 
are available yet. Therefore, there is an urgent need for further elucidation of the 
mechanisms underlying the pathogenesis of MS. So far, current evidence suggests 
that MS is mediated by inflammatory attacks against components of the myelin 
sheath of nerve axons in the CNS. 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS 
and greatly advanced our knowledge on the pathogenesis of autoimmunity affecting 
the CNS. Together with clinical observations, data from animal experiments 
suggest that an initial CD4+-mediated autoreactive T cell response initiates a 
cascade of inflammatory events including complement activation, production of 
reactive oxygen and nitrogen species and digestion of myelin by macrophages 
(MΦ) that finally result in impaired nerve conduction, demyelination, axonal loss 
and neurological impairment1-3. The formation of mononuclear cell infiltrates in 
the CNS as well as the activation of T- and B- cell mediated effector mechanisms 
require intercellular communication between antigen presenting (APC) and effector 
cells. Thus, various chemokines and cytokines, as well as specific interactions 
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through accessory/activation molecules on the cell surfaces regulate the initiation 
and progression of autoimmune responses. 
Several adhesion molecule interactions, i.e. VLA-4/α4 integrin and LFA-1/
ICAM-1, have been implicated to play a crucial role in the development of MS and 
EAE4-6. CD44 and its variant isoforms (CD44v) are also important adhesion molecules. 
Ten CD44v isoform exons (v1-v10) can be alternatively spliced and inserted into the 
CD44s backbone, potentially forming over a thousand different CD44v isoforms. 
Interestingly, CD44 and its isoforms are involved in various biological processes 
such as lymphocyte activation, migration, adhesion, extravasation into inflammatory 
sites and protection against apoptosis7-11. Furthermore, MMP-9, involved in the 
degradation of type IV collagen, can bind specific glycans of CD44 and in addition 
may activate latent TGF-β12. Additionally, osteopontin, a proinflammatory cytokine, 
can bind to CD44v6/v7 isoforms13. Both these ligands have been shown to promote 
the progression of MS and EAE14-16. CD44 plays not only an essential role in EAE17,18 
but also in other autoimmune disease models such as rheumatoid arthritis19,20, and 
diabetes21. In these models, treatment with an anti-panCD44 Mab, which recognizes 
all CD44 molecules, completely abrogated disease development. 
Physiologically, CD44s is ubiquitously expressed on various cells, while the 
expression of CD44v isoforms is restricted to activated leukocytes and epithelial cells22. 
Recently CD44 has been shown to associate with VLA-4 on T cells extravasating to 
inflammatory lesions9. Targeting CD44v isoforms, which are specifically upregulated 
on activated leukocytes, may therefore reduce inflammatory responses and refine 
therapeutic approaches. In fact, blocking a selected number of CD44v isoforms 
reduces or prevents autoimmune disease development. In TNBS-induced colitis, an 
animal model for inflammatory bowel disease, treatment with Mab anti-CD44v7, but 
not with Mab anti-CD44v10 prevents disease23. Accordingly, mice with a targeted 
deletion for CD44v7 develop only transient and minimal disease8,24,25. Corresponding 
lesions contain high numbers of apoptotic cells, indicating that absence of CD44v7 
might protect from autoimmunity by mediating apoptosis of inflammatory cells. 
So far, very little is known about the role of different variant isoforms of CD44 in 
MS and its animal model EAE. Increased expression of CD44 on astrocytes in active 
lesions in MS brain could be associated with the pathogenesis of the disease26. 
In an adoptive transfer mouse EAE model, it has been shown that CNS infiltrated 
MBP-specific CD4+ T cells, representing the effector/memory phenotype, specifically 
expressed CD44 and CD45RB(low)27. Previously, we have shown panCD44 and 
CD44v10 expression on mononuclear cells infiltrating the CNS of mice with EAE, 
whereas CD44v6 was not expressed. 
In order to determine the functional involvement of selected CD44v isoforms in 
EAE and MS we assessed the expression of CD44v3-v10 in post-mortem MS brain 
tissue. Furthermore, we specifically addressed the role of CD44v7 and CD44v10 
in EAE development using mice with single deletions for these specific CD44v 
isoforms. 
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Materials and methods
Patients and brain tissue samples
Human post-mortem brain tissue was provided by the Netherlands Brain Bank 
(Coordinator: Dr. R. Ravid, Amsterdam). Information regarding MS patients and 
non-demented control subjects is shown in Tables 1a and b, respectively.
Histological staging of MS brain lesions
Brain lesions were quantified by immunohistology. To determine the stage of 
the MS lesions, a generally accepted staging system was used28. An additional 
stage, the so called pre-active lesion had been described in combination with 
MRI measurements29. Despite the fact that it is not proven that pre-active lesions 
progress into active lesions, they reflect abnormalities in the white matter, that 
Table 1b. Clinical and neuropathological data of non-demented controls. 
Case Sex Age 
(yrs)
Neuropathology
94/104 M 79 Many HLA-II-expressing cells in one area of the tissue.
94/110 M 83 No abnormalities.
96/016 M 63 Individual HLA-II-expressing cells throughout the tissue.
96/030 F 68 Some clusters and individual HLA-II-expressing cells throughout the tissue.
96/132 F 90 Small clusters of HLA-II-expressing cells in one area of the tissue.
96/238 F 87 Many HLA-II-expressing cell clusters throughout the tissue.
96/249 F 78 Many HLA-II-expressing cell clusters throughout the tissue.
Table 1a. Clinical and neuropathological data of MS patients.
Case Sex Age
(yrs)
Disease 
duration (yrs)
Number 
of lesions
Lesion stages
93/089 F 71       23 3 pre-active
93/319 F 39         3 1 chronic active
95/148 F 56         6 4 pre-active
96/102* F 74       24    1 pre-active
96/232a F 40         4 4 3 pre-active and 1 active demyelinating
3 pre-active, active demyelinating and 
chronic inactive
96/234 F 81      49 0
96/352 F 53      13 2 active demyelinating and chronic inactive
97/024# F 62      25 1 pre-active
97/189 F 82      15 3 pre-active
97/202 M 50      17 2 pre-active* and chronic active
* Not analyzed for CD44v10 expression
# Not analyzed for CD44v3 expression
a Two different tissue samples
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might preceed the development of active lesions and were therefore included in 
our study. 
Pre-active lesions include the presence of HLA-II-expressing clusters of 
activated microglia cells, few perivascular inflammatory cells, but no phagocytic 
cells containing myelin breakdown products or areas of demyelination. Active 
lesions are represented by the additional presence of demyelinated areas. 
Phagocytic cells in these areas contain myelin breakdown products, which can be 
visualized by oil red O, a histochemical staining for neutral lipids. In these lesions, 
HLA-II is strongly expressed by perivascular and parenchymal MΦ. To evaluate cell 
numbers in lesions we used a previously published 5-point scale system6.
Immunohistological staining for CD44v isoforms in human brain tissue
Immunohistological staining was performed as described30,31. In addition, the 
Tyramide Signal Amplification (TSA) Biotin System (Perkin Elmer, Boston, MA) 
was used, according to the manufacturer’s instructions. Antibodies of the isotype 
IgG2a (Table 2) were applied with 25% normal human serum to prevent binding to 
Fc-receptors. Horseradish peroxidase conversed 3-amino-9-ethyl-carbazole into a 
bright red precipitate. Nuclei were counterstained by hematoxylin. Reactive human 
tonsil sections were included in each staining procedure as positive control tissue.
Generation of CD44v10-deficient mice
The mouse CD44variant region was isolated from a 129SV genomic library. Two 34 
bp loxP sites were inserted in direct repeats into a single BstEII site 5’ of exon v10 
and at the 3’ end of the neor cassette, which was then inserted into the single BstXI 
site 3’ of exon v10. For electroporation the targeting vector was linearized with PvuI 
and 20 µg were transfected into 107 R1 embryonic stem cells. Embryonic stem 
Table 2. Antibodies against human CD44v isoforms. 
Marker Isotype-label Clone designation Supplier/ Reference
CD44v3 IgG2b 3G5 R&D Systems, Oxon, UK
CD44v4 IgG2a-biotin FW11.10 22
CD44v5 IgG1-biotin VFF-8 Bender Medsystems, Vienna, Austria 
CD44v6 IgG2a-biotin FW11.9 22
CD44v7 IgG1 VFF-9 Bender Medsystems
CD44v7 polyclonal n.a. Chemicon International, Hampshire, UK
CD44v7/v8 IgG1-biotin VFF-17 Bender Medsystems
CD44v9 IgG1 FW11.24 22
CD44v10 IgG1 VVF-14 Bender Medsystems
Isotype control IgG1 11711.11 R&D Systems
Isotype control IgG2b MPC-11 BD Biosciences, San Jose, CA 
Isotype control IgG2a 20102.1 R&D Systems
Isotype control IgG2a-biotin 20102.1 R&D Systems
(n.a.) not applicable 
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cells were maintained on a feeder layer of embryonic fibroblasts in the presence of 
leukemia inhibitory factor. After selection with G418 (300 µg/mL) 391 clones were 
analyzed by Southern blotting using a 3’ external probe (HindII-BamHI). BamHI 
digests revealed that 2 clones showed homologous recombination. Positive clones 
were injected into C57BL/6 blastocysts and chimaeric male offspring was mated 
with C57BL/6 cre deleter females. Offspring was genotyped by PCR using exon 
v10 flanking oligos and analyzing for deletion of the loxP targeted region.
Mice
Female CD44v7-/- and CD44v10-/- mice were bred in the mouse facility at the Institute 
of Medical Microbiology, Basel or at the Erasmus MC, Rotterdam and backcrossed 
for ≥ 10 generations on the appropriate C57BL/6 or SJL/J background depending 
on the experiment. All mouse experiments were performed in accordance with 
Swiss and Dutch law and were approved by institutional ethics comittees and the 
local authorities. Mice were housed under specified pathogen free conditions and 
received water and food ad libitum. Paralyzed mice with EAE scores over 2.5 were 
afforded easier access to food and water. 
Induction and clinical evaluation of EAE 
C57BL/6 mice were immunized s.c., at four sites (axillar and inguinal), with 200 µg 
MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) in 0.1 ml PBS emulsified in an equal 
volume of CFA containing 100 µg Mycobacterium tuberculosis (H37/Ra; Difco 
Laboratories, Detroit, MI). All mice were injected i.p. with 200 ng of Bordetella 
pertussis toxin in 0.2 ml PBS on days 0 and 2 (Sigma-Aldrich). SJL/J mice were 
immunized with 50 or 100 µg PLP139-151 (HSLGKWLGHPDKF) in 0.1 ml PBS 
emulsified in 0.11 ml of CFA containing 110 µg M. tuberculosis. For adoptive 
transfer, lymph nodes (SJL/J) or lymph nodes and spleens (C57BL/6) were isolated 
10 days after immunization. Crude cell suspensions (4x106/ml) were cultured at 
37°C and 5% CO2 in the presence of 10 µg/ml MOG35-55 (C57BL/6) or 10 µg/ml 
PLP139-151 (SJL/J) for 4 days, washed and then injected into recipient mice. 
Mice were weighed and scored for clinical signs of EAE daily according to the 
following internationally accepted scoring system: 0, no disease; 0.5, partial tail 
paralysis; 1, complete tail paralysis; 1.5, limb weakness without tail paralysis; 2, 
limb weakness and tail paralysis; 2.5, partial limb and tail paralysis; 3, complete 
hind or front limb paralysis; 3.5, paraplegia; 4, quadriplegia; 5, death due to EAE. 
Cumulative EAE scores were calculated by adding up all the scores per animal over 
the indicated time points after EAE induction, representing a total disease load. 
Histopathology of mouse CNS
Mice were euthanized and brain or spinal cord tissues were snap frozen in liquid 
nitrogen. Frozen sections were fixed in acetone and stained with hematoxylin.
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Isolation of mononuclear brain cells
Mononuclear cells were isolated from brain tissues as described32. Briefly, brains 
were removed and single cell suspensions were prepared by passage through 
a wire mesh. After washing, cells were resuspended in 7 ml of 80% Percoll 
(Pharmacia, Uppsala, Sweden), and then overlaid with 8 ml of 40% Percoll to form 
a discontinuous gradient in a 15-ml centrifuge tube. The gradient was centrifuged at 
400 g for 40 min at 21ºC, and the cells at the 40–80% interface were harvested. 
Flow cytometry
Immunofluorescence analysis of cells was performed on a FACScanTM (Becton 
Dickinson, Mountain View, CA). PLP139-151-restimulated lymph node cells and 
mononuclear brain cells were incubated with the specific Mabs for 30 min at 4°C 
in staining buffer (PBS with 2% FCS and 0.02% sodium azide). The following 
antibodies were used: CD4 (clone GK1.5, rat IgG2b), CD8 (Ly-2)(clone 53-6.7, 
Rat IgG2a), CD45R (B220)(clone RA3-6B2, rat IgG2a) and CD11b (Mac-1)(clone 
M1/70, rat IgG2b), isotype control (clone R35-95, rat IgG2a), all purchased from 
PharMingen (San Diego, CA) and CD44v10 (clone K926, rat IgG2a)33. The goat 
anti-rat IgG secondary antibody used to detect CD44v10-expressing cells was 
obtained from Southern Biotechnology, Birmingham, AL. As a negative control for 
CD44v10 an isotype matched control antibody of irrelevant specificity was used. 
Dead cells and debris were excluded using propidium iodide. 
MOG35-55- and PLP139-151-specific T cell proliferation assay
Lymph node cells (4x105/well) were cultured in 96-well plates in 200 µl of RPMI 
1640 supplemented with 10% heat-inactivated FCS (Sigma-Aldrich), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Bio Whittaker) in the presence or absence 
of MOG35-55 or PLP139-151. After 72 h of culture, 1 µCi of [3H]-thymidine (Amersham 
Biosciences, Buckinghamshire, England) was added for 16 h. Incorporation of [3H]-
thymidine was measured in triplicate using a filtermat harvester and a beta-plate 
counter (Perkin Elmer, Wellesley, MA). Alternatively, supernatants from MOG35-55 
proliferation assays were harvested 96 h after culture, centrifuged and stored for 
further cytokine analysis at -20°C.
Establishment of autoantigen-specific cell lines
After the first in vitro restimulation with 10 µg/ml MOG35-55 (C57BL/6) or PLP139-151 
(SJL/J) for 4 days, lymph node cells were washed and diluted 1:1 in complete 
RPMI. After a resting period of 10 days, cells were restimulated (1x106 cells/ml) 
with 1 µg/ml peptide for 4 days. Conditions of each following restimulation cycle 
were identical to the second restimulation.
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Cytokine measurement
IL-4, IL-10, IFN-γ and TNF-α levels were measured using OptEIA ELISA kits 
(BD Biosciences) according to the manufacturer’s instructions. Small volumes of 
supernatants were tested with the Cytometric Bead Array Th1/Th2 Cytokine kit (BD 
Biosciences) for the content of IL-2, IL-4, IL-5, IFN-γ and TNF-α by FACS analysis 
according to the manufacturer’s instructions.
Statistical evaluation
Statistical evaluation was performed using SPSS 11 software. The Mann-Whitney 
U test was used for the evaluation of differences in the onset of EAE, maximum and 
cumulative EAE severity scores. For analyzing differences in EAE incidences a χ2 
test was used. For analyzing statistical differences in proliferation, the stimulation 
index was used (cpm of antigen-stimulated cells divided by cpm of non-stimulated 
cells). Proliferation responses and cytokine levels were compared using ANOVA 
and the t-test. A p value of < 0.05 was considered statistically significant.
Results
CD44v3 and v10 are expressed in MS brain lesions 
To determine whether CD44v isoforms are expressed in MS and non-demented 
control brain tissues, we assessed the presence of CD44v3, v4, v5, v6, v7, v7/v8, 
v9 and v10 in post-mortem frozen brain sections by immunohistochemistry (Table 
2). Frozen sections of human tonsil were used as positive control tissue for the 
expression of CD44v isoforms. 
We did not observe specific staining for CD44v7 and CD44v7/v8 in reactive 
human tonsil and brain tissue. In accordance with these finding, it has been shown 
that immuno-staining with both Mab anti-CD44v7 (VFF-9) and anti-CD44v7/v8 
(VFF-17), by flow cytometry and immunohistochemistry resulted in false negative 
results34. By using transfected cell lines it was shown that Mab anti-CD44v7 (VFF-
9) does not detect unglycosylated CD44v7 molecules. Glycosaminoglycan side 
chains can modulate the conformation of CD44 molecules35, and can expose the 
CD44v7 epitope for Mab binding. Most likely, CD44v7 molecules are expressed 
in MS and reactive human tonsil, since this epitope is specifically upregulated at 
sites of chronic inflammation, in patients with Crohn’s disease and rheumatoid 
arthritis36,37. Therefore, we have functionally assessed the role of the CD44v7 
molecule in the development of mouse EAE, as described below. 
In contrast to epithelial cells in human tonsil tissue, we could not detect CD44v4, 
v5, v6 and v9 expressing cells in MS and non-demented control brain tissue. 
CD44v3 and v10, on the other hand, were expressed in MS brain tissue samples 
(n=9 patients) containing different lesion stages (Table 1a and Table 3). CD44v3-
expressing cells were sporadically observed in perivascular infiltrates of pre-active 
CD44v isoforms in MS and EAE 137
lesions (Table 3). In active lesions, CD44v3 was expressed by many of the foamy 
MΦ. CD44v10 was expressed on endothelial cells in brain tissue from MS patients 
and non-demented controls (Figure 1C). CD44v10 was also expressed on cells with 
a glial morphology in pre-active (Figure 1B, C) and active MS lesions, as well as in 
areas also containing HLA-II-expressing parenchymal cells from six out of seven 
non-demented control brain tissues (Table 1b). The number of v10-expressing 
cells was higher compared to the number of HLA-II-expressing cells (Figures 1 A, 
B). In 78% of pre-active perivascular infiltrates (n=72 infiltrates), few leukocytes 
expressed CD44v10 (Figure 1C). In addition, CD44v10 was also expressed by 
occasional to moderate numbers of foamy MΦ (Table 3 and Figure 1D). 
Figure 1. CD44v10 is expressed in MS brain tissue.
Pre-active lesions are characterized by HLA-DP/DQ/DR-expressing activated MΦ/microglia (A), 
which are located in perivascular infiltrates or in clusters in the brain parenchyma (A). An abundant 
cell number expressed CD44v10 in the parenchyma within pre-active lesions (B). These parenchymal 
v10-expressing cells had a fibrillary glial morphology (arrowhead) (C). Besides glial cells also few 
perivascular cells (arrow) and endothelial cells (asteriks) expressed CD44v10 (C). In active lesions a 
moderate to an abundant number of foamy MΦ expressed CD44v10 (D). Bar = 100 µm. 
(See Appendix page 227 for a full-color representation of this figure.)
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In conclusion, CD44v isoforms were differentially expressed in MS and non-
demented control white matter brain tissue. In normal white matter, glial cells did 
neither express CD44v3 nor CD44v10. However, in activated (HLA-II-expressing) 
areas, in both MS and non-demented control brain, fibrillary glial cells expressed 
CD44v10. In pre-active and active MS lesions, but neither in normal white matter 
from MS or non-demented controls, perivascular infiltrating leukocytes and foamy 
MΦ expressed both, CD44v3 and CD44v10.
CD44v10 expression correlates with EAE development
In accordance with our findings in MS lesions, we have previously shown that 
CD44v10 is also expressed by infiltrating cells in mouse EAE spinal cord tissue. 
Moreover, it is known that the combined treatment with Mab against the CD44v6, 
v7 and v10 isoforms reduces EAE severity38. To more specifically assess the 
functional role of CD44v10, we asked whether EAE development in C57BL/6 mice 
correlates with CD44v10 expression on specific brain cell subsets. 
Brain cells were isolated and evaluated for the expression of CD44v10 
on different cell subsets by flow cytometry at different time points after 
immunization. Analysis of mononuclear brain cell suspensions from both, CFA and 
CFA/MOG35-55 immunized mice, revealed CD44v10 expression on CD4
+ and 
CD8+ T cells, CD11b+ MΦ and B220+ B cells (Figure 2A-D). Thus, the presence 
of inflammatory cells is not dependent on encephalitogenic immune responses 
but rather correlates with the non-specific inflammatory response. However, 
the maximum number of all CD44v10+-expressing cells peaks earlier in 
CFA/MOG35-55 immunized mice than in CFA immunized controls (Figure 
2A-E). Furthermore, the number of CD4+ CD44v10-expressing cells was 
2-fold higher in mice immunized with CFA/MOG35-55 compared with CFA 
Table 3. Expression of CD44v3 and v10 in MS brain lesions.
CD44v isoform v3 v10#
lesion type area
pre-active parenchymal - +++*
perivascular ± +
active demyelinating ++/+++ +
chronic active hypercellular border
hypocellular rim
++
±
++
±
chronic inactive ± ±
* glial cells
# endothelial cell expression
positive cell number:
- none
± occasional
+ few
++ moderate, compare to perivascular CD44v10-expressing cells in Figure 1C
+++ abundant, compare to parenchymal CD44v10-expressing cells in Figure 1B
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immunized mice at days 11 and 15 after immunization (Figure 2A). In 
addition, CD44v10-expressing CD4+ T cells persisted in low numbers in 
CFA/MOG35-55 immunized mice, whereas a decrease back to baseline levels 
at day 54 after immunization was found in CFA immunized mice (Figure 2A).
In relation to the EAE course, elevated numbers of CD44v10-expressing cells 
were found in CFA/MOG35-55 immunized mice as early as 5 days after immunization 
(Figure 2E). Maximum numbers of CD44v10-expressing cells were detectable at 
day 11 after immunization, and preceded the peak of disease between days 17-22 
after immunization. During the remission phase (days 29 and 54 after immunization) 
CD44v10 cell numbers also decreased. 
Taken together, induction of non-specific inflammation results in the accumulation 
of CD44v10-expressing T cells, B cells and MΦ in the brain. Development of EAE is 
associated with a significant increase of infiltrating CD44v10+CD4+ T cells in CFA/
MOG35-55 immunized mice. These CD44v10-expressing cells persisted in the brain 
of EAE mice for up to 54 days after immunization.
Figure 2. Increase in brain infiltrating CD44v10+ cells upon CFA immunization.
C57BL/6 mice were naïve (open bars) or immunized with CFA alone (gray bars) or MOG35-55 with CFA 
(black bars). Brain cells were isolated at different time points after immunization. Bars represent the 
absolute number of CD44v10-expressing CD4+ T cells (A), CD8+ T cells (B), CD11b+ MΦ (C) B220+ B 
cells (D) and total brain mononuclear cells (E). Numbers above the bars indicate mean EAE scores (n=4 
mice). Note the higher scales for D and E, reflecting higher number of MΦ.
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Autoreactive CD4+ T cells express CD44v10 
Next, we addressed the capacity of CD44v10+ CD4+ T cells to mount autoreactive, 
encephalitogenic responses. First we determined the numbers of CD44v10- 
expressing CD4+ T cells in the draining lymph nodes of C57BL/6 mice after 
immunization with MOG35-55/CFA and in SJL/J mice immunized with PLP139-151 
at day 10 after immunization. Whereas CD44v10+ CD4+ T cells were present in 
lymph nodes of immunized C57BL/6 mice, they were detectable in SJL/J mice 
only after in vitro restimulation with PLP139-151. After two rounds of restimulation with 
PLP139-151, CD4
+ T cells proliferated dose-dependently (Figure 3A) accompanied 
by a dose-dependent upregulation of CD44v10 and CD25 (IL-2R, T cell activation 
marker)(Figure 3B). After three rounds of in vitro restimulation CD44v10 was 
upregulated on 86-97% of the CD4+ T cells. 
Figure 3. CD44v10+ CD4+ T cells respond specifically to autoantigen.
CD4+ T cells were restimulated and proliferated dose-dependently to PLP139-151 (A). Upon restimulation, 
CD44v10 was dose-dependently upregulated on PLP139-151-specific CD4
+ T cells (B). Ten days after 
MOG35-55/CFA immunization CD4
+ T cells were sorted for CD44v10 expression. CD4+CD44v10+ T cells 
responded specifically to MOG35-55 (C) and survived thirteen rounds of restimulation (D). 
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To determine whether CD44v10 is important for APC cell proliferation, 
lymph node cells were isolated 11 days after immunization of 
C57BL/6 mice with MOG35-55/CFA and CD4
+ T cells were sorted for CD44v10 
expression. As shown in Figure 3C, CD4+CD44v10+ T cells expanded in vitro 
on MOG35-55-pulsed irradiated APC. In contrast, CD4
+CD44v10- T cells did not 
proliferate. An intrinsic defect of CD4+CD44v10- T cells to respond to activation 
was excluded by the observation that these cells showed strong proliferation upon 
ConA stimulation (data not shown). In addition, CD4+CD44v10+ T cells survived 
thirteen rounds of in vitro restimulation with MOG35-55 (Figure 3D). 
Taken together, these data show that antigen-specific in vitro expansion of CD4+ 
T cells is restricted to the CD44v10-expressing population. 
Genetic deletion of CD44v7 and CD44v10 protects from EAE
To test the hypothesis that CD44v7 and v10 are crucial for the development of 
EAE, we determined how genetic deletion of CD44v7 or CD44v10 affects EAE 
susceptibility. 
As shown in Tables 4a, 5, and Figure 4, disease severity was significantly 
reduced by deletion of CD44v7 in both SJL/J and C57BL/6 mice compared to 
wild type mice. Genetic deletion of one CD44v7 allele (CD44v7+/-) did not affect 
EAE (Table 5). Histopathological analysis of SJL/J spinal cord tissues obtained 
at different time points after immunization revealed a delayed development of 
infiltrates in CD44v7-deficient mice (Figure 5). As expected, a correlation was 
found between delayed infiltration and delayed onset of EAE development (Table 
5, experiment 1).This delay in onset of EAE between CD44v7-/- and wild type mice 
was observed in 2 out of 6 experiments, suggesting that deletion of CD44v7 does 
not per se lead to a delayed influx of inflammatory cells into the spinal cord. 
Table 4a. Clinical parameters of actively-induced EAE in C57BL/6 mice. 
Genotype Number of 
mice
Disease 
incidence (%)
Disease onset# 
(day)
Maximum 
score#
Cumulative 
score# (day)
wild type 6 100 11.7 ± 0.5 3.1 ± 0.3 26.3 ± 9.3 (29)
CD44v7-/- 7 71 10.4 ± 1.9 1.9 ± 1.2 12.5 ± 8.2* (29)
wild type 16a 100 11.7 ± 1.4 3.4 ± 0.6 44.0 ± 7.8 (28)
CD44v7-/- 13a 92 14.7 ± 2.8** 3.1 ± 1.0 31.4 ± 13.7* (28)
wild type 13 77 10.3 ± 1.3 1.7 ± 1.1 23.0 ± 24.4 (55)
CD44v7-/- 12 67 18.0 ± 10.3 1.5 ± 1.4 14.5 ± 17.0 (55)
CD44v10-/- 14 43 12.5 ± 1.4* 0.4 ± 0.5** 4.6 ± 7.7* (55)
wild type 6 100 10.2 ± 1.3 2.0 ± 0.5 4.8 ± 2.4 (12)
CD44v7-/- 6 33* 10.5 ± 0.7 1.5 ± 0.7* 1.1 ± 2.0* (12)
CD44v10-/- 6 0.0** 0.0** 0.0** (12)
# mean values ± SD
a 1 mouse died due to EAE (score 5), and was excluded from calculations after that time point 
* p < 0.05 compared with wild type mice
** p < 0.005 compared with wild type mice
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Fifteen and 20 days after immunization, spinal cord infiltrates were reduced in 
number and size in six out of eight CD44v7-/- mice compared to wild type mice. 
These findings correlated with the absence of EAE development or reduced EAE 
severity in CD44v7-/- mice (Figure 5). In contrast, no differences in the number 
and size of infiltrates were observed in brain tissue derived from wild type and 
CD44v7-/- mice 5, 10, 15 and 20 days after immunization (data not shown). 
Similar to CD44v7-/- mice, CD44v10-/- C57BL/6 mice also showed significantly 
reduced cumulative EAE scores compared to wild type controls after MOG35-55/CFA 
immunization (Table 4a). Histological analysis of brain and spinal cord tissues 12 
days after immunization revealed a similar extent of infiltrates in the brain tissue of 
CD44v10-/- and wild-type mice (Table 4b). However, analysis of spinal cord tissues 
Figure 4. CD44v7 deletion in two different mouse strains results in reduced EAE burden, induced 
by active immunization.
C57BL/6 were immunized with MOG35-55 (A, C) and SJL/J mice were immunized with PLP139-151 
(B, D). Cumulative scores of wild type mice (A, B) were significantly higher (p<0.05) compared to 
CD44v7-/- mice (C, D). Mice were weighed and scored for clinical signs of EAE daily. Bars represent the 
mean clinical scores, lines the mean weight.
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revealed no infiltrates in CD44v10-/- mice compared to wild type controls. Accordingly, 
CD44v10-/- mice did not develop clinical signs of EAE, 12 days after immunization.
 In summary, both CD44v7- and CD44v10-deficient mice develop reduced clinical 
EAE scores compared to wild type mice. Strikingly, this observation is paralleled 
by reduced inflammatory infiltrates in the spinal cord, but not in the brain tissue of 
CD44v7- and CD44v10-deficient mice.
Distinct roles for CD44v7 and CD44v10 isoforms expressing antigen-specific 
T cells
As previously described, CD44v isoforms are involved in APC-T cell interactions 
and modulation of T cell proliferation and cytokine production33,39-41. In order to 
address the mechanisms explaining the reduced EAE severity in CD44v7-/- and 
CD44v10-/- mice, we asked whether autoantigen-specific lymph node cell proliferation 
Table 4b. Histological analysis of CNS infiltrates in C57BL/6 mice.
Genotype Cumulative 
score 
Infiltrate number Infiltrate size
brain sc brain sc
wild type 4.5 10 6 ++ ++
wild type 6.0 7 8 + ++
CD44v7-/- 5 4 10 + ++
CD44v7-/- 0 2 1 ± ±
CD44v10-/- 0 7 0 ++ -
CD44v10-/- 0 7 0 ++ -
sc spinal cord
Infiltrate size
- no infiltrating cells
± 1-50 cells  small
+ 51-500 cells  medium
++ > 500 cells  large
Table 5. Clinical parameters of actively-induced EAE induced in SJL/J mice.
Genotype Number 
of mice
Disease 
incidence (%)
Disease onset# 
(day)
Maximum 
score#
Cumulative 
score# (day)
wild type 10 70 11.1 ± 0.7 1.6 ± 1.5 7.4 ± 5.4 (20)
CD44v7-/- 9 33 13.0 ± 1.0* 2.0 ± 1.4 1.8 ± 3.9* (20)
wild type 10 80 12.1 ± 0.8 1.6 ± 1.1 10.7 ± 13.2 (48)
CD44v7+/- 5 80 12.5 ± 1.7 1.6 ± 1.2 12.3 ± 17.0 (48)
CD44v7-/- 6 33 13.5 ± 1.5 0.4 ± 0.2* 1.0 ± 1.4* (48)
wild type 10 70 11.7 ± 0.8 0.8 ± 1.1 10.2 ± 10.6 (35)
CD44v7+/- 10 40 13.0 ± 1.4 0.6 ± 0.8 6.5 ± 12.2 (35)
CD44v7-/- 10 20* 12.5 ± 0.7 0.3 ± 0.7 1.1 ± 2.3* (35)
# mean values ± SD
* p < 0.05 compared to wild type mice
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and cytokine production is altered. 
Results from three independent experiments showed that in SJL/J and C57BL/6 
mice, CD44v7-deficiency resulted in moderate time-dependent effects on 
autoantigen-specific T cell proliferation (Figure 6A-C). At day 5 after immunization, 
lymph node cells from CD44v7-deficient SJL/J mice (n=5 mice) showed a variable 
proliferative response against PLP139-151, which was significantly increased (p<0.05) 
Figure 5. Reduced infiltration in spinal cord tissue from CD44v7-/- SJL/J mice.
Wild type and CD44v7-/- SJL/J mice were immunized with PLP139-151 in CFA. The number and size of 
infiltrates was determined in spinal cord tissues, which were isolated at the indicated time points. Bars 
indicate the number and size of infiltrates in individual mice.
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Figure 6. Time-related effects of CD44v7 deletion on autoantigen-specific T cell proliferation. 
At different time points after immunization with PLP139-151 (A, B) or MOG35-55 (C) in CFA, draining lymph 
node cells were isolated and restimulated in vitro with the respective antigens for 4 days. Autoantigen- 
specific T cell proliferation of CD44v7-/- or CD44v7+/- cells was compared to wild type cells. Lines 
represent cpm values of individual mice. (∗) p<0.05
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compared with wild type cell proliferation (Figure 6A). 
Twelve days after immunization, C57BL/6 CD44v7-/- and CD44v10-/- lymph node 
cells proliferated equally well as wild type cells upon in vitro restimulation with 
MOG35-55 (data not shown). Similar results were found with SJL/J mice at days 10 
and 15, respectively (Figure 6A). No overt differences were observed in IFN-γ levels 
between C57BL/6 CD44v10-/- and wild-type lymph node cells (wild type: 2413 ± 84 
pg/ml, CD44v10-/-: 2806 ± 78 pg/ml) with 10 µg/ml MOG35-55. Upon restimulation with 
10 µg/ml MOG35-55, CD44v10-/- cells produced higher levels of IL-10 (356 ± 2 pg/ml) 
compared to wild type cells (114 ± 6 pg/ml). In both, groups the levels of TNF-α and 
IL-4 were below the detection limit of the ELISA. In SJL/J mice IFN-γ, IL-4 and IL-10 
levels did not differ between wild type and CD44v7-/- mice (data not shown).
To assess whether differences were present in the T cell or APC compartment, we 
purified CD4+ T cells from wild type and CD44v7-/- mice at day 10 after immunization. 
CD44v7-/- and wild type CD4+ T cells were co-cultured with CD44v7-/- and wild type 
irradiated spleen cells as APC and restimulated with different concentrations of 
MOG35-55. In all combinations, T cells proliferated equally well in a dose-dependent 
response upon restimulation with MOG35-55 (data not shown). Furthermore, levels of 
IFN-γ, TNF-α, IL-2, IL-4 and IL-5 did not differ (data not shown).
 In the remission phase of EAE, 20 days after immunization, a modest decrease 
in T cell proliferation of SJL/J CD44v7-/- lymph node cells compared to wild type cells 
was observed with 20 µg/ml PLP139-151 (Figure 6A). Also at day 52 after immunization, 
CD44v7-/-, but not CD44v7+/-, lymph node cells (n=10 mice per group) proliferated 
significantly less (p<0.05) upon restimulation compared to wild type cells. More 
pronounced effects of CD44v7 deletion were observed in C57BL/6 MOG35-55-specific 
T cell proliferation responses at day 43 after immunization. While autoantigen-
specific T cell proliferation was observed with cells from all wild type mice (n=4), 
CD44v7-/- cells did not respond to MOG35-55 restimulation, with the exception of 1 
animal (Figure 6C). Addition of IL-2 only partially restored proliferation, since a 
significant decrease (p<0.05) in T cell proliferation compared to wild type cells was 
still observed in CD44v7-/- mice (n=4).
These data indicate that CD44v7-/- lymph node cells were capable to proliferate 
in an autoantigen-specific manner, however the capacity to expand upon antigen 
challenge is reduced during the remission phase of EAE (day 20-52). 
CD44v7 deficiency affects both autoreactive T cells and the non-T cell 
compartment 
To determine how CD44v7 affects the capacity of T cells to transfer EAE in recipient 
mice, C57BL/6 wild type mice were injected with MOG35-55-specific, either wild 
type or CD44v7-deficient CD4+ T cells (Table 6). Compared to wild type cells, 
MOG35-55-specific CD44v7
-/- cells did not induce EAE after transfer in C57BL/6 wild type 
recipients. CD44v7 deletion in recipient mice also resulted in a significantly reduced 
severity of EAE compared to wild type mice, upon injection with wild type cells. 
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In SJL/J mice, both wild type and CD44v7-deficient effector cells induced disease 
in wild type mice (Table 6). Two individual adoptive transfer experiments in SJL/J 
mice were performed in separate laboratories (Table 6, Figure 7). Injection of 5 or 
15 million wild type cells into wild type recipients showed similar cumulative disease 
scores, however in contrast to our expectation, the maximum EAE score was higher 
in the experiment where 5 million cells were injected. In both SJL/J experiments wild 
type and CD44v7-deficient effector cells could induce disease efficiently in wild 
type mice (Table 6). Disease onset was delayed upon injection of 5 million, but 
not 15 million CD44v7-/- cells compared to wild type cells. A significant reduction 
in cumulative EAE scores occurred upon injection of 15 million cells into CD44v7-/- 
recipient mice, but not in the experiment where 5 million donor cells were injected 
(Figure 7). However, using 5 million cells, a pronounced reduction in total EAE 
burden was also found when both donor and recipient cells were deficient for 
CD44v7 (Figure 7A). 
Taken together, these data show in two different mouse strains that CD44v7 
deficiency affects both the autoreactivity of CD4+ T cells and susceptibility of the 
recipient.
Table 6. Clinical parameters of EAE induced by adoptive transfer.
Strain cell 
numbera
Genotype
cells – mice
Number 
of mice
Disease 
incidence (%)
Disease
onset# (day)
Maximum 
score#
Cumulative 
score# (day)
C57BL/6 wt – wt 5 100 8.2 ± 1.6 2.5 ± 0.3 17.8 ± 5.9 (33)
4x106 wt – v7-/- 5 60 7.0 ± 0.0 1.8 ± 0.5* 6.3 ± 5.7* (33)
v7-/- – wt 5 0*** 0.0** 0.0** (33)
SJL/J wt – wt 4 100 7.5 ± 0.9 3.1 ± 0.4 42.3 ± 19.0 (37)
5x106 wt – v7-/- 4b 100 6.5 ± 0.5 3.9 ± 0.7 65.0 ± 17.9 (37)
v7-/- – wt 4 100 12.8 ± 3.9* 2.5 ± 0.8 25.3 ± 16.9 (37)
v7-/- – v7-/- 4 100 10.8 ± 2.5 2.5 ± 0.6 17.6 ± 8.5 (37)
SJL/J wt – wt 6 100 7.2 ± 1.0 2.5 ± 0.6 41.1 ± 3.6 (30)
15x106 wt – v7-/- 6 83 9.8 ± 3.1 1.4 ± 0.9 7.3 ± 4.4*** (30)
v7-/- – wt 6 83 7.0 ± 0.9 2.5 ± 0.4 33.4 ± 13.1 (30)
v7-/- – v7-/- 6 100 7.8 ± 1.9 2.1 ± 1.1 16.6 ± 8.7*** (30)
wt wild type
v7-/- CD44v7-/-
# mean values ± SD
a number of injected in vitro reactivated auotantigen-specific cells
b 1 mouse died due to EAE, and was excluded from calculations after that time point
mice – cells donor cells injected into recipient mice
*  p < 0.05 compared to wt - wt
**  p < 0.01 compared to wt - wt
***  p < 0.005 compared to wt - wt
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Discussion
This study shows that CD44v3 and CD44v10 are expressed in inflammatory brain 
lesions in MS patients. In agreement with previous findings where combined Mab 
treatment against CD44v6, v7 and v10 reduced EAE disease burden38, we here 
moreover show that absence of CD44v7 or CD44v10 by genetic deletion reduced 
the severity of EAE, which was associated with reduced infiltration of the spinal 
cord. 
A role for CD44v3 and v10 in MS 
It has been shown previously that panCD44 is expressed constitutively by normal 
white matter astrocytes under normal conditions and expression is upregulated in 
MS brain lesions26,42-45. In contrast, CD44v isoforms are not expressed by glial cells 
under normal conditions45. However, upon in vitro stimulation, mouse astrocytes do 
express CD44v6/v7- and CD44v10-containing isoforms46. In agreement with these 
findings we describe here that glial expression of CD44v10 isoforms is restricted to 
activated areas (HLA-II-positive) of the brain, in non-demented controls and in MS 
patients. CD44v3-v6 and CD44v9 were not expressed in these activated regions. 
We could not assess the expression of CD44v7 and CD44v7/v8 isoforms, which 
may partly be explained by the incapability of the Mabs to stain unglycosylated 
Figure 7. CD44v7-deficiency reduces EAE severity, induced by adoptive transfer. 
CD44v7-/- or wild type donor mice were immunized with PLP139-151 in CFA. Draining lymph node cells 
were isolated at day 10 after immunization and restimulated for 4 days with 10 µg/ml PLP139-151. Wild 
type or CD44v7-/- recipient mice were injected with 5 or 15x106 wild type or CD44v7-deficient PLP139-151 
reactivated lymph node cells (A and B, respectively). Mice were weighed and scored for clinical signs 
of EAE daily. Bars represent mean cumulative EAE scores. The cumulative EAE score is a measure for 
the severity of the disease. This was calculated by adding up all the scores per animal over the indicated 
time points after EAE induction, representing the total disease load. 
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CD44v isoforms, as previously described34. 
Furthermore, CD44v10 was expressed by endothelium and perivascular 
infiltrating cells in MS brain tissue and may well participate in the migration and 
adhesion of cells, as such functions of CD44v10 have been described previously47,48. 
Additionally, CD44v3 is involved in extravasation of leukocytes as described in 
mouse delayed-type hypersensitivity49, and may as well participate in leukocyte 
extravasation in MS. Under inflammatory conditions, such as TNF-α stimulation, 
human monocytes differentiate into dendritic cells and express CD44v350. This 
finding may explain why CD44v3 is expressed only occasionally by perivascular 
infiltrating cells (including monocytes) in pre-active lesions, but by many foamy 
MΦ in active MS brain lesions. CD44 can be post-translationally modified by 
the attachment of sulfate groups51,52. Sulfated proteoglycans are binding sites 
for growth factors, chemoattractants and cytokines53,54. CD44v3- and CD44v10-
expressing cells in MS brain can potentially carry heparin and chondroitin sulfate 
side chains and as such may function as a collector of inflammatory mediators. 
Additionally, CD44v3-expression may stimulate the production of proinflammatory 
cytokines, since blocking CD44v3 in Th cell and APC interactions by Mab treatment 
reduced the production of IL-2, IL-12 and IFN-γ49.
How might CD44v10 deletion impair the development of EAE? 
A minority of mouse lymph node cells expresses CD44v10 under normal 
conditions55. However, upon in vitro or in vivo stimulation CD44v10 expression 
is upregulated by T cells, B cells and MΦ49,55. In agreement with these findings, 
we here show that CD44v10 expression is specifically upregulated on in vitro 
restimulated encephalitogenic CD4+ T cells. CD44v10 is also expressed by brain 
infiltrating leukocytes and CD44v10 expression parallels the development of EAE. 
Extravasation of CD44v10-expressing leukocytes to brain tissue is autoantigen 
independent, since these cells were also detected in brain tissue of CFA immunized 
control mice. This observation is not surprising, because it is well known that 
activated or resting memory T cells with irrelevant antigen specificity can migrate 
to the CNS27,56-58. MOG35-55-specific CD4
+CD44v10+ sorted T cells proliferate upon 
MOG35-55 restimulation, while CD4
+CD44v10- cells do not respond. As described 
previously, treatment with Mab anti-CD44v10 did not affect the proliferation of 
ConA stimulated spleen cells55. According with these findings, we demonstrate 
here that CD44v10-/- and wild type lymph node cells proliferate equally well upon 
restimulation with MOG35-55. Therefore it can be excluded that the reduced EAE 
burden in CD44v10-/- mice is the result of a lack of proliferation. 
Whereas proliferation was similar comparing wild type and CD44v10-/- cells, 
CD44v10-/- lymph node cells produced IFN-γ and elevated levels of IL-10 upon in 
vitro restimulation with MOG35-55. It has been described very recently that antigen- 
specific regulatory T cells producing IL-10 and IFN-γ develop during Th1 polarized 
responses59. The fact that MOG35-55-restimulated CD44v10
-/- lymph node cells 
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produced elevated levels of IL-10 compared with wild type cells may indicate that 
regulatory T cells are elevated or induced in CD44v10-/- mice and may explain the 
reduced EAE burden. Indeed, it was recently demonstrated that upon stimulation 
more CD4+CD25+CTLA-4+ T regulatory cells are present in CD44v7-/- mice60. Further 
evaluation of MOG35-55-restimulated CD44v10
-/- cells may demonstrate expression 
of the transcription factor Foxp3, which is known to be specifically expressed by 
regulatory T cells61.
How might CD44v7 deletion impair the development of EAE? 
Here we show in two mouse strains that the severity of EAE, induced by active 
immunization or adoptive transfer, was significantly reduced in CD44v7-deficient 
mice compared to wild type controls. Similar, but more pronounced effects of 
CD44v7-deficiency were observed in adoptive transfer EAE and T cell proliferation 
of C57BL/6 mice, compared with SJL/J mice. CD44v7 deficiency reduced EAE 
burden by modulating APC and/or T cell effector functions, since CD44v7 deficiency 
affected both compartments in adoptive transfer EAE. Proliferation of autoantigen-
specific cells was gradually regulated by CD44v7, since modest differences were 
observed in proliferation of CD44v7-/- cells before the onset and in the remission 
phase of EAE, compared to wild type cells. IL-2 could partially restore T cell 
proliferation defects of CD44v7-/- C57BL/6 cells, which is in agreement with the fact 
that CD44 can enhance T cell proliferation and IL-2 production, as described62,63. 
In conclusion, these findings may imply that early after sensitization CD44v7-
deficient cells proliferate faster, but eventually also exhaust faster, i.e. by a higher 
susceptibility to apoptosis, than wild type cells. 
Interestingly, reduced EAE burden in CD44v7-/- and CD44v10-/- mice is 
associated with a reduced number and size of infiltrates in spinal cord, but not in 
brain tissue. This finding may imply an impaired migration into the spinal cord or an 
increase in apoptosis of infiltrated cells. Accordingly, it was previously suggested 
that CD44v6 and CD44v10 may participate in the development of HAM/TSP, a 
chronic inflammatory disease of the spinal cord64. Alternatively, CD44v7/v10-
deleted cells may infiltrate the spinal cord, but are more susceptible to apoptosis. 
Constitutive CD44v7-expression prevents T cells from going into apoptosis, as was 
shown by in vitro anti-CD3 stimulation of in vivo pre-activated mesenteric lymph 
node cells. CD44v7 deletion resulted in opposite results60. Also in vivo, reduced 
disease development in TNBS-induced colitis in CD44v7-/- mice was associated 
with high numbers of apoptotic cells in inflammatory lesions of the gut8,24,25. Taken 
together, absence of CD44v7 might protect from EAE by an impaired adhesion 
to spinal cord tissue. Additionally, induction of apoptosis of inflammatory cells or 
induction of regulatory T cells could also reduce inflammation in CD44v7-/- mice.
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Concluding remarks 
Here we show that CD44v3 and CD44v10 were expressed in inflammatory 
lesions in the CNS of MS patients. In the development of mouse EAE, the 
number of CD44v10-expressing brain infiltrating cells correlated with disease 
activity. Furthermore, we provide functional evidence that CD44v7 and CD44v10 
deficiency reduced the clinical severity of mouse EAE. We have demonstrated a 
reduced number of inflammatory cells in the spinal cord tissue of CD44v7-/- and 
CD44v10-/- mice compared to wild type mice. CD44v10-/- mice produced elevated 
levels of IL-10 upon in vitro restimulation of lymph node cells with MOG35-55. In 
addition, a reduced proliferation of CD44v7-/- lymph node cells was found in the 
remission phase of EAE, upon in vitro autoantigen restimulation. The contribution 
of CD44v7 and CD44v10 in the development of EAE is likely dependent on cell 
migration, adhesion, apoptosis and T cell regulation, functions already attributed 
to these variant isoforms of CD44. These data indicate that modulating CD44v 
isoform expression and function might be used as a directed therapeutical 
approach for MS.
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Discussion
Autoantigen-specific T and B cells are a part of the physiologic immune repertoire 
in humans1,2, marmoset and rhesus monkeys3,4, but in general do not cause 
autoimmune disease. Even abnormally high frequencies of autoantigen-specific T 
cells do not induce disease, as in naïve SJL/J mice in which PLP139-151-specific T 
cells are not deleted during negative selection in the thymus5,6. So, an additional 
trigger is necessary to activate autoantigen-specific cellular effector functions. 
Several studies have demonstrated that the conditions in which autoantigen 
reactive cells are activated are crucial for the following events. In MS, autoreactive 
T and B cells might be activated in the CNS or in the periphery, as at both locations 
autoantigens can be presented by APC. In part I of this chapter it is discussed how 
PG and other TLR ligands may contribute to pathogenic immune responses in the 
CNS and in the periphery during MS and EAE.
The interactions between cell-cell and cell-ECM components are of crucial 
importance in the immunopathogenesis of MS and EAE. CD97 and CD44v isoforms 
have several cellular and ECM-related ligands and direct a wide variety of biological 
processes, e.g. leukocyte activation, costimulation, adhesion, transmigration and 
apoptosis. Both molecules participate in the immunopathogenesis of other chronic 
inflammatory diseases, as colitis and RA. We have examined the functional 
relevance of CD97 and CD44v isoforms in the immunopathogenesis of MS and 
EAE, which is discussed in part II. 
Part I, Does PG contribute to autoantigen-specific attacks 
against the CNS?
PG-containing cell subsets in MS and in EAE-affected non-human primate 
brain tissue 
The first indication that PG might be involved in the immunopathogenesis of MS 
arose from the fact that significantly higher numbers of PG containing cells were 
found in post-mortem brain tissue of MS patients than in control brain tissue7. PG 
was mostly present within MΦ, but also in DC. In chapter 2 we demonstrated that 
PG is also present within granulocytes in MS brain tissue. The cells that contained 
PG were localized in the edge of active lesions, around blood vessels, and in 
the normal appearing white matter. PG-containing cells in MS brain expressed 
antigen presenting (HLA-DR) and costimulatory molecules (CD40, CD80, CD86). 
Furthermore, PG-containing cells expressed proinflammatory (TNF-α, IL-1β, IL-6, 
IL-12, IFN-γ), anti-inflammatory (IL-4) and regulatory (IL-10) cytokines. These data 
indicate that PG-containing APC in MS brain are in a fully activated state.
In chapter 2 it is shown that numbers of PG-containing cells are also 
significantly elevated in the brain of marmoset and rhesus monkeys that developed 
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EAE, compared to non-EAE controls. The cells that contained PG in EAE-
affected monkey brain tissue were mostly neutrophils, some DC and although not 
determined here, most likely also MΦ and microglia. Granulocytes are one of the 
first cells that are present at inflammatory sites. They have a limited life span of 
approximately 4-22 h. By producing chemokines and cytokines, granulocytes are 
important in the attraction and activation of other leukocytes. PG might induce the 
production of inflammatory mediators by granulocytes. In agreement with this, in 
vitro studies demonstrated that PG induced production of MIP-2 and TNF-α by 
mouse granulocytes8. 
Most of the cells that contained PG in EAE-affected monkey brain tissue 
expressed CD11b (84-100%). CD11b expression is mainly restricted to myeloid 
cells, including monocytes, DC, MΦ, microglia and granulocytes. CD11b (also known 
as αM integrin) complexes with CD18 (β2 integrin) to form the Mac-1 heterodimer 
(also known as CR3) and binds to ICAM-1, C3b, fibrinogen and coagulation factor 
X. Mac-1 is involved in adherence of monocytes and granulocytes to stimulated 
endothelium and also in the phagocytosis of complement coated particles. EAE 
studies demonstrated that CD11b is functionally involved in the pathogenesis of 
EAE, since administration of anti-CD11b Mab delayed the onset and reduced the 
disease load of EAE when treatment was initiated at the first appearance of clinical 
signs9.
Recent in vitro data demonstrated that S. aureus PG induced expression of 
Mac-1 on human monocytes (Oude Nijhuis et al., 2005, submitted). Under shear 
stress, PG-induced Mac-1 expression enhanced the adhesion of monocytes to 
L-cells and ICAM-1 coated beads that could be inhibited by β2-integrin blocking 
antibodies. Furthermore, PG-stimulated monocytes migrated better towards the 
chemoattractant C5a. Other cell types are likely to respond to TLR triggering in 
a similar way. In accordance, the TLR4 agonist LPS induced Mac-1 expression 
on murine granulocytes, whereas expression was absent in TLR4-/- mice10. These 
granulocytes also adhered and transmigrated across endothelial cells in a CD11b-
dependent manner upon stimulation by LPS. Thus, PG and LPS induce CD11b 
expression (Figure 1), which is essential for the adhesion and transmigration of 
monocytes and granulocytes, and this likely applies to other myeloid cells as well. 
In addition, PG-induced CD11b expression may stimulate myelin phagocytosis by 
microglia and MΦ, a functional characteristic of CD11b11,12. 
Persistence of PG in the brain in relation to expression of lytic enzymes 
Lysozyme and NAMLAA/PGRP-L are the best characterized enzymes which in 
joint action abrogate the stimulatory capacity of PG13. Strikingly, lysozyme was 
only expressed occasionally by cells near blood vessels in MS and EAE-affected 
brain tissue (chapter 2), which is in agreement with previous studies14,15. These 
findings suggest that once cells have migrated into the brain, lysozyme production 
is turned off. In marmoset and MS brain tissue also NAMLAA was also expressed 
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in a restricted manner. In contrast, EAE-affected brain tissue from rhesus monkeys 
contained high numbers of NALMAA-expressing cells. This finding is not surprising, 
because rhesus monkeys develop an acute disease course, accompanied by 
large necrotic lesions with many neutrophils. Double labeling demonstrated that 
NAMLAA+ cells in the rhesus monkey brain lesions were predominantly neutrophils. 
The restricted expression of lysozyme and NAMLAA (except for NAMLAA that is 
highly expressed in rhesus monkey EAE) in brain tissue suggests that PG is not 
at risk to be degraded by these enzymes in the CNS. This does not exclude the 
possibility that the PG within granulocytes, DC and MΦ is partially degraded, 
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Figure 1. Model for the activation of autoreactive T cells by APC primed with S. aureus PG.
PG stimulates the immune system by binding to innate receptors (TLR2/Nod) on and within APC. 
S. aureus-derived PG is a potent activator of APC, by increasing antigen uptake, costimulatory and 
adhesion molecule expression, and antigen presentation. Furthermore, PG stimulates the production 
of many proinflammatory cytokines and chemokines. These proinflammatory factors can block 
immunosuppression by regulatory T cells (TR)
44. PG drives (auto)antigen-specific CD4+ Th1 polarization 
and expansion. Experimental evidence for this is provided in chapter 3. In addition, CD4+ Th1 cells 
may reciprocally activate APC, provide help for B cell responses (not depicted here), and help for the 
activation and expansion of autoreactive CD8+ T cells. PG may also induce activation of IL-6/IL-17 
producing CD4+ T cells by stimulating IL-23 production. These events can occur both in the periphery, 
within secondary lymphoid organs, and at sites of inflammation, i.e. the CNS in MS and EAE. The term 
APC in this figure represents several cell types, dependent on the location, e.g. DC, MΦ and microglia.
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since enzyme digestion might already have taken place in the periphery. The 
restricted expression of lyzosyme and NAMLAA in the CNS may contribute to PG 
accumulation and persistence inside the CNS, as described previously16. 
Only 25 to 48% of NAMLAA+ cells coexpressed CD11b, whereas 86% of 
PG-containing cells expressed CD11b in rhesus monkey EAE brain tissue. This 
difference is even more pronounced in marmoset EAE brain tissue. In this case an 
average of 95% of PG-containing cells expressed CD11b, whereas of all NAMLAA+ 
cells no more than 2% expressed CD11b. Comparable patterns were found in 
spleen tissue. In conclusion, these data strongly imply that PG and NAMLAA are 
mostly present in different cells. These data can be interpreted to mean that PG 
is partially or fully degraded in NAMLAA-expressing cells, at least to the degree 
that the remaining PG fragments are unrecognizable by Mab 2E9. Alternatively, 
NAMLAA expression might be switched on and off. That expression of NAMLAA 
can be induced is implied by the findings that peripheral blood monocytes and 
spleen MΦ do not express NAMLAA17, but under inflammatory conditions, as in MS 
brain (chapter 2), a few to moderate numbers of foamy MΦ expressed NAMLAA. 
Future research should assess how the expression of NAMLAA is regulated in 
granulocytes, MΦ and DC and whether the presence of PG modulates NAMLAA 
expression.
Microbial stimulation of autoimmune inflammatory responses within the 
CNS
Can CNS cells respond to PG?
PG accumulates during local inflammation in the brain tissue of patients with MS 
and EAE-affected marmoset and rhesus monkeys (chapter 2). PG stimulates 
the innate immune system by engaging TLR2/6 or Nod receptors (Figure 1). 
Cultured human glial cells, i.e. microglia, astrocytes and oligodendrocytes all 
expressed TLR2 mRNA18. By using quantitative TaqMan analysis it was shown 
that Nod2 mRNA was expressed at low levels in mouse brain tissue19. In contrast, 
expression of Nod 2 and Nod1 was not observed in human brain, as determined 
by Northern blot analysis20,21. This discrepancy may be related to the sensitivity 
of the techniques used to detect Nod2 mRNA in the different studies. It would 
be informative to determine which cells express Nod2 in brain tissue. Thus, in 
theory, glial cells can respond to PG, because they express the receptors that 
recognize PG. In vitro studies have indeed shown that PG is recognized by 
microglia and astrocytes. Primary mouse microglia22,23 and astrocytes24 produced 
several inflammatory cytokines (IL-1β, TNF-α) and chemokines (MIP-1β, MIP-2, 
MCP-1) after incubation with S. aureus PG (Figure 1). The inflammatory response 
of microglia and astrocytes was partially mediated by TLR2, since PG-induced 
responses were also present, although reduced, in TLR2-/- cells. S. aureus PG also 
induced expression of MHC-I and MHC-II and costimulatory molecules (CD80, 
CD86, ICAM-1) on murine microglia22,25. This means that PG-activated microglia 
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can potentially present antigens to CNS infiltrating T cells. This hypothesis was 
tested in vitro by using microglia from SJL/J mice25. Microglia were activated by 
S. aureus PG and subsequently incubated with PLP139-151. It appeared that PG-
stimulated peptide-pulsed microglia could induce proliferation of a costimulation-
dependent PLP139-151-specific CD4
+ T cell line. Microglia could also enhance the 
inflammatory potential of PG, because microglia have the capacity to digest S. 
aureus and release inflammatory muramyl peptides in vitro26. Taken together, 
microglia and astrocytes are fully equipped to recognize and respond to PG. 
By which mechanisms might PG in the CNS contribute to the development of 
autoimmune disease? 
A recent study has provided important insights on this issue27. In C57BL/6 mice, 
EAE does not develop unless PTX is injected systemically after immunization 
with MOG35-55 in CFA
28. Immunization with MOG35-55 in CFA induced activation 
and clonal expansion of potentially pathogenic autoantigen-specific Th1 cells, 
since these cells could efficiently transfer disease after in vitro reactivation with 
MOG35-55. The action of PTX is diverse and includes induction of differentiation 
and clonal expansion of Th1 cells, migration and adhesion to the BBB, and 
impairment of the BBB29-32. Nevertheless, migration of MOG35-55-specific Th1 cells 
into the CNS is not enough to induce disease, because BBB damage induced by 
an aseptic cryoinjury did not lead to autoimmune disease. Strikingly, intracerebral 
injection of CpG-DNA, a TLR9 ligand, induced severe clinical symptoms in mice 
that were immunized with MOG35-55 in CFA, but not in OVApeptide-CFA immunized 
control mice. Intracerebral injection of CpG induced mRNA expression of IP-10, 
MCP-3, MIP-1α, MCP-1 and CD40. Brain tissue injected with CpG-DNA contained 
an 11-fold increased frequency of MOG35-55-specific T cells compared to OVApeptide-
specific T cells. Furthermore, in vitro studies with brain derived APC demonstrated 
that the amount of IFN-γ produced by individual MOG35-55-specific CD4+ T cells 
was 3-fold increased upon incubation with MOG-pulsed CpG-activated APC, as 
compared to non-CPG DNA-treated APC. Collectively, these data show that the 
immunostimulatory state of APC inside the target organ determines whether or not 
autoantigen-specific T cells are retained and reactivated. 
In the model described above, a single cerebral injection of CpG-DNA induced 
an upregulation of CD40 mRNA for at least 5 days in CFA-MOG35-55 immunized 
mice, whereas expression was not detected on day 5 after injection in CFA-OVApeptide 
immunized mice27. This indicates that the effect of CpG-DNA on CNS resident APC 
is only transient and probably resolves as soon as the causative agent (CpG-DNA) 
is cleared from the CNS. It is therefore noteworthy that PG can persist in cells 
and accumulates in the brain after systemic administration16. Interestingly, brain 
pathology and mild clinical EAE can also be initiated by CFA-PTX immunization 
without CNS autoantigen, in transgenic mice with an astrocyte-targeted expression 
of IL-12p7033. CFA-PTX immunization induces a polyclonal T cell population, 
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reactive against the different antigens inside the immunization mix. Initial CNS 
infiltration in mice with an astrocyte-targeted expression of IL-12p70 was most 
probably independent on the recognition of self-antigen. However, autoreactive 
T cells may have co-migrated as bystander cells and could be activated in the 
CNS when autoantigens are released during inflammation. Upon release of new 
myelin epitopes bystander activation may also influence the process of epitope 
spreading, which is known to be associated with disease progression34. Thus even 
in the absence of peripheral autoantigens, a peripheral infection may result in CNS 
damage, when CNS microglia or astrocytes are already in an inflammatory state. 
This inflammatory state may be created by intracellular PG, which can act as a local 
adjuvant by producing chemokines, inflammatory cytokines and expressing MHC 
and costimulatory molecules by resident APC. To test this hypothesis, sPG from S. 
aureus can be injected intracerebrally into C57BL/6 wild type, NOD1-/-, NOD2-/- and 
TLR2-/- mice. Upon systemic activation of T and B cells, by immunization with CFA-
MOG35-55 (without PTX), it is expected that wild type and NOD1
-/- mice will develop 
clinical EAE signs and neuropathology, since CNS resident APC will be activated 
by PG via ligation to TLR2 or Nod2 receptors. Accordingly, it is predicted that 
TLR2- and Nod2-deficient mice do not develop autoimmune disease. When PG 
is persistently present inside CNS APC, myelin-specific T cells may be activated 
in the CNS, even without prior activation in the periphery. To test this, a similar 
experimental approach may be used in which mice are immunized with CFA-
OVApeptide instead of CFA-MOG35-55.
Microbial stimulation of autoimmune inflammatory responses in the 
periphery
PG-containing APC in secondary lymphoid organs, functional implications
Also in the periphery, PG may contribute to development or perpetuation of 
autoimmune disease, by stimulating APC (Figure 1). Previous studies have 
revealed that PG in sterile human spleen tissue was biologically active. Upon 
stimulation of whole blood cells, spleen-derived PG induced production of IL-
1β, IL-6, IL-8, IL-12, IL-10, TNF-α and MMP-935. Interestingly, spleen-derived 
PG was 10-100 times more potent in the induction of proinflammatory cytokines 
compared to PG isolated from human feces36. As in human spleen tissue, we 
demonstrated in chapter 2 that intracellular PG is also present in marmoset spleen. 
In marmosets, the number of PG-containing spleen cells was similar in CFA-MOG 
immunized monkeys, compared to control monkeys, which were not immunized or 
immunized with OVA in CFA. In CFA immunized monkeys, PG in spleen and brain 
may have originated from the adjuvant depots, which contained M. tuberculosis. 
Furthermore, PG may have been transported by APC from mucosal tissues37-40 
that are continuously exposed to large quantities of bacteria. Notably, in rhesus 
monkeys with an acute EAE course, clusters of PG-containing APC were present 
in the marginal zone of the spleen (chapter 2, Figure 4a, b). PG-clusters were 
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also present in draining lymph nodes and spleens from mice immunized with 
MOG35-55 admixed in IFA with sPG from S. aureus and were identified as DC 
(chapter 3, Figure 4). PG-containing DC clusters were already found at 4 hours 
after immunization, and were still present at day 37 (unpublished data). Most 
likely, DC transported sPG and autoantigens from the injection site to the draining 
lymph nodes and spleens where naïve autoantigen-specific T cells were activated 
and expanded in an inflammatory environment. Additional in vitro studies using 
bone marrow-derived DC demonstrated that PG stimulated antigen uptake, DC 
maturation and antigen-specific Th1 cell development and expansion (Figure 1). 
In accordance, immunization of autoantigen in sPG-IFA stimulated the polarization 
and expansion of MOG35-55-specific Th1 cells. Thus, in the periphery, inflammatory 
PG stimulated autoantigen-specific immune responses by modulating APC and 
subsequent T cell effector functions. 
PG promotes the production of proinflammatory cytokines
Also other TLR ligands have been shown to contribute to autoimmune 
disease development by stimulating APC function in the periphery. By using a 
similar approach as used in chapter 3, EAE can be induced in SJL/J mice by 
immunization with autoantigen admixed in CpG-DNA and IFA41. Disease induction 
by administration of autoantigen in microbial adjuvant was related to the ability of 
CpG-DNA to induce IL-12, since EAE did not develop in IL-12-/- mice. IL-12 and IL-
23 share a common p40 subunit, but these cytokines have different activities. IL-12 
promotes the differentiation of naïve T cells into IFN-γ producing Th1 cells. IL-23 
does not promote Th1 cell development, but is required for the expansion of a IL-6, 
IL-17 and TNF-α producing highly encephalitogenic T cell population42,43. It is not 
known whether PG stimulates IL-23 production by APC. Nevertheless, sPG from 
S. aureus is a potent inducer of IL-12p70 and IL-6 (chapter 2 and 3). PG-induced 
IL-6 may block immunosuppression by regulatory T cells (Figure 1), as observed 
with other TLR agonists44. S. aureus PG induced high levels of IL-12p70 following 
stimulation of mouse bone marrow-derived DC or marmoset and rhesus monkey 
PBMC. Subsequent culture of sPG-stimulated OVA-pulsed murine DC with naïve 
T cells transgenic for the TCR recognizing OVApeptide promoted the development 
and expansion of IFN-γ producing Th1 cells. It would be interesting to determine 
whether PG promotes IL-23 production by APC and subsequent development of 
IL-17 producing T cells (Figure 1). 
We and others have demonstrated that immunization of EAE-susceptible 
mice with myelin antigens in IFA did not induce EAE. Myelin-specific T cells were 
generated in the draining lymph nodes and expanded upon in vitro restimulation, 
proving that these cells were not deleted and were responsive to the antigen of 
immunization. However, IFA-autoantigen primed T cells did not have the capacity 
to adoptively transfer disease except when microbial or inflammatory (LPS, CpG, 
IL-12)41,45,46 stimuli were applied during in vitro reactivation. Even when mice 
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were tolerized to myelin antigens prior to EAE induction by systemic injection 
of autoantigen, unresponsive autoantigen-specific lymph node cells could be 
converted into pathogenic effector T cells, when stimulated in vitro in the presence 
of IL-12, CpG-DNA or agonistic anti-CD40 Mab47. Obviously, these model systems 
create an optimal situation for autoantigen-specific Th1 cell polarization and 
expansion, because all APC are exposed to the autoantigen and inflammatory 
stimulus simultaneously. It is questionable whether this process can also take 
place in vivo. In that respect, it is interesting to note that additional systemic 
administration of CpG at the time of autoantigen immunization in IFA did not lead 
to EAE development41. It is unknown whether PG administered separately from 
MOG/IFA is able to overcome tolerance to self-antigens in vivo, when tolerance 
is promoted by immunization with autoantigens in IFA. It can be argued that 
CpG is less efficient than PG, because CpG may be rapidly cleared from the 
circulation, whereas PG can persist inside cells. Therefore, it would be interesting 
to determine whether EAE can develop upon systemic administration of PG at the 
time of IFA-autoantigen immunization. In such a scenario, PG-containing cells in 
spleen or brain tissue may exert dangerous proinflammatory bystander affects on 
autoantigen-specific APC-T/B cell interactions.
Figure 1 provides a hypothetical scheme by which PG may exert its effect, 
focused on autoreactive T cell activation, either in the periphery or in the CNS. In 
addition, PG likely stimulates the development of activated autoreactive B cells as 
well.
Structural characteristics of inflammatory PG in relation to its degrading 
enzymes
Inflammatory potential of insoluble versus soluble PG 
Several factors can determine differences in immunostimulatory capacity of PG, 
which are all related to the structure of PG. The composition of PG is highly variable 
between different bacterial strains and even varies within a single strain. As an 
example, Figure 2 depicts the structural diversity of PG in S. aureus. In our studies 
we have used two different PG forms purified from S. aureus, insoluble PG (iPG) 
or soluble PG (sPG) (chapter 2 and 3). The sPG was predominantly composed 
of low molecular weight multimers, whereas in iPG multimers of high molecular 
weight predominated (Figure 2). Both in vitro and in vivo data demonstrated that 
sPG was much more effective than iPG. sPG, but not iPG, was able to induce IL-8 
production in TLR2 transfected HEK293 cells (unpublished observation). Both iPG 
and sPG could induce EAE in mice when admixed in IFA with MOG35-55
48(chapter 
3). However, the dosage required for EAE induction was 8-10 times lower for 
sPG compared to iPG. sPG induced IL-6, IL-12p70 and TNF-α by bone marrow-
derived DC, whereas a similar dose of iPG induced TNF-α only. Thus, at similar 
concentrations, S. aureus iPG is less inflammatory than sPG.
As recently described, both Nod1 and Nod2 recognize specific motifs of PG, 
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as depicted in Table 1 (and Figure 3c Introduction). Nod1 does not recognize S. 
aureus PG, since S. aureus PG does not contain the DAP at position 3 of the 
stem peptide which is required for Nod1 recognition. In contrast, Nod2 does not 
recognize MurNAc-TriDAP, but instead recognizes GM-DP and longer stem peptides 
with an L-lysine (in S. aureus) or L-ornithine at position 349. In the compact structure 
of insoluble S. aureus PG, the Nod recognition sites are most likely hidden from 
detection by Nod2 proteins, whereas these motifs are likely accessible for 
detection in sPG. This idea is supported by studies in which PG from Eubacterium 
aerofaciens was partially digested by lysozyme or bacterial-derived mutanolysin, 
which both cleave PG identically50. The biological activity of the arthritogenic 
E. aerofaciens (ATCC 25986) was significantly increased after mutanolysin 
treatment51. Muramidase treatment does not abolish recognition for either Nod1 
or Nod2, since after cleavage both GM-TriDAP and GM-DP can be formed (Figure 
3b/c Introduction). In contrast, digestion of PG by NAMLAA results in loss of PG 
detection by Nod2, since PG recognition by Nod2 is dependent on the presence 
of MurNAc. Accordingly, combined treatment of E. aerofaciens (ATCC 25986) PG 
by lysozyme and NAMLAA abrogated its inflammatory effects both in vivo and in 
vitro13. Staphylococci are resistant to lysozyme degradation. In S. aureus bacteria, 
this resistance depends on the O-acetyl moieties at the C6 hydroxyl group of N-
acetylmuramyl residues of PG52. This perhaps explains why iPG from S. aureus is 
not as effective as sPG, since partial degradation by lysozyme does not occur. 
Taken together, partial digestion of PG by muramidases can result in the release 
of highly immunogenic PG motifs. In the periphery, phagocytes contain lysozyme, 
as a part of their machinery to attack invaded microbes. However, lysozyme is 
3%
G-M
Ala
Glx
Lys
Ala
Ala
6%
G-M
Ala
Glx
Lys  (Gly)5 Lys  (Gly)5
Ala
Ala
10%
G-M
Ala
Glx
Ala
Lys  (Gly)5
G-M
Ala
Glx
Ala
>65%
Higher
multimers
Figure 2. Structural diversity of S. aureus PG. 
Stem peptides crosslink the glycan chains and differ in composition between bacterium strains. 
In S. aureus the stem peptides are composed of L-alanine-D-isoglutamine-L-lysine-D-alanine-(D-
alanine). Stem peptides can be attached directly to each other or indirectly via interpeptide bridges. 
The interpeptide bridges in S. aureus PG are formed by pentaglycines (Gly)5. There is a great variety 
in crosslinking and composition of stem peptides. S. aureus PG is predominantly composed of high 
molecular weight multimers (65%), and to a lesser extent of low molecular weight forms. Percentages 
indicate the relative abundance in overall cell wall composition. (G-M) GlucNAc-MurNAc. Adapted from 
de Jonge et al., 1992205.
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only sporadically expressed in MS and EAE-affected monkey brain (chapter 2), 
despite the presence of many activated phagocytes in infiltrates. This does not 
necessarily mean that the PG inside APC of the CNS is not partially digested, 
since APC most likely have transported PG from the periphery, where they are 
able to produce lysozyme. It would be interesting to determine the effects of 
lysozyme and NAMLAA expression during EAE, induced by immunization with 
autoantigen in PG-adjuvant. This could be accomplished by generating mice 
that constitutively express lysozyme and/or NAMLAA under the MHC-II promoter, 
specifically targeting enzyme expression in APC, including microglia. The other 
way around, EAE induction in mice with a single or combined deletion for lysozyme 
and NAMLAA would provide valuable insights into the role of these enzymes in 
EAE. Both lysozyme- and NAMLAA-deficient mice are viable and available on the 
EAE-susceptible C57BL/6 background53,54.
Inflammatory potential of PG depends on the composition of stem peptides
Not all bacteria are susceptible to lysozyme degradation, as described above. 
Besides structural modification by O-acetylation, also other PG modifications 
increase the resistance to lysozyme degradation, including the degree of 
crosslinkage between stem peptides56. Other bacterial cell wall components, 
such as polysaccharides, LTA and TA can also reduce muralytic degradation56,57. 
Resistance of bacterial cell walls to lysozyme degradation is important for the 
retention of PG in liver, spleen, lymph nodes and synovial tissues51,58. There 
appears to be a positive correlation between the capacity of bacterial cell walls to 
induce chronic arthritis and the resistance of cell walls to lysozyme degradation, as 
summarized by Šimelyte et al.55. However, there are exceptions, e.g. Streptococcus 
faecium cell wall is sensitive to lysozyme degradation and induces arthritis in 
rats55,59. On the other hand, E. alactolyticum cell walls are resistant to lysozyme 
degradation, but could not induce arthritis57. Thus, lysozyme-resistance alone is not 
decisive for the arthritogenicity of bacterial cell walls. 
Several studies have indicated that the amino acid at position 3 of the stem 
peptide plays an important role in the stimulatory capacity of PG in experimental 
arthritis, as shown in Table 1. Cell walls from the arthritogenic E. aerofaciens (ATCC 
25986) and the nonarthritogenic E. aerofaciens (ATCC 35085) differ in amino acid 3 
of the stem peptide. The nonarthritogenic cell walls have L-ornithine at position 3 of 
the stem peptide, whereas the arthritogenic cells walls have L-lysine. Arthritogenic 
cell walls were more resistant to lysozyme degradation. Upon digestion with 
lysozyme, arthritogenic PG induced elevated levels of TNF-α and MCP-1 upon 
stimulation of peritoneal MΦ60. No differences were found when undigested PG was 
used. Moreover, after i.p. injection, arthritogenic PG accumulated in significantly 
higher quantities in spleen and liver compared to nonarthritogenic PG, and was 
also detected in synovial tissue, whereas nonarthritigenic PG was not. It should be 
noted that L-lysine at position 3 of the stem peptide is not crucial for the induction 
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of arthritis since L. plantarum bacteria with mDAP at position 3 can induce arthritis 
as well (Table 1)55. But, all other bacteria with ornithine or mDAP at position 3 of the 
stem peptide did not induce arthritis and among the nonarthritogenic bacteria none 
contained L-lysine at potision 3 of the stem peptide. Within the structure of PG, 
Nod2 both recognizes GM-Trilysine and GM-Triornithine, while the latter does not appear 
to induce arthritis (Table 1). It remains to be determined whether Nod2 responds 
differently to these two distinct structures. Taken together, L-lysine at position 3 
of the stem peptide appears important for the inflammatory capacity of PG, while 
lysozyme resistance appears important for retention of PG at inflammatory sites. 
For the induction of EAE, it is expected that bacteria that contain L-lysine at position 
3 of the stem peptide of PG (e.g. S. aureus) will stimulate autoimmune disease 
development, whereas PG with other amino acids at this position will be less 
efficient (mDAP) or incapable (ornithine) to such effects (Table 1). 
Where does PG present in lymphoid organs and CNS come from?
PG can be derived from all mucosa, and both from bacterial infections and 
from the normal physiological flora of skin and mucosa, notably the gut. PG is 
released throughout bacterial infection, both during bacterial replication through 
cell wall biosynthesis, and by uptake/infection and degradation by phagocytes. 
Exacerbations of MS are often associated with bacterial infections61-63. Moreover, 
bacterial products, including PG, are continuously exposed to the immune system 
at all mucosal sites, with the highest concentration of bacteria being present in 
the gut. The highest number of intestinal bacteria occurs in the lumen of the 
distal ileum and colon. In the gut lumen, obligate anaerobic bacteria (108-1012 per 
gram of luminal content) outnumber aerobic bacteria (106-108)64,65. Of the obligate 
Table 1. Nod recognition sites in PG from Gram-positive and Gram-negative bacteria.
PG
molecular motif
Nod1 Nod2 arthritis induction55 (predicted)/proven
adjuvant function in EAE
Gram-positive -* +
GM-DP - + n.d. (-)
GM-Triornithine - + - (-)
GM-Trilysine - + + + (chapter 3)
Gram-negative + +
GM-DP - + n.d. (-)
GM-TriDAP / mDAP** + - - 
§ (-)
Composition of PG (see also Figure 3 Introduction): (GM) GlcNAc-MurNAc, (GM-DP) GM-L-Ala-D-Glu, 
(mDAP) meso-diaminopimelic acid, (GM-Triornithine/lysine/DAP) GM-L-Ala-D-Glu-ornithine//lysine/mDAP. 
(*) Exceptions to the general rule: several Gram-positive bacteria contain GM-TriDAP, and can therefore be 
recognized by Nod1; e.g. Eubacterium alactolyticum, Lactobacillus plantarum, Listeria monocytogenes, 
Bacillus cereus and Bacillus anthracis. 
(**) For Nod1 binding mDAP needs to be present as the terminal amino acid49. 
(§) arthritogenic bacteria with mDAP at position 3 of the stem peptide, e.g. L. plantarum. 
(n.d.) not determined.
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anaerobes, the dominating Gram-positive species include Bifidobacterium, 
Clostridium, Eubacterium, Lactobaccilus and Peptostreptococcus64. Cell walls from 
particular substrains of these commensals could efficiently induce arthritis by i.p. 
injection into rats55 and induced inflammatory cytokine and chemokine responses 
by in vitro stimulation of mononuclear cells51. PG polysaccharides can be absorbed 
in the gastrointestinal tract, as demonstrated by oral feeding of these complexes 
to rats. Orally fed radiolabeled PG polysaccharides were found in liver, spleen, 
mesenteric lymph nodes, cardiac blood and joints, demonstrating that PG was 
absorbed across the epithelial barrier of the mucosa and redistributed into different 
tissues66. Intestinal absorption of PG was increased when high concentrations of 
PG polysaccharides were injected into the gut lumen or when intestinal bacteria 
were experimentally overgrown in a surgically created jejunal blind loop67. Both 
in humans68-70 and in experimental models71, bacterial overgrowth in the small 
bowel was associated with joint inflammation, indicating that PG translocation may 
stimulate the development of joint inflammation in susceptible hosts. 
Is there a role for the intestinal flora in MS?
In healthy individuals, the mucosal immune response to antigens of the indigenous 
flora is tightly regulated, in order to prevent chronic inflammation in the intestine. 
It is generally assumed that a loss of tolerance to the commensal flora is involved 
in the development and perpetuation of IBD. In accordance, it was shown that 
immune tolerance is generated against antigens of the enteric flora, since intestinal 
lymphocytes of mice do not proliferate upon stimulation with antigens of their own 
intestinal flora, but do proliferate when antigens of intestinal flora of other mice are 
encountered72. In patients with IBD, a defective epithelial barrier may cause a loss 
of tolerance to the normal enteric flora. The additional development of RA in 5-23% 
of patients with IBD highlights that the bacterial flora may play an important role in 
autoimmune disease development64. 
Although limited, there are also indications that the intestinal flora plays a role 
in MS and EAE. Spontaneous EAE in MBP-specific T cell receptor transgenic 
mice only developed in a non-sterile environment73. Oral administration of different 
Lactobacillus strains, prior to the induction of EAE, either enhanced or reduced 
EAE74, and was positively related to the adjuvant inducing capacity of the different 
strains75. Conversely, EAE was ameliorated by treatment with the oral antibiotic 
vancomycin, which specifically targets Gram-positive, but not Gram-negative 
bacteria76. Increased gut permeability to lactulose / mannitol was observed in 5 
out of 20 MS patients77. Evidently, larger patient numbers need to be screened 
to assess whether an increased intestinal permeability is associated with MS. 
Patients with CD and successive development of MS-like disease have been 
described78,79, but this link is not strong in epidemiological terms. One study 
describes the co-occurrence of CD and MS in 4 out of 832 patients with CD80. 
Of the total group of IBD patients, 3% suffered from neurological complications. 
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Hypointense T2-weighted focal white matter lesions were present in 50-70% of 
IBD subjects compared to 16% in healthy age-matched controls81. Additionally, a 
case study presented a patient with CD in which inflammatory brain lesions were 
accompanied by either clinical signs of ADEM or a first attack of MS82. 
NOD2/CARD15 has been identified as susceptibility gene for CD83,84. Nod2 
recognizes MDP or longer GM-TriLys-containing structures in PG and is expressed 
on monocytes, granulocytes, DC and MΦ. In CD patients, three common single 
nucleotide polymorphisms of the NOD2 gene have been identified, i.e. IBD8 
(Arg702Trp), IBD12 (Gly908Arg) and IBD13 (1007fsins)85. These mutations are 
carried by 30-50% of CD patients and 15-20% of healthy controls. The risk for 
CD is only 2-3 times elevated in heterozygous carriers; however, the relative 
risk is increased to 20-40 in homozygous carriers. Genetic analysis of 631 MS 
patients showed no significant difference in allele frequency of IBD8, IBD12 and 
IBD13 as compared with controls86. These data suggest that the NOD2 gene does 
not contribute to MS susceptibility. However, there are 29 additional rare NOD2 
mutations described for CD. With respect to their basal expression levels of NF-
кB and PG-induced NF-кB activation, 13 of these additional NOD2 variants were 
shown to differ from wild type NOD287. It would be interesting to determine whether 
these NOD2 variants are also present and associated with MS susceptibility. 
What is the functional role of Nod2 in the intestine? Normal intestinal epithelial 
cells express low levels of Nod2, whereas expression is greatly upregulated by 
epithelial cells in CD patients88. Nod2 expression has also been found in Paneth 
cells89. Paneth cells are located in deep crypts of the intestinal epithelium. Paneth 
cells can efficiently kill bacterial cells by the secretion of defensins upon stimulation 
by MDP90. Recently, animal models have demonstrated that Nod2 is important for 
bacterial clearance by Paneth cells. Nod2-/- mice displayed increased susceptibility 
to gastrointestinal infection. Microarray analysis revealed that the expression of 
a subgroup of cryptidins, the equivalent of human α-defensins, was significantly 
reduced in the terminal ileum of infected Nod2-/- mice91. In accordance, expression 
of α-defensins was reduced in CD patients, specifically in patients with NOD2 
mutations92,93. A defect in bacterial sensing by Nod2 by intestinal Paneth cells may 
result in increased numbers of intestinal bacteria and thus in greater quantities of 
PG in the circulation and tissues.
Proinflammatory PG as a cofactor in MS an EAE
We have shown previously that immunocompetent APC within the CNS of MS 
patients contain PG, a major cell wall component of Gram-positive bacteria. In the 
present study we assessed whether proinflammatory PG can act as a cofactor in 
MS and EAE development. Figure 3 illustrates how PG might be distributed and 
how PG might contribute to MS and EAE, as described below.
Where does PG come from under physiological conditions? PG (circles) can be 
derived from bacteria at all mucosal sites ①. The flora of the intestine represents 
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the largest load of bacteria among mucosal surfaces. In the intestine, bacteria can 
be translocated across the epithelial barrier by M cells and specialized APC. In 
this way, bacteria are sampled and transported into the circulation and peripheral 
lymphoid organs as a part of a physiologically occurring process. However, when 
the mucosal integrity is disturbed, e.g. by infection or by chemical substances, 
higher numbers of bacteria and perhaps also other bacterium strains can cross the 
gut barrier, resulting in higher levels of PG in the circulation and tissues. PG can 
also be derived from bacterial infections at non-mucosal sites ②, by the release of 
PG fragments during bacterial replication or by uptake and processing of bacteria 
by APC. In MS, bacterial infections are associated with clinical relapses. Thus, 
endothelial cells
granulocyte
infection
adjuvant depot
myelin peptide
PG
microglia
CD11b/CD18
basement membranes
astrocyte
endfeet
astrocyte
circulation
CNS
secondary
lymphoid
organ
mucosa
e.g. gut
APCT
T
T
B
APC
APC
APC
APC
APC
ICAM-1
CD4
B
CD8
?
APC
1
2
3
4
5
6
altered gut barrier function
proliferation
Figure 3. Proinflammatory PG as a cofactor in MS an EAE. 
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PG can be derived from different anatomical locations (all mucosa) and levels are 
increased during bacterial infection or when the permeability of mucosal sites is 
increased.
In our mouse EAE model, we have artificially administered PG from the 
pathogenic bacterium S. aureus by s.c. immunization in IFA ③. In EAE, S. aureus 
PG could replace whole M. tuberculosis in CFA. Addition of PG to an emulsion 
of IFA and myelin peptides (triangles) was associated with autoreactive T cell 
priming and development of EAE. In vitro studies revealed that PG stimulates 
antigen uptake and maturation of DC. Most likely DC transported PG and myelin 
peptides from the adjuvant depot into the draining lymph nodes ④. Accordingly, 
PG-containing DC were found in the draining lymph nodes already at 4 h after 
immunization. It is apparent that immunization with myelin peptides in IFA-PG 
provides an optimal condition for PG to stimulate myelin peptide-specific immune 
responses, since phagocytes at the immunization site can engulf the PG and 
myelin peptides simultaneously. However, also in non-artificial conditions, PG and 
myelin peptides may be in close proximity, as both substances are confined within 
APC of peripheral lymphoid organs. 
PG-stimulated APC can prime naïve T and B cells in secondary lymphoid 
organs, and in the presence of (auto)antigens induce development of (auto)antigen-
specific effector lymphocytes (Figure 1). These effector lymphocytes can enter 
the circulation and adhere to activated endothelial cells in the CNS. Encounter 
with their targets (myelin peptides) in the CNS parenchyma, presented by DC 
or MΦ/microglia initiates an inflammatory cascade that includes the attraction of 
other leukocytes. Among these leukocytes, PG-containing phagocytes may also 
enter the CNS by utilizing CD11b/CD18-mediated adhesion and transmigration 
across the BBB endothelium ⑤. Thus, during CNS inflammation, PG-containing 
cells accumulate in the CNS, and may promote local inflammation and disease 
perpetuation. PG may also be present within resident microglia ⑥, by uptake of 
PG-fragments which originated from the blood stream, by uptake of apoptotic cells 
that contained PG, or by uptake of bacteria that have infected the CNS (although 
there is little evidence for local replication). We propose that PG persists in the 
CNS and that this persistence may be related to the restricted expression of PG-
degrading enzymes in the CNS. Taken together, our data show that S. aureus PG 
is a sufficient proinflammatory stimulus to break T cell tolerance. PG likely mediates 
this by stimulating DC-T cell interactions in lymph nodes, and potentially also acts 
in the CNS. 
Future research
When we consider that PG is important in autoimmune disease development 
and perpetuation, the following research questions and experiments can be 
envisaged to provide additional insight in how and where PG may contribute to the 
immunopathogenesis in MS and EAE. 
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Is the quantity and nature (chemical composition) of PG important in MS and 
EAE?   
PG-containing cells are present in peripheral blood leukocytes of a number of 
healthy subjects and patients (incl. MS and RA), but no clear differences were 
detected in the occurrence of PG between the different groups94. The proportion of 
individuals with circulating PG-containing leukocytes decreases with age. However, 
there may be differences between MS patients and healthy controls with respect to 
1) the quantity and nature (chemical composition) of PG in the circulating leukocytes 
and 2) the cellular subsets (monocytes, MΦ, DC and granulocytes) that can contain 
PG. Moreover, it is not clear whether relapse-associated infections in MS patients 
are accompanied with elevated numbers of PG-containing cells in the peripheral 
blood. These questions can be addressed by using immunocytochemistry and 
mass spectrometry. EAE can be used to functionally address the question whether 
PG is able to induce relapses. EAE should be induced by adoptive transfer, to 
exclude effects of previous adjuvant depots. After recovery from EAE, animals may 
be injected with PG to evaluate whether such injections can induce relapses. 
In MS, aside from bacterial infections, other factors may contribute to increased 
PG concentrations within secondary lymphoid organs, the circulation and 
inflammatory sites including the activity of PG-degrading enzymes (see below) 
and permeability of the gut. Does the permeability of the intestine contribute to 
disease development and does bacterial overgrowth in the intestine influence 
disease development? These questions can be addressed in EAE, where the gut 
permeability can be increased by chemical disruption. Bacterial overgrowth can be 
established by creating an intestinal blind loop.
In accordance with previous findings in MS7, chapter 2 shows that significantly 
higher numbers of cells contain PG (quantity) in marmoset and rhesus monkeys 
that had developed EAE, compared to controls. We also demonstrated that low 
numbers of PG-containing cells are present inside the CNS of humans and non-
human primates that did not develop CNS disease. This raises the question 
whether intracellular PG in healthy brain tissue is structurally different (nature) from 
PG in MS brain tissue, which can be assessed by in situ NMR, or laser dissection 
followed by mass spectrometry. Assuming that the chemical structure of PG is 
important for its proinflammatory effects, it will be of interest to determine whether 
PG with GM-Trilysine, GM-TriDAP or GM-Triornithine exerts different effects on APC 
function. Additionally, these distinct substances can be tested for their capacity as 
adjuvant in EAE induction (Table 1).
Is the interaction of PG with its degrading enzymes and receptors important in MS 
and EAE?
In chapter 2, we demonstrate that expression of lysozyme and NAMLAA is 
restricted in EAE-affected marmoset and MS brain tissue. This finding was 
surprising, because several cell types that normally express these enzymes in 
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the periphery were present in the infiltrates. This raises the question which factors 
determine the expression of these PG-degrading enzymes. In view of that, it would 
be interesting to determine whether PG modulates the expression of NAMLAA and 
lysozyme, and whether the expression of NAMLAA and lysozyme differs between 
PG-activated APC subsets (incl. microglia). PG-degrading enzymes are known to 
affect the immunostimulatory potential of PG13. Can the inflammatory potential of 
PG (sPG and iPG) be increased or decreased by modulating the NAMALAA and 
lysozyme expression and does NAMLAA or lysozyme expression influence EAE, 
induced by autoantigens in IFA-PG? These questions can be addressed by using 
NAMLAA- and lysozyme-deficient mice.
It has been shown previously that PG stimulates the innate immune system by 
binding to TLR2/6 and Nod1/2 receptors (for details see Introduction). However, 
it remains unclear whether or not a combination of these receptors is required for 
the inflammatory action of S. aureus PG in EAE. Both in vitro studies (using bone 
marrow-derived DC) and in vivo studies (using EAE) in mice with single deletions 
for TLR2, Nod1 and Nod2 will provide answers to this question. In this respect, 
it would be of interest to determine whether PG-containing cells in secondary 
lymphoid organs and CNS tissue express TLR2/6 and Nod1/2 receptors.
Is the location of PG in relation to myelin antigens important for MS and EAE?
We and others have demonstrated that myelin antigens are present within APC 
in secondary lymphoid organs95-97. Thus, in principle, PG-containing APC may 
exert proinflammatory effects on APC that contain myelin antigens, by bystander 
activation. Alternatively, and less likely, PG and myelin antigens are present 
within the same APC. To address these issues, the following hypothesis can be 
tested: 1) myelin antigens and PG need to be in close proximity of each other 
to induce autoimmune disease (see page 162: PG promotes the production of 
proinflammatory cytokines), 2) PG is present within microglial cells during EAE, 
3) PG can exert its adjuvant effect solely in the CNS (see page 160: By which 
mechanisms might PG in the CNS contribute to the development of autoimmune 
disease? and 4) PG is present in APC that contain myelin within lymph nodes of MS 
patients, non-human primates with EAE and not in controls.
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Part II, Functional contributions of CD97 and CD44v isoforms in 
MS and EAE
Implications for involvement of CD97 in MS and EAE
CD97 has been associated with several chronic inflammatory conditions, as RA98,99. 
Until recently, CD97 has not been studied in relation to CNS inflammation. The best-
described cellular ligand for CD97 is CD55, also known as decay accelerating factor 
(DAF). The complement system is thought to contribute to MS and EAE development 
and as a component of this system, CD55 may participate in the inflammatory 
process as well. Hypothesizing that CD97-CD55 interactions are involved in the 
inflammatory process in MS, we determined the expression of CD97 and its ligand 
CD55 in MS brain lesions, and measured sCD97 in serum and CSF of MS patients. 
Additionally, we assessed whether CD97EGF1 interactions are functionally involved 
in the development of EAE, by administration of blocking CD97EGF1 Mab.
In chapter 4, we demonstrate abundant expression of CD97 in MS brain lesions. 
In confirmation of previous findings we found that CD97 was not expressed by 
glial cells under normal conditions100, but was expressed in all stages of MS brain 
lesions. In MS brain lesions, CD97 was expressed by different cellular subsets e.g. 
MΦ or microglial cells and T cells. CD55 was highly expressed by endothelial cells in 
pre-active and active lesions, while in normal white matter only modest expression 
by endothelial cells was found. In pre-active lesions, CD55 was only occasionally 
expressed by T cells and MΦ or microglial cells, while in active lesions, many MΦ 
or microglial cells expressed both CD55 and CD97. Furthermore sCD97 was found 
by ELISA in serum, but not in CSF, of a significant number of MS patients (37%) 
compared to healthy controls (8%).
CD97 and/or EMR2 expression in MS brain lesions?
CD97 can be expressed as three different isoforms, containing three, four or five 
EGF domains (Figure 3 Introduction). Here we studied the expression of CD97 by 
using an antibody recognizing EGF domain 1 (Mab CLB-CD97/1) that is present 
in all three isoforms. EMR2 is one of the other five EGF-TM7 family members that 
have been identified in humans. The EGF domains of EMR2 and CD97 differ by 
only 6 amino acids and Mab CLB-CD97/1 does not distinguish between EMR2 and 
CD97. We also determined whether EMR2 was expressed in MS brain tissue by 
staining with Mab 2A1 that specifically detects the stalk region of EMR2, but not 
of CD97. We concluded that CLB-CD97/1 staining was specific for CD97, since 
EMR2 expression was absent in MS lesions (data not shown). Immunoreactivity 
with 2A1 was observed in adenoid tissue, demonstrating that lack of expression in 
MS lesions was not caused by failing of the staining procedure. To ascertain that 
CD97 was expressed in MS brain, we also confirmed expression of CD97 by Mab 
MEM-180 and CLB-CD97/3 that specifically detect the stalk region of CD97 (data 
not shown).
174 Chapter 6
Variation in CD97EGF domains influences ligand binding 
The known ligands of CD97 include CD55101-104, CS-B105,106, α5β1 (VLA-5) and αvβ3 
(CD51/CD61) integrins107. Integrins mediate a diversity of biological responses e.g. 
angiogenesis, proliferation, survival and adhesion. The VLA-5 and αvβ3 integrins were 
recently identified as CD97-ligands important for CD97-mediated angiogenesis107. 
The EGF domain composition in CD97 controls ligand binding (Table 2). At least 3 
EGF domains are needed to establish CD55 binding, such that all CD97 isoforms 
can bind CD55. However, the short isoform CD97(EGF1,2,5) binds CD55 with higher 
affinity than the larger isoforms (EGF1,2,3,5) and CD97EGF(1-5)102. 
In contrast, binding of the glycosaminoglycan CS-B is solely dependent on 
EGF domain 4 (in the mouse EGF domain 3) that is only present in the larger 
CD97 isoforms. The EGF domains 4 and 5 are identical for CD97 and EMR2, 
thus EMR2 also binds CS-B105. CS-B is present in the ECM and on cell surfaces, 
attached to proteoglycans (Figure 4). Cell-surface associated glycosaminoglycan 
are heterogeneous in strucure with differences in chain length, degree of sulfation 
and epimerization108. These factors co-determine binding to their receptors, as for 
CD97. CD97-binding of CS-B is so far detected on primary B cells and within ECM 
of arthritogenic synovial tissue106,109. EMR2-binding of CS-B furthermore occurs on 
fibroblasts, monocyte-derived MΦ and within ECM of different tissues, but not in 
normal brain tissue105.
Three EGF domains are required for CD97-integrin interaction107. All human 
CD97 molecules contain an Arg-Gly-Asp (RGD) sequence at 110 amino acids from 
the carboxy-terminal site of EGF598 that is required for VLA-5 and αvβ3 integrin 
binding107. Taken together it can be speculated that the expression of different 
isoforms takes place under specific regulation, leading to a different outcome in 
cellular adhesion or activation in short CD97 isoforms than in larger ones. Therefore, 
it would be of interest to determine whether different splice variants of CD97 are 
expressed in MS brain lesions, and if these splice variants can be correlated with a 
specific lesion stage or cell type. This can be done by using an immunohistochemical 
double labeling procedure with Mab MEM-180 directed against the common stalk 
region of CD97, and Mab 1B5 directed against the fourth EGF domain of CD97. 
An alternative approach includes the analysis of mRNA expression levels of CD97 
isoforms in MS and control brain tissues. 
Table 2. The composition of CD97 EGF domains determines its ligand binding capacity.
                 ligand
hCD97 isoform
CD55 CS-B VLA-5
αvβ3 integrin
EGF 1,2,5 +++ - +
EGF 1,2,3,5 ++ - +
EGF 1,2,3,4,5 + +++ +
(hCD97) human CD97, (EGF) epidermal growth factor domain, (CS-B) chondroitin sulfate B. 
Binding is indicated as none (-) to strong (+++).
General discussion 175
CD97 ligand expression in MS brain lesions
In MS brain lesions, perivascular T cells and MΦ or microglial cells expressed 
CD97 (chapter 4). Both CD97-ligands CD55 and αvβ3 integrins were expressed 
on the luminal side of endothelial cells in MS brain lesions and their expression 
was dramatically increased compared to normal appearing white matter of controls 
(chapter 4)110,111. Luminal surface expression implies the potential of αvβ3 integrins 
and CD55 molecules to bind CD97-expressing leukocytes, which may facilitate 
extravasation of these cells into the CNS parenchyma. It would be of interest to 
determine whether other integrins with specificity for RGD sequences112,113 can also 
bind CD97. CD97-CD55/integrin interactions may contribute to adhesive events at 
the BBB, together with other adhesive interactions which are known to be involved 
in MS and EAE, such as LFA-1/ICAM-1 and VLA-4/VCAM-1114. 
Is there also a possibility for CD97-CS-B interaction in the CNS? CS 
proteoglycans are the most abundant ECM components in the adult CNS and 
are produced by neurons, astrocytes and other cells115. In controls, CS-B was 
expressed homogeneously in the white matter116. In contrast, scattered granular 
heterogeneous aggregates of CS-B were present in the ECM of the normal 
appearing white matter and in peri-lesional areas in MS brain. Additionally, 
Figure 4. CD97-mediated leukocyte adhesion to activated CNS endothelium in MS.
In MS brain tissue activated endothelial cells express increased levels of CD55, αvβ3 integrin and 
possibly CS. These cell surface molecules and cell-associated (by glycoproteins) ECM molecules may 
facilitate the adhesion of activated leukocytes by binding their respective receptors, as explained in the 
text.
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elevated expression of CS-B was detected at edges of active lesions, associated 
with astrogliosis. It has been implied previously that ECM accumulation in the CNS 
inhibits tissue repair, e.g. axonal regeneration and remyelination117. Conversely, 
chondroitinase ABC treatment has been shown to promote tissue regeneration and 
functional recovery after spinal cord injury118. Increased CS-B in MS white matter 
may serve as binding regions for CD97-expressing cells, and may be involved in 
the retention of infiltrating cells. It will be of interest to determine whether CD97-
CD55, CD97-CS and CD97-integrin interactions are involved in BBB adhesion 
and transmigration, and retention in the CNS during MS and EAE. Figure 4 
illustrates the potential CD97-ligand interaction between activated leukocytes and 
activated CNS endothelial cells in MS and EAE. By using CD97-specific multivalent 
probes, MS brain tissue can be analyzed for CD97-specific ligands, as has been 
reported recently for RA synovial tissue109. Whether CD97-ligand interactions are 
functionally involved in MS can be modeled in EAE, by using Mab against different 
EGF domains of CD97, as described below.
Blocking CD97 interactions in mouse EAE
We assessed whether blocking CD97-CD55 interactions affects mouse EAE. 
SJL/J mice were immunized with PLP139-151 in CFA and additionally injected with 
heat-killed B. pertussis bacteria. Mice were treated with 0.25 - 0.5 or 1 mg blocking 
Mab hamster anti-mouse CD97EGF1 (clone 1B2) or hamster immunoglobulin as a 
control from two days before immunization and every other day thereafter, until day 
12 after immunization. It appeared that EAE onset and severity were not reduced 
by the anti-CD97EGF1 (1B2) treatment (Figure 5). Treatment of collagen-induced 
arthritis in mice with the same antibody, however, significantly reduced disease 
onset and severity, ankle joint swelling and bone destruction (E.N. Kop, personal 
communication). In this case, the arthritis was induced by immunization with 
collagen II in CFA. Mice received a booster injection with collagen on day 21 and 
were subsequently treated with 0.25 or 0.5 mg Mab anti-CD97EGF1 (1B2) for 3 
times a week until the day of sacrifice. The early phase of collagen-induced arthritis 
was characterized by synovial tissue infiltration by T cells, which was followed by 
infiltration of neutrophils and MΦ. Clinical signs developed between day 21 and 
28 and subsided around day 42. Anti-CD97EGF1 treatment significantly reduced 
the synovial tissue infiltration and analysis of the cellular subsets revealed a trend 
in reduction of neutrophils at day 49 after immunization. However, as the authors 
point out, this does not exclude the possibility that CD97-CD55 blockade inhibits 
infiltration of other cell subsets at earlier time points. 
The reason for the different results between EAE and experimental arthritis 
with respect to CD97-CD55 interactions in disease development is not clear at 
this point, but may simply relate to differences in treatment duration. Alternatively, 
differences may relate to anatomical differences (joint in experimental arthritis 
vs. CNS in EAE), or to the possible dependency on neutrophils in disease 
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development. Blocking of CD97-CD55 interactions alters neutrophil function, as 
demonstrated in two different in vivo models. Mab anti-CD97EGF1 (1B2) inhibited 
neutrophil migration in experimental colitis and reduced the neutrophil-dependent 
IL-8 induced hematopoietic stem cell mobilization119(M.J. Kwakkenbos, personal 
communication). Taken together, these data indicate that CD97-CD55 interactions 
are specifically important for neutrophil adhesion or function, and may affect 
other cell types as well. Abundant numbers of neutrophils are present in rhesus 
monkeys120,121, rats122 and mice123 with hyperacute EAE, representing models for 
acute forms of MS or ADEM. In this respect, it would be of interest to determine 
whether blocking CD97-CD55 interactions in these models can reduce EAE.
 Apart from Mab anti-CD97EGF1, also Mab anti-CD97EGF3 (clone 1C5), which 
targets CS-binding EGF domains, inhibited neutrophil migration119 and experimental 
Figure 5. Early treatment with anti-CD97EGF1 (1B2) does not affect EAE development.
SJL/J mice were immunized with PLP139-151 in CFA. Treatment (arrows) with CD97EGF1 Mab or hamster 
immunoglobulin control antibody was initiated two days before immunization (arrowheads) and applied 
every other day thereafter, until day 12 after immunization. In two separate experiments mice received 
0.25, 0.5 or 1 mg CD97EGF1 Mab. Mice were weighed and scored for clinical signs of EAE daily. Bars 
represent the mean clinical scores, lines the mean weight. (*) two mice died before the onset of EAE.
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arthritis development (E.N. Kop, personal communication). It is of note that 1C5 
binds CD97, but not EMR2, since mice lack the EMR2 gene. This also applies for all 
other anti-mouse CD97 Mab. Combined CD97-ligand interaction with either CD55/
CS or VLA-5/CS have been shown to act synergistically on cell function106,107. This 
is interesting, because combined targeting of EGF domain 1 and EGF domain 3 (in 
the mouse) of CD97 by Mab treatments would likely result in enhanced treatment 
efficacy. The functional role of CD97 in EAE can be elucidated using mice with a 
targeted deletion for the total CD97 gene. Other species than mice should be used 
to determine the functional effect of CD97-integrin interactions, since mouse CD97 
does not contain the RGD motif that is present in human CD97103,124. 
Role for CD55 in protection from complement-mediated damage in MS brain 
tissue
Complement activation is thought to contribute significantly to inflammation of the 
CNS in MS and EAE125,126. The anaphylatoxins C3a and C5a are involved in the 
recruitment of inflammatory cells into the CNS127,128. Deposition of C3b increases 
myelin phagocytosis and interaction with its receptor on MΦ or microglial cells 
can induce release of TNF-α and nitric oxide129. Complement can also exert 
direct cytotoxic effects by deposition of the membrane attack complex on myelin 
producing cells in the CNS, the oligodendrocytes130. Membrane bound or soluble 
regulatory proteins inhibit formation of C3 and/or C5 convertases and normally 
protect tissues against the complement system. These proteins include CD46, 
CD55, CD59, complement receptor type-1 (CR-1), C4b binding protein, and factors 
H and I. CD55 protects cells from complement-mediated damage by accelerating 
the decay of C3/C5 convertases and is therefore also known as decay accelerating 
factor (DAF)131. CD55 plays the major role in protecting endothelial cells from 
complement-mediated damage132. In vitro expression of CD55, but not of CD46 
and CD59, by endothelial cells can be increased by the proinflammatory cytokines 
TNF-α and IFN-γ, and also by the membrane attack complex. This increase in 
CD55 expression reduced complement deposition significantly132. In MS brain 
lesions different cytokines and complement components are present which might 
also be capable of upregulating CD55. Indeed, we observed upregulated CD55 
expression by endothelial cells in MS brain lesions compared to expression in 
normal white matter (chapter 4). In MS brain, CD55 may also protect neurons 
from complement-mediated damage by expressing CD55. In corroboration, it 
was recently demonstrated that neurons in EAE-affected grey matter tissue of 
marmoset monkeys also expressed CD55133. Neurons that expressed CD55 were 
located in close vicinity to inflammatory lesions, whereas CD55 was not expressed 
by neurons in non-affected areas. These findings indicate that CD55 is induced 
on neurons under inflammatory conditions. Additional in vitro studies showed that 
ectopic expression of CD55 was critical in protecting human neuroblastoma cells 
from complement-mediated damage. In conclusion, during inflammatory attacks 
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on the CNS, as in MS, brain endothelial cells and neurons are likely protected from 
complement-mediated damage by increased expression of CD55.
CD55 is involved in cellular activation and signal transduction
Besides preventing cells from complement-mediated damage, CD55 is also involved 
in cell activation and signal transduction of different cell types, even though the CD55 
molecule does not traverse the plasma membrane134. Incubation of monocytes with 
an antibody against CD55, which blocks complement protection, has been shown 
to result in increased glucose consumption and phagocytic uptake of latex beads 
as well135. Crosslinking of CD55 on human monocytes and granulocytes nduced 
cytoplasmic Ca2+ influx and oxidative burst136. Also T cells respond to CD55-mediated 
signaling. CD55 expressed at low levels by resting human T cells was upregulated 
after activation by mitogens. Crosslinking of CD55 by antibodies, together with 
costimulation by phorbol esters, induced T cell proliferation. This anti-CD55 induced 
proliferation was blocked by phospholipase C, which removes the GPI-linked CD55 
from the cell137. 
These data imply that CD55 acts as a receptor involved in signal transduction. The 
involvement of CD55 in signal transduction was demonstrated by transfection of murine 
thymoma cells with CD55. Transfection resulted in the transduction of early activation 
events, leading to tyrosine phosphorylation and association with Scr-related kinases 
p56lck and p59fyn138. More recently, it has been shown that crosslinking of CD55 on 
Jurkatt T cells was insufficient to induce Ca2+ influx and phosphorylation of PLC-γ. 
However, TCR-ζ, p56lck and ZAP-70 tyrosine residues were phosphorylated, leading 
to IL-2 secretion139. Taking these data into consideration, it is tempting to speculate 
that binding of CD97 to CD55 can lead to cell activation and signal transduction of 
the CD55 expressing cell. Therefore, it is possible that binding of CD97 to CD55 
leads to reverse signaling of the CD55 expressing cell. As CD55 is expressed by 
infiltrating leukocytes (T cells and MΦ) and by resident activated microglia cells in 
MS brain lesions, CD97-CD55 ligation on MΦ or microglial cells may stimulate the 
phagocytosis of myelin and the production of oxygen radicals, while T cells might be 
able to proliferate when appropriate costimulatory signals are available.
Functional aspects of CD44v3, v7 and v10 in MS and EAE
Under defined conditions, such as leukocyte activation, CD44v isoforms are 
specifically upregulated140-142. Particular CD44v isoforms have been implicated to play 
a role in the development of autoimmune disease in man. Experimental models for 
IBD, RA and alopecia areata (a skin-associated autoimmune disease) have confirmed 
that a selected number of CD44v isoforms contribute significantly to disease 
development, by using antibody treatment or genetic deletion of specific isoforms. We 
therefore hypothesized that CD44v isoforms are crucial for the development of MS 
and EAE. Previously, we showed that PLP139-151-induced EAE could be ameliorated by 
early treatment (day 0, 2, 4 and 6 post immunization) of SJL/J mice with a mixture of 
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antibodies against CD44v6, v7 and v10 isoforms. Mice treated with control antibody 
showed expression of CD44s and CD44v10 by infiltrated mononuclear cells in the 
CNS. 
As previously demonstrated, CD44v4-v6 were not expressed in normal 
human white matter, whereas astrocytes expressed CD44s and endothelial cells 
expressed both CD44s and CD44v10143. Expression of CD44s was upregulated in 
inflammatory brain lesions of MS patients144 and EAE-affected mice145,146, however 
it was not known whether these molecules also contained the variant regions. We 
therefore explored whether CD44v3-v10 (excl. v7) isoforms are expressed in MS 
brain lesions (chapter 5). The CD44v4, v5, v6 and v9 isoforms were not expressed 
in MS and in control brain tissue. Expression of CD44v7 could not be assessed 
by immunohistochemistry (for details, see chapter 5), but it is known that murine 
astrocytes and activated leukocytes express CD44v7 upon activation147. We 
demonstrated that both CD44v3 and v10 were expressed in MS brain lesions. The 
expression patterns of CD44v3 differed from CD44v10. Endothelial cells expressed 
CD44v10, but not CD44v3 in MS and control brain. Perivascular cells in pre-active 
lesions expressed both CD44v3 and v10, but more cells expressed CD44v10 than 
CD44v3. Moreover, in activated (HLA-II+) areas, large numbers of astrocyte-like 
cells expressed CD44v10, but not CD44v3. In active lesions, MΦ-like cells with 
a foamy appearance expressed both CD44v3 and CD44v10. Taken together, 
increased expression of CD44v3, (v7) and v10 in MS brain lesions suggests that 
these isoforms functionally contribute to MS. By using mice with a single genetic 
deletion for CD44v7 or CD44v10, we analyzed whether these isoforms contribute 
to the development of EAE, induced by active immunization or adoptive transfer. 
CD44 ligands in MS brain tissue
During MS and EAE, leukocytes adhere to the vascular endothelium in the CNS, 
extravasate and form perivascular infiltrates (Figure 2, Introduction). Adhesion and 
transmigration of cells through the BBB involves a multi-step process, consisting of 
capture, rolling, firm adhesion and subsequent diapedesis. This process depends 
on the expression of several adhesion molecules, chemokines and interactions 
with ECM components. CD44 and its variant isoforms play an important role in 
leukocyte adhesion and transmigration by binding different components of the ECM 
(HA, CS, HS, collagen, fibronectin and laminin), chemokines (MIP-1β, RANTES), 
OPN and gelatinases (MMP-2/9). All these CD44-ligands are present in the brain 
during MS and EAE and may regulate CD44-mediated leukocyte entry during 
inflammation. 
CD44-ECM interactions in the CNS
GAG-modified CD44 molecules can bind collagen, fibronectin and laminin. In 
contrast to other tissues, these ECM components are limited to vascular and 
perivascular areas of the brain, since connective tissue is lacking148. CD44-
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expressing infiltrating leukocytes may utilize these components to facilitate their 
CNS transendothelial migration. HA is a linear polysaccharide that is non-covalently 
linked to many other ECM components, such as proteoglycans of the lectican 
family (e.g aggrecan and versican) and CS. HA is not bound to a core protein, in 
contrast to CS and HS. The ECM of the brain is mainly composed of HA, which is 
probably produced by astrocytes149. HA is not present in the perivascular basement 
membrane, but expression of HA is inducible on microvascular endothelial cells 
by stimulation with LPS or proinflammatory cytokines (TNF-α, IL-1β)150. Activated 
cells that express an active form of CD44 are recruited to sites of inflammation by 
binding to endothelium-bound HA (Figure 6)151. CD44-HA interactions are required 
for initial capture and rolling of leukocytes on endothelial cells. The binding of 
CD44 to HA results in upregulation of VCAM-1 and ICAM-1 on endothelial cells152. 
It was recently demonstrated that the subsequent step of transmigration, i.e. firm 
adhesion, is crucially dependent on the association of CD44 with VLA-4 that form 
a bimolecular complex within the cytoplasm (Figure 6). Both anti-CD44 and anti-
VLA-4 Mab can reduce CNS infiltration and EAE development153,154. Mab anti-CD44 
specifically prevents leukocyte migration into the CNS and does not affect lymph 
node migration, whereas Mab anti-VLA-4 prevents cells from trafficking into the 
CNS and lymph nodes153,154. Interestingly, a placebo-controlled double-blind clinical 
trial demonstrated that treatment of relapsing-remitting MS patients with the α4-
integrin antagonist Natalizumab reduced the number of inflammatory brain lesions 
and clinical relapses155. 
Binding of CD44 to HA can be regulated by CD44v isoforms. In rat carcinoma 
cells, CD44v isoforms form homotypic molecular aggregates in the plasma 
membrane. This aggregation of CD44v proteins significantly increased the binding 
capacity to HA156. In activated human T cells, combined expression of CD44v 
isoforms is required for adhesion to HA, and can be induced by cross-linking with 
Mab157. Conversely, depending on the cell type used, splice variants can also inhibit 
HA-mediated binding158. Thus, depending on the cell type, ligation of CD44 to HA 
appears to depend on the presence and combination of spliced variants. By an 
in vitro tissue-binding assay (Stamper-Woodruff), using human cerebellar tissue, 
it was demonstrated that CD44-HA interactions contributed to peripheral blood 
lymphocyte adherence to white matter regions. This interaction was abrogated 
by anti-CD44 Mab and hyaluronidase treatment159. By using specific CD44v-
transfected Namalwa cells, it was subsequently demonstrated that CD44v isoforms 
did not contribute to CD44-HA-mediated binding to white matter regions160. 
However, as discussed above, this does not exclude the possibility that CD44v 
isoforms may contribute to HA-mediated binding by other cells to brain tissue. In 
this particular model, the brain tissue was not in an inflammatory state. In inflamed 
brain tissue, HA may be present in immunostimulatory low molecular weight forms. 
Endothelial cells likely also express HA, which may change the binding capacity for 
variant isoform regions in CD44. Alternatively, CD44v-mediated binding may occur 
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independent of HA, as discussed below. It will be of interest to determine whether 
particular isoform combinations adhere to normal and MS brain tissue. This can 
be studies by using multivalent CD44v isoform probes, in a comparable approach 
used for CD97. 
CD44 as a docking site for inflammatory mediators in MS and EAE brain tissue
Several CD44 binding components such as gelatinases, MIP-1β, RANTES and 
OPN are produced by inflammatory cells in MS and EAE lesions. In normal human 
brain different cell types express MMP-9, e.g. endothelial cells, perivascular 
mononuclear cells, astrocytes and microglia. There is a widespread dominant 
expression of MMP-9 by MΦ and reactive astrocytes in demyelinating MS 
lesions161,162. In EAE, increased MMP-9 mRNA expression levels in brain tissue 
coincided with the peak of the clinical disease course163,164. Intracerebral injection 
or induction of MMP-2 and MMP-9 resulted in leukocyte recruitment, ECM 
degradation and impairment of BBB function165-167. MIP-1β and RANTES were 
produced by perivascular and parenchymal foamy MΦ in MS brain lesions168. 
Additionally, in MS brain tissue RANTES was also expressed by endothelial cells, 
astrocytes and perivascular T cells169,170. In a relapsing-remitting EAE model, 
relapses were associated with elevated MIP-1β and RANTES expression levels 
in the spinal cord171. OPN transcripts are exclusively upregulated in MS patients 
and not in controls, as demonstrated by cDNA microarray analysis of brain tissue 
samples from MS patients (plaques) and controls172. Both MS and rat EAE CNS 
lesions contained OPN-expressing astrocytes and MΦ146. In EAE, OPN levels 
were significantly increased at the onset of disease and expression of CD44 was 
detected on similar cell types. Taken together, these findings suggest that in MS 
and EAE brain lesions, CD44 molecules can collect and locally concentrate matrix-
degrading enzymes, chemokines and cytokines, which may contribute to the 
development and chronicity of the disease.
Are CD44v3 and v10 involved in CNS infiltration in MS and EAE?
Peripheral blood lymphocytes of MS patients express elevated levels of CD44s 
compared to healthy controls. It was previously demonstrated by RT-PCR that 
CD44v6-v10 isoforms are expressed on PBMC of MS patients173. This study 
focused on the expression of CD44v6+v10 in patients with human T-lymphotropic 
virus type 1 (HLTV-1)-associated myelopathy/tropical spastic paraparesis (HAM-
TSP), a chronic disease of the spinal cord. Expression of CD44v6+v10 isoforms 
was increased in PBMC of HAM-TSP patients compared to controls. The number 
of MS patients was, however, too small to conclude whether or not there are 
significant differences in CD44v6+v10 expression compared to healthy controls. 
It has been shown that specific splice variants of CD44 are upregulated in other 
autoimmune diseases, including CD44v3 and CD44v7 on activated peripheral 
blood leukocytes of patients with IBD, RA and Sjögren’s syndrome174. It would be 
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interesting to determine whether the combination of CD44v isoforms expressed 
by peripheral blood leukocytes from MS patients differs from healthy controls and 
whether their expression is related to disease activity. Furthermore, it is of interest 
to assess whether leukocytes from MS patients exhibit an increased CD44v 
isoform specific adherence and transmigration through endothelial cells, by using 
blocking CD44v Mab.
During MS and EAE leukocytes may utilize CD44v isoforms for adhesion and 
transmigration into the CNS. In chapter 5 we demonstrate that CD44v3 and v10-
expressing cells were present in perivascular infiltrates in MS brain. Increased 
numbers of brain infiltrated CD4+ T cells expressed CD44v10 in EAE mice, 
compared to control immunized mice. The number of CD4+CD44v10+ cells was 
positively correlated with the disease course. CD44v3 plays an important role 
in leukocyte extravasation. This was demonstrated by the fact that anti-CD44v3 
Mab impaired leukocyte egress in mouse DTH responses, where CD44v3 was 
expressed by endothelial cells and infiltrated leukocytes175. However, in MS brain 
CD44v3 was not expressed by the endothelium. Nevertheless, CD44v3 may 
facilitate transmigration of brain infiltrating leukocytes by attaching to HS and 
CS (Figure 6). In brain tissue, HS-proteoglycans are expressed by endothelial 
cells and within basement membranes. By using an in vitro adhesion and 
transmigration assay, it was demonstrated that the transmigration of monocytes 
across an endothelial cell monolayer is partly dependent on HS structures on both 
monocytes and endothelial cells176. It remains to be determined whether CD44v3 
also contributes to this process. The maturation of monocytes into mature DC is 
accompanied by an increased CD44v3 expression. That CD44v3 participates in 
adhesion is demonstrated by the fact that adhesion of mature DC to immobilized 
HA was inhibited by anti-CD44v3 Mab. Thus CD44v3 may facilitate diapedesis by 
enhanced binding of leukocytes to HA and HS on brain endothelium (Figure 6). 
Like CD44v3, CD44v10 is mainly involved in cell migration, adhesion and 
extravasation177,178. Blocking of CD44v10 by Mab in mouse DTH and alopecia 
areata reduced the cellular infiltration at the site of inflammation175,179. In white 
matter of MS patients and controls we found that CD44v10 was expressed by 
endothelial cells (chapter 5)(Figure 6), which is in accordance with previous 
findings143. CD44v10-expressing cells can attach in a HA-independent manner 
to CD44s-expressing activated microvascular endothelial cells. This binding was 
significantly reduced by pre-incubation of lymphocytes with Mab against CD44v10. 
Moreover, in a cellular aggregation assay, CD44v10-expressing lymphocytes 
formed homotypic clusters that were not formed in the presence of anti-CD44v10 
Mab178. More recently, it was demonstrated that homotypic CD44v10/CD44v10 and 
heterotypic CD44v10/CD44s interactions are controlled by CS-side chains  (Figure 
6) which bind to a Bx7B motif within the CD44v10 region180. Additionally, CD44-CS 
interactions have been shown to mediate leukocyte rolling under shear stress181. 
However, it is unclear whether CD44v10 participated in this process. Altogether, 
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these data provide evidence that CD44v10 and CD44s on activated MS brain 
endothelial cells may serve as ligands for CD44v10-expressing blood leukocytes. 
In activated (HLA-II+) areas in MS and control brain tissue astrocyte-like cells 
expressed CD44v10. In accordance, CD44v6/v7 and v10 isoform expression can 
be induced in vitro on murine astrocytes by stimulation with phorbolesters or TNF-
α/IFN-γ147. Co-incubation of activated astrocytes with CD44v-expressing T cells 
resulted in HA-dependent adhesion. In this way, CD44v-HA-CD44v interactions 
between astrocytes and T cells may control the retention of lymphocytes within the 
CNS. 
CD44v3+v10 may also stimulate inflammation in MS in a different way. By 
their capacity to obtain HS (binding CD44v3) and CS (binding CD44v3+v10) 
side chains182,183, CD44v3 and CD44v10 can collect and locally concentrate 
proinflammatory OPN184,185, growth factors (i.e. heparin-binding growth factor)186, 
MIP-1β187 and RANTES188, thereby attracting cells and creating a proinflammatory 
environment. Moreover, blocking CD44v3 or CD44v10 expression resulted in 
reduced production of proinflammatory cytokines by monocytes175,189. These data 
indicate that expression of CD44v3 and CD44v10 in MS brain may promote chronic 
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Figure 6. CD44v-mediated leukocyte adhesion to activated CNS endothelium in MS.
In MS brain tissue activated endothelial cells express increased levels of HA, HS and possibly CS. 
Furthermore, endothelial cells in brain tissue constitutively express CD44v10. These cell surface and 
cell-associated (by glycoproteins) ECM molecules may facilitate the adhesion of activated leukocytes by 
binding their respective receptors, as explained in the text.
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inflammation by stimulating cell adhesion and transmigration and by increasing the 
levels of proinflammatory mediators. Figure 6 illustrates the potential CD44v-ligand 
interactions between activated leukocytes and activated CNS endothelial cells in 
MS and EAE.
Possible contributions of CD44v7 in autoimmune disease
Using two different mouse EAE models (active immunization and adoptive transfer), 
and two different mouse strains (SJL/J and C57BL/6) we demonstrated in chapter 
5 that EAE was reduced by genetic deletion of CD44v7. At present it is not clear by 
which mechanism CD44v7 exerts its effects in EAE, but previous studies suggest 
that CD44v7 isoforms modulate 1) cellular activation, 2) Th1 cell development and 
3) apoptosis, extrapolated from the following observations. 
1) CD44v7 is expressed after CD40 ligation on lamina propria mononuclear 
cells190. Transgenic mice that constitutively express CD44v4-v7 on thymocytes 
and peripheral T cells exhibit accelerated responsiveness to stimulation with T cell 
mitogens and T-dependent antigens191. Conversely, blocking of CD44v7 expression 
by Mab or genetic deletion downmodulates CD40L expression and lymphocyte 
proliferation192,193. These studies furthermore demonstrated that CD44v7 affects 
lymphocyte priming, whereas antigen-specific recall responses where not or only 
slightly affected. In agreement, we did not observe effects of CD44v7-deletion on 
autoantigen-specific T cell proliferation around the day of EAE onset, by in vitro 
restimulation. 
2) Blocking CD44v7 by Mab treatment or genetic deletion reduces the 
production of proinflammatory cytokines (TNF-α, IL-12, IFN-γ)174,190,192,194,195. In a 
Th1-dependent DTH model, anti-CD44v7 Mab treatment reduced the number of 
IFN-γ producing cells and increased the number of IL-10 producing cells at the 
inflammatory site194. In TNBS-induced colitis, treatment with anti-CD44v7 did 
not prevent mild infiltration of the intestine195. However, inflammation in treated 
mice was only transient and was followed by complete recovery with increased 
production of IL-10 and decreased production of IL-12 at the inflammatory site as 
well as in the periphery. The IL-10 contributed significantly to the recovery from 
inflammation, as could be deduced from the observation that co-administration 
of neutralizing anti-IL-10 antibodies completely abolished the therapeutic effect 
of Mab anti-CD44v7196. Moreover, chronic enterocolitis in IL-10-/- mice was 
diminished in mice with an additional deletion of CD44v7190. Also in CD patients, 
increased levels of IL-10 were observed after in vitro treatment of peripheral blood 
leukocytes with CD44v7 Mab174. It is intriguing that CD44v7 is one of the isoforms 
binding OPN. OPN is a Th1 cytokine/chemokine and has been described to play 
an important role in MS and EAE146,172,197. OPN-deleted mice developed EAE, but 
the disease severity was reduced in the progressive phase with an increased 
occurance of remissions compared with wild type mice. The reduced EAE in OPN-
deleted mice was associated with increased IL-10 and reduced IFN-γ and IL-12 
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levels. Furthermore, DNA vaccination against OPN, protected mice from EAE 
development198. CD44v7-cell binding to OPN can promote spreading, motility and 
chemotactic behavior of cells199.
3) It has been suggested that upregulation of CD44v7 in response to CD40 
ligation protects leukocytes from apoptosis. In experimental colitis, the reduction 
in the initial inflammatory response in CD44v7-/- mice correlates with increased 
numbers of apoptotic cells in the inflamed mucosa190,200,201. In patients with CD, 
CD44v7 expression is constitutively upregulated on lamina propria mononuclear 
cells at inflammatory sites174. In vitro blockade of CD44v7 with Mab or recombinant 
fusion protein induces apoptosis of lamina propria leukocytes of CD patients, which 
was not observed for cells obtained from normal mucosal tissue201. Constitutive 
CD44v7 expression prevents T cells from going into apoptosis, as was shown by 
in vitro anti-CD3 stimulation of in vivo pre-activated mesenteric lymph node cells, 
whereas CD44v7 deletion resulted in opposite effects193. Increased susceptibility 
to apoptosis in CD44v7-/- mice was associated by an upregulation of anti-apoptotic 
genes.
Does genetic deletion of CD44v7 promote apoptosis in EAE?
Reduced EAE burden in CD44v7-/- SJL/J mice is associated with a reduced number 
and size of infiltrates in spinal cord tissue compared with wild type mice (chapter 
5). This finding may imply an impaired migration into the spinal cord or an increase 
in apoptosis of infiltrated cells. Moreover, autoantigen-specific lymph node cell 
proliferation appeared to be reduced in CD44v7-/- mice at late time points after EAE 
induction in both SJL/J and C57BL/6, compared to wild type mice. This may mean 
that at late time points after EAE induction the frequency of autoantigen-specific 
lymphocytes is reduced in CD44v7-/- mice or that autoantigen-specific CD44v7-/- cells 
divide less or are more susceptible to apoptosis after late restimulation. In a pilot 
experiment we aimed to detect differences in MOG35-55-specific in vitro proliferation 
versus cell death between wild type and CD44v7-deficient mice. Draining lymph 
node cells were isolated and labeled with CFSE (carboxyfluorescein diacetate 
succinimidyl ester) at day 12 after immunization with MOG35-55. Four days after in 
vitro restimulation with MOG35-55, cells were harvested and stained with annexin-
V and propidium iodide to determine the number of apoptotic cells. Percentages 
of proliferating cells (diluted CFSE) and apoptotic cells (annexin-V positive) were 
similar between wild type and CD44v7-/- cells (unpublished data), arguing that 
CD44v7 deletion does not promote apoptosis. 
These data contradict with the finding that CD44v7-/- cells are more susceptible 
to apoptosis than wild type cells in a TNBS-induced experimental colitis model193. 
In this model it was shown earlier that increased apoptotic activity was present 
in inflamed lesions of CD44v7-/- mice, as demonstrated by TUNEL assay190. Mice 
were treated with TNBS and mesenteric lymph node cells were subsequently 
stimulated with anti-CD3 Mab or PHA. Possible explanations for the discrepancy 
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in data may include differences in the mouse strains, cells, and stimulations used. 
Similar findings were reported about OX40 (by using AND TCR transgenic mice), 
whereas early cellular division rates and apoptotic cell numbers, at day 4 after 
antigen stimulation, were not affected by stimulation or deletion of OX40202,203. 
However, a dramatic increase in cell death of OX40-/- T cells occurred between day 
6 and day 12 after in vitro antigen stimulation203. OX40 stimulation promoted the 
accumulation of dividing cells through more cellular division cycles and decreased 
apoptosis of antigen-specific T cells in vivo and in vitro202,203. It is still unclear whether 
or not CD44v7 deficiency influences antigen-specific survival versus apoptosis in 
EAE development. By using PLP139-151 TCR transgenic mice
204 backcrossed with 
CD44v7-/- mice, the hypothesis that CD44v7 deficiency decreases the life span of 
antigen-activated CD4+ T cells by promoting the induction of apoptosis could be 
further tested.
Concluding remarks
Taken together, the studies described in this thesis suggest that PG, CD97 
and CD44v isoforms are involved in MS and EAE. We postulate that during 
demyelinating disease, phagocytes carry PG into the CNS. We have demonstrated 
that PG accumulates in the CNS of MS patients and of non-human primates with 
EAE inside different cell subsets including granulocytes, MΦ and DC. PG may 
persist in the CNS, because the CNS lacks lysozyme and NAMLAA, enzymes 
that can degrade PG. In mice, S. aureus PG facilitated an autoantigen-specific 
inflammatory immune reponse in the CNS, that resulted in EAE development. S. 
aureus PG stimulated antigen uptake, antigen presentation, costimulation and 
proinflammatory cytokine production by DC in vitro. Furthermore, PG induced Th1 
cell polarization and expansion via DC. Therefore, in MS as well as in EAE, PG may 
stimulate autoimmune-mediated reactions in the periphery and in the CNS.
CD97 and CD44v isoforms contribute to a variety of cellular processes, e.g. 
cell activation, adhesion and apoptosis. We have demonstrated that CD97 and its 
ligand CD55, and CD44v3 and CD44v10 were expressed by different cell types in 
MS brain lesions. In functional experiments in mice, it appeared that EAE was not 
reduced by blockade of the CD97-CD55 interaction early after disease induction. 
Further research is required to determine whether CD97 parcipitates in MS and 
EAE by interacting with its other ligands (CS-B, VLA-5 and αvβ3 integrins). Genetic 
deletion of CD44v7 or CD44v10 in mice did reduce EAE. Additional studies are 
required to elucidate by which mechanisms CD44v7 and CD44v10 contribute to MS 
and EAE. Based on studies in experimental colitis and DTH responses, CD44v7 
and CD44v10 may participate in EAE and MS by stimulating cellular activation, 
adhesion, Th1 cell development and/or apoptosis.  
188 Chapter 6
References
1. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S, Ekre HP, Link H: Autoreactive 
T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J 
Immunol 1991, 21:1461-1468.
2. Archelos JJ, Storch MK, Hartung HP: The role of B cells and autoantibodies in multiple sclerosis. 
Ann Neurol 2000, 47:694-706.
3. Mein LE, Hoch RM, Dornmair K, de Waal Malefyt R, Bontrop RE, Jonker M, Lassmann H, 
Hohlfeld R, Wekerle H, ‘t Hart BA: Encephalitogenic potential of myelin basic protein-specific T 
cells isolated from normal rhesus macaques. Am J Pathol 1997, 150:445-453.
4. Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP: Frequency, heterogeneity 
and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive 
outbred primates. Eur J Immunol 2001, 31:2942-2950.
5. Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK: High frequency 
of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: 
mechanisms of selection of the self-reactive repertoire. J Exp Med 2000, 191:761-770.
6. Klein L, Klugmann M, Nave KA, Tuohy VK, Kyewski B: Shaping of the autoreactive T-cell 
repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med 2000, 
6:56-61.
7. Schrijver IA, van Meurs M, Melief MJ, Ang CW, Buljevac D, Ravid R, Hazenberg MP, Laman 
JD: Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple 
sclerosis. Brain 2001, 124:1544-1554.
8. Strassheim D, Asehnoune K, Park JS, Kim JY, He Q, Richter D, Kuhn K, Mitra S, Abraham E: 
Phosphoinositide 3-kinase and Akt occupy central roles in inflammatory responses of Toll-like 
receptor 2-stimulated neutrophils. J Immunol 2004, 172:5727-5733.
9. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y: Both anti-CD11a (LFA-1) and anti-
CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune 
encephalomyelitis. J Neuroimmunol 1995, 62:153-160.
10. Zhou X, Gao XP, Fan J, Liu Q, Anwar KN, Frey RS, Malik AB: Toll-like receptor 4 (TLR4) induces 
the expression of CD11b/CD18 integrin in neutrophils. Am J Physiol Lung Cell Mol Physiol 
2004.
11. Rotshenker S: Microglia and macrophage activation and the regulation of complement-receptor-
3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and disease. J Mol Neurosci 2003, 21:
65-72.
12. Reichert F, Rotshenker S: Complement-receptor-3 and scavenger-receptor-AI/II mediated 
myelin phagocytosis in microglia and macrophages. Neurobiol Dis 2003, 12:65-72.
13. Hoijer MA, Melief MJ, Debets R, Hazenberg MP: Inflammatory properties of peptidoglycan are 
decreased after degradation by human N-acetylmuramyl-L-alanine amidase. Eur Cytokine Netw 
1997, 8:375-381.
14. Ulvestad E, Williams K, Mörk S, Antel J, Nyland H: Phenotypic differences between human 
monocytes/macrophages and microglial cells studied in situ and in vitro. J Neuropathol Exp 
Neurol 1994, 53:492-501.
15. Adams CW, Poston RN, Buk SJ: Pathology, histochemistry and immunocytochemistry of lesions 
in acute multiple sclerosis. J Neurol Sci 1989, 92:291-306.
16. Ladesic B, Perovic S, Hrsak I: Pharmacokinetics of an immunomodulator peptidoglycan 
monomer in mice after intravenous administration. Int J Immunopharmacol 1993, 15:145-150.
17. Hoijer MA, Melief MJ, Calafat J, Roos D, van den Beemd RW, van Dongen JJ, Hazenberg MP: 
Expression and intracellular localization of the human N-acetylmuramyl- L-alanine amidase, a 
bacterial cell wall-degrading enzyme. Blood 1997, 90:1246-1254.
General discussion 189
18. Bsibsi M, Ravid R, Gveric D, van Noort JM: Broad expression of Toll-like receptors in the human 
central nervous system. J Neuropathol Exp Neurol 2002, 61:1013-1021.
19. Iwanaga Y, Davey MP, Martin TM, Planck SR, DePriest ML, Baugh MM, Suing CM, Rosenbaum 
JT: Cloning, sequencing and expression analysis of the mouse NOD2/CARD15 gene. Inflamm 
Res 2003, 52:272-276.
20. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G: Nod2, a Nod1/Apaf-1 family 
member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001, 276:4812-
4818.
21. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, Carrio R, Merino J, Liu D, Ni J, Nunez G: 
Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem 1999, 274:
14560-14567.
22. Kielian T, Mayes P, Kielian M: Characterization of microglial responses to Staphylococcus aureus: 
effects on cytokine, costimulatory molecule, and Toll-like receptor expression. J Neuroimmunol 
2002, 130:86-99.
23. Kielian T, Esen N, Bearden ED: Toll-like receptor 2 (TLR2) is pivotal for recognition of S. aureus 
peptidoglycan but not intact bacteria by microglia. Glia 2005, 49:567-576.
24. Esen N, Tanga FY, DeLeo JA, Kielian T: Toll-like receptor 2 (TLR2) mediates astrocyte activation 
in response to the Gram-positive bacterium Staphylococcus aureus. J Neurochem 2004, 88:
746-758.
25. Olson JK, Miller SD: Microglia initiate central nervous system innate and adaptive immune 
responses through multiple TLRs. J Immunol 2004, 173:3916-3924.
26. Fincher EFt, Johannsen L, Kapas L, Takahashi S, Krueger JM: Microglia digest Staphylococcus 
aureus into low molecular weight biologically active compounds. Am J Physiol 1996, 271:R149-
156.
27. Darabi K, Karulin AY, Boehm BO, Hofstetter HH, Fabry Z, LaManna JC, Chavez JC, Tary-
Lehmann M, Lehmann PV: The third signal in T cell-mediated autoimmune disease? J Immunol 
2004, 173:92-99.
28. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, Karulin A, Lehmann PV: 
Revisiting tolerance induced by autoantigen in incomplete Freund’s adjuvant. J Immunol 2000, 
164:5771-5781.
29. Hofstetter HH, Shive CL, Forsthuber TG: Pertussis toxin modulates the immune response to 
neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental 
autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 
2002, 169:117-125.
30. Agarwal RK, Sun SH, Su SB, Chan CC, Caspi RR: Pertussis toxin alters the innate and the 
adaptive immune responses in a pertussis-dependent model of autoimmunity. J Neuroimmunol 
2002, 129:133-140.
31. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo RC, Bonder C, James 
WG, Robbins SM, Kubes P: TLR4 contributes to disease-inducing mechanisms resulting in 
central nervous system autoimmune disease. J Immunol 2004, 173:7070-7077.
32. Linthicum DS, Munoz JJ, Blaskett A: Acute experimental autoimmune encephalomyelitis in mice. 
I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased 
vascular permeability of the central nervous system. Cell Immunol 1982, 73:299-310.
33. Lassmann S, Kincaid C, Asensio VC, Campbell IL: Induction of type 1 immune pathology in the 
brain following immunization without central nervous system autoantigen in transgenic mice with 
astrocyte-targeted expression of IL-12. J Immunol 2001, 167:5485-5493.
34. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD: Pathologic role and 
temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune 
encephalomyelitis. J Immunol 2000, 164:670-678.
190 Chapter 6
35. Schrijver IA, Melief MJ, Markusse HM, Van Aelst I, Opdenakker G, Hazenberg MP, Laman JD: 
Peptidoglycan from sterile human spleen induces T-cell proliferation and inflammatory mediators 
in rheumatoid arthritis patients and healthy subjects. Rheumatology 2001, 40:438-446.
36. Schrijver IA, Melief MJ, Eulderink F, Hazenberg MP, Laman JD: Bacterial peptidoglycan 
polysaccharides in sterile human spleen induce proinflammatory cytokine production by human 
blood cells. J Infect Dis 1999, 179:1459-1468.
37. Kraehenbuhl JP, Hopkins SA, Kerneis S, Pringault E: Antigen sampling by epithelial tissues: 
implication for vaccine design. Behring Inst Mitt 1997:24-32.
38. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl 
JP, Ricciardi-Castagnoli P: Dendritic cells express tight junction proteins and penetrate gut 
epithelial monolayers to sample bacteria. Nat Immunol 2001, 2:361-367.
39. Macpherson AJ, Uhr T: Induction of protective IgA by intestinal dendritic cells carrying commensal 
bacteria. Science 2004, 303:1662-1665.
40. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, 
Fox JG, Littman DR, Reinecker HC: CX3CR1-mediated dendritic cell access to the intestinal 
lumen and bacterial clearance. Science 2005, 307:254-258.
41. Segal BM, Chang JT, Shevach EM: CpG oligonucleotides are potent adjuvants for the activation 
of autoreactive encephalitogenic T cells in vivo. J Immunol 2000, 164:5683-5688.
42. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan 
T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune 
inflammation. J Exp Med 2005, 201:233-240.
43. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, 
Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: 
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of 
the brain. Nature 2003, 421:744-748.
44. Pasare C, Medzhitov R: Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated 
suppression by dendritic cells. Science 2003, 299:1033-1036.
45. Hamada T, Driscoll BF, Kies MW, Alvord EC, Jr.: LPS augments adoptive transfer of experimental 
allergic encephalomyelitis in the Lewis rat. Autoimmunity 1989, 2:275-284.
46. Conant SB, Swanborg RH: Autoreactive T cells persist in rats protected against experimental 
autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J 
Immunol 2004, 172:5322-5328.
47. Ichikawa HT, Williams LP, Segal BM: Activation of APCs through CD40 or Toll-like receptor 9 
overcomes tolerance and precipitates autoimmune disease. J Immunol 2002, 169:2781-2787.
48. Visser L, de Heer HJ, Boven LA, van Riel D, van Meurs M, Melief MJ, Zähringer U, van Strijp 
J, Lambrecht BN, Nieuwenhuis EE, Laman JD: Proinflammatory bacterial peptidoglycan as a 
cofactor for the development of central nervous system autoimmune disease. J Immunol 2005, 
174:808-816.
49. Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-
Lecreulx D: Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol 
Chem 2003, 278:41702-41708.
50. Siegel JL, Hurst SF, Liberman ES, Coleman SE, Bleiweis AS: Mutanolysin-induced spheroplasts 
of Streptococcus mutants are true protoplasts. Infect Immun 1981, 31:808-815.
51. Zhang X, Rimpiläinen M, Šimelyte E, Toivanen P: Enzyme degradation and proinflammatory 
activity in arthritogenic and nonarthritogenic Eubacterium aerofaciens cell walls. Infect Immun 
2001, 69:7277-7284.
52. Bera A, Herbert S, Jakob A, Vollmer W, Gotz F: Why are pathogenic staphylococci so lysozyme 
resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme 
resistance of Staphylococcus aureus. Mol Microbiol 2005, 55:778-787.
General discussion 191
53. Ganz T, Gabayan V, Liao HI, Liu L, Oren A, Graf T, Cole AM: Increased inflammation in lysozyme 
M-deficient mice in response to Micrococcus luteus and its peptidoglycan. Blood 2003, 101:
2388-2392.
54. Xu M, Wang Z, Locksley RM: Innate immune responses in peptidoglycan recognition protein L-
deficient mice. Mol Cell Biol 2004, 24:7949-7957.
55. Šimelyte E, Rimpiläinen M, Zhang X, Toivanen P: Role of peptidoglycan subtypes in the 
pathogenesis of bacterial cell wall arthritis. Ann Rheum Dis 2003, 62:976-982.
56. Ginsburg I: How are cell-wall components of pathogenic microorganisms degraded in infectious 
and inflammatory sites?: facts and myths. In: Biological properties of peptidoglycan (Seidl PH 
and Schleifer KH, eds), Walter de Gruyter, Berlin 1986:167-185.
57. Zhang X, Rimpiläinen M, Šimelyte E, Toivanen P: What determines arthritogenicity of bacterial 
cell wall? A study on Eubacterium cell wall-induced arthritis. Rheumatology (Oxford) 2000, 39:
274-282.
58. Šimelyte E, Rimpiläinen M, Lehtonen L, Zhang X, Toivanen P: Bacterial cell wall-induced 
arthritis: chemical composition and tissue distribution of four Lactobacillus strains. Infect Immun 
2000, 68:3535-3540.
59. Stimpson SA, Brown RR, Anderle SK, Klapper DG, Clark RL, Cromartie WJ, Schwab JH: 
Arthropathic properties of cell wall polymers from normal flora bacteria. Infect Immun 1986, 51:
240-249.
60. Zhang X, Rimpiläinen M, Šimelyte E, Toivanen P: Characterisation of Eubacterium cell wall: 
peptidoglycan structure determines arthritogenicity. Ann Rheum Dis 2001, 60:269-274.
61. Rapp NS, Gilroy J, Lerner AM: Role of bacterial infection in exacerbation of multiple sclerosis. 
Am J Phys Med Rehabil 1995, 74:415-418.
62. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van der Meché FG, van 
Doorn PA, Hintzen RQ: Prospective study on the relationship between infections and multiple 
sclerosis exacerbations. Brain 2002, 125:952-960.
63. Buljevac D, Verkooyen RP, Jacobs BC, Hop W, van der Zwaan LA, van Doorn PA, Hintzen RQ: 
Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients. Ann Neurol 
2003, 54:828-831.
64. Hazenberg MP, Klasen IS, Kool J, Ruseler-van Embden JG, Severijnen AJ: Are intestinal 
bacteria involved in the etiology of rheumatoid arthritis? Review article. Apmis 1992, 100:1-9.
65. Donaldson RM, Jr.: Normal bacterial populations of the intestine and their relation to intestinal 
function. N Engl J Med 1964, 270:938-945.
66. Sartor RB, Bond TM, Compton KY, Cleland DR: Intestinal absorption of bacterial cell wall 
polymers in rats. Adv Exp Med Biol 1987, 216A:835-839.
67. Lichtman SN, Keku J, Schwab JH, Sartor RB: Evidence for peptidoglycan absorption in rats with 
experimental small bowel bacterial overgrowth. Infect Immun 1991, 59:555-562.
68. Le Quintrec JL, Puechal X, Marin A, Lamy P, Gendre JP, Menkes CJ: Chronic erosive arthritis 
associated with an unusual intestinal bypass. Clin Exp Rheumatol 1991, 9:529-532.
69. Ross CB, Scott HW, Pincus T: Jejunoileal bypass arthritis. Baillieres Clin Rheumatol 1989, 3:
339-355.
70. Henriksson AE, Blomquist L, Nord CE, Midtvedt T, Uribe A: Small intestinal bacterial overgrowth 
in patients with rheumatoid arthritis. Ann Rheum Dis 1993, 52:503-510.
71. Lichtman SN, Wang J, Currin RT, Lemasters JJ: Induction of TNF-alpha release by bacterial 
cell wall polymers: comparison of peptidoglycan-polysaccharide with endotoxin. In: Cells of the 
hepatic sinusoid (Wisse E, Knook DL, Wake K, eds), Kupfer Cell Foundation, Leiden 1995:7-9.
72. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance 
exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). 
Clin Exp Immunol 1995, 102:448-455.
192 Chapter 6
73. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM: Transgenic mice that express a 
myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993, 72:
551-560.
74. Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, 
Boersma WJ, Claassen E: Strain-dependent induction of cytokine profiles in the gut by orally 
administered Lactobacillus strains. Vaccine 2000, 18:2613-2623.
75. Maassen CB, van Holten JC, Balk F, Heijne den Bak-Glashouwer MJ, Leer R, Laman JD, 
Boersma WJ, Claassen E: Orally administered Lactobacillus strains differentially affect the 
direction and efficacy of the immune response. Vet Q 1998, 20 Suppl 3:S81-83.
76. Nieuwenhuis EE, Visser MR, Kavelaars A, Cobelens PM, Fleer A, Harmsen W, Verhoef J, 
Akkermans LM, Heijnen CJ: Oral antibiotics as a novel therapy for arthritis: evidence for a 
beneficial effect of intestinal Escherichia coli. Arthritis Rheum 2000, 43:2583-2589.
77. Yacyshyn B, Meddings J, Sadowski D, Bowen-Yacyshyn MB: Multiple sclerosis patients have 
peripheral blood CD45RO+ B cells and increased intestinal permeability. Dig Dis Sci 1996, 41:
2493-2498.
78. Purrmann J, Arendt G, Cleveland S, Borchard F, Furst W, Gemsa R, Bertrams J, Hengels KJ: 
Association of Crohn’s disease and multiple sclerosis. Is there a common background? J Clin 
Gastroenterol 1992, 14:43-46.
79. Buccino GP, Corrente G, Visintini D: Crohn’s disease and multiple sclerosis: a single case report. 
Ital J Neurol Sci 1994, 15:303-306.
80. Beaugerie L, Lamy P, Ganne N, Carbonnel F, Le Quintrec Y, Cosnes J, Gendre JP: Morbid 
associations in Crohn’s disease. Study of a series of 832 patients. Presse Med 1997, 26:892-
894.
81. Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Scholmerich 
J: Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995, 
345:897-898.
82. Agranoff D, Schon F: Are focal white matter lesions in patients with inflammatory bowel disease 
linked to multiple sclerosis? Lancet 1995, 346:190-191.
83. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain 
CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, 
Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants 
with susceptibility to Crohn’s disease. Nature 2001, 411:599-603.
84. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas 
R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: 
A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 
411:603-606.
85. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull 
M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, 
Jannot AS, Thomas G, Hugot JP: CARD15/NOD2 mutational analysis and genotype-phenotype 
correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002, 70:845-
857.
86. Sawcer S, Maranian M, Hensiek A, Roxburgh R, Gray J, Compston A: Crohn’s associated 
NOD2 gene variants are not involved in determining susceptibility to multiple sclerosis. J Neurol 
Neurosurg Psychiatry 2003, 74:1157.
87. Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, Bui TH, Giovannini M, 
Zaehringer U, Penard-Lacronique V, Sansonetti PJ, Hugot JP, Thomas G: Gene-environment 
interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S 
A 2003, 100:3455-3460.
General discussion 193
88. Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, 
Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M: Card15 gene 
overexpression in mononuclear and epithelial cells of the inflamed Crohn’s disease colon. Gut 
2003, 52:840-846.
89. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nunez G, Keshav S: 
Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003, 125:47-
57.
90. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ: Secretion of microbicidal 
alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-
118.
91. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA: Nod2-
dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:
731-734.
92. Schmid M, Fellermann K, Wehkamp J, Herrlinger K, Stange EF: The role of defensins in the 
pathogenesis of chronic-inflammatory bowel disease. Z Gastroenterol 2004, 42:333-338.
93. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, 
Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF: NOD2 
(CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin 
expression. Gut 2004, 53:1658-1664.
94. Lehtonen L, Eerola E, Toivanen P: Muramic acid in human peripheral blood leucocytes in 
different age groups. Eur J Clin Invest 1997, 27:791-792.
95. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ, van der Valk P, Ravid R, Rensing S, 
Boon L, ‘t Hart BA, Laman JD: Transfer of central nervous system autoantigens and presentation 
in secondary lymphoid organs. J Immunol 2002, 169:5415-5423.
96. Liu H, MacKenzie-Graham AJ, Palaszynski K, Liva S, Voskuhl RR: “Classic” myelin basic 
proteins are expressed in lymphoid tissue macrophages. J Neuroimmunol 2001, 116:83-93.
97. MacKenzie-Graham AJ, Pribyl TM, Kim S, Porter VR, Campagnoni AT, Voskuhl RR: Myelin 
protein expression is increased in lymph nodes of mice with relapsing experimental autoimmune 
encephalomyelitis. J Immunol 1997, 159:4602-4610.
98. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, Stetler-Stevenson MA, Siebenlist 
U, Kelly K: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with 
inflammation. J Immunol 1996, 157:5438-5447.
99. Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP: Expression of the 
activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 
1999, 42:650-658.
100. Jaspars LH, Vos W, Aust G, Van Lier RA, Hamann J: Tissue distribution of the human CD97 
EGF-TM7 receptor. Tissue Antigens 2001, 57:325-331.
101. Hamann J, Vogel B, van Schijndel GM, van Lier RA: The seven-span transmembrane receptor 
CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996, 184:1185-1189.
102. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, van Lier RA: Characterization of the 
CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 
1998, 28:1701-1707.
103. Hamann J, van Zeventer C, Bijl A, Molenaar C, Tesselaar K, van Lier RA: Molecular cloning and 
characterization of mouse CD97. Int Immunol 2000, 12:439-448.
104. Lin HH, Stacey M, Saxby C, Knott V, Chaudhry Y, Evans D, Gordon S, McKnight AJ, Handford 
P, Lea S: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-
mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem 2001, 
276:24160-24169.
105. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, Hamann J, Gordon S, 
Lin HH: The epidermal growth factor-like domains of the human EMR2 receptor mediate cell 
attachment through chondroitin sulfate glycosaminoglycans. Blood 2003, 102:2916-2924.
194 Chapter 6
106. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, van Lier RA, Hamann 
J: Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific 
interaction with chondroitin sulfate on B cells. J Leukoc Biol 2005, 77:112-119.
107. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K: CD97, an adhesion 
receptor on inflammatory cells, stimulates angiogenesis through binding integrin counter 
receptors on endothelial cells. Blood 2004.
108. Prydz K, Dalen KT: Synthesis and sorting of proteoglycans. J Cell Sci 2000, 113 Pt 2:193-205
109. Kop EN, Kwakkenbos MJ, Teske GJ, Kraan MC, Smeets TJ, Stacey M, Lin HH, Tak PP, Hamann 
J: Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan 
sulfate in rheumatoid synovial tissue. Arthritis Rheum 2005, 52:442-450.
110. Sobel RA, Chen M, Maeda A, Hinojoza JR: Vitronectin and integrin vitronectin receptor 
localization in multiple sclerosis lesions. J Neuropathol Exp Neurol 1995, 54:202-213.
111. Sobel RA, Hinojoza JR, Maeda A, Chen M: Endothelial cell integrin laminin receptor expression 
in multiple sclerosis lesions. Am J Pathol 1998, 153:405-415.
112. Ruoslahti E: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 
12:697-715.
113. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW: Ligand binding to integrins. J Biol Chem 2000, 
275:21785-21788.
114. Lee SJ, Benveniste EN: Adhesion molecule expression and regulation on cells of the central 
nervous system. J Neuroimmunol 1999, 98:77-88.
115. Yamaguchi Y: Chondroitin sulfate proteoglycans in the nervous system. In: Proteoglycans-
structure, biology, ans molecular interactions (Lozzo RV, ed), Marcel Dekker, New York 2000:
379-402.
116. Sobel RA, Ahmed AS: White matter extracellular matrix chondroitin sulfate/dermatan sulfate 
proteoglycans in multiple sclerosis. J Neuropathol Exp Neurol 2001, 60:1198-1207.
117. Sobel RA: The extracellular matrix in multiple sclerosis lesions. J Neuropathol Exp Neurol 1998, 
57:205-217.
118. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB: 
Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416:
636-640.
119. Leemans JC, te Velde AA, Florquin S, Bennink RJ, de Bruin K, van Lier RA, van der Poll T, 
Hamann J: The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is 
required for neutrophil migration and host defense. J Immunol 2004, 172:1125-1131.
120. Kerlero de Rosbo N, Brok HP, Bauer J, Kaye JF, ‘t Hart BA, Ben-Nun A: Rhesus monkeys 
are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin 
oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes. J 
Neuroimmunol 2000, 110:83-96.
121. Brok HP, Bauer J, Jonker M, Blezer E, Amor S, Bontrop RE, Laman JD, ‘t Hart BA: Non-human 
primate models of multiple sclerosis. Immunol Rev 2001, 183:173-185.
122. Levine S, Saltzman A: The hyperacute form of allergic encephalomyelitis produced in rats 
without the aid of pertussis vaccine. J Neuropathol Exp Neurol 1989, 48:255-262.
123. Maatta JA, Sjoholm UR, Nygardas PT, Salmi AA, Hinkkanen AE: Neutrophils secreting tumor 
necrosis factor alpha infiltrate the central nervous system of BALB/c mice with experimental 
autoimmune encephalomyelitis. J Neuroimmunol 1998, 90:162-175.
124. Qian YM, Haino M, Kelly K, Song WC: Structural characterization of mouse CD97 and study 
of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 
1999, 98:303-311.
125. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H: Multiple sclerosis: in 
situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998, 43:465-
471.
General discussion 195
126. Barnum SR: Inhibition of complement as a therapeutic approach in inflammatory central nervous 
system (CNS) disease. Mol Med 1999, 5:569-582.
127. Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR: Receptor for the C3a anaphylatoxin is 
expressed by neurons and glial cells. Glia 1999, 26:201-211.
128. Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR: Enhanced expression of 
chemotactic receptors in multiple sclerosis lesions. J Neurol Sci 1996, 144:135-141.
129. van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Döpp EA, Dijkstra CD: Macrophage 
phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 
and induces production of tumor necrosis factor-alpha and nitric oxide. J Neuroimmunol 1996, 
70:145-152.
130. Rus HG, Niculescu F, Shin ML: Sublytic complement attack induces cell cycle in oligodendrocytes. 
J Immunol 1996, 156:4892-4900.
131. Lublin DM, Atkinson JP: Decay-accelerating factor: biochemistry, molecular biology, and 
function. Annu Rev Immunol 1989, 7:35-58.
132. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO: Induction of decay-
accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial 
cells against complement deposition. Blood 1999, 94:1673-1682.
133. van Beek J, van Meurs M, ‘t Hart BA, Brok HP, Neal JW, Chatagner A, Harris CL, Omidvar N, 
Morgan BP, Laman JD, Gasque P: Decay-accelerating factor (CD55) is expressed by neurons in 
response to chronic but not acute autoimmune central nervous system inflammation associated 
with complement activation. J Immunol 2005, 174:2353-2365.
134. Nicholson-Weller A, Wang CE: Structure and function of decay accelerating factor CD55. J Lab 
Clin Med 1994, 123:485-491.
135. Shibuya K, Abe T, Fujita T: Decay-accelerating factor functions as a signal transducing molecule 
for human monocytes. J Immunol 1992, 149:1758-1762.
136. Lund-Johansen F, Olweus J, Symington FW, Arli A, Thompson JS, Vilella R, Skubitz K, Horejsi 
V: Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosp
hatidylinositol-anchored antigens. Eur J Immunol 1993, 23:2782-2791.
137. Davis LS, Patel SS, Atkinson JP, Lipsky PE: Decay-accelerating factor functions as a signal 
transducing molecule for human T cells. J Immunol 1988, 141:2246-2252.
138. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM: Signal transduction 
through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and 
protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992, 149:3535-3541.
139. Tosello AC, Mary F, Amiot M, Bernard A, Mary D: Activation of T cells via CD55: recruitment of 
early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998, 48:
13-27.
140. Günthert U: CD44 in malignant disorders. Curr Top Microbiol Immunol 1996, 213:271-285.
141. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U: Expression and modulation 
of CD44variant isoforms in humans. J Cell Biol 1994, 124:71-82.
142. Stauder R, Eisterer W, Thaler J, Günthert U: CD44variant isoforms in non-Hodgkin’s lymphoma: 
a new independent prognostic factor. Blood 1995, 85:2885-2899.
143. Kaaijk P, Pals ST, Morsink F, Bosch DA, Troost D: Differential expression of CD44 splice variants 
in the normal human central nervous system. J Neuroimmunol 1997, 73:70-76.
144. Girgrah N, Letarte M, Becker LE, Cruz TF, Theriault E, Moscarello MA: Localization of the CD44 
glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active 
lesions in multiple sclerosis. J Neuropathol Exp Neurol 1991, 50:779-792.
145. Zeine R, Owens T: Direct demonstration of the infiltration of murine central nervous system by 
Pgp-1/CD44high CD45RB(low) CD4+ T cells that induce experimental allergic encephalomyelitis. 
J Neuroimmunol 1992, 40:57-69.
196 Chapter 6
146. Kim MD, Cho HJ, Shin T: Expression of osteopontin and its ligand, CD44, in the spinal cords of 
Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 151:78-
84.
147. Haegel H, Tölg C, Hofmann M, Ceredig R: Activated mouse astrocytes and T cells express 
similar CD44variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 1993, 122:1067-1077
148. Gladson CL: The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp 
Neurol 1999, 58:1029-1040.
149. Asher R, Bignami A: Localization of hyaluronate in primary glial cell cultures derived from 
newborn rat brain. Exp Cell Res 1991, 195:401-411.
150. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M: Proinflammatory stimuli 
regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin 
Invest 1998, 101:97-108.
151. DeGrendele HC, Estess P, Siegelman MH: Requirement for CD44 in activated T cell 
extravasation into an inflammatory site. Science 1997, 278:672-675.
152. Isacke CM, Yarwood H: The hyaluronan receptor, CD44. Int J Biochem Cell Biol 2002, 34:718-
721.
153. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T: Antibodies to CD44 and integrin 
alpha4, but not L-selectin, prevent central nervous system inflammation and experimental 
encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999, 
96:6896-6901.
154. Brennan FR, O’Neill JK, Allen SJ, Butter C, Nuki G, Baker D: CD44 is involved in selective 
leucocyte extravasation during inflammatory central nervous system disease. Immunology 1999, 
98:427-435.
155. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, 
Dalton CM, Miszkiel KA, O’Connor PW: A controlled trial of natalizumab for relapsing multiple 
sclerosis. N Engl J Med 2003, 348:15-23.
156. Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H: Regulated clustering of variant 
CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 1996, 135:1139-1150.
157. Galluzzo E, Albi N, Fiorucci S, Merigiola C, Ruggeri L, Tosti A, Grossi CE, Velardi A: Involvement 
of CD44variant isoforms in hyaluronate adhesion by human activated T cells. Eur J Immunol 
1995, 25:2932-2939.
158. van der Voort R, Manten-Horst E, Smit L, Ostermann E, van den Berg F, Pals ST: Binding of cell-
surface expressed CD44 to hyaluronate is dependent on splicing and cell type. Biochem Biophys 
Res Commun 1995, 214:137-144.
159. Aho R, Jalkanen S, Kalimo H: CD44-hyaluronate interaction mediates in vitro lymphocyte 
binding to the white matter of the central nervous system. J Neuropathol Exp Neurol 1994, 53:
295-302.
160. Aho R, Kalimo H, Salmi M, Smith D, Jalkanen S: Binding of malignant lymphoid cells to the white 
matter of the human central nervous system: role of different CD44 isoforms, beta 1, beta 2 and 
beta 7 integrins, and L-selectin. J Neuropathol Exp Neurol 1997, 56:557-568.
161. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J: The 
expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous 
inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion 
evolution. J Neuropathol Exp Neurol 1996, 55:1194-1204.
162. Maeda A, Sobel RA: Matrix metalloproteinases in the normal human central nervous system, 
microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996, 55:300-309.
163. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, 
Ward GA, Gearing AJ, Miller KM: Matrix metalloproteinase expression during experimental 
autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour 
necrosis factor-alpha inhibitor. J Neuroimmunol 1997, 74:85-94.
General discussion 197
164. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, Gearing AJ, Hartung HP: 
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. 
Brain 1998, 121:159-166.
165. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG: TIMP-2 
reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992, 576:
203-207.
166. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG: Injury-induced 92-
kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 1994, 71:417-422.
167. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, Wells GM, Clements JM, 
Chandler S, Gearing AJ, Perry VH: Matrix metalloproteinase expression in an experimentally-
induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998, 87:62-72.
168. Boven LA, Montagne L, Nottet HS, De Groot CJ: Macrophage inflammatory protein-1alpha (MIP-
1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active 
demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol 2000, 122:257-263.
169. Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR, Bernard CC: 
Perivascular T cells express the proinflammatory chemokine RANTES mRNA in multiple 
sclerosis lesions. Scand J Immunol 1997, 46:195-203.
170. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of monocyte chemoattractant 
protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis 
lesions. J Neuroimmunol 1998, 84:238-249.
171. Glabinski AR, Bielecki B, Ransohoff RM: Chemokine upregulation follows cytokine expression 
in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol 2003, 58:
81-88.
172. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, 
Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L: The influence of the proinflammatory 
cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
173. Matsuoka E, Usuku K, Jonosono M, Takenouchi N, Izumo S, Osame M: CD44 splice variant 
involvement in the chronic inflammatory disease of the spinal cord: HAM/TSP. J Neuroimmunol 
2000, 102:1-7.
174. Wittig B, Seiter S, Schmidt DS, Zuber M, Neurath M, Zöller M: CD44variant isoforms on blood 
leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. 
Lab Invest 1999, 79:747-759.
175. Seiter S, Engel P, Föhr N, Zöller M: Mitigation of delayed-type hypersensitivity reactions by 
a CD44variant isoform v3-specific antibody: blockade of leukocyte egress. J Invest Dermatol 
1999, 113:11-21.
176. Floris S, van den Born J, van der Pol SM, Dijkstra CD, De Vries HE: Heparan sulfate 
proteoglycans modulate monocyte migration across cerebral endothelium. J Neuropathol Exp 
Neurol 2003, 62:780-790.
177. Yoshinari C, Mizusawa N, Byers HR, Akasaka T: CD44variant isoform CD44v10 expression 
of human melanoma cell lines is upregulated by hyaluronate and correlates with migration. 
Melanoma Res 1999, 9:223-231.
178. Weimann TK, Wagner C, Funk R, Hirche H, Goos M, Wagner SN: Hyaluronan-independent 
adhesion of CD44H+ and CD44v10+ lymphocytes to dermal microvascular endothelial cells and 
keratinocytes. J Invest Dermatol 2001, 117:949-957.
179. Freyschmidt-Paul P, Seiter S, Zöller M, König A, Ziegler A, Sundberg JP, Happle R, Hoffmann R: 
Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/
HeJ mice. J Invest Dermatol 2000, 115:653-657.
180. Hayes GM, Chiu R, Carpenito C, Dougherty ST, Dougherty GJ: Identification of sequence motifs 
responsible for the adhesive interaction between exon v10-containing CD44 isoforms. J Biol 
Chem 2002, 277:50529-50534.
198 Chapter 6
181. Murai T, Sougawa N, Kawashima H, Yamaguchi K, Miyasaka M: CD44-chondroitin sulfate 
interactions mediate leukocyte rolling under physiological flow conditions. Immunol Lett 2004, 
93:163-170.
182. Kugelman LC, Ganguly S, Haggerty JG, Weissman SM, Milstone LM: The core protein of 
epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J Invest 
Dermatol 1992, 99:886-891.
183. Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N: Proteoglycan forms of the 
lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J 
Cell Biol 1995, 128:673-685.
184. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and 
osteopontin (Eta-1). Science 1996, 271:509-512.
185. Lin YH, Huang CJ, Chao JR, Chen ST, Lee SF, Yen JJ, Yang-Yen HF: Coupling of osteopontin 
and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or 
granulocyte-macrophage colony-stimulating factor. Mol Cell Biol 2000, 20:2734-2742.
186. Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman 
G, Aruffo A: CD44 isoforms containing exon v3 are responsible for the presentation of heparin-
binding growth factor. J Cell Biol 1995, 128:687-698.
187. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S: T-cell adhesion induced by 
proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993, 361:79-82.
188. Wolff EA, Greenfield B, Taub DD, Murphy WJ, Bennett KL, Aruffo A: Generation of artificial 
proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction 
between rantes and chondroitin sulfate. J Biol Chem 1999, 274:2518-2524.
189. Rösel M, Föger N, Zöller M: Involvement of CD44 exon v10 in B-cell activation. Tissue Antigens 
1998, 52:99-113.
190. Wittig BM, Johansson B, Zöller M, Schwärzler C, Günthert U: Abrogation of experimental colitis 
correlates with increased apoptosis in mice deficient for CD44variant exon 7 (CD44v7). J Exp 
Med 2000, 191:2053-2064.
191. Moll J, Schmidt A, van der Putten H, Plug R, Ponta H, Herrlich P, Zöller M: Accelerated immune 
response in transgenic mice expressing rat CD44v4-v7 on T cells. J Immunol 1996, 156:2085-
2094.
192. Seiter S, Schmidt DS, Zöller M: The CD44variant isoforms CD44v6 and CD44v7 are expressed 
by distinct leukocyte subpopulations and exert non-overlapping functional activities. Int Immunol 
2000, 12:37-49.
193. Marhaba R, Bourouba M, Zöller M: CD44v7 interferes with activation-induced cell death by up-
regulation of anti-apoptotic gene expression. J Leukoc Biol 2003, 74:135-148.
194. Wittig B, Seiter S, Föger N, Schwärzler C, Günthert U, Zöller M: Functional activity of murine 
CD44variant isoforms in allergic and delayed type hypersensitivity. Immunol Lett 1997, 57:217-
223.
195. Wittig B, Schwärzler C, Föhr N, Günthert U, Zöller M: Curative treatment of an experimentally 
induced colitis by a CD44variant v7-specific antibody. J Immunol 1998, 161:1069-1073.
196. Wittig B, Zöller M, Zeitz M, Stallmach A: IL-10 regulates the therapeutic effect of anti-CD44v7 
antibody in experimental colitis. Z Gastroenterol 1999, 37:164.
197. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L: Elevated osteopontin levels in 
active relapsing-remitting multiple sclerosis. Ann Neurol 2003, 53:819-822.
198. Steinman L, Youssef S, van Venrooij WJ, Chabas D, Baranzini SE, Rittling SR, Denhardt DT, 
Sobel RA, Lock C, Pedotti R: Response to comment on ‘The influence of the proinflammatory 
cytokine, osteopontin, on autoimmune demyelinating disease’. Science 2003, 299:1845.
199. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, 
Murakami M, Saiki I, Chambers AF, Uede T: CD44variants but not CD44s cooperate with beta1-
containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-
aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999, 59:219-226.
General discussion 199
200. Günthert U: Importance of CD44variant isoforms in mouse models for inflammatory bowel 
disease. Curr Top Microbiol Immunol 1999, 246:307-312; discussion 313.
201. Wittig BM, Stallmach A, Zeitz M, Günthert U: Functional involvement of CD44variant 7 in gut 
immune response. Pathobiology 2002, 70:184-189.
202. Weatherill AR, Maxwell JR, Takahashi C, Weinberg AD, Vella AT: OX40 ligation enhances cell 
cycle turnover of Ag-activated CD4 T cells in vivo. Cell Immunol 2001, 209:63-75.
203. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M: OX40 promotes Bcl-xL and Bcl-2 expression 
and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455.
204. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK: Fulminant spontaneous autoimmunity 
of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell 
receptor. Proc Natl Acad Sci U S A 2000, 97:3412-3417.
205. de Jonge BL, Chang YS, Gage D, Tomasz A: Peptidoglycan composition of a highly methicillin-
resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J Biol Chem 
1992, 267:11248-11254.
 
Abbreviations 201 
Abbreviations
ADEM   acute disseminated encephalomyelitis
APC   antigen presenting cell(s)
BBB   blood-brain barrier
CARD   caspase recruitment domain
CD   Crohn’s disease
CD44-/-   CD44 knock-out
CD44s   CD44 standard
CD44v   CD44variant
CFA   complete Freund’s adjuvant
CFSE   carboxyfluorescein diacetate succinimidyl ester
CNS   central nervous system
CpG   cytosin-guanosin dinucleotide
CR-1   complement receptor type-1
CS   chondroitin sulfate
CSF   cerebrospinal fluid
DAF   decay accelerating factor
DC   dendritic cell(s)
DTH   delayed-type hypersensitivity
DTPA   diethylene-triamine-pentaacetic acid
EAE   experimental autoimmune encephalomyelitis
ECM   extracellular matrix
EGF   epidermal growth factor
EMR   EGF-like module containing mucin-like receptor protein
ETL   EGF-TM7-latrophilin-related protein 
FIRE   F4/80-like-receptor
GAG   glycosaminoglycan
GlucNAc  N-acetylglucosamine
GM   GlucNAc-MurNAc
GM-DP  GM-L-ala-D-Glu 
GM-TriDAP/lysine  GM-L-ala-D-Glu-mDAP/lysine
GPI   glycosylphosphatidylinositol
HA   hyaluronic acid
HAM-TSP  HTLV-1-associated myelopathy/tropical spastic
   paraparesis 
HC   healthy controls
HLA   human leukocyte antigens
HLTV-1  human T-lymphotropic virus type 1 
HS   heparan sulfate
IBD   inflammatory bowel disease
IFA   incomplete Freund’s adjuvant
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iPG   insoluble peptidoglycan
IRF-3   interferon regulatory factor 3
LFB   luxol fast blue
LPS   lipopolysaccharide(s)
LRR   leucine-rich repeat
LTA   lipoteichoic acid(s)
Mab   monoclonal antibody
MAG   myelin associated glycoprotein 
MΦ   macrophage(s)
MBP   myelin basic protein
mDAP   meso-diaminopimelic acid
MDP   muramyl dipeptide
MHC   major histocompability complex
MMP   matrix metalloproteinase(s)
MOG   myelin oligodendrocyte glycoprotein
MRI   magnetic resonance imaging
MS   multiple sclerosis
MurNAc  N-acetylmuramic acid
NAMLAA  N-acetylmuramyl-L-alanine amidase = PGRP-L
NBS   nucleotide-binding site
NO   nitric oxide
Nod   nucleotide-binding oligomerization domain
OIND   other inflammatory neurological diseases
OND   other neurological diseases
OPN   osteopontin
PAMP   pathogen associated molecular pattern(s)
PAS   periodic acid-Schiff
PBMC   peripheral blood mononuclear cells
PG   peptidoglycan
PGRP-L  peptidoglycan recognition protein long form = NAMLAA
PHA   phytohemagglutinin
PLP   proteolipid protein
PMA   phorbol 12-myristate 13-acetate
PRR   pattern recognition receptors
PTX   Bordetella pertussis toxin
RA   rheumatoid arthritis
RGD   Arg-Gly-Asp
sCD97   soluble CD97α
sPG   soluble peptidoglycan
TA   teichoic acid(s)
TCM   cell-culture medium
Th   T helper
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TIR    Toll/IL-1 receptor 
TLR   Toll-like receptor(s)
TM7   seven-span transmembrane domain
TNBS   trinitrobenzene sulfonic acid
chemokine nomenclature
IL-8   CXCL8
IP-10   CXCL10
MCP-1   CCL2
MCP-3   CCL7
MIP-1β  CCL4
MIP-2   CXCL2
RANTES  CCL5
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Multiple sclerosis (MS) is a chronic inflammatory disease of the central 
nervous system (CNS). We are interested in the mechanisms involved in the 
immunopathogenesis of MS, especially in microbial signals able to break T cell 
tolerance, and in the function of molecules on the activated cells in costimulation, 
migration, adhesion and apoptosis. 
Peptidoglycan (PG) is a major cell wall component of Gram-positive bacteria, 
that activates the innate immune system by binding to TLR2/6, Nod1 (Card4) and 
Nod2 (Card 15) receptors. The enzymes lysozyme and NAMLAA are produced 
by phagocytic cells and can degrade PG. However, after bacterial phagocytosis, 
PG can persist intracellularly when the digestion is incomplete. During chronic 
inflammation, PG-containing antigen presenting cells (APC) accumulate at 
inflammatory sites, as previously demonstrated in patients with colitis, arthritis and 
MS. At these inflammatory sites or in peripheral lymphoid tissues PG may serve 
as a costimulatory factor in autoimmune disease by overriding tolerance against 
self-antigens. 
To obtain more insight into the functional relevance of PG in MS, we compared 
the presence of PG and its degrading enzymes in the CNS of two distinct non-
human primate EAE models (chapter 2). As in brain tissue of MS patients we here 
demonstrate that EAE-affected brain tissue from marmoset and rhesus monkeys 
contained elevated numbers of cells with PG, compared to control immunized 
animals. Interestingly, chronic EAE in marmoset monkeys was accompanied by 
a modest number of PG-containing cells in the brain, whereas brain tissue from 
rhesus monkeys that had developed acute EAE contained abundant numbers of 
PG-containing cells. Lysozyme was only sporadically expressed in EAE-affected 
brain tissue from both monkey species. In contrast, NAMLAA was expressed on 
many perivascular cells in EAE-affected brain tissue from rhesus monkeys, but 
only by few perivascular cells in marmoset monkeys. Double-labeling revealed that 
NAMLAA was mostly expressed by neutrophils. Thus, in EAE-affected brain tissue, 
PG was present within significantly higher numbers of APC compared to controls. 
Conversely, lysozyme was mainly absent in normal and inflamed brain tissue, and 
NAMLAA was only abundantly expressed during acute CNS inflammation in rhesus 
monkeys. These data suggest that PG persists inside APC in the CNS and may 
contribute to the inflammation by stimulating TLR/Nod receptors. 
To further elucidate the functional contribution of PG to autoimmune disease 
we investigated the hypothesis that PG acts as a costimulatory factor for disease 
development in MS, by using mouse EAE (chapter 3). EAE is normally induced 
by s.c. immunization of autoantigens admixed in a strong adjuvant with attenuated 
Mycobacterium tuberculosis bacteria. Inflammatory Staphylococcus aureus PG 
could replace whole M. tuberculosis in EAE induction. We demonstrate that 
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S. aureus PG was transported to the spleen and draining lymph nodes after 
immunization with S. aureus PG-containing adjuvant. In the draining lymph 
nodes S. aureus PG was localized within dendritic cell (DC) clusters. Clusters 
of PG-containing cells were also present in the spleen of rhesus monkeys that 
developed EAE (chapter 2). Compared to control mice that were immunized with 
autoantigen in incomplete Freund’s adjuvant (IFA), PG increased autoantigen-
specific T cell proliferation and Th1 cell development, when the autoantigen-IFA 
mix was supplemented with PG. By using bone marrow-derived DC, S. aureus PG 
was shown to stimulate antigen uptake by DC, DC maturation, and subsequent 
differentiation and proliferation of Th1 cells. Taken together, proinflammatory PG 
may stimulate autoimmune-mediated processes in MS, either in the CNS or in 
the periphery, by accelerating (auto)antigen uptake, initiating DC maturation, and 
polarizing and expanding (auto)antigen-specific T cells.
CD97 and CD44 are membrane-expressed molecules required for cell-cell 
and cell-matrix interactions. These molecules contribute to disease development 
in experimental models for other chronic inflammatory diseases, e.g. arthritis and 
colitis and may determine interactions between leukocytes, endothelium and the 
extracellular matrix (ECM) of the CNS during MS and EAE. Here we assessed 
whether CD97 and CD44v isoforms are involved in the immunopathogenesis of 
MS and EAE.
CD97 is a member of the 7-span transmembrane receptor family that is expressed 
on leukocytes early after activation. CD97 is involved in migration and adhesion, 
by binding to CD55 (decay accelerating factor), α5/β1 and αvβ3 integrins and ECM 
components. The CD97-ligand CD55 is expressed on several cell types, protecting 
them from complement-mediated damage. Here we examined the expression of 
CD97 and CD55 by immunohistochemistry in MS brain tissue. Chapter 4 shows 
that cells in normal white matter did not express CD97, whereas many MΦ or 
microglial cells and T cells in MS brain lesions expressed CD97. Endothelial cells 
in normal white matter only modestly expressed CD55. In contrast, in MS brain 
lesions, endothelial cells expressed high levels of CD55 and different leukocyte 
subsets also expressed CD55. In active lesions, expression of CD55 was 
predominantly detected on MΦ or microglial cells. In these lesions, a substantial 
proportion of cells also expressed CD97. The soluble form of CD97 was found in 
serum, but not in CSF of a significant number of MS patients. 
These findings suggest that local CD97-CD55 interactions may contribute to the 
immunopathogenesis of MS. CD55 expressed on brain endothelial cells may serve 
to protect the vessels from complement-mediated damage. Additionally, CD97-
expressing cells may utilize CD55 on activated brain endothelial cells to facilitate 
adhesion and transmigration into the CNS. To determine whether CD97-CD55 
interactions are important in disease development, we blocked the interaction 
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between CD97 and CD55 by CD97 Mab treatment in the priming phase of mouse 
EAE. This treatment regimen did not affect the onset and severity of disease. 
However, these data do not exclude the possibility that CD97-CD55 interactions 
are involved in EAE development, since the treatment duration might have been 
suboptimal. Alternatively, CD97 may participate in MS and EAE by binding to 
integrins or ECM components. By using mice with a genetic deletion for CD97, we 
can elucidate whether CD97 functionally contributes to EAE development.  
CD44 and its variant isoforms (CD44v1-v10) are required for many different 
biological processes such as lymphocyte activation, costimulation, adhesion/
extravasation into inflammatory sites and apoptosis. The CD44 molecule also 
serves as a docking site for mediators of inflammation by binding cytokines, growth 
factors and chemoattractants. One gene encodes different CD44v isoforms, which 
emerge as a result of complex RNA splicing. We determined whether CD44v 
isoforms are involved in the immunopathogenesis of MS and EAE (chapter 5). 
It appeared that only CD44v10 was expressed by normal white matter 
endothelium, whereas both CD44v3 and v10 were expressed by cells in 
perivascular infiltrates and by microglia or MΦ in active lesions. Due to technical 
difficulties, we could not assess expression of CD44v7. All other isoforms were 
not expressed in MS and control brain. Also in mouse EAE, brain-infiltrating cells 
expressed CD44v10 and were already detected before clinical signs. The number 
of leukocytes that expressed CD44v10 paralleled the extent of clinical EAE 
symptoms. CD44v10-expressing CD4+ T cells persisted in EAE brain until late time 
points after immunization, whereas these cells were absent in control-immunized 
mice. Single deletion for either CD44v7 or CD44v10 resulted in reduced EAE, 
which was accompanied by reduced infiltration of the spinal cord. Adoptive transfer 
experiments demonstrated that CD44v7 exerted its effect on the donor lymphocyte 
compartment as well as on the recipients APC. No clear differences were detected 
in autoantigen-specific T cell proliferation and cytokine production around the day 
of onset. In the remission phase of EAE, CD44v7-deleted lymph node cells showed 
a reduced proliferation compared to wild type cells. At present, it is unclear by 
which mechanism CD44v7 and CD44v10 reduced EAE. Currently we are exploring 
the possibility that deficiency of CD44v7 or v10 promote clearance of inflammation 
by the induction of apoptosis. Additionally, CD44v10 may also affect cell migration, 
as indicated in animal models for Th1-mediated DTH responses. It remains to be 
determined whether CD44v3 can functionally contribute to EAE.
   
Taken together these data show that a single bacterial component, PG, can create 
an inflammatory environment. During an autoimmune attack, PG-containing cells 
most likely enter the inflammatory site and contribute to the pathological process. 
Intracellular PG may activate cells by engaging TLR or Nod receptors. PG 
promotes antigen uptake, DC maturation and proinflammatory cytokine production. 
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In the presence of autoantigens, PG induces autoantigen-specific Th1 cell priming 
and expansion. This is relevant in MS, since elevated numbers of PG-containing 
APC are found in the CNS, where autoantigens are released during inflammatory 
attacks. Moreover, autoantigens and PG are present within APC of peripheral 
lymphoid organs, where similar events may take place. 
CD97 and CD44v isoforms may facilitate cellular activation, costimulation, 
adhesion, extravasation and survival. By their interactions with other cellular ligands 
and different ligands in ECM these molecules likely contribute to tissue damage and 
chronic inflammation in MS. We here show that CD97 and CD44v molecules are 
expressed in MS brain lesions. EAE models demonstrated that by targeting CD44v7 
or CD44v10 the clinical symptoms of the disease can be reduced. Total prevention 
of CD97 expression, by genetic deletion or long-lasting antibody treatment against 
ligand-binding CD97EGF domains may give similar effects. Eventually, altering the 
immune response by the modulation of PG, CD97 and CD44v isoforms in EAE will 
give more insights in the possibilities for therapeutic interventions in MS.
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Multipele sclerose (MS) wordt beschouwd als een chronische ziekte van het 
centrale zenuwstelsel (CZS: hersenen en ruggenmerg). Bij MS patiënten wordt 
gedacht dat het afweersysteem ontspoord is. Het afweersysteem is normaliter 
gericht tegen lichaamsvreemde, bedreigende componenten, zoals virussen en 
bacteriën. Bij MS patiënten worden door het afweersysteem ook lichaamseigen 
componenten in het CZS aangevallen, zoals de beschermende schede rondom 
de uitlopers van zenuwcellen (de zogeheten myelineschede). Schade aan de 
myelineschede en zenuwcellen verstoort de zenuwfunctie. Het klinische beeld 
wordt bepaald door de plaats van myeline afbraak. MS wordt gekarakteriseerd 
door ontstekingshaarden (infiltraten) in het CZS. Deze infiltraten worden gevormd 
door cellen van het afweersysteem, de leukocyten. Er bestaan verschillende typen 
leukocyten, zoals antigeen presenterende cellen (APC), T en B cellen. APC kunnen 
bacteriën of virussen, maar ook andere componenten opnemen. De APC herkent 
bepaalde structuren van bacteriën en virussen en worden hierdoor geactiveerd. 
In dit proefschrift hebben we onderzocht of een bacterieel celwand component, 
het peptidoglycaan, kan bijdragen aan MS. Verder hebben we onderzocht of de cel 
oppervlakte moleculen CD97 en CD44 betrokken zijn bij MS.
Peptidoglycaan (PG) is een belangrijk bestanddeel van de celwand  van 
bacteriën en werkt ontstekingsbevorderend via activering van specifieke 
receptoren voor PG. Deze receptoren zijn aanwezig op en in APC. APC kunnen 
PG vervoeren van de slijmvliezen of van plaatsen van infectie naar de lymfoïde 
organen. Daarnaast worden PG-bevattende APC ook in hoge aantallen gevonden 
op plaatsen van chronische ontsteking, zoals in de gewrichten van patiënten met 
reuma. Eerder onderzoek heeft aangetoond dat ook in hersenweefsel van MS 
patiënten meer PG-bevattende APC aanwezig zijn in vergelijking met controle 
personen. 
Wij denken dat PG bijdraagt aan de chronische ontsteking bij patiënten met 
MS door activering van APC. Om deze hypothese te toetsen hebben we gebruik 
gemaakt van diermodellen voor MS. In die diermodellen wordt het op MS gelijkende 
ziektebeeld experimentele autoimmuun encefalomyelitis (EAE) genoemd. 
Lysozym en amidase zijn twee enzymen die geproduceerd worden door APC, 
en die PG kunnen afbreken. Hierdoor verliest PG zijn ontstekingsbevorderende 
werking. In hoofdstuk 2 hebben we de aanwezigheid van PG-bevattende cellen 
en PG-afbrekende enzymen bepaald in hersenweefsel van twee verschillende 
aapmodellen voor MS. Voor deze studie hebben we ingevroren weefsels gebruikt 
uit voorgaande experimenten. EAE in marmoset apen verloopt chronisch, terwijl 
resus apen een acuut ziekteverloop vertonen. In beide modellen werden bij apen 
met EAE meer PG-bevattende cellen in de hersenen gedetecteerd in vergelijking 
met controle dieren zonder EAE. Hersenweefsel van resus apen die een acuut 
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ziektebeeld vertonen bevatte veel meer cellen met PG in vergelijking met marmoset 
apen waar het ziektebeeld chronisch verloopt. Verder zagen we dat amidase alleen 
aanwezig was in infiltraten in het hersenweefsel van resus apen met EAE, en niet 
in marmoset apen. Lysozym daarentegen, was afwezig was in alle dieren (resus en 
marmoset), met of zonder EAE. Deze gegevens impliceren dat tijdens EAE cellen 
naar de hersenen migreren die PG bevatten, waarbij het aantal PG-bevattende 
cellen afhangt van het verloop van de ziekte. De afwezigheid van PG-afbrekende 
enzymen in de hersenen suggereert dat PG op deze plek niet afgebroken kan 
worden en mogelijk bijdraagt aan de chronische ontsteking. 
In hoofdstuk 3 hebben we aangetoond dat PG daadwerkelijk kan bijdragen 
aan EAE ontwikkeling in muizen. EAE treedt niet spontaan op, maar wordt 
geïnduceerd door een injectie van myeline antigenen in een emulsie van olie met 
ontstekingbevorderende componenten (gewoonlijk dode tuberculose bacteriën). 
Het huidige onderzoek toont aan dat PG, als een enkel component van de 
bacteriële celwand, de gehele tuberkel bacterie kan vervangen voor de inductie 
van EAE. Verder zagen we dat het ingespoten PG al na 4 uur aanwezig was 
in de lymfoïde organen in een gespecialiseerd type APC, de dendritische cel. 
APC kunnen andere cellen activeren, zoals T en B cellen die specifiek gericht 
zijn tegen de antigenen (deeltjes) die de APC presenteren. Dit gebeurt onder 
normale omstandigheden in lymfoïde organen, zoals de lymfeklieren en de milt. 
In een kweeksysteem hebben we dit nagebootst. We hebben aangetoond dat PG 
de dendritische cel kan stimuleren tot een verhoogde opname van antigenen en 
productie van ontstekingsbevorderende eiwitten. PG kon via dendritische cellen 
ook T cellen laten delen en uitrijpen tot ontstekingsbevorderende T helper 1 cellen. 
Deze gegevens suggereren dat PG in lymfoïde organen of zelfs in het CZS kan 
bijdragen aan MS, door het geven van ontstekingssignalen aan APC. 
Activatie en migratie van cellen vanuit de lymfoïde organen naar plaatsen van 
ontsteking (bij MS patiënten het CZS) is een zorgvuldig gereguleerd proces. Dit 
proces wordt onder andere gecoördineerd door moleculen die aanwezig zijn op het 
oppervlak van zowel de migrerende cellen als de cellen van de bloedvaatjes op 
plaatsen waar een ontstekingsreactie is. De moleculen van de migrerende cellen 
en de receptor moleculen op andere cellen grijpen in elkaar als een sleutel en slot. 
Door deze signalen kunnen de cellen de bloedbaan uit migreren. In dit proefschrift 
hebben we tevens onderzocht of de cel oppervlakte moleculen CD97 en CD44 
bijdragen aan het ziekteproces in MS, zoals hieronder beschreven.
CD97 en CD44 zijn moleculen die voorkomen op het oppervlak van verschillende 
celtypen. Eerder onderzoek heeft aangetoond dat deze moleculen een belangrijke 
rol spelen bij reuma en chronische darmontsteking (colitis). Deze moleculen dragen 
mogelijk bij aan het ziekteproces in MS door coördinatie van verschillende cellulaire 
processen, zoals activatie, deling en migratie naar plaatsen van ontsteking.  
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CD97 is betrokken bij de activatie, migratie en adhesie van cellen. CD55 was de 
enige ligand voor CD97 dat in de literatuur bekend was tijdens het onderzoek voor 
dit proefschrift. Inmiddels is bekend dat CD97 zich ook kan binden aan integrinen 
en componenten van de extracellulaire matrix (tussenstof). CD55 beschermt cellen 
tegen complement factoren. Het complement systeem bestaat uit moleculen die 
helpen bij het bestrijden van infecties. Doordat lichaamseigen cellen moleculen 
zoals CD55 op hun oppervlakte dragen worden zij niet aangevallen door het 
complement. Het onderzoek beschreven in hoofdstuk 4 toont aan dat CD97 en 
CD55 aanwezig zijn op plaatsen van ontsteking in het CZS van MS patiënten. 
CD97 kwam niet en CD55 kwam nauwelijks tot expressie op cellen in normaal 
hersenweefsel. Daarentegen werd in ontstekingsgebieden in MS hersenweefsel 
een verhoogde expressie van CD55 gevonden op endotheelcellen (cellen 
die de wand van bloedvaten aan de binnenzijde bekleden). Direct naast deze 
endotheelcellen kwam CD97 tot expressie op infiltrerende APC, T en B cellen. 
Daarom veronderstellen wij dat CD97 op leukocyten bijdraagt aan de migratie van 
cellen uit de bloedbaan naar het CZS, door interactie met CD55 op endotheelcellen. 
Om te bepalen of CD97 interacties met CD55 van belang zijn voor MS, hebben we 
EAE in muizen behandeld met een blokkerende antistof die de interactie tussen 
CD97-CD55 voorkomt. Het gebruikte behandelingsschema resulteerde niet in een 
verminderde ziektelast. Dit kan betekenen dat 1) de CD97-CD55 interactie niet 
van belang is in muizen met EAE, of 2) de behandeling van te korte duur was om 
de ziektelast te verminderen. In vervolgonderzoek kunnen we gebruik maken van 
muizen die het gen voor CD97 ontberen, om zodoende een beter inzicht te krijgen 
in de functionele rol van CD97 in MS.
CD44 en de variant isovormen van CD44 (CD44v1-v10) spelen een belangrijke 
rol bij allerlei biologische processen, zoals celactivatie, -costimulatie, -migratie, -
adhesie en geprogrammeerde celdood. Geprogrammeerde celdood is van belang 
bij het beëindigen van een ontstekingsreactie, b.v. als het infectiegevaar geweken 
is. Daarnaast kan CD44 als een magneet fungeren voor ontstekingsmediatoren. 
Zodoende kan CD44 ervoor zorgen dat er lokaal een verhoogde concentratie 
ontstaat van deze ontstekingsmediatoren. In hoofdstuk 5 hebben we aangetoond 
dat bepaalde CD44v isovormen specifiek tot expressie komen in hersenweefsel van 
MS patiënten en muizen met EAE. In muizen met EAE hebben we op verschillende 
tijdstippen na ziekte inductie de expressie van CD44v10 bestudeerd in de 
hersenen. CD44v10 kwam tot expressie op verschillende CZS infiltrerende cellen 
(APC, T en B cellen). Met name CD44v10+ T helper cellen konden zelfs nog op late 
tijdstippen na EAE inductie gedetecteerd worden, terwijl deze cellen afwezig waren 
in controlemuizen. Daarnaast laten we zien dat muizen, die het gen voor CD44v7 
of CD44v10 missen, een verminderde ziektelast vertoonden na EAE inductie. 
Deze gegevens tonen aan dat CD44v isovormen een belangrijke bijdrage kunnen 
leveren aan EAE. Deze isovormen zijn mogelijk ook betrokken bij het ziekteproces 
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in MS. Verder onderzoek moet aantonen op welke manier CD44v moleculen een 
rol spelen in de ziekte (b.v. bij adhesie of geprogrammeerde celdood).   
Kort samengevat heeft dit proefschrift de volgende inzichten opgeleverd. PG kan 
bijdragen aan MS door activatie van APC. PG-bevattende cellen kunnen mee 
migreren naar het CZS tijdens MS of EAE en dragen daar mogelijk bij aan een 
ontstekings-bevorderend milieu. Niet alleen in het CZS, maar ook in lymfoïde 
organen zou PG een bijdrage kunnen leveren aan MS en EAE. Hier kan PG 
bijdragen door stimulatie van T en B cellen die gericht zijn tegen componenten 
van het CZS (zoals myeline), via APC. CD97 en CD44v isovormen kunnen ervoor 
zorgen dat celactivatie, -migratie, -adhesie en -overleving gestimuleerd worden 
tijdens MS en EAE. We laten zien dat CD97 en CD44v isovormen tot expressie 
komen in ontstekingshaarden in het CZS van MS patiënten. EAE in muizen kan 
worden verminderd door afwezigheid van CD44v7 of CD44v10. Soortgelijke 
effecten worden verwacht bij afwezigheid van het CD97 molecuul. Dit proefschrift 
verschaft een verbeterd inzicht in de pathogenese van MS en draagt mogelijk bij in 
een rationele doelgerichte ontwikkeling van nieuwe therapeutische benaderingen. 
Dankwoord 213
Dankwoord
En dan is het is zover, het boek is af! Mijn naam staat dan wel als enige op de 
voorkant, maar dit boek is met hulp van velen tot stand gekomen, die ik hierbij dan 
ook eerst allemaal in het algemeen wil bedanken,                
    BEDANKT!
Prof. Benner, beste Rob, graag wil ik je hierbij bedanken voor de gelegenheid 
die ik vanuit een analistenpositie heb gekregen om mij verder te ontplooien als 
AIO op deze afdeling. Het opleidingsprogramma voor AIO’s op de afdeling is van 
uitstekende kwaliteit (met name ook dankzij Rudi en Frank) en geeft AIO’s een 
goede set aan gereedschap om in de toekomst mee te werken.
 Tijdens deze AIO-jaren ben ik begeleid door mijn copromotor, Jon Laman. Beste 
Jon, mijn wetenschappelijke loopbaan is bij jou gestart, als stagiaire bij TNO. Na 
twee jaar gewerkt te hebben als researchanalist wilde ik verder. Jij hebt mij bij 
deze keuze gestimuleerd en deze groei mogelijk gemaakt. Ik ben je daarvoor zeer 
dankbaar. Verder heb je mij gedreven tot het behalen van dit resultaat. Ondanks dat 
er, zoals in de meeste onderzoeken, nogal eens iets niet ging zoals we verwacht 
hadden, heb jij nooit de moed opgegeven (met mij en het onderzoek!). Ik heb door 
de diversiteit aan onderwerpen een brede opleiding genoten. Als je het vergelijkt 
met een auto, dan heb jij er mede voor gezorgd dat ik van de eerste naar de derde 
versnelling ben gegroeid (misschien wel per onderwerp één versnelling), met af 
en toe wat haperingen als de motor het even zwaar had. De andere versnellingen 
staan natuurlijk symbool voor de doorgroeimogelijkheden! 
Om in volgorde van het proefschrift te beginnen, wil ik eerst Bert ’t Hart bedanken 
voor de mogelijkheid tot het ontstaan van chapter 2 in dit boekje! De laatste 
maanden hebben we dit tot een mooi artikel gemaakt (al zeg ik het zelf), ook 
onder andere met de hulp van Sandra, Ella en Jeffrey, ook daarvoor mijn dank. Het 
hoofdstuk waarbij we gewerkt hebben aan peptidoglycaan in muizen EAE (chapter 
3) is mede tot stand gekomen dankzij samenwerking met Edward Nieuwenhuis 
en Bart Lambrecht. Edward, bedankt voor je aanstekelijke enthousiaste kijk op de 
wetenschap en alle input bij het bedenken van proeven en schrijven van het artikel. 
Ook wil ik Bart bedanken voor de wetenschappelijke input en de mogelijkheid om 
proeven uit te voeren met mooie modelsystemen. Ook met name Hendrik Jan wil 
ik daarbij bedanken voor alle inzet! 
Chapter 4 is mede tot stand gekomen in samenwerking met Rogier Hintzen 
en Jörg Hamann. Beste Rogier en Jörg, jullie hebben mij begeleid in het werk 
met het CD97 molecuul. Ik heb met veel plezier aan dit onderwerp gewerkt en 
hierover mijn eerste artikel geschreven. Dit was een bijzondere ervaring, die mede 
dankzij jullie begeleiding soepeltjes is verlopen. Ook wil ik Else bedanken voor 
214 Dankwoord
de updates van CD97 in het reuma onderzoek en de gezelligheid bij het Oxford 
congres. De solidariteit bij het krijgen van een kindje in de afrondingsfase van een 
promotieonderzoek vind ik geweldig! 
Dear Ulla, thank you for guiding me in the complex world of CD44! During the 
last years we collaborated extensively by long mails, phone calls and several visits, 
that resulted in chapter 5 of this thesis. I highly appreciate that I could come to Basel 
and work in your group. Besides the long days in the lab, you always managed to 
organize nice diners or trips to beautiful sceneries or museums. Thank you for your 
hospitality and scientific help (in any way). I also want to thank Britt for the technical 
support and friendship. Tina, we met at the Basel Institute for Immunology, were we 
both visited Ulla to work on CD44, in different models. I enjoyed the time we both 
shared inside and outside the lab.
Dan kom ik bij al mijn labgenoten van 802. In het lab 802 heerst een gezond 
onderzoeksklimaat. Dit wordt onderschreven door de enorme groei in het aantal 
mensen dat hier in de laatste jaren is komen werken. Ik zal daarom niet iedereen 
bij name noemen, maar wil wel benadrukken dat ik ieders inzet en betrokkenheid 
hoog waardeer. Wat in dit lab en trouwens op de gehele afdeling geldt, is dat 
iedereen altijd met plezier bereid is om te helpen, met kleine tot grote ‘dingen’. Op 
ons lab 802 heb ik nauw samengewerkt met Marjan, Marie-José en Debby. Het is 
zo klaar als een klontje dat ik hier mede sta door jullie inspanningen! 
Paranimf Marjan, niet alleen tijdens de promotie sta je naast me, dat heb je 
ook gedaan vanaf de tijd dat ik hier ben komen werken. Samen waren we vaak 
te vinden in het EDC waar we in onze witte pakken vele muizen lieten schrikken. 
Daarna gingen wij (inclusief de andere EAE scoorders) ze dagelijks bezoeken, ook 
in vele weekenden (om het weer goed te maken). Je hebt me wegwijs gemaakt 
met vele technieken en ook bijgestaan tijdens de mega experimenten (samen met 
Debby). Bedankt voor al je inzet, gezelligheid en je steun. 
Marie-José, zo georganiseerd als jij bent, daar kunnen weinig mensen aan 
tippen. Soms leek het wel, als we vandaag overleg hadden gehad over een nieuw 
experiment bij jou de resultaten de dag daarvoor al bekend waren. Ik heb heel fijn 
met je samengewerkt en wil je daarvoor van harte bedanken! Debby, jij hebt de 
meest hardnekkige onderwerpen van het onderzoek aangevallen. Dit was zeker 
niet altijd even motiverend, maar je hebt je er knap doorheen geworsteld! Bedankt 
voor al je inzet en voor de gezellige tijd die we hebben gehad in het lab 802 en in 
Zwitserland, tijdens je werkbezoek in Basel. 
Dan zijn er ook mijn kamergenootjes (naast Marjan), de twee andere L’en; 
Leslie en Leonie. Als wij met z’n vieren de kamer af kwamen lopen was iedereen 
onder de indruk (lang en/of blond)! Ondertussen hebben jullie geleerd hoe je een 
plant in leven moet houden, iets dat ik nooit zal leren. Ik kon altijd bij jullie terecht 
met allerlei vragen en wetenschappelijke frustraties, hiervoor bedankt! Verder wil ik 
ook Alex en Leonie bedanken voor alle wetenschappelijke discussies.    
Dankwoord 215
Dan wil ik graag nog alle mede AIO’s bedanken voor de leuke retraites, borrels 
en andere onder onsjes. Daarbij wil ik met name Karin, Wai Kwan, Sabine, Tanja, 
Sacha, Gerben en Laura noemen, WE ZIJN KLAAR!!! (nou ja, bijna…. voor Karin, 
Laura en mijzelf). Nog even, dan hebben we deze berg overmeesterd. Wellicht 
komt er weer een stuk om te klimmen, maar dat is goed voor de gezondheid. Deze 
klim vindt voor jullie plaats in een andere richting. Heel veel succes hierbij.
Dit proefschrift was lang niet zo mooi geworden zonder de hulp van Tar en Wendy. 
Tar heeft van mijn soms wat onduidelijke tekeningen altijd prachtige plaatjes weten 
te maken, zoals te zien is in dit proefschrift. Ik bedank je voor je inzet en hartelijkheid 
tijdens deze samenwerking. Wendy, jij hebt dit proefschrift mooi vorm gegeven en 
liet je daarbij niet door de paashaas tegenhouden, bedankt! Daarnaast wil ik ook 
Marcia en Erna bedanken voor al de secretariële ondersteuning in de afgelopen 
jaren. Ik had niet zo goed met de computer kunnen samenwerken zonder de hulp 
van Marcel en mijn broer Edwin.
Tenslotte wil ik mijn familie en vrienden bedanken voor alle steun. Lieve ouders, 
jullie hebben mij altijd gestimuleerd om verder te studeren. Daarvoor was alles 
mogelijk en heb ik van jullie maximale steun gekregen. Ook mijn schoonouders, 
Hans en Helen wil ik met name bedanken voor alle steun en de gezonde 
maaltijden! Mirjam, ik wil je alvast bedanken omdat je mijn paranimf wilt zijn. Zoals 
we ooit in onze opleiding zijn begonnen, staan we straks weer zij aan zij in een 
wetenschappelijke omgeving. 
 Lieve Jörgen en Björn, bedankt dat jullie er zijn! In deze enkele zinnen kan ik 
onmogelijk aangeven wat jij, Jörgen, allemaal voor mij betekend hebt in de afgelopen 
jaren. Je stond vanaf het begin volledig achter me en toonde onuitputtelijk geduld 
als ik weer eens verweven zat in het werk. Bedankt voor al je liefde en toewijding! 
Björn, jij zorgde voor een aangename afwisseling van de wetenschappelijke wereld 
naar de baby wereld en leert mij om een goede mama te zijn.
 
Curriculum vitae 217
Curriculum vitae
14 april 1975   Geboren te Molenaarsgraaf  
1987 - 1991    Da Costa, MAVO, Sliedrecht
1991 - 1993   Dordtwijck, HAVO, Dordrecht
1993 - 1997   Hoger Laboratorium Onderwijs (HLO), Delft
 Stage: “Manipulatie van de CD40-CD40L interactie 
voor het induceren van T cel tolerantie in EAE” 
(o.l.v. dr. J.D. Laman), afdeling Immunologische 
en Infectieziekten, TNO Preventie en Gezondheid, 
Leiden (sept 1996 - juni 1997)
1997 - 1999 Research analist, afdeling Immunologische en 
Infectieziekten, TNO Preventie en Gezondheid, 
Leiden. Project: “Verbetering van het therapeutische 
effect van IFN-β door IL-10 in EAE”
1999 - 2005 Promotieonderzoek “Modulation of MS models 
by peptidoglycan, CD97 and CD44” (o.l.v. dr. 
J.D. Laman en prof. dr. R. Benner), afdeling 
Immunologie, Erasmus MC, Rotterdam
Ervaring in het buitenland 
In het kader van het promotieonderzoek zes maanden werkervaring op het Basel 
Institute for Immunology (BII) i.s.m. dr. U. Günthert
Gevolgde cursussen
•  Proefdierkunde (artikel 9 en artikel 12)
•  Klinische en Experimentele Endocrinologie en Immunoendocrinologie, Rotterdam
•  Introductiecursus Medische Immunologie, Rotterdam
•  Introductiecursus Molecular Medicine, Rotterdam
•  Training Vaardigheden voor practicumassistenten, Rotterdam
•  Stralingscursus 5B, Delft
•  Cursus onderzoeksmanagement, Nederlands Instituut voor Biologie, Driebergen
•  Oxford Higher examination in English as a foreign language, Rotterdam 
•  Advanced course Molecular Immunology, Rotterdam
•  Praktische cursus Moleculaire Biologie, Rotterdam
•  Biostatistiek cursus en examen gebaseerd op D.G. Altman, “Practical statistics 
 for medical research”, Rotterdam 
Onderwijsactiviteiten
• Practicumassistent Histologie voor eerstejaars geneeskundestudenten, 
 Rotterdam
• Practicumassistent Immunologie voor tweedejaars geneeskundestudenten, 
 Rotterdam
 
Publications 219
Publications
Visser L, Johansson B, Mielgo A, van Riel D, Melief M, van Meurs M, Laman JD 
and Günthert U: Involvement of specific CD44variant isoforms in multiple sclerosis 
and experimental autoimmune encephalomyelitis, in preparation.
Visser L, Melief M, van Riel D, van Meurs M, Sick EA, Inamura S, Bajramovic JJ, 
Amor S, Hintzen RQ, Boven LA, ’t Hart BA, Laman JD: Phagocytes carry a disease 
promoting TLR/Nod ligand into the brain during demyelinating disease in primates, 
submitted.
Visser L, de Heer HJ, Boven LA, van Riel D, van Meurs M, Melief M, Zähringer U, 
van Strijp J, Lambrecht BN, Nieuwenhuis EE, Laman JD: Proinflammatory bacterial 
peptidoglycan as a cofactor for the development of central nervous system 
autoimmune disease. J Immunol 2005; 174: 808-816.
Maassen CB, Laman JD, van Holten-Neelen C, Hoogteijling L, Groenewegen L, 
Visser L, Schellekens MM, Boersma WJ, Claassen E: Reduced experimental 
autoimmune encephalomyelitis after intranasal and oral administration of 
recombinant lactobacilli expressing myelin antigens. Vaccine 2003; 21: 4685-4693.
Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, Laman JD, 
Hintzen RQ: Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) 
in multiple sclerosis. J Neuroimmunol 2002; 132: 156-163.
Laman JD, Visser L, Maassen CB, de Groot CJ, de Jong LA, ‘t Hart BA, van Meurs 
M, Schellekens MM: Novel monoclonal antibodies against proteolipid protein 
peptide 139-151 demonstrate demyelination and myelin uptake by macrophages in 
MS and marmoset EAE lesions. J Neuroimmunol 2001; 119: 124-130.
Luca ME, Visser L, Lucas CJ, Nagelkerken L: IFN-β modulates specific T cell 
responses in vitro but does not affect experimental autoimmune encephalomyelitis 
in the SJL mouse. J Neuroimmunol 1999; 100: 190-196.
Laman JD, Maassen CB, Schellekens MM, Visser L, Kap M, de Jong E, van 
Puijenbroek M, van Stipdonk MJ, van Meurs M, Schwärzler C, Günthert U: Therapy 
with antibodies against CD40L (CD154) and CD44variant isoforms reduces 
experimental autoimmune encephalomyelitis induced by a proteolipid protein 
peptide. Mult Scler 1998; 4: 147-153.
 
Appendix 221
Chapter 2: Figure 2
�
��
��
��
�� ������
� �������������
������
����������
������
����������
���
�
�
��
�
��
��
��
��
��
��
��
�
��
��
��
��
��
��
��
���
���
���
���
��
��
��
�
�
��
��
��
���
���
���
���
���
��
�
��
��
��
��
�
��
��
��
��
��
��
��
���
���
��
��
�
�
�
������
������
� ������������������
������
����
������
��������
���
�
��
��
��
��
���
���
��
�
��
��
��
��
�
��
��
��
��
��
��
��
���
���
��
��
�
�
�
� �������������
������
����������
������
����������
���
� �
� �
� �
������ ��������
Figure 2. PG-containing cells are present in rhesus and marmoset brain. 
Left column: rhesus brain tissue and right column marmoset brain tissue. Many cells in infiltrates of (A) 
rhesus EAE brain tissue (animal 9) and a modest cell number in infiltrates of marmoset EAE brain tissue 
(animal 10) contain PG (B, D). Significant higher numbers of cells in infiltrates of marmoset EAE brain tissue 
(D) contain PG when compared to control brain tissue. Many PG-containing infiltrates are present in rhesus 
EAE brain tissue (C). Significantly elevated numbers of PG-containing cells are present in the parenchyma 
of rhesus (E), but not in marmoset EAE brain tissue (F), compared to control brain tissue. Bar = 100 µm. 
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Figure 4. High numbers of PG-containing cells in rhesus EAE spleen.
High numbers of PG-containing cells are present in the marginal zone of rhesus monkeys that developed 
EAE (animal 10)(A, B). In control immunized rhesus monkeys (animal 5) NAMLAA-expressing cells are 
present in clusters within the red pulp (C). Bar = 100 µm. 
Figure 3. Restricted NAMLAA expression in MS and monkey EAE brain.
In rhesus EAE brain tissue (animal 9) many perivascular infiltrates are present with a moderate to high 
number of NAMLAA-containing cells (A, B). In marmoset EAE brain tissue (animal 10) some NAMLAA-
containing cells are localized near blood vessels (C). Foamy MΦ in active MS brain lesions (sample 
97-160) express NAMLAA (D). Expression of NAMLAA is restricted to a certain subpopulation of foamy 
MΦ (E). Occasionally also perivascular cells express NAMLAA in MS brain tissue (sample 00-082) (F). 
Bar = 100 µm. 
Appendix 223
Chapter 3: Figure 2
Figure 2. Immunization with PG-containing adjuvant induces classical EAE histopathology.
Brain tissues were isolated between 4 to 7 weeks after immunization. Frozen brain sections were 
stained with hematoxylin in combination with MHC-II (A, B), CD3 (C, D) and B220 (E, F). 
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Figure 4. PG is redistributed from the site of immunization to DC in draining lymph nodes.
Draining lymph nodes were isolated at 4 h after s.c. immunization with MOG35-55 in IFA-sPG. Frozen 
sections were stained by immunofluorescence for DC (CD11c in red, A) and for PG (green, B). Overlay 
in C demonstrates clusters of DC containing PG. D is a lightmicroscopic image of the same area.
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Figure 1. Expression of CD97 and CD55 in human MS brain.
Left column, CD97 expression; and right column, CD55 expression. In pre-active lesions, parenchymal 
cells as well as infiltrating cells expressed CD97 (A and C, respectively). In normal white matter, CD55 
was expressed at low levels by endothelial cells (B), while in pre-active lesions, CD55 was expressed at 
high levels by endothelial cells and by some infiltrating cells (D). In active lesions, in which phagocytic 
cells contain myelin debris, numerous cells expressed CD97 (E) and also a moderate number of cells 
expressed CD55 (F). Bar = 45µm. 
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Figure 2. Identification of CD97- and CD55-expressing cell types in pre-active MS brain lesions.
Left column, CD97 expression; and right column, CD55 expression. CD97 (red) is not expressed 
by endothelial cells (laminin in blue)(A). In contrast, double labeling showed co-expression (arrow) 
for CD55 (red) and laminin (blue; asterisk)(B). Many infiltrating CD3+ T cells (blue) expressed CD97 
(arrow)(C), and some expressed CD55 (arrow)(D). A moderate number of HLA-DR positive (red; 
asterisk) infiltrating MΦ and resident microglial cells co-expressed CD97 (arrow)(E), while only a few 
co-expressed CD55 (arrow)(F). Bar = 45µm. Asterisks indicate single expression (red or blue). Arrows 
indicate double expression (purple).
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Figure 1. CD44v10 is expressed in MS brain tissue
Pre-active lesions are characterized by HLA-DP/DQ/DR-expressing activated MΦ/microglia (A), 
which are located in perivascular infiltrates or in clusters in the brain parenchyma (A). An abundant 
cell number expressed CD44v10 in the parenchyma within pre-active lesions (B). These parenchymal 
v10-expressing cells had a fibrillary glial morphology (arrowhead) (C). Besides glial cells also few 
perivascular cells (arrow) and endothelial cells (asteriks) expressed CD44v10 (C). In active lesions a 
moderate to an abundant number of foamy MΦ expressed CD44v10 (D). Bar = 100 µm.
 
